data_1hzl_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1hzl _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.48 0.727 0 N-CA-C 110.39 -0.658 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.462 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.491 HG12 HG12 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.608 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.608 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.533 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.497 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' SER . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.565 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 3' ' ' ALA . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.471 ' HB2' HG22 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.553 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.568 ' CE1' HD22 ' A' ' 100' ' ' LEU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.461 HD11 ' O ' ' A' ' 94' ' ' GLY . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.483 ' HA ' HD13 ' A' ' 93' ' ' LEU . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.472 ' HB1' ' OH ' ' A' ' 71' ' ' TYR . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.483 ' O ' HG13 ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.542 ' HB3' ' CA ' ' A' ' 73' ' ' GLY . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.488 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.488 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.453 HG21 ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.529 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.589 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.458 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.586 ' CZ ' HG13 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.542 ' CA ' ' HB3' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.495 ' N ' ' HB3' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 79' ' ' THR . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.48 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.415 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.586 HG13 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.464 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.441 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.441 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.455 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' A' ' 104' ' ' HIS . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HB1' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.568 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.462 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.491 HG12 HG12 ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.455 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.533 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.589 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 C--O 1.215 -0.671 0 N-CA-C 110.127 -0.759 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.464 HG12 HG12 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.431 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.402 ' C ' ' O ' ' A' ' 15' ' ' GLY . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.484 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.537 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.45 ' CG2' ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.538 ' CD1' ' HB1' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.473 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.46 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.475 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.406 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.475 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.483 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.447 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.462 ' HA ' ' HB3' ' A' ' 34' ' ' ALA . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.5 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.423 HG21 ' N ' ' A' ' 55' ' ' THR . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.537 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.451 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.518 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.489 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.489 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.49 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.478 ' O ' ' HB2' ' A' ' 109' ' ' PHE . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.543 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB1' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.473 HD13 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.538 ' HB1' ' CD1' ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.485 ' C ' ' O ' ' A' ' 97' ' ' ASN . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.422 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.468 HD13 ' CD2' ' A' ' 31' ' ' TYR . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 1.6 p80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.464 HG12 HG12 ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.454 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.46 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.497 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 41.9 Cg_endo . . . . . 0 C--O 1.214 -0.724 0 N-CA-C 110.381 -0.661 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.524 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.524 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.613 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.426 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.508 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.472 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.469 ' HB3' ' HD3' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.521 ' O ' ' CG2' ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 6' ' ' VAL . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.524 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.508 ' N ' HG13 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.56 ' CG1' ' CD2' ' A' ' 102' ' ' LEU . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.474 ' HB2' HG23 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.43 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.461 HD12 HD22 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.482 HG11 ' O ' ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.541 ' CB ' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.446 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.519 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.474 HG23 ' HB2' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.442 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.559 ' HB3' ' CE1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.448 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.446 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.416 ' C ' ' O ' ' A' ' 74' ' ' SER . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.54 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.54 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.522 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 91' ' ' CYS . 30.5 m120 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.476 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.56 ' CD2' ' CG1' ' A' ' 22' ' ' VAL . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.467 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.524 HG11 ' CG1' ' A' ' 6' ' ' VAL . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.426 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.559 ' CE1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo . . . . . 0 C--O 1.216 -0.584 0 N-CA-C 110.257 -0.709 . . . . 0.0 110.257 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.517 ' CD1' HG21 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.475 HG11 HG12 ' A' ' 105' ' ' VAL . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.643 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.643 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.413 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.458 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.507 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.461 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.547 HG22 ' CZ ' ' A' ' 53' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.602 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.459 ' OE2' ' O ' ' A' ' 28' ' ' GLY . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.602 ' CZ ' ' HB3' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' O ' HG22 ' A' ' 33' ' ' ILE . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.4 ' C ' HD13 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.468 ' O ' HG22 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.417 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.547 ' CZ ' HG22 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.53 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.533 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.428 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.524 ' O ' ' O ' ' A' ' 74' ' ' SER . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.47 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.407 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.453 ' OD2' HG22 ' A' ' 88' ' ' THR . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.453 HG22 ' OD2' ' A' ' 85' ' ' ASP . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.4 HD13 ' C ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA2' HD11 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.472 HD11 ' O ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.472 ' O ' HD11 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.485 HD11 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.52 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.559 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 3.6 m-70 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.475 HG12 HG11 ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.423 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.464 ' O ' ' OG1' ' A' ' 108' ' ' THR . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.403 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.53 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo . . . . . 0 C--O 1.215 -0.651 0 N-CA-C 110.323 -0.684 . . . . 0.0 110.323 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.503 HG11 ' CG1' ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.628 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.628 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 12' ' ' LEU . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.459 ' O ' ' CG2' ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.493 HG13 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.493 ' N ' HG13 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.579 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.476 HD11 ' HB2' ' A' ' 95' ' ' ALA . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.529 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.515 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 29.4 t30 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 49' ' ' THR . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 29' ' ' GLU . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.524 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.518 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.458 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.415 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 33' ' ' ILE . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.428 ' OD1' ' HA ' ' A' ' 31' ' ' TYR . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.53 ' CD2' ' HG3' ' A' ' 2' ' ' PRO . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.571 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.415 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.503 ' CG1' HG11 ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.433 ' O ' HD21 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.457 ' HG2' ' O ' ' A' ' 101' ' ' ASP . 44.3 Cg_endo . . . . . 0 C--O 1.217 -0.56 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 22' ' ' VAL . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.573 ' CD2' ' HB2' ' A' ' 95' ' ' ALA . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.522 HG13 ' CG1' ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.447 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.447 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.453 HG12 ' HG2' ' A' ' 8' ' ' PRO . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.414 ' CG1' ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.476 HG12 ' O ' ' A' ' 3' ' ' ALA . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HB2' HG22 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HA ' ' OE1' ' A' ' 29' ' ' GLU . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.551 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.467 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.506 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.506 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.402 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.467 ' O ' HG21 ' A' ' 30' ' ' THR . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.503 HG23 ' N ' ' A' ' 55' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.503 ' N ' HG23 ' A' ' 54' ' ' THR . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.548 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.411 ' HB2' HG21 ' A' ' 55' ' ' THR . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.513 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 79' ' ' THR . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.418 ' O ' ' OG1' ' A' ' 75' ' ' THR . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.429 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.429 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.456 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA3' ' CD2' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.573 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.457 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.464 HD22 ' CG1' ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.572 ' CD2' ' HA3' ' A' ' 94' ' ' GLY . 64.0 m80 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.522 ' CG1' HG13 ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 C--O 1.215 -0.642 0 N-CA-C 110.261 -0.707 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.466 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.514 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.597 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.597 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.527 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' SER . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.461 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.466 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.524 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 28' ' ' GLY . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.421 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.582 ' CE1' HD23 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.492 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.53 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.454 ' O ' HG21 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.53 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.428 ' ND2' ' CD2' ' A' ' 71' ' ' TYR . 5.1 t-20 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.421 ' OG1' HG23 ' A' ' 30' ' ' THR . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.524 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.55 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.494 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.593 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.411 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.428 ' CD2' ' ND2' ' A' ' 46' ' ' ASN . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 45' ' ' CYS . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 79' ' ' THR . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 75' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 85' ' ' ASP . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.454 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.441 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.446 HD12 HD12 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.582 HD23 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.408 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.514 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.527 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.593 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.48 0.709 0 N-CA-C 110.224 -0.721 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.508 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.455 HG11 HG12 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' SER . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.56 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.516 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' CG1' HD22 ' A' ' 102' ' ' LEU . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.522 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.551 ' CB ' ' HA ' ' A' ' 57' ' ' ALA . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.499 ' CG2' ' CG2' ' A' ' 51' ' ' THR . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.429 ' NE2' HD11 ' A' ' 107' ' ' LEU . 0.6 OUTLIER -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 84' ' ' VAL . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.466 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.466 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.578 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.585 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.522 HG22 ' CB ' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.534 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.551 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.465 HG21 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.578 ' CE1' ' HB2' ' A' ' 46' ' ' ASN . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.41 ' C ' ' OG ' ' A' ' 74' ' ' SER . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.509 HG21 ' CG2' ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.487 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.487 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.509 ' CG2' HG21 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.529 ' CG1' ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.508 ' OD1' ' CB ' ' A' ' 70' ' ' SER . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.492 ' OD1' ' O ' ' A' ' 92' ' ' ASN . 12.3 p30 -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.468 HD13 HG12 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ASP . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.524 HD22 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.473 ' O ' ' CD2' ' A' ' 104' ' ' HIS . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.473 ' CD2' ' O ' ' A' ' 103' ' ' GLY . 46.3 m170 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 ' N ' ' A' ' 106' ' ' ALA . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.512 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.452 HD12 ' HB2' ' A' ' 93' ' ' LEU . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 N--CA 1.479 0.663 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.503 ' CZ ' HG13 ' A' ' 20' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.574 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.482 ' HA ' ' OE1' ' A' ' 16' ' ' GLN . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.482 ' OE1' ' HA ' ' A' ' 12' ' ' LEU . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.503 HG13 ' CZ ' ' A' ' 4' ' ' PHE . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.473 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.473 ' CG1' HD23 ' A' ' 102' ' ' LEU . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.444 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.488 ' HB3' HG23 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.475 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.547 HD12 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.547 ' N ' HD12 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.55 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.472 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.535 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.444 ' CB ' ' CG1' ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.437 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.455 ' C ' HG21 ' A' ' 51' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.472 ' O ' HG23 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.488 HG23 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.547 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.497 ' HA ' ' HB3' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.464 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.486 ' O ' ' HG3' ' A' ' 68' ' ' ARG . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.486 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.531 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.474 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.452 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.452 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.477 HD13 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.481 ' HB3' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.473 HD23 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.574 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.48 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.531 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 N--CA 1.483 0.862 0 N-CA-C 109.927 -0.836 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.548 ' CG1' HG12 ' A' ' 105' ' ' VAL . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.656 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.485 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.458 ' O ' HG23 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.41 HG12 ' HG2' ' A' ' 8' ' ' PRO . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.461 ' CG1' HD23 ' A' ' 102' ' ' LEU . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.487 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.513 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.509 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE1' ' HB3' ' A' ' 29' ' ' GLU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.443 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.436 ' HB3' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.539 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.478 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.483 HG23 ' HD2' ' A' ' 68' ' ' ARG . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.525 HG22 ' N ' ' A' ' 55' ' ' THR . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.525 ' N ' HG22 ' A' ' 54' ' ' THR . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.513 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.442 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HD2' HG23 ' A' ' 49' ' ' THR . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.579 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HA ' HG21 ' A' ' 81' ' ' VAL . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.412 ' C ' ' O ' ' A' ' 74' ' ' SER . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.519 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.519 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.444 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.508 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.436 ' SG ' ' HB3' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.518 ' HA ' ' HA ' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.465 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.461 HD23 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.499 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.552 HG11 ' N ' ' A' ' 106' ' ' ALA . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.552 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.579 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.679 0 N-CA-C 110.226 -0.721 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.598 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.484 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.646 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.646 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 9' ' ' ALA . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.425 HD21 ' OE1' ' A' ' 16' ' ' GLN . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.454 ' O ' HG21 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.54 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.478 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.41 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.41 ' HG3' ' C ' ' A' ' 28' ' ' GLY . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.558 ' CG ' ' O ' ' A' ' 30' ' ' THR . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.525 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.443 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 71' ' ' TYR . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.502 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.454 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.478 HG22 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.542 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.451 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.463 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.454 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.536 ' HE3' ' CB ' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.465 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.455 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.414 ' C ' HG22 ' A' ' 81' ' ' VAL . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.469 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.449 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.536 ' CB ' ' HE3' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.489 ' O ' ' CA ' ' A' ' 104' ' ' HIS . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.456 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.516 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.489 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.407 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.455 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo . . . . . 0 C--O 1.215 -0.646 0 N-CA-C 110.271 -0.703 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.584 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.616 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.616 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.432 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.491 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.467 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.467 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.537 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.465 ' CG1' ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.465 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.526 ' CG1' HD23 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.49 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.523 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.457 ' OE1' HD11 ' A' ' 100' ' ' LEU . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.459 HG21 ' O ' ' A' ' 53' ' ' PHE . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.563 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.584 HD11 ' CZ ' ' A' ' 4' ' ' PHE . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.442 ' HB3' ' SG ' ' A' ' 45' ' ' CYS . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.467 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.451 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.464 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 0.3 OUTLIER -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.563 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 29' ' ' GLU . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.523 HG22 ' CB ' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.516 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.464 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.495 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.44 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.433 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.495 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.508 HG12 ' N ' ' A' ' 85' ' ' ASP . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.508 ' N ' HG12 ' A' ' 84' ' ' VAL . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.406 HD21 HD12 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.463 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.526 HD23 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.465 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.7 m170 -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.516 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo . . . . . 0 C--O 1.215 -0.654 0 N-CA-C 109.935 -0.833 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.513 ' CD1' ' CG2' ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.514 ' CG1' HG12 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.617 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.479 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.538 ' OE1' ' N ' ' A' ' 13' ' ' SER . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.522 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.404 ' CG1' ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.513 ' CG2' ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 24' ' ' GLY . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.562 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.564 ' CG ' ' O ' ' A' ' 30' ' ' THR . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.599 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.466 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.474 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.482 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.494 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.599 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CZ ' ' CB ' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.481 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.562 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.481 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.43 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.484 ' N ' HG13 ' A' ' 66' ' ' VAL . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.498 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.523 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.493 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 79' ' ' THR . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.456 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.523 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.487 ' HB3' ' OD1' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.532 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 34' ' ' ALA . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.449 ' HB1' HD13 ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 100' ' ' LEU . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.449 HD13 ' HB1' ' A' ' 95' ' ' ALA . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.532 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.514 HG12 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.483 ' O ' HD21 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.483 HD21 ' O ' ' A' ' 106' ' ' ALA . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.479 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.498 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.445 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.634 -0.564 . . . . 0.0 110.634 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.587 ' CE2' HG22 ' A' ' 105' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.442 HG11 HG12 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.476 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.406 HD21 ' HB2' ' A' ' 8' ' ' PRO . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.455 ' HB3' ' O ' ' A' ' 13' ' ' SER . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.426 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.492 ' CG1' HD22 ' A' ' 102' ' ' LEU . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.529 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.402 ' O ' HG21 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.572 ' CE1' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.472 ' O ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.452 ' HB2' ' O ' ' A' ' 47' ' ' PRO . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.529 HG22 ' CB ' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.569 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.465 ' OG1' ' O ' ' A' ' 79' ' ' THR . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.465 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.401 ' N ' HG12 ' A' ' 81' ' ' VAL . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.433 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.473 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.463 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.572 HD22 ' CE1' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.461 ' O ' HD21 ' A' ' 100' ' ' LEU . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.492 HD22 ' CG1' ' A' ' 22' ' ' VAL . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 3.4 m80 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.587 HG22 ' CE2' ' A' ' 4' ' ' PHE . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.429 ' O ' HD22 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 106' ' ' ALA . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.569 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo . . . . . 0 C--O 1.214 -0.696 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.587 ' CD2' HG21 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.542 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.431 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.452 HD22 ' OE1' ' A' ' 16' ' ' GLN . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.467 ' O ' HG21 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.481 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.587 HG21 ' CD2' ' A' ' 4' ' ' PHE . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB1' HG23 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.41 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.549 HD11 ' CD1' ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.477 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.556 ' HB3' ' CG1' ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.407 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.402 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.443 ' O ' HG23 ' A' ' 51' ' ' THR . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 50' ' ' ALA . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.405 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.465 HG23 ' N ' ' A' ' 55' ' ' THR . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.473 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.473 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.467 HG21 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.566 ' CZ ' HG13 ' A' ' 84' ' ' VAL . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.475 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.479 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 71' ' ' TYR . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.424 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.444 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.549 ' CD1' HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.41 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 99' ' ' GLY . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.456 HD21 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.542 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.448 ' HG2' HD23 ' A' ' 102' ' ' LEU . 44.2 Cg_endo . . . . . 0 N--CA 1.48 0.687 0 N-CA-C 110.519 -0.608 . . . . 0.0 110.519 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.551 ' CE2' HG21 ' A' ' 105' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.533 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.449 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.446 HG13 ' HG2' ' A' ' 8' ' ' PRO . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.477 ' CG1' HD22 ' A' ' 102' ' ' LEU . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.428 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.428 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' O ' ' A' ' 53' ' ' PHE . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' HB3' ' A' ' 97' ' ' ASN . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.46 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.521 HD11 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.521 ' N ' HD11 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.419 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.454 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.403 ' HG3' ' CB ' ' A' ' 74' ' ' SER . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.46 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.419 ' OG1' HG21 ' A' ' 30' ' ' THR . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.461 HG22 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.551 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.44 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.459 ' O ' ' HG3' ' A' ' 68' ' ' ARG . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.461 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.529 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.483 ' HB ' ' OE2' ' A' ' 77' ' ' GLU . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.409 ' O ' ' C ' ' A' ' 77' ' ' GLU . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.483 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 81' ' ' VAL . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 80' ' ' PRO . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.486 ' CD1' HD13 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.618 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.418 ' HB3' HD13 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.583 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.458 ' HB3' ' OD1' ' A' ' 97' ' ' ASN . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.488 ' HB2' ' HA2' ' A' ' 96' ' ' GLY . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.618 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 1.3 m80 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.551 HG21 ' CE2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.532 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.449 ' HB3' HD12 ' A' ' 12' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.715 0 N-CA-C 110.448 -0.635 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.509 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' HG12 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.49 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.448 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.448 ' HB2' ' HB3' ' A' ' 13' ' ' SER . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.577 ' CG1' ' CD2' ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.526 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.466 ' O ' HG21 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.575 ' CE1' HD23 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.456 ' O ' ' C ' ' A' ' 40' ' ' GLY . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.524 ' CB ' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.471 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.469 ' O ' HG21 ' A' ' 51' ' ' THR . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.474 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.466 HG21 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.539 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.47 ' O ' ' HB1' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.581 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.466 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.524 ' HA3' ' CB ' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.437 ' C ' ' O ' ' A' ' 74' ' ' SER . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 82' ' ' GLY . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.451 ' N ' HG13 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.468 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.414 ' CG ' ' N ' ' A' ' 98' ' ' SER . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.462 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.575 HD23 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.577 ' CD2' ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 21.0 m-70 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.535 HG12 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.49 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.547 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo . . . . . 0 N--CA 1.479 0.662 0 N-CA-C 110.237 -0.716 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.539 ' HB2' ' CD1' ' A' ' 102' ' ' LEU . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.528 HG12 ' CG1' ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.65 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.65 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 107' ' ' LEU . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.53 ' CD1' HD23 ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.447 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.447 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.453 HG13 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.48 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.547 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.474 ' CB ' ' OH ' ' A' ' 31' ' ' TYR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG22 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.474 ' OH ' ' CB ' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.477 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CD1' ' A' ' 93' ' ' LEU . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.461 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.45 ' HB3' ' SG ' ' A' ' 86' ' ' CYS . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.505 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.421 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.461 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.456 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.523 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.446 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 30' ' ' THR . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.467 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.407 ' HA ' ' HB3' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.456 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.525 HG21 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.543 ' CB ' ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.525 ' CG2' HG21 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.519 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.478 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.425 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.542 ' CD1' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.542 ' CB ' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.45 ' C ' ' CD1' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.539 ' CD1' ' HB2' ' A' ' 4' ' ' PHE . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.528 ' CG1' HG12 ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.521 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.53 HD23 ' CD1' ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.491 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo . . . . . 0 C--O 1.215 -0.641 0 N-CA-C 110.081 -0.777 . . . . 0.0 110.081 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.423 ' CD1' HG21 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.506 HG12 HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.42 ' O ' ' OG ' ' A' ' 10' ' ' SER . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.486 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.492 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.421 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' A' ' 8' ' ' PRO . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 60' ' ' ALA . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.53 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.407 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG22 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.594 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.472 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.516 ' OE1' ' CG1' ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.458 ' O ' HG22 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 38' ' ' PRO . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.7 OUTLIER -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 46' ' ' ASN . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.549 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.444 HG22 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.53 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.516 ' CG1' ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.485 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.468 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.468 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.45 ' HA ' ' HB1' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.535 ' O ' ' CA ' ' A' ' 104' ' ' HIS . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.472 ' OD1' ' CB ' ' A' ' 100' ' ' LEU . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.594 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.455 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.419 HD11 HG12 ' A' ' 22' ' ' VAL . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 1.4 p-80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.506 HG11 HG12 ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.486 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo . . . . . 0 C--O 1.215 -0.668 0 N-CA-C 110.436 -0.64 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.523 ' CD2' HG23 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.618 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.618 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.495 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.492 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.474 HG11 ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.523 HG23 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.448 ' N ' HG11 ' A' ' 22' ' ' VAL . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.447 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.536 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.459 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.429 ' C ' ' CD1' ' A' ' 31' ' ' TYR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.582 ' CD2' ' HB3' ' A' ' 97' ' ' ASN . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.498 ' C ' ' CD1' ' A' ' 33' ' ' ILE . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.453 ' HB1' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.526 ' HB2' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.495 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.462 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.412 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.453 HG21 ' HB2' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.567 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.526 ' N ' ' HB2' ' A' ' 44' ' ' ALA . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.45 ' OG1' ' O ' ' A' ' 79' ' ' THR . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.468 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.508 ' CG2' ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.508 ' HD2' ' CG2' ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.45 ' HB ' ' HB1' ' A' ' 44' ' ' ALA . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.467 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.446 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.46 HD12 HD13 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.582 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 99' ' ' GLY . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.443 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.1 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.54 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.49 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.495 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.567 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.5 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.478 ' CD2' HG21 ' A' ' 105' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.425 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.429 ' O ' HG21 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.452 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.417 ' CG1' ' HE1' ' A' ' 4' ' ' PHE . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.419 ' CG2' ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.5 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.478 ' HB2' HG23 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 54' ' ' THR . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.597 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.465 HD11 ' CE2' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.435 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.403 ' O ' HG11 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.447 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.428 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.435 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.428 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.404 HG21 HG23 ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.428 HG21 ' O ' ' A' ' 29' ' ' GLU . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 25' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.539 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.465 ' CE2' HD11 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.429 HG21 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.528 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.607 ' CE1' ' CG1' ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.528 HG22 ' CG2' ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.447 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.528 ' CG2' HG22 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.607 ' CG1' ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.499 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.499 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.487 ' O ' ' CB ' ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.597 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.444 HD11 ' OH ' ' A' ' 31' ' ' TYR . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.487 ' CB ' ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.538 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.528 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo . . . . . 0 C--O 1.214 -0.7 0 N-CA-C 110.376 -0.663 . . . . 0.0 110.376 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.469 HG13 HG13 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.666 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.666 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.482 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.531 ' OE1' ' N ' ' A' ' 13' ' ' SER . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.461 HG11 ' HG2' ' A' ' 8' ' ' PRO . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.44 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.507 HG21 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.526 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.453 ' HA ' ' OE1' ' A' ' 29' ' ' GLU . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.438 HG21 ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.591 HD13 ' CZ ' ' A' ' 4' ' ' PHE . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.417 ' O ' ' HB1' ' A' ' 44' ' ' ALA . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.453 ' O ' HG12 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.508 ' CG1' HG21 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.465 ' CG ' HG21 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.46 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.603 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.437 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.438 ' O ' HG21 ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.531 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.603 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.46 ' HA3' ' HB3' ' A' ' 44' ' ' ALA . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.558 ' CG2' ' CG2' ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.558 ' CG2' ' CG2' ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.508 HG21 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 109' ' ' PHE . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.44 ' HB2' ' HE3' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.499 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.424 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.454 ' O ' ' HB2' ' A' ' 101' ' ' ASP . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.454 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.522 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.533 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.616 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 2.4 m-70 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.469 HG13 HG13 ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.499 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.482 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.461 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 N-CA-C 110.121 -0.761 . . . . 0.0 110.121 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.584 ' CD2' HG23 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.619 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.483 ' HA ' ' CB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.497 ' OE1' ' N ' ' A' ' 13' ' ' SER . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.451 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.584 HG23 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.526 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.411 ' HG3' ' C ' ' A' ' 28' ' ' GLY . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.476 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.439 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 42' ' ' GLN . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.518 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.556 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.419 ' O ' HG21 ' A' ' 51' ' ' THR . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.457 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 55' ' ' THR . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.462 ' N ' HG23 ' A' ' 54' ' ' THR . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.461 ' HB2' ' CD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.562 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.458 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.469 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.556 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 79' ' ' THR . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.54 ' OG1' ' CG2' ' A' ' 79' ' ' THR . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.54 ' CG2' ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.482 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.464 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.462 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.48 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.458 HD23 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.469 HG11 HG12 ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.462 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.483 ' CB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.458 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB2' HD22 ' A' ' 102' ' ' LEU . 43.7 Cg_endo . . . . . 0 C--O 1.216 -0.618 0 N-CA-C 109.933 -0.833 . . . . 0.0 109.933 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.503 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.401 ' HA ' HG23 ' A' ' 105' ' ' VAL . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.568 HG12 ' CG1' ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.61 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.61 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.535 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.456 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.456 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.554 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.503 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.515 ' CG1' HD21 ' A' ' 102' ' ' LEU . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.53 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.53 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.562 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.427 ' CD ' ' O ' ' A' ' 28' ' ' GLY . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.583 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.466 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.524 ' NE2' HG13 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HB1' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.488 ' O ' HG23 ' A' ' 39' ' ' VAL . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 38' ' ' PRO . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.437 ' C ' ' OD1' ' A' ' 43' ' ' ASP . 1.1 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.529 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.42 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.438 ' O ' ' O ' ' A' ' 55' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.443 ' CG2' ' HB2' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.418 ' HB2' ' O ' ' A' ' 60' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.562 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.418 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.446 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.524 HG13 ' NE2' ' A' ' 35' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.463 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.529 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.435 ' C ' ' O ' ' A' ' 74' ' ' SER . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.457 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.49 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.49 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 71' ' ' TYR . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 84' ' ' VAL . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.506 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 12.5 t-20 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.434 ' HG ' ' OH ' ' A' ' 31' ' ' TYR . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.515 HD21 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.471 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.568 ' CG1' HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.506 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.479 0.664 0 N-CA-C 109.959 -0.823 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.592 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.521 ' CG1' HG12 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 107' ' ' LEU . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.485 HD13 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.412 ' O ' HG21 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.455 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.558 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.486 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.467 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HB2' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.476 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.431 HG22 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 29' ' ' GLU . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.558 HG21 ' CB ' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.401 HG13 ' N ' ' A' ' 67' ' ' VAL . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.412 HG21 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.516 ' CE2' ' CG1' ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.457 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.516 ' CG1' ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.626 ' ND2' ' CE1' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.467 HD13 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.498 ' HB2' ' O ' ' A' ' 30' ' ' THR . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.559 HD22 ' CE1' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.515 ' N ' HD21 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.476 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.626 ' CE1' ' ND2' ' A' ' 92' ' ' ASN . 4.7 t60 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.523 HG11 ' N ' ' A' ' 106' ' ' ALA . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.523 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' HD13 ' A' ' 12' ' ' LEU . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.481 0.762 0 N-CA-C 110.632 -0.565 . . . . 0.0 110.632 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.516 ' O ' ' CG1' ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.554 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.621 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.462 HD13 ' HB3' ' A' ' 107' ' ' LEU . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.46 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.46 ' OE1' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.428 ' O ' ' OG ' ' A' ' 17' ' ' SER . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.556 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.468 ' CG1' ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.52 HG11 ' CD2' ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.552 ' CB ' HG23 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.445 ' O ' ' CG2' ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.455 HG21 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.576 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.459 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.457 ' CD1' HD22 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.437 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 26.3 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.518 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB3' ' CA ' ' A' ' 73' ' ' GLY . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.482 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.459 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.576 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.455 ' OG1' HG21 ' A' ' 30' ' ' THR . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.552 HG23 ' CB ' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.547 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CA ' ' HA ' ' A' ' 55' ' ' THR . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 67' ' ' VAL . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.513 ' N ' HG12 ' A' ' 66' ' ' VAL . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.482 ' HG3' HG21 ' A' ' 49' ' ' THR . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.522 ' CA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 75' ' ' THR . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.471 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.471 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.49 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.49 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.426 HG22 ' HB2' ' A' ' 44' ' ' ALA . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.518 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.475 ' HB2' HD11 ' A' ' 107' ' ' LEU . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.526 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.481 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.52 ' CD2' HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . 0.526 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 0.5 OUTLIER -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.554 HG11 ' CG1' ' A' ' 6' ' ' VAL . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.497 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.475 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.459 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.0 Cg_endo . . . . . 0 N--CA 1.48 0.734 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.523 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.514 HG21 ' N ' ' A' ' 7' ' ' SER . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.652 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.652 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.478 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.421 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.532 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.523 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.463 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.52 ' CG1' HD22 ' A' ' 102' ' ' LEU . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.458 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.559 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.507 ' OH ' ' CD1' ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.505 ' N ' HD12 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.441 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' N ' ' A' ' 41' ' ' GLY . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.496 ' NE2' HG23 ' A' ' 81' ' ' VAL . 19.2 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.451 ' HB2' ' HA3' ' A' ' 73' ' ' GLY . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.411 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.411 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.473 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.559 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.473 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.457 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.451 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.427 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 79' ' ' THR . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.496 HG23 ' NE2' ' A' ' 42' ' ' GLN . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.476 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' HB3' ' OD2' ' A' ' 85' ' ' ASP . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.464 HD11 ' O ' ' A' ' 34' ' ' ALA . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB2' HD12 ' A' ' 102' ' ' LEU . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA2' HD13 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.507 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.52 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.459 HG12 HG11 ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.478 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.423 ' N ' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.3 Cg_endo . . . . . 0 C--O 1.215 -0.644 0 N-CA-C 110.077 -0.778 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.523 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.471 HD13 ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.449 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.449 ' HB3' ' O ' ' A' ' 13' ' ' SER . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.439 HG13 ' HG2' ' A' ' 8' ' ' PRO . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.455 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.41 ' CG2' ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.538 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.538 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.555 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG22 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.466 HG22 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 33' ' ' ILE . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.41 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.448 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 42' ' ' GLN . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . 0.45 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . 0.443 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 45' ' ' CYS . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.466 ' OG1' HG22 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.466 ' CG2' ' HB2' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.555 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.451 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.439 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.563 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.482 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.478 ' O ' ' OG1' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.478 ' OG1' ' O ' ' A' ' 74' ' ' SER . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.47 ' CG2' ' CG2' ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.517 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.456 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.448 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.456 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.466 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.467 ' C ' ' CD1' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.481 HG13 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.471 ' HB3' HD13 ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.563 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.216 -0.596 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . 0.494 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.5 HG11 HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.701 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.701 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.43 HD11 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.474 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' SER . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 21' ' ' SER . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.516 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.528 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.528 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.556 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.47 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.47 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.513 ' O ' ' CB ' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.503 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.432 HG12 HD13 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.475 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.532 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.481 ' HB2' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' THR . . . . . 0.457 ' CG2' ' HD3' ' A' ' 68' ' ' ARG . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.539 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.518 HG21 ' N ' ' A' ' 55' ' ' THR . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.518 ' N ' HG21 ' A' ' 54' ' ' THR . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.556 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.457 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.449 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.521 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.481 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.531 ' O ' ' O ' ' A' ' 74' ' ' SER . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.464 ' O ' HG21 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.5 HG13 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.431 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 34' ' ' ALA . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.513 ' CB ' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.409 HD12 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.516 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.5 HG11 HG11 ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.43 ' HB3' HD11 ' A' ' 12' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 C--O 1.214 -0.703 0 N-CA-C 110.42 -0.646 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.448 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.515 ' OE1' ' N ' ' A' ' 13' ' ' SER . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.513 HG13 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG13 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.523 HG13 ' CD2' ' A' ' 102' ' ' LEU . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' CB ' HG23 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.429 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.465 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.525 HD11 ' CD1' ' A' ' 65' ' ' PHE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' GLN . . . . . 0.564 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 7.5 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.456 ' O ' ' C ' ' A' ' 40' ' ' GLY . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.444 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.429 HG21 ' CG2' ' A' ' 33' ' ' ILE . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.438 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.525 ' CD1' HD11 ' A' ' 33' ' ' ILE . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.434 ' N ' HG13 ' A' ' 66' ' ' VAL . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . 0.563 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.564 ' CE1' ' OE1' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA3' ' HB3' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 74' ' ' SER . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.41 ' HB3' ' CD1' ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.551 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.523 ' CD2' HG13 ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 120.745 0.307 . . . . 0.0 110.289 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -73.32 -167.32 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.078 1.568 . . . . 0.0 110.39 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.462 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.491 HG12 HG12 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.608 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.608 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.533 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.497 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' SER . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.565 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 3' ' ' ALA . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.471 ' HB2' HG22 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.553 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.568 ' CE1' HD22 ' A' ' 100' ' ' LEU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.461 HD11 ' O ' ' A' ' 94' ' ' GLY . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.483 ' HA ' HD13 ' A' ' 93' ' ' LEU . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.472 ' HB1' ' OH ' ' A' ' 71' ' ' TYR . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.483 ' O ' HG13 ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.542 ' HB3' ' CA ' ' A' ' 73' ' ' GLY . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.488 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.519 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.488 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.453 HG21 ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.529 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.589 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.458 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.586 ' CZ ' HG13 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.542 ' CA ' ' HB3' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.495 ' N ' ' HB3' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 79' ' ' THR . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.599 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.48 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.415 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.586 HG13 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.464 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.441 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.455 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.522 ' O ' ' CB ' ' A' ' 104' ' ' HIS . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.444 ' HB1' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.458 ' O ' CL21 ' A' ' 111' ' ' ROM . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.568 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.462 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.491 HG12 HG12 ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.455 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.533 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.474 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.589 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.599 ' C7X' ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.837 0.351 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.41 179.7 5.27 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.042 1.548 . . . . 0.0 110.127 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.464 HG12 HG12 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.431 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.402 ' C ' ' O ' ' A' ' 15' ' ' GLY . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.484 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.537 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.45 ' CG2' ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.538 ' CD1' ' HB1' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.473 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.46 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.475 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.406 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.475 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.483 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.453 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.447 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.462 ' HA ' ' HB3' ' A' ' 34' ' ' ALA . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.5 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.423 HG21 ' N ' ' A' ' 55' ' ' THR . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.537 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.506 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.451 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.518 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.459 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.489 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.489 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.49 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.478 ' O ' ' HB2' ' A' ' 109' ' ' PHE . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.543 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB1' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.437 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.473 HD13 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.538 ' HB1' ' CD1' ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.485 ' C ' ' O ' ' A' ' 97' ' ' ASN . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.422 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.468 HD13 ' CD2' ' A' ' 31' ' ' TYR . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 1.6 p80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.464 HG12 HG12 ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.454 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.46 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.633 ' C23' ' C7 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.818 0.342 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.497 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 41.9 Cg_endo -69.74 -168.28 0.26 Allowed 'Trans proline' 0 C--N 1.302 -1.891 0 O-C-N 124.07 1.563 . . . . 0.0 110.381 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.524 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.524 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.613 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.426 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.508 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.472 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.469 ' HB3' ' HD3' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.521 ' O ' ' CG2' ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.418 HG11 ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 6' ' ' VAL . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.524 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.508 ' N ' HG13 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.56 ' CG1' ' CD2' ' A' ' 102' ' ' LEU . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.474 ' HB2' HG23 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.43 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.43 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.461 HD12 HD22 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.438 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.482 HG11 ' O ' ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.541 ' CB ' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.505 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.519 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.474 HG23 ' HB2' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.442 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.521 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.559 ' HB3' ' CE1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.448 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' CB ' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.446 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.416 ' C ' ' O ' ' A' ' 74' ' ' SER . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.538 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.423 ' CD ' ' H11' ' A' ' 111' ' ' ROM . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.54 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.54 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.522 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 91' ' ' CYS . 30.5 m120 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.476 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.56 ' CD2' ' CG1' ' A' ' 22' ' ' VAL . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.467 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.524 HG11 ' CG1' ' A' ' 6' ' ' VAL . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.426 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.559 ' CE1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.631 ' C4B' ' C6B' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 120.722 0.296 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo -81.89 -177.74 3.73 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.924 1.486 . . . . 0.0 110.257 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.517 ' CD1' HG21 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.475 HG11 HG12 ' A' ' 105' ' ' VAL . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.643 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.643 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.413 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.458 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.507 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.461 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.547 HG22 ' CZ ' ' A' ' 53' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.602 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.459 ' OE2' ' O ' ' A' ' 28' ' ' GLY . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.602 ' CZ ' ' HB3' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' O ' HG22 ' A' ' 33' ' ' ILE . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.4 ' C ' HD13 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.468 ' O ' HG22 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.468 HG22 ' O ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.417 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.547 ' CZ ' HG22 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.53 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.533 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.428 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.524 ' O ' ' O ' ' A' ' 74' ' ' SER . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.562 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.407 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.453 ' OD2' HG22 ' A' ' 88' ' ' THR . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.453 HG22 ' OD2' ' A' ' 85' ' ' ASP . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.4 HD13 ' C ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA2' HD11 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.464 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.472 HD11 ' O ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.472 ' O ' HD11 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.485 HD11 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.52 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.559 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 3.6 m-70 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.475 HG12 HG11 ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.423 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.464 ' O ' ' OG1' ' A' ' 108' ' ' THR . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.403 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.562 ' C7X' ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 120.778 0.323 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.53 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo -73.49 -159.06 0.08 OUTLIER 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.941 1.495 . . . . 0.0 110.323 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.503 HG11 ' CG1' ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.628 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.628 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.496 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 12' ' ' LEU . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.459 ' O ' ' CG2' ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.493 HG13 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.493 ' N ' HG13 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.524 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.406 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.579 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' HB3' " O'2" ' A' ' 111' ' ' ROM . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.476 HD11 ' HB2' ' A' ' 95' ' ' ALA . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.521 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.529 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.408 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.515 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 29.4 t30 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 49' ' ' THR . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 29' ' ' GLU . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.524 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.518 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.458 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.472 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.459 ' CG2' ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.415 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 33' ' ' ILE . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.447 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.53 ' CD2' ' HG3' ' A' ' 2' ' ' PRO . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.571 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.415 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.503 ' CG1' HG11 ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.433 ' O ' HD21 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.571 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.721 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.457 ' HG2' ' O ' ' A' ' 101' ' ' ASP . 44.3 Cg_endo -73.61 -158.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.811 0 O-C-N 123.989 1.521 . . . . 0.0 110.218 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 22' ' ' VAL . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.573 ' CD2' ' HB2' ' A' ' 95' ' ' ALA . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.522 HG13 ' CG1' ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.447 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.447 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.453 HG12 ' HG2' ' A' ' 8' ' ' PRO . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.414 ' CG1' ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.476 HG12 ' O ' ' A' ' 3' ' ' ALA . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HB2' HG22 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HA ' ' OE1' ' A' ' 29' ' ' GLU . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.551 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.467 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.506 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.506 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.402 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.467 ' O ' HG21 ' A' ' 30' ' ' THR . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.503 HG23 ' N ' ' A' ' 55' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.503 ' N ' HG23 ' A' ' 54' ' ' THR . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.548 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.411 ' HB2' HG21 ' A' ' 55' ' ' THR . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.513 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.474 ' O ' H7A2 ' A' ' 111' ' ' ROM . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.542 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.418 ' O ' ' OG1' ' A' ' 75' ' ' THR . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.429 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.429 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.456 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA3' ' CD2' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.573 ' HB2' ' CD2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.459 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.449 ' HB2' ' O9 ' ' A' ' 111' ' ' ROM . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.457 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.464 HD22 ' CG1' ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.572 ' CD2' ' HA3' ' A' ' 94' ' ' GLY . 64.0 m80 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.522 ' CG1' HG13 ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.554 ' C6D' H4B3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -73.87 -166.49 0.32 Allowed 'Trans proline' 0 C--N 1.302 -1.88 0 O-C-N 124.031 1.542 . . . . 0.0 110.261 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.466 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.514 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.597 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.597 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.527 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' SER . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.461 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.466 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.524 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 28' ' ' GLY . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.421 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.582 ' CE1' HD23 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.492 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.53 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.53 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.454 ' O ' HG21 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.53 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.428 ' ND2' ' CD2' ' A' ' 71' ' ' TYR . 5.1 t-20 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.421 ' OG1' HG23 ' A' ' 30' ' ' THR . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.524 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.55 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.494 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.593 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.411 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.428 ' CD2' ' ND2' ' A' ' 46' ' ' ASN . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 45' ' ' CYS . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 79' ' ' THR . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.514 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.472 ' O ' ' OG1' ' A' ' 75' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 85' ' ' ASP . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.454 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.441 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.446 HD12 HD12 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.466 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.582 HD23 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.408 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.514 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.527 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.593 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.581 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.836 0.351 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.37 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.961 1.506 . . . . 0.0 110.224 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.508 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.455 HG11 HG12 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' SER . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.56 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.516 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' CG1' HD22 ' A' ' 102' ' ' LEU . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.522 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.551 ' CB ' ' HA ' ' A' ' 57' ' ' ALA . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.499 ' CG2' ' CG2' ' A' ' 51' ' ' THR . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.429 ' NE2' HD11 ' A' ' 107' ' ' LEU . 0.6 OUTLIER -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 84' ' ' VAL . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.466 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.466 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.578 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.539 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.585 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.522 HG22 ' CB ' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.534 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.551 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.465 HG21 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.578 ' CE1' ' HB2' ' A' ' 46' ' ' ASN . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.41 ' C ' ' OG ' ' A' ' 74' ' ' SER . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.509 HG21 ' CG2' ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.562 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.487 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.487 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.509 ' CG2' HG21 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.529 ' CG1' ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.508 ' OD1' ' CB ' ' A' ' 70' ' ' SER . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.492 ' OD1' ' O ' ' A' ' 92' ' ' ASN . 12.3 p30 -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.468 HD13 HG12 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.463 ' O ' ' O ' ' A' ' 101' ' ' ASP . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.524 HD22 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.473 ' O ' ' CD2' ' A' ' 104' ' ' HIS . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.473 ' CD2' ' O ' ' A' ' 103' ' ' GLY . 46.3 m170 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 ' N ' ' A' ' 106' ' ' ALA . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.512 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.452 HD12 ' HB2' ' A' ' 93' ' ' LEU . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.587 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.724 0.297 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.32 -159.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.982 1.517 . . . . 0.0 110.418 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.503 ' CZ ' HG13 ' A' ' 20' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.574 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.482 ' HA ' ' OE1' ' A' ' 16' ' ' GLN . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.482 ' OE1' ' HA ' ' A' ' 12' ' ' LEU . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.528 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.503 HG13 ' CZ ' ' A' ' 4' ' ' PHE . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.473 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.473 ' CG1' HD23 ' A' ' 102' ' ' LEU . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.444 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.488 ' HB3' HG23 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.475 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.547 HD12 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.547 ' N ' HD12 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.55 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.472 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.535 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.444 ' CB ' ' CG1' ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.477 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.486 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.437 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.455 ' C ' HG21 ' A' ' 51' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.472 ' O ' HG23 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.488 HG23 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.547 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.497 ' HA ' ' HB3' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.464 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.41 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.486 ' O ' ' HG3' ' A' ' 68' ' ' ARG . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.486 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.531 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.474 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.452 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.525 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.452 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.473 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.477 HD13 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.481 ' HB3' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.461 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.493 ' HB2' ' O9 ' ' A' ' 111' ' ' ROM . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.446 ' OD1' CL21 ' A' ' 111' ' ' ROM . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.473 HD23 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.574 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.48 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.434 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.531 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.545 ' C4D' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 120.841 0.353 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.46 -153.26 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.163 1.612 . . . . 0.0 109.927 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.548 ' CG1' HG12 ' A' ' 105' ' ' VAL . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.656 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.485 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.458 ' O ' HG23 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.41 HG12 ' HG2' ' A' ' 8' ' ' PRO . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.461 ' CG1' HD23 ' A' ' 102' ' ' LEU . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.487 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.513 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.509 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE1' ' HB3' ' A' ' 29' ' ' GLU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.443 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.436 ' HB3' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.539 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.478 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.488 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.483 HG23 ' HD2' ' A' ' 68' ' ' ARG . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.525 HG22 ' N ' ' A' ' 55' ' ' THR . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.525 ' N ' HG22 ' A' ' 54' ' ' THR . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.513 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.442 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HD2' HG23 ' A' ' 49' ' ' THR . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.579 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.539 ' O ' ' C7X' ' A' ' 111' ' ' ROM . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.458 ' C ' H7A2 ' A' ' 111' ' ' ROM . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.55 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.519 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.519 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.471 HG21 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.444 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.508 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.436 ' SG ' ' HB3' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.518 ' HA ' ' HA ' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.499 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.488 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.465 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.461 HD23 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.499 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.552 HG11 ' N ' ' A' ' 106' ' ' ALA . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.552 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.579 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.628 ' C4B' ' C6B' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 120.799 0.333 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.8 -167.21 0.29 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 O-C-N 124.087 1.572 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.598 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.484 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.646 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.646 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 9' ' ' ALA . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.425 HD21 ' OE1' ' A' ' 16' ' ' GLN . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.454 ' O ' HG21 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.478 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.41 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.41 ' HG3' ' C ' ' A' ' 28' ' ' GLY . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.558 ' CG ' ' O ' ' A' ' 30' ' ' THR . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.525 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.443 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 71' ' ' TYR . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.502 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.502 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.533 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.454 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.478 HG22 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.542 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.451 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.463 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.454 HG21 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.454 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.536 ' HE3' ' CB ' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.465 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.497 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.455 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.414 ' C ' HG22 ' A' ' 81' ' ' VAL . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.469 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.449 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.536 ' CB ' ' HE3' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.489 ' O ' ' CA ' ' A' ' 104' ' ' HIS . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.456 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.516 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.489 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.407 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.455 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.567 ' C22' ' C6 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 120.693 0.282 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.49 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo -73.96 154.41 47.88 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.013 1.533 . . . . 0.0 110.271 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.584 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.616 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.616 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.432 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.491 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.467 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.467 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.537 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.465 ' CG1' ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.465 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.526 ' CG1' HD23 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.49 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.523 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.457 ' OE1' HD11 ' A' ' 100' ' ' LEU . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.459 HG21 ' O ' ' A' ' 53' ' ' PHE . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.563 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.584 HD11 ' CZ ' ' A' ' 4' ' ' PHE . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.442 ' HB3' ' SG ' ' A' ' 45' ' ' CYS . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.467 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.484 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.451 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.464 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.462 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 0.3 OUTLIER -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB2' " C'2" ' A' ' 111' ' ' ROM . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.563 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.451 HG23 ' O ' ' A' ' 29' ' ' GLU . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.523 HG22 ' CB ' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.516 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.464 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.495 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.522 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.433 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.495 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.508 HG12 ' N ' ' A' ' 85' ' ' ASP . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.508 ' N ' HG12 ' A' ' 84' ' ' VAL . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.406 HD21 HD12 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.433 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.463 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.526 HD23 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.465 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.7 m170 -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.516 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.562 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 120.72 0.295 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.28 -163.2 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.912 1.48 . . . . 0.0 109.935 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.513 ' CD1' ' CG2' ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.514 ' CG1' HG12 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.617 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.479 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.538 ' OE1' ' N ' ' A' ' 13' ' ' SER . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.522 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.404 ' CG1' ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.513 ' CG2' ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.468 ' O ' ' O ' ' A' ' 24' ' ' GLY . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.562 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.564 ' CG ' ' O ' ' A' ' 30' ' ' THR . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.599 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.466 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.474 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.482 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.494 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.487 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.599 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CZ ' ' CB ' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.481 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.562 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.481 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.43 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.484 ' N ' HG13 ' A' ' 66' ' ' VAL . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.498 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.523 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.493 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.47 ' O ' H7A3 ' A' ' 111' ' ' ROM . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.492 ' HB3' ' O13' ' A' ' 111' ' ' ROM . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.456 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.523 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.487 ' HB3' ' OD1' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.532 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.466 HD12 ' O ' ' A' ' 34' ' ' ALA . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.449 ' HB1' HD13 ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 100' ' ' LEU . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.449 HD13 ' HB1' ' A' ' 95' ' ' ALA . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.532 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.514 HG12 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.483 ' O ' HD21 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.483 HD21 ' O ' ' A' ' 106' ' ' ALA . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.479 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.498 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.52 ' C6 ' ' C22' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 120.667 0.27 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.445 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo -72.2 -159.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.919 1.484 . . . . 0.0 110.634 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.587 ' CE2' HG22 ' A' ' 105' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.442 HG11 HG12 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.476 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.406 HD21 ' HB2' ' A' ' 8' ' ' PRO . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.455 ' HB3' ' O ' ' A' ' 13' ' ' SER . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.426 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.492 ' CG1' HD22 ' A' ' 102' ' ' LEU . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.529 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.402 ' O ' HG21 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.572 ' CE1' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.472 ' O ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.518 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.452 ' HB2' ' O ' ' A' ' 47' ' ' PRO . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.529 HG22 ' CB ' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.532 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.569 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.476 ' O ' H7A2 ' A' ' 111' ' ' ROM . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.465 ' OG1' ' O ' ' A' ' 79' ' ' THR . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.465 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.401 ' N ' HG12 ' A' ' 81' ' ' VAL . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.433 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.473 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.463 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.432 ' C ' ' H8 ' ' A' ' 111' ' ' ROM . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.572 HD22 ' CE1' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.461 ' O ' HD21 ' A' ' 100' ' ' LEU . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.492 HD22 ' CG1' ' A' ' 22' ' ' VAL . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 3.4 m80 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.587 HG22 ' CE2' ' A' ' 4' ' ' PHE . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.429 ' O ' HD22 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.429 HD22 ' O ' ' A' ' 106' ' ' ALA . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.569 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.627 ' C6B' ' C4D' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 120.772 0.32 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.487 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo -73.37 -159.27 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.017 1.535 . . . . 0.0 110.262 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.587 ' CD2' HG21 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.542 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.431 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.431 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.452 HD22 ' OE1' ' A' ' 16' ' ' GLN . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.467 ' O ' HG21 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.481 ' CG1' ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.481 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.587 HG21 ' CD2' ' A' ' 4' ' ' PHE . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.46 ' HB1' HG23 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.41 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.549 HD11 ' CD1' ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.477 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.556 ' HB3' ' CG1' ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.464 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.407 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.49 ' HA ' " C'6" ' A' ' 111' ' ' ROM . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.443 ' O ' HG23 ' A' ' 51' ' ' THR . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.443 HG23 ' O ' ' A' ' 50' ' ' ALA . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.405 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.465 HG23 ' N ' ' A' ' 55' ' ' THR . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.473 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.473 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.467 HG21 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.566 ' CZ ' HG13 ' A' ' 84' ' ' VAL . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.475 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.479 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.566 HG13 ' CZ ' ' A' ' 71' ' ' TYR . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.424 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.444 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.549 ' CD1' HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.457 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 99' ' ' GLY . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.456 HD21 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.542 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.589 ' C23' ' C7 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 120.814 0.34 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.448 ' HG2' HD23 ' A' ' 102' ' ' LEU . 44.2 Cg_endo -73.43 -173.48 1.33 Allowed 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.126 1.593 . . . . 0.0 110.519 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.551 ' CE2' HG21 ' A' ' 105' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.533 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.449 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.446 HG13 ' HG2' ' A' ' 8' ' ' PRO . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.477 ' CG1' HD22 ' A' ' 102' ' ' LEU . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.428 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.428 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' O ' ' A' ' 53' ' ' PHE . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' HB3' ' A' ' 97' ' ' ASN . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.46 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.521 HD11 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.521 ' N ' HD11 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.419 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.454 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.454 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.458 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.46 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.419 ' OG1' HG21 ' A' ' 30' ' ' THR . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.461 HG22 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.551 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.44 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.459 ' O ' ' HG3' ' A' ' 68' ' ' ARG . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.461 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.529 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.493 ' O ' H7A3 ' A' ' 111' ' ' ROM . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.483 ' HB ' ' OE2' ' A' ' 77' ' ' GLU . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.485 ' HB3' ' O13' ' A' ' 111' ' ' ROM . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.483 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 81' ' ' VAL . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.407 HG21 ' O ' ' A' ' 80' ' ' PRO . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.486 ' CD1' HD13 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.618 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.418 ' HB3' HD13 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.583 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.466 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.458 ' HB3' ' OD1' ' A' ' 97' ' ' ASN . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.488 ' HB2' ' HA2' ' A' ' 96' ' ' GLY . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.618 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 1.3 m80 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.551 HG21 ' CE2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.532 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.449 ' HB3' HD12 ' A' ' 12' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.442 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.591 ' C4B' ' C6D' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 120.799 0.333 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.67 154.5 54.53 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.985 1.518 . . . . 0.0 110.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.509 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' HG12 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.49 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.448 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.448 ' HB2' ' HB3' ' A' ' 13' ' ' SER . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.448 ' CG1' ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.577 ' CG1' ' CD2' ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.526 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.466 ' O ' HG21 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.464 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.575 ' CE1' HD23 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.456 ' O ' ' C ' ' A' ' 40' ' ' GLY . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.524 ' CB ' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.494 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.471 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.469 ' O ' HG21 ' A' ' 51' ' ' THR . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.474 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.466 HG21 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.539 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.445 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.47 ' O ' ' HB1' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.581 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.466 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.45 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.524 ' HA3' ' CB ' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.558 ' O ' H7A1 ' A' ' 111' ' ' ROM . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.548 ' HA ' H7A1 ' A' ' 111' ' ' ROM . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 82' ' ' GLY . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.451 ' N ' HG13 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.521 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.468 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.478 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.414 ' CG ' ' N ' ' A' ' 98' ' ' SER . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.462 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.575 HD23 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.577 ' CD2' ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 21.0 m-70 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.535 HG12 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.49 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.615 ' C6 ' ' C23' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.547 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo -73.54 -158.16 0.07 OUTLIER 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.994 1.523 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.539 ' HB2' ' CD1' ' A' ' 102' ' ' LEU . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.528 HG12 ' CG1' ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.65 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.65 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 107' ' ' LEU . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.53 ' CD1' HD23 ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.447 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.447 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.453 HG13 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.48 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.547 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.474 ' CB ' ' OH ' ' A' ' 31' ' ' TYR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG22 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.474 ' OH ' ' CB ' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.538 ' CE1' " O2'" ' A' ' 111' ' ' ROM . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CD1' ' A' ' 93' ' ' LEU . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.535 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.461 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.45 ' HB3' ' SG ' ' A' ' 86' ' ' CYS . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.505 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.51 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.461 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.456 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.523 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.446 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 30' ' ' THR . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.467 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.553 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.407 ' HA ' ' HB3' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.491 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.519 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.456 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.525 HG21 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.456 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.543 ' CB ' ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.543 ' HD2' ' CB ' ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.525 ' CG2' HG21 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.519 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.478 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.425 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.542 ' CD1' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.542 ' CB ' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.407 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.45 ' C ' ' CD1' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.539 ' CD1' ' HB2' ' A' ' 4' ' ' PHE . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.528 ' CG1' HG12 ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.521 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.53 HD23 ' CD1' ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.491 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.538 " O2'" ' CE1' ' A' ' 32' ' ' TYR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.88 -175.21 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.779 1.41 . . . . 0.0 110.081 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.423 ' CD1' HG21 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.506 HG12 HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.42 ' O ' ' OG ' ' A' ' 10' ' ' SER . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.486 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.492 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.421 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.459 HG11 ' HG2' ' A' ' 8' ' ' PRO . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 60' ' ' ALA . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.53 ' HB1' ' CG2' ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.407 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG22 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.594 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.472 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.516 ' OE1' ' CG1' ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.458 ' O ' HG22 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 38' ' ' PRO . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.515 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.7 OUTLIER -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.433 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.549 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.444 HG22 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.53 ' CG2' ' HB1' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.544 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.516 ' CG1' ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.454 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.485 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.468 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.45 ' HA ' ' HB1' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.535 ' O ' ' CA ' ' A' ' 104' ' ' HIS . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.472 ' OD1' ' CB ' ' A' ' 100' ' ' LEU . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.473 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.594 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.455 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.419 HD11 HG12 ' A' ' 22' ' ' VAL . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 1.4 p-80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.506 HG11 HG12 ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.486 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.411 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.552 " C'7" ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo -74.03 -166.81 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.031 1.542 . . . . 0.0 110.436 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.523 ' CD2' HG23 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.54 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.618 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.618 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.495 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.492 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.474 HG11 ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.426 ' N ' HG13 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.523 HG23 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.448 ' N ' HG11 ' A' ' 22' ' ' VAL . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.447 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.536 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.433 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.459 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.429 ' C ' ' CD1' ' A' ' 31' ' ' TYR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.582 ' CD2' ' HB3' ' A' ' 97' ' ' ASN . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.498 ' C ' ' CD1' ' A' ' 33' ' ' ILE . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.453 ' HB1' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.526 ' HB2' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.495 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.439 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.462 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.412 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.453 HG21 ' HB2' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.536 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.567 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.526 ' N ' ' HB2' ' A' ' 44' ' ' ALA . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.45 ' OG1' ' O ' ' A' ' 79' ' ' THR . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.468 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.508 ' CG2' ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.508 ' HD2' ' CG2' ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.45 ' HB ' ' HB1' ' A' ' 44' ' ' ALA . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.467 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.467 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.446 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.46 HD12 HD13 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.582 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.426 ' C ' ' O ' ' A' ' 99' ' ' GLY . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.443 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.1 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.54 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.49 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.495 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.567 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.555 ' O15' ' C5 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 120.816 0.341 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.5 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo -73.11 -162.15 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 124.023 1.538 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.478 ' CD2' HG21 ' A' ' 105' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.425 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.429 ' O ' HG21 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.452 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.417 ' CG1' ' HE1' ' A' ' 4' ' ' PHE . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.419 ' CG2' ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.5 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.478 ' HB2' HG23 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.428 ' O ' HG21 ' A' ' 54' ' ' THR . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.597 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.465 HD11 ' CE2' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.435 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.403 ' O ' HG11 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.447 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.428 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.491 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.428 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.404 HG21 HG23 ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.428 HG21 ' O ' ' A' ' 29' ' ' GLU . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.478 HG23 ' HB2' ' A' ' 25' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.539 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.465 ' CE2' HD11 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.429 HG21 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.528 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.607 ' CE1' ' CG1' ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.463 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.528 HG22 ' CG2' ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.553 ' HB3' " C'9" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.447 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.528 ' CG2' HG22 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.607 ' CG1' ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.499 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.499 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.487 ' O ' ' CB ' ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.597 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.444 HD11 ' OH ' ' A' ' 31' ' ' TYR . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.487 ' CB ' ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.411 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.538 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.528 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.628 ' C6 ' ' C23' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo -75.81 165.99 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.965 1.508 . . . . 0.0 110.376 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.591 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.469 HG13 HG13 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.666 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.666 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.482 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.531 ' OE1' ' N ' ' A' ' 13' ' ' SER . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.461 HG11 ' HG2' ' A' ' 8' ' ' PRO . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.44 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.507 HG21 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.526 ' CB ' HG22 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.453 ' HA ' ' OE1' ' A' ' 29' ' ' GLU . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.438 HG21 ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.591 HD13 ' CZ ' ' A' ' 4' ' ' PHE . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.417 ' O ' ' HB1' ' A' ' 44' ' ' ALA . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.453 ' O ' HG12 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.508 ' CG1' HG21 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.465 ' CG ' HG21 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.46 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.603 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.523 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.437 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.438 ' O ' HG21 ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.45 HG22 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.531 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.603 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.487 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.46 ' HA3' ' HB3' ' A' ' 44' ' ' ALA . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.558 ' CG2' ' CG2' ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.474 ' HB3' " H'8" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.558 ' CG2' ' CG2' ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.508 HG21 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 109' ' ' PHE . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.44 ' HB2' ' HE3' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.499 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.424 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.511 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.454 ' O ' ' HB2' ' A' ' 101' ' ' ASP . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.454 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.522 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.533 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.616 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 2.4 m-70 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.469 HG13 HG13 ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.499 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.482 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.601 ' C7 ' ' C21' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.461 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo -74.1 150.27 42.56 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.858 1.452 . . . . 0.0 110.121 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.584 ' CD2' HG23 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.619 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.483 ' HA ' ' CB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.497 ' OE1' ' N ' ' A' ' 13' ' ' SER . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.451 ' CG1' ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.584 HG23 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.526 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.411 ' HG3' ' C ' ' A' ' 28' ' ' GLY . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.476 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.439 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.518 ' CG1' ' HB3' ' A' ' 42' ' ' GLN . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.518 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.556 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.459 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.469 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.419 ' O ' HG21 ' A' ' 51' ' ' THR . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.457 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.462 HG23 ' N ' ' A' ' 55' ' ' THR . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.462 ' N ' HG23 ' A' ' 54' ' ' THR . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.546 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.455 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.461 ' HB2' ' CD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.562 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.458 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.469 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.556 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 79' ' ' THR . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.54 ' OG1' ' CG2' ' A' ' 79' ' ' THR . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.545 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.54 ' CG2' ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.482 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.464 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.462 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.48 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.458 HD23 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.469 HG11 HG12 ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.462 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.483 ' CB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.458 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.586 ' C4D' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 120.758 0.313 . . . . 0.0 110.365 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB2' HD22 ' A' ' 102' ' ' LEU . 43.7 Cg_endo -71.71 -171.99 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 123.922 1.485 . . . . 0.0 109.933 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.503 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.401 ' HA ' HG23 ' A' ' 105' ' ' VAL . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.568 HG12 ' CG1' ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.61 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.61 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.535 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.456 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.456 ' HB2' ' OG ' ' A' ' 13' ' ' SER . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.554 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.503 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.515 ' CG1' HD21 ' A' ' 102' ' ' LEU . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.53 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.53 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.562 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.427 ' CD ' ' O ' ' A' ' 28' ' ' GLY . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.583 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.466 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.524 ' NE2' HG13 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HB1' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.488 ' O ' HG23 ' A' ' 39' ' ' VAL . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.488 HG23 ' O ' ' A' ' 38' ' ' PRO . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.437 ' C ' ' OD1' ' A' ' 43' ' ' ASP . 1.1 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.529 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.42 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.438 ' O ' ' O ' ' A' ' 55' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.443 ' CG2' ' HB2' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.418 ' HB2' ' O ' ' A' ' 60' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.562 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.418 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.446 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.524 HG13 ' NE2' ' A' ' 35' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.463 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.529 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.512 ' O ' H7A2 ' A' ' 111' ' ' ROM . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.486 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.49 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.49 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 71' ' ' TYR . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' HG13 ' A' ' 84' ' ' VAL . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.506 ' HB2' ' CD1' ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 12.5 t-20 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.434 ' HG ' ' OH ' ' A' ' 31' ' ' TYR . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.515 HD21 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.471 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.568 ' CG1' HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.506 ' CD1' ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.535 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.559 ' C4D' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.68 -158.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.42 0 O-C-N 123.816 1.43 . . . . 0.0 109.959 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.592 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.521 ' CG1' HG12 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 107' ' ' LEU . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.485 HD13 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.412 ' O ' HG21 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.455 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.592 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.558 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.486 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.467 ' O ' HD13 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HB2' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.518 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.476 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.537 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.431 HG22 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.486 HG23 ' O ' ' A' ' 29' ' ' GLU . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.558 HG21 ' CB ' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.54 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.477 ' HA3' ' CA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.401 HG13 ' N ' ' A' ' 67' ' ' VAL . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.412 HG21 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.515 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.516 ' CE2' ' CG1' ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.457 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.522 ' O ' ' C7X' ' A' ' 111' ' ' ROM . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.559 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.516 ' CG1' ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.417 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.626 ' ND2' ' CE1' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.467 HD13 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' CL21 ' A' ' 111' ' ' ROM . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.498 ' HB2' ' O ' ' A' ' 30' ' ' THR . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.559 HD22 ' CE1' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.515 ' N ' HD21 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.476 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.626 ' CE1' ' ND2' ' A' ' 92' ' ' ASN . 4.7 t60 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.523 HG11 ' N ' ' A' ' 106' ' ' ALA . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.523 ' N ' HG11 ' A' ' 105' ' ' VAL . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' HD13 ' A' ' 12' ' ' LEU . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.565 ' C6 ' ' C21' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 120.858 0.361 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.48 -170.05 0.54 Allowed 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 124.167 1.614 . . . . 0.0 110.632 179.979 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.516 ' O ' ' CG1' ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.554 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.621 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.462 HD13 ' HB3' ' A' ' 107' ' ' LEU . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.46 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.46 ' OE1' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.428 ' O ' ' OG ' ' A' ' 17' ' ' SER . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.556 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.468 ' CG1' ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.52 HG11 ' CD2' ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.552 ' CB ' HG23 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.445 ' O ' ' CG2' ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.455 HG21 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.576 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.459 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.457 ' CD1' HD22 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.522 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.437 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 26.3 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.518 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB3' ' CA ' ' A' ' 73' ' ' GLY . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.48 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.482 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.459 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.576 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.455 ' OG1' HG21 ' A' ' 30' ' ' THR . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.552 HG23 ' CB ' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.547 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.524 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.43 ' CA ' ' HA ' ' A' ' 55' ' ' THR . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 67' ' ' VAL . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.513 ' N ' HG12 ' A' ' 66' ' ' VAL . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.482 ' HG3' HG21 ' A' ' 49' ' ' THR . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.522 ' CA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.444 ' O ' ' O ' ' A' ' 75' ' ' THR . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.471 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.515 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.49 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.49 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.426 HG22 ' HB2' ' A' ' 44' ' ' ALA . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.518 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.475 ' HB2' HD11 ' A' ' 107' ' ' LEU . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.526 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.481 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.471 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.52 ' CD2' HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . 0.526 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 0.5 OUTLIER -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.554 HG11 ' CG1' ' A' ' 6' ' ' VAL . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.497 ' N ' HG13 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.475 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.551 ' O23' ' C11' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.781 0.324 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.459 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.0 Cg_endo -71.59 -169.28 0.41 Allowed 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.996 1.524 . . . . 0.0 110.386 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.523 ' CE1' ' CG1' ' A' ' 20' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.514 HG21 ' N ' ' A' ' 7' ' ' SER . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.652 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.652 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.478 ' CB ' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.421 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.532 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.523 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.463 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.52 ' CG1' HD22 ' A' ' 102' ' ' LEU . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.458 ' HB3' HG22 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.559 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.507 ' OH ' ' CD1' ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.505 ' N ' HD12 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.441 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' N ' ' A' ' 41' ' ' GLY . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.496 ' NE2' HG23 ' A' ' 81' ' ' VAL . 19.2 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.451 ' HB2' ' HA3' ' A' ' 73' ' ' GLY . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.411 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.534 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.473 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.559 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.473 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.457 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.451 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.427 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.483 ' O ' H7A2 ' A' ' 111' ' ' ROM . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.529 ' HB3' ' O13' ' A' ' 111' ' ' ROM . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.452 ' HG3' H6A1 ' A' ' 111' ' ' ROM . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.496 HG23 ' NE2' ' A' ' 42' ' ' GLN . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.476 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' HB3' ' OD2' ' A' ' 85' ' ' ASP . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.464 HD11 ' O ' ' A' ' 34' ' ' ALA . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB2' HD12 ' A' ' 102' ' ' LEU . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA2' HD13 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.428 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.507 ' CD1' ' OH ' ' A' ' 31' ' ' TYR . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.52 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.468 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.459 HG12 HG11 ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.478 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.423 ' N ' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.608 ' C6 ' ' C21' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.488 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.3 Cg_endo -71.63 -159.65 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.844 1.444 . . . . 0.0 110.077 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.523 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.471 HD13 ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.449 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.449 ' HB3' ' O ' ' A' ' 13' ' ' SER . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.439 HG13 ' HG2' ' A' ' 8' ' ' PRO . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.455 ' N ' ' CG1' ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.41 ' CG2' ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.538 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.538 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.555 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG22 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.466 HG22 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.454 ' O ' HG22 ' A' ' 33' ' ' ILE . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.438 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.448 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' CG1' ' HB3' ' A' ' 42' ' ' GLN . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . 0.45 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.443 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.521 ' N ' H7A3 ' A' ' 111' ' ' ROM . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.466 ' OG1' HG22 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.466 ' CG2' ' HB2' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.555 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.451 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.439 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.429 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.563 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.482 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.478 ' O ' ' OG1' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.478 ' OG1' ' O ' ' A' ' 74' ' ' SER . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.47 ' CG2' ' CG2' ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.517 ' O ' ' CB ' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.456 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.448 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.456 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.466 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.467 ' C ' ' CD1' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.481 HG13 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.471 ' HB3' HD13 ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.563 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.561 ' C4D' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.71 -157.08 0.05 OUTLIER 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.952 1.501 . . . . 0.0 110.435 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . 0.494 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.5 HG11 HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.701 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.701 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.43 HD11 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.474 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' SER . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 21' ' ' SER . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.516 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.528 ' O ' ' CB ' ' A' ' 26' ' ' ALA . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.528 ' CB ' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.556 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.47 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.47 ' HG3' ' O ' ' A' ' 28' ' ' GLY . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.513 ' O ' ' CB ' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.503 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.432 HG12 HD13 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.475 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.532 ' O ' ' CG2' ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.481 ' HB2' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.53 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.457 ' CG2' ' HD3' ' A' ' 68' ' ' ARG . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.539 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.518 HG21 ' N ' ' A' ' 55' ' ' THR . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.518 ' N ' HG21 ' A' ' 54' ' ' THR . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.556 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.457 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.449 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.521 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.481 ' HA3' ' HB2' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.535 ' O ' H7A2 ' A' ' 111' ' ' ROM . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.524 ' HA ' ' C7X' ' A' ' 111' ' ' ROM . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.464 ' O ' HG21 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.5 HG13 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.431 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 34' ' ' ALA . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.513 ' CB ' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.402 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.409 HD12 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.516 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.5 HG11 HG11 ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.43 ' HB3' HD11 ' A' ' 12' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.553 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.73 0.3 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -71.83 -170.25 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.013 1.533 . . . . 0.0 110.42 179.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.448 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.515 ' OE1' ' N ' ' A' ' 13' ' ' SER . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.513 HG13 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG13 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.523 HG13 ' CD2' ' A' ' 102' ' ' LEU . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' CB ' HG23 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.429 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.465 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.47 ' CD2' " O'2" ' A' ' 111' ' ' ROM . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.525 HD11 ' CD1' ' A' ' 65' ' ' PHE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' GLN . . . . . 0.564 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 7.5 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.456 ' O ' ' C ' ' A' ' 40' ' ' GLY . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.444 ' HB3' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' CYS . . . . . 0.468 ' SG ' H142 ' A' ' 111' ' ' ROM . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.466 ' HA ' H7A1 ' A' ' 111' ' ' ROM . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.429 HG21 ' CG2' ' A' ' 33' ' ' ILE . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.438 ' HB ' ' HA2' ' A' ' 59' ' ' GLY . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.549 ' O ' ' CB ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.438 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.525 ' CD1' HD11 ' A' ' 33' ' ' ILE . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.434 ' N ' HG13 ' A' ' 66' ' ' VAL . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.563 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.564 ' CE1' ' OE1' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA3' ' HB3' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' THR . . . . . 0.428 ' C ' ' O ' ' A' ' 74' ' ' SER . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.545 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.455 ' CB ' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.41 ' HB3' ' CD1' ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.551 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.422 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD1' CL21 ' A' ' 111' ' ' ROM . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.523 ' CD2' HG13 ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' ROM . . . . . 0.605 ' C4B' " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.48 0.727 0 N-CA-C 110.39 -0.658 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.534 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.907 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.639 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.639 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.504 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.593 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 21' ' ' SER . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.41 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.819 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.835 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 29' ' ' GLU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 95' ' ' ALA . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.493 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.553 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.755 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.491 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.491 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.439 ' O ' HG22 ' A' ' 33' ' ' ILE . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 30' ' ' THR . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.819 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.835 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.769 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.708 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.477 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.755 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.548 HG23 ' CG2' ' A' ' 81' ' ' VAL . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.435 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.409 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.548 ' CG2' HG23 ' A' ' 75' ' ' THR . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.423 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.491 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.447 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.459 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.924 ' HB2' HD11 ' A' ' 107' ' ' LEU . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.71 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.58 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.534 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.907 HG11 ' CG1' ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.459 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.924 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.504 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 C--O 1.215 -0.671 0 N-CA-C 110.127 -0.759 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.53 ' CD1' HG22 ' A' ' 22' ' ' VAL . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.908 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.443 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.423 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG12 ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.569 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.822 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.764 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.669 ' O ' HG23 ' A' ' 54' ' ' THR . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.88 ' OH ' HD13 ' A' ' 100' ' ' LEU . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.858 HD12 ' HB2' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.484 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.571 ' OE1' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.415 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.423 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.453 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.769 ' O ' HG23 ' A' ' 30' ' ' THR . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 29' ' ' GLU . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.822 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.764 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.453 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.565 ' CA ' ' CE2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.702 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.708 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.708 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.702 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.732 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.564 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.732 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.449 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.484 HD12 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.858 ' HB2' HD12 ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.485 ' C ' ' O ' ' A' ' 97' ' ' ASN . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.88 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.464 HD12 ' HA2' ' A' ' 96' ' ' GLY . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 7.7 p-80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.908 HG11 ' CG1' ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.515 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.571 HD12 ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.565 ' CE2' ' CA ' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 41.9 Cg_endo . . . . . 0 C--O 1.214 -0.724 0 N-CA-C 110.381 -0.661 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.881 ' CD1' HG22 ' A' ' 22' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.76 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.77 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.77 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.45 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.496 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.472 ' HB3' ' HG2' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.951 ' O ' HG22 ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HB ' ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.554 HG12 ' N ' ' A' ' 21' ' ' SER . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.554 ' N ' HG12 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.881 HG22 ' CD1' ' A' ' 4' ' ' PHE . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.502 ' H ' HG12 ' A' ' 22' ' ' VAL . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.844 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.435 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HD21 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.507 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.738 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.444 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.647 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.844 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.584 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.46 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.738 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.444 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.571 HG23 ' CG2' ' A' ' 81' ' ' VAL . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.573 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.573 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 75' ' ' THR . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 33' ' ' ILE . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.567 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.812 HG23 ' CD2' ' A' ' 4' ' ' PHE . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.518 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.473 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo . . . . . 0 C--O 1.216 -0.584 0 N-CA-C 110.257 -0.709 . . . . 0.0 110.257 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.531 ' CD1' HG22 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.885 HG22 ' HD2' ' A' ' 8' ' ' PRO . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.665 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.885 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 107' ' ' LEU . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.408 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.57 HG12 ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.57 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.903 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.736 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.805 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.816 ' O ' HG23 ' A' ' 54' ' ' THR . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.797 ' CZ ' ' HB1' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.44 HG12 HD11 ' A' ' 93' ' ' LEU . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.787 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.417 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.417 HG23 ' C ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.416 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.521 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 29' ' ' GLU . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.903 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.805 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.772 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.432 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.588 HG23 ' CG2' ' A' ' 81' ' ' VAL . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.484 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.588 ' CG2' HG23 ' A' ' 75' ' ' THR . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.609 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.609 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.787 HD12 ' O ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.649 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.664 HD13 ' N ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.664 ' N ' HD13 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.649 HD12 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 2.5 m80 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.808 HG11 ' CG1' ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.415 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.553 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo . . . . . 0 C--O 1.215 -0.651 0 N-CA-C 110.323 -0.684 . . . . 0.0 110.323 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.575 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.918 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.629 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.459 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.855 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' H ' HG22 ' A' ' 18' ' ' VAL . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.601 HG12 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.601 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 4' ' ' PHE . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.791 ' OH ' HD13 ' A' ' 100' ' ' LEU . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 51' ' ' THR . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 81' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.583 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.507 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 3.4 t-20 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 49' ' ' THR . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.592 ' O ' HG22 ' A' ' 33' ' ' ILE . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.598 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.855 HG22 ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.625 HG23 HG21 ' A' ' 81' ' ' VAL . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.516 HG23 ' OG1' ' A' ' 75' ' ' THR . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 39' ' ' VAL . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.512 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.444 ' OD1' ' HA ' ' A' ' 31' ' ' TYR . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.791 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.705 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.918 HG11 ' CG1' ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.556 ' HG3' HD21 ' A' ' 100' ' ' LEU . 44.3 Cg_endo . . . . . 0 C--O 1.217 -0.56 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.874 ' CD2' HG22 ' A' ' 22' ' ' VAL . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.932 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.454 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.681 HG12 HE22 ' A' ' 16' ' ' GLN . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.536 HG12 ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.536 ' N ' HG12 ' A' ' 20' ' ' VAL . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.874 HG22 ' CD2' ' A' ' 4' ' ' PHE . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.576 ' O ' HG23 ' A' ' 54' ' ' THR . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.589 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.558 HD13 ' HZ ' ' A' ' 63' ' ' PHE . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.775 ' OE1' HG12 ' A' ' 67' ' ' VAL . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.427 ' CB ' HG11 ' A' ' 84' ' ' VAL . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.519 ' C ' HG23 ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.519 HG23 ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.669 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' ' 30' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.476 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 67' ' ' VAL . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.775 HG12 ' OE1' ' A' ' 35' ' ' GLN . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.497 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.669 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.443 HG23 ' CG2' ' A' ' 81' ' ' VAL . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.443 ' CG2' HG23 ' A' ' 75' ' ' THR . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.531 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.427 HG11 ' CB ' ' A' ' 37' ' ' ALA . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.751 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.463 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.786 ' HB2' HD11 ' A' ' 107' ' ' LEU . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.401 ' HA3' ' CE1' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.603 ' HB2' ' CE2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.556 HD21 ' HG3' ' A' ' 2' ' ' PRO . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.674 HD13 HG11 ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 66.3 m-70 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.932 HG11 ' CG1' ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 C--O 1.215 -0.642 0 N-CA-C 110.261 -0.707 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.925 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.606 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.732 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.732 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.532 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.816 ' O ' HG22 ' A' ' 67' ' ' VAL . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 21' ' ' SER . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.506 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.605 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.888 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.519 ' O ' HG23 ' A' ' 54' ' ' THR . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 1.078 ' CE1' HD22 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.781 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.781 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.514 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.474 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.503 ' C ' HG23 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.503 HG23 ' C ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.493 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.514 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 63.1 t30 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' THR . . . . . 1.009 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.888 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.816 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.405 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.405 ' HB3' ' O ' ' A' ' 70' ' ' SER . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.797 HG23 HG23 ' A' ' 81' ' ' VAL . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.453 ' O ' HG23 ' A' ' 79' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.797 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' HB3' ' A' ' 37' ' ' ALA . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.758 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.758 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.481 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 1.078 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.481 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.421 ' CE1' HD22 ' A' ' 92' ' ' ASN . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.925 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.621 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.621 HD23 ' O ' ' A' ' 106' ' ' ALA . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.48 0.709 0 N-CA-C 110.224 -0.721 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.899 ' HD1' HG22 ' A' ' 22' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.674 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.6 HG12 ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.6 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' HD1' ' A' ' 4' ' ' PHE . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.94 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.414 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.794 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CE1' HD13 ' A' ' 100' ' ' LEU . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.811 HD11 HD21 ' A' ' 93' ' ' LEU . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.569 ' C ' HG23 ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.569 HG23 ' C ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.453 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.574 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.574 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.522 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.94 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.794 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.633 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.403 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.819 ' CE2' HG11 ' A' ' 84' ' ' VAL . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.453 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 HG23 ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.509 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.495 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.495 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.55 HG23 HG23 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.819 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.767 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.636 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.4 OUTLIER -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.811 HD21 HD11 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.594 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . 0.466 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 6' ' ' VAL . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 106' ' ' ALA . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 N--CA 1.479 0.663 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.721 ' CD2' HG22 ' A' ' 22' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.525 HG11 HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.519 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.476 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.755 HD12 ' HB3' ' A' ' 107' ' ' LEU . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.793 ' O ' HG22 ' A' ' 67' ' ' VAL . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.555 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.61 HG12 ' N ' ' A' ' 21' ' ' SER . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.61 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.721 HG22 ' CD2' ' A' ' 4' ' ' PHE . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.447 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.802 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.976 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.087 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.794 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.576 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.791 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.636 ' HB2' HG13 ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.579 ' O ' HG22 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.802 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.976 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.474 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.507 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.517 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.527 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.546 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.546 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 1.087 HD11 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.494 HD22 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.534 HG12 ' N ' ' A' ' 106' ' ' ALA . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.534 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.755 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.517 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 N--CA 1.483 0.862 0 N-CA-C 109.927 -0.836 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.893 ' CD1' HG22 ' A' ' 22' ' ' VAL . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 8' ' ' PRO . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.682 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.54 HD12 ' HB3' ' A' ' 107' ' ' LEU . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.786 ' O ' HG22 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.564 HG12 ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.564 ' N ' HG12 ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.893 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.708 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.726 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.632 ' O ' HG23 ' A' ' 54' ' ' THR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.5 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.603 ' OH ' HD13 ' A' ' 100' ' ' LEU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.526 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.567 ' HB3' HD13 ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB2' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 1.046 HG12 ' O ' ' A' ' 42' ' ' GLN . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 1.046 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.6 mp0 -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.606 ' CG ' ' HG1' ' A' ' 49' ' ' THR . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.606 ' HG1' ' CG ' ' A' ' 46' ' ' ASN . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.632 HG23 ' O ' ' A' ' 29' ' ' GLU . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.708 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.726 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.536 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.585 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.412 ' C ' ' O ' ' A' ' 74' ' ' SER . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.55 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.55 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.439 HG23 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.509 HG11 ' CE1' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.685 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.685 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.603 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.597 ' N ' HD23 ' A' ' 100' ' ' LEU . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.428 HD22 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.494 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.606 HG11 HG11 ' A' ' 6' ' ' VAL . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.494 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.54 ' HB3' HD12 ' A' ' 12' ' ' LEU . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.585 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.679 0 N-CA-C 110.226 -0.721 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.872 ' CD1' HG22 ' A' ' 22' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.87 HG22 ' HD2' ' A' ' 8' ' ' PRO . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.669 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.87 ' HD2' HG22 ' A' ' 6' ' ' VAL . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.475 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.44 ' O ' HG13 ' A' ' 66' ' ' VAL . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.567 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.563 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.872 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 31' ' ' TYR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.459 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.413 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.436 ' O ' HG23 ' A' ' 54' ' ' THR . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CE1' HD13 ' A' ' 100' ' ' LEU . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.838 HD11 HD21 ' A' ' 93' ' ' LEU . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.603 ' C ' HG23 ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.603 HG23 ' C ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.485 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CD2' ' HB1' ' A' ' 61' ' ' ALA . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 29' ' ' GLU . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.452 HG23 ' CE2' ' A' ' 31' ' ' TYR . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.798 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.485 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.578 ' CE ' ' HB2' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.665 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.665 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.578 ' HB2' ' CE ' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HD11 ' A' ' 33' ' ' ILE . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 100' ' ' LEU . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.646 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.858 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.475 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo . . . . . 0 C--O 1.215 -0.646 0 N-CA-C 110.271 -0.703 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.611 ' HB2' HD22 ' A' ' 102' ' ' LEU . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.644 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.512 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.502 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 1.014 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.513 ' O ' HG23 ' A' ' 54' ' ' THR . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.641 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.595 ' OH ' HD13 ' A' ' 100' ' ' LEU . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.89 HD11 HD21 ' A' ' 93' ' ' LEU . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.456 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.416 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.51 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.46 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 11.1 t-20 -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.641 ' OG1' HG23 ' A' ' 30' ' ' THR . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' THR . . . . . 1.014 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.494 ' O ' HG22 ' A' ' 18' ' ' VAL . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.509 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.51 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.774 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.452 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.774 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.55 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.89 HD21 HD11 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.595 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.611 HD22 ' HB2' ' A' ' 4' ' ' PHE . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.487 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.578 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB3' HD12 ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.509 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo . . . . . 0 C--O 1.215 -0.654 0 N-CA-C 109.935 -0.833 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 1.034 ' CD1' HG22 ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.763 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.542 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.473 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.779 ' O ' HG22 ' A' ' 67' ' ' VAL . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.556 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 1.034 HG22 ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.446 ' N ' HG12 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.731 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.961 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.61 ' O ' HG23 ' A' ' 54' ' ' THR . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.664 ' OH ' HD22 ' A' ' 100' ' ' LEU . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.402 ' H ' HG22 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.573 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.495 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.795 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.415 ' C ' HG12 ' A' ' 39' ' ' VAL . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.899 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.495 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 51' ' ' THR . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.594 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.731 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.961 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.779 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.485 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.482 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.574 HG23 ' CG2' ' A' ' 81' ' ' VAL . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.899 HG11 ' HB2' ' A' ' 44' ' ' ALA . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.414 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.747 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.525 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.556 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.683 ' HB2' HD11 ' A' ' 107' ' ' LEU . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.455 ' HB3' ' HB2' ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.664 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' A' ' 31' ' ' TYR . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.556 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.763 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.488 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.683 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.634 -0.564 . . . . 0.0 110.634 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.752 ' CD1' HG22 ' A' ' 22' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.828 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.554 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.596 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.707 HG22 ' O ' ' A' ' 65' ' ' PHE . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.549 ' N ' HG12 ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.752 HG22 ' CD1' ' A' ' 4' ' ' PHE . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.941 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.884 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.438 ' O ' HG23 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.752 ' OH ' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.502 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.502 HG23 ' C ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.941 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.884 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.647 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.493 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.707 ' O ' HG22 ' A' ' 18' ' ' VAL . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.551 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.77 HG23 HG21 ' A' ' 81' ' ' VAL . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.601 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.601 ' HD2' HG22 ' A' ' 79' ' ' THR . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.811 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.811 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.623 ' HB2' HD11 ' A' ' 107' ' ' LEU . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.421 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.752 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.519 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 7.3 m-70 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.828 HG11 ' CG1' ' A' ' 6' ' ' VAL . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.586 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.623 HD11 ' HB2' ' A' ' 93' ' ' LEU . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.551 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.521 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo . . . . . 0 C--O 1.214 -0.696 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.625 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.594 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.437 HD12 ' HB3' ' A' ' 107' ' ' LEU . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.653 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.575 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.833 ' CG1' HD22 ' A' ' 102' ' ' LEU . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.521 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 1.041 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.628 ' O ' HG23 ' A' ' 54' ' ' THR . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.527 HG23 ' OG1' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.563 ' CE1' HD22 ' A' ' 100' ' ' LEU . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.027 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.926 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.596 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.483 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 39' ' ' VAL . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.483 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.508 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.409 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.402 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 33' ' ' ILE . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.628 HG23 ' O ' ' A' ' 29' ' ' GLU . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 1.041 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.528 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 82' ' ' GLY . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 75' ' ' THR . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.586 HG23 HG23 ' A' ' 81' ' ' VAL . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.489 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.586 HG23 HG23 ' A' ' 75' ' ' THR . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.596 HG11 ' HB3' ' A' ' 37' ' ' ALA . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.637 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 1.027 HD11 HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.409 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.563 HD22 ' CE1' ' A' ' 31' ' ' TYR . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.486 ' N ' HD23 ' A' ' 100' ' ' LEU . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.833 HD22 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.594 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.422 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.706 HD11 ' HB2' ' A' ' 93' ' ' LEU . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo . . . . . 0 N--CA 1.48 0.687 0 N-CA-C 110.519 -0.608 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.922 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.69 HG11 HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.448 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.81 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 18' ' ' VAL . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 20' ' ' VAL . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.922 HG22 ' CD1' ' A' ' 4' ' ' PHE . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.717 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.42 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.482 ' O ' HG23 ' A' ' 54' ' ' THR . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.459 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.797 ' OH ' HD13 ' A' ' 100' ' ' LEU . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.468 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.049 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.65 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.65 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.468 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' GLU . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.717 HG21 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.793 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.81 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 14' ' ' ASP . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HG3' ' HB3' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.58 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.409 ' O ' ' C ' ' A' ' 77' ' ' GLU . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.491 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 75' ' ' THR . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.418 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 1.049 HD11 HD11 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.628 ' HA3' ' CE1' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB3' HD12 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.524 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.595 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.797 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.643 HD12 ' HB3' ' A' ' 95' ' ' ALA . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLY . . . . . 0.517 ' N ' HD13 ' A' ' 102' ' ' LEU . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.628 ' CE1' ' HA3' ' A' ' 94' ' ' GLY . 4.2 m-70 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.792 HG23 ' CD2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.481 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.515 HD11 ' HB2' ' A' ' 93' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.469 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.715 0 N-CA-C 110.448 -0.635 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.814 ' CD2' HG22 ' A' ' 22' ' ' VAL . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.748 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.604 HD12 ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.777 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.847 ' CG1' HD22 ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.71 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.642 ' O ' HG23 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.75 ' CE1' HD22 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.441 ' H ' HG22 ' A' ' 33' ' ' ILE . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.558 ' O ' HG12 ' A' ' 39' ' ' VAL . 12.0 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 1.08 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.477 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 33' ' ' ILE . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.642 HG23 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.71 HG21 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.654 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.519 ' O ' ' HB3' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.489 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.439 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 1.08 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.485 HG23 HG21 ' A' ' 81' ' ' VAL . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.485 HG21 HG23 ' A' ' 75' ' ' THR . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.461 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.655 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.531 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.44 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.421 ' HB2' ' HA ' ' A' ' 31' ' ' TYR . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.75 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.847 HD22 ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.531 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 29.5 m80 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.748 HG11 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.401 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.604 ' HB3' HD12 ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.552 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo . . . . . 0 N--CA 1.479 0.662 0 N-CA-C 110.237 -0.716 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.586 ' CD1' HG22 ' A' ' 22' ' ' VAL . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.861 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.621 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.664 HD12 ' HB3' ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.614 ' O ' HG22 ' A' ' 67' ' ' VAL . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.505 HG12 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 21' ' ' SER . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.841 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.783 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.986 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.766 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.664 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.754 ' OH ' ' HB1' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.477 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.025 HD13 ' HB2' ' A' ' 95' ' ' ALA . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.465 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.48 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.793 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.425 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.474 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.78 ' OG1' HG23 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.766 HG23 ' O ' ' A' ' 29' ' ' GLU . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.783 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.986 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.474 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' THR . . . . . 1.001 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.615 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.615 ' HD2' HG22 ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 1.001 ' CG2' HG23 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.691 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.479 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.691 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.804 ' CG ' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.806 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 1.025 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.597 HD13 ' C ' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.841 HD11 HG13 ' A' ' 22' ' ' VAL . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.861 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.664 ' HB3' HD12 ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.524 ' HG2' HD23 ' A' ' 102' ' ' LEU . 45.9 Cg_endo . . . . . 0 C--O 1.215 -0.641 0 N-CA-C 110.081 -0.777 . . . . 0.0 110.081 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.97 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.855 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.532 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.636 HD12 ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.672 ' O ' HG22 ' A' ' 67' ' ' VAL . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG22 ' H ' ' A' ' 18' ' ' VAL . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.605 HG12 ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.605 ' N ' HG12 ' A' ' 20' ' ' VAL . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.97 HG22 ' CD1' ' A' ' 4' ' ' PHE . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.901 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.568 ' O ' HG23 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.45 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.603 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.611 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.925 ' OE1' HG12 ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.422 ' C ' HG23 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 39' ' ' VAL . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.9 HD22 ' H ' ' A' ' 35' ' ' GLN . 17.0 p30 -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 46' ' ' ASN . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.453 ' HB ' ' CE1' ' A' ' 65' ' ' PHE . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.901 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.719 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.925 HG12 ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.498 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.471 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 75' ' ' THR . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.751 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.611 HD12 ' O ' ' A' ' 34' ' ' ALA . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.55 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 100' ' ' LEU . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.603 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.489 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 96' ' ' GLY . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 3.6 p80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.855 HG11 ' CG1' ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.436 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.636 ' HB3' HD12 ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo . . . . . 0 C--O 1.215 -0.668 0 N-CA-C 110.436 -0.64 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.852 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.653 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.653 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.534 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.498 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.638 HE22 HG12 ' A' ' 18' ' ' VAL . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.638 HG12 HE22 ' A' ' 16' ' ' GLN . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.453 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.852 HG22 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.47 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.924 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.748 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.95 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.413 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.542 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.435 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.919 ' OH ' HD22 ' A' ' 100' ' ' LEU . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.966 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.863 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.621 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.619 HG11 ' CG1' ' A' ' 81' ' ' VAL . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.471 ' O ' HG21 ' A' ' 81' ' ' VAL . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.653 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 46' ' ' ASN . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.439 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.526 ' O ' HG22 ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.924 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.95 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.462 ' O ' HG22 ' A' ' 18' ' ' VAL . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.548 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.653 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.927 HG23 HG23 ' A' ' 81' ' ' VAL . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.454 ' O ' ' OE2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.894 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.894 ' HD2' HG22 ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 75' ' ' THR . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.621 HG11 ' HB3' ' A' ' 37' ' ' ALA . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.71 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.71 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.465 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.966 HD11 HD11 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.919 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.418 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 106' ' ' ALA . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.663 HD11 ' HB2' ' A' ' 93' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.548 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.482 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.946 ' CD1' HG22 ' A' ' 22' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.844 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.554 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.848 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.743 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 18' ' ' VAL . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.946 HG22 ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.594 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.841 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.612 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.404 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.432 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.471 HG23 ' CG2' ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.42 ' HG ' ' HD2' ' A' ' 32' ' ' TYR . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.626 ' HA ' ' HB2' ' A' ' 61' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.841 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.448 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.626 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.743 HG22 ' OG ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.848 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.668 ' CE1' HG11 ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.404 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.561 HG23 HG21 ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.458 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.561 HG21 HG23 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.668 HG11 ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.795 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.795 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.478 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.522 ' O ' HD13 ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.612 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.522 HD13 ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.844 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.554 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.503 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo . . . . . 0 C--O 1.214 -0.7 0 N-CA-C 110.376 -0.663 . . . . 0.0 110.376 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.544 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.617 ' O ' HG22 ' A' ' 67' ' ' VAL . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.589 HG12 ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.589 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 1.021 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.846 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.631 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.638 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.5 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.546 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.49 ' CG ' HG23 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.599 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.429 HG21 ' HD2' ' A' ' 68' ' ' ARG . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.416 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' THR . . . . . 1.021 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.846 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.656 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.499 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.429 ' HD2' HG21 ' A' ' 49' ' ' THR . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.711 HG23 HG23 ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.711 HG23 HG23 ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.559 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.561 HG22 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.726 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.726 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.832 ' HB2' HD11 ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' CE1' ' A' ' 31' ' ' TYR . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.638 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' A' ' 104' ' ' HIS . 1.5 m80 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.447 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.832 HD11 ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.544 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.489 ' HB2' ' O ' ' A' ' 86' ' ' CYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 N-CA-C 110.121 -0.761 . . . . 0.0 110.121 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.741 ' CD2' HG22 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.718 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.508 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.53 ' O ' HG22 ' A' ' 67' ' ' VAL . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.593 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.522 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.741 HG22 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.756 ' O ' ' HB2' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.756 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.623 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.416 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.655 ' O ' HG23 ' A' ' 54' ' ' THR . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.5 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.434 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.644 ' O ' HG13 ' A' ' 39' ' ' VAL . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.541 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.493 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.465 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.857 ' HD2' ' HB1' ' A' ' 61' ' ' ALA . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.655 HG23 ' O ' ' A' ' 29' ' ' GLU . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.609 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.623 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' A' ' 55' ' ' THR . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.857 ' HB1' ' HD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' OG ' ' A' ' 17' ' ' SER . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.421 ' HG2' HG21 ' A' ' 49' ' ' THR . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.468 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.527 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.82 HG23 HG21 ' A' ' 81' ' ' VAL . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.503 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.578 HG22 ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.82 HG21 HG23 ' A' ' 75' ' ' THR . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.488 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.478 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.861 ' HB2' HD11 ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.5 ' HB3' ' O ' ' A' ' 30' ' ' THR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.6 ' C ' HD23 ' A' ' 100' ' ' LEU . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.672 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.508 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.427 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 C--O 1.216 -0.618 0 N-CA-C 109.933 -0.833 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.779 ' CD1' HG22 ' A' ' 22' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 1.026 HG12 HG11 ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.572 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.74 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.584 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.464 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.779 HG22 ' CD1' ' A' ' 4' ' ' PHE . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.746 ' O ' ' HB3' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.746 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.589 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.59 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.69 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.503 ' NE2' HG12 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.661 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 39' ' ' VAL . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.4 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.725 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.69 ' OG1' HG23 ' A' ' 30' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.714 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.589 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.531 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.74 HG22 ' O ' ' A' ' 16' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.566 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.478 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.503 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.725 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' H ' ' A' ' 75' ' ' THR . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.485 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.485 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG2' HG23 ' A' ' 75' ' ' THR . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.661 HG11 ' HB3' ' A' ' 37' ' ' ALA . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.641 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.945 ' HB2' HD11 ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.643 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 46.1 t30 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.485 HD12 ' HG ' ' A' ' 102' ' ' LEU . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.701 HD22 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.488 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 1.026 HG11 HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.945 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.572 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.479 0.664 0 N-CA-C 109.959 -0.823 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.941 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.677 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.442 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.574 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.559 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.941 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.981 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.857 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.501 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 33' ' ' ILE . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.491 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.489 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.572 ' OG1' HG23 ' A' ' 30' ' ' THR . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.981 HG21 ' HB3' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.857 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.501 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.795 ' CE2' HG11 ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.436 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.439 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.721 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.441 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.721 ' CG2' HG23 ' A' ' 75' ' ' THR . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.587 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.795 HG11 ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.536 ' OD1' ' HB2' ' A' ' 89' ' ' ALA . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.441 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.536 ' HB2' ' OD1' ' A' ' 85' ' ' ASP . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.776 ' HB2' ' CE1' ' A' ' 104' ' ' HIS . 13.8 p30 -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.491 HD12 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.486 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.503 ' HB2' ' O ' ' A' ' 30' ' ' THR . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.53 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.501 ' N ' HD23 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.616 HD22 HG13 ' A' ' 22' ' ' VAL . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' HIS . . . . . 0.776 ' CE1' ' HB2' ' A' ' 92' ' ' ASN . 6.2 t-80 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 6' ' ' VAL . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 9' ' ' ALA . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.481 0.762 0 N-CA-C 110.632 -0.565 . . . . 0.0 110.632 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.717 ' O ' HG13 ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.546 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.831 HG22 ' HD2' ' A' ' 8' ' ' PRO . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.642 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.831 ' HD2' HG22 ' A' ' 6' ' ' VAL . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.485 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.485 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.939 HG11 HD22 ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.62 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.404 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.62 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.842 ' O ' HG23 ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.773 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.591 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.426 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.947 HD11 HD21 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.47 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 107' ' ' LEU . 6.6 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.516 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.729 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.907 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.442 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.426 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.842 HG23 ' O ' ' A' ' 29' ' ' GLU . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.62 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.62 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.54 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.518 ' HB1' ' HD1' ' A' ' 53' ' ' PHE . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.489 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.597 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.426 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.907 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.474 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.474 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.488 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.488 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG23 ' HA ' ' A' ' 74' ' ' SER . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.516 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.947 HD21 HD11 ' A' ' 33' ' ' ILE . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.497 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.939 HD22 HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.596 HG12 ' N ' ' A' ' 106' ' ' ALA . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.596 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.522 HD12 ' HG3' ' A' ' 35' ' ' GLN . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.597 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HG3' HD21 ' A' ' 100' ' ' LEU . 43.0 Cg_endo . . . . . 0 N--CA 1.48 0.734 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.899 ' CD1' HG22 ' A' ' 22' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.753 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.672 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.724 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.454 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.692 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.716 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.723 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 1.068 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.81 ' CE2' HD13 ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.96 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.96 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.573 ' HA ' HD12 ' A' ' 93' ' ' LEU . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.447 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.484 HG12 ' O ' ' A' ' 39' ' ' VAL . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.454 ' OE1' HG22 ' A' ' 81' ' ' VAL . 7.7 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.447 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.406 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.406 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.723 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 1.068 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.49 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.442 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.411 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.818 HG23 HG23 ' A' ' 81' ' ' VAL . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.818 HG23 HG23 ' A' ' 75' ' ' THR . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.483 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.49 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 35' ' ' GLN . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 100' ' ' LEU . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.863 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 103' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.753 HG11 ' CG1' ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 108' ' ' THR . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.421 ' HA3' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 43.3 Cg_endo . . . . . 0 C--O 1.215 -0.644 0 N-CA-C 110.077 -0.778 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 2' ' ' PRO . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.687 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 9' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.463 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.732 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.417 ' H ' HG22 ' A' ' 18' ' ' VAL . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.687 HG22 ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 1.066 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.753 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.833 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.405 ' O ' HG23 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.516 ' CE2' ' HB1' ' A' ' 25' ' ' ALA . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.479 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' GLN . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.683 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 45' ' ' CYS . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.467 ' OG1' HG23 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' THR . . . . . 1.066 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.833 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.436 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.732 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.674 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.559 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.683 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.572 HG23 HG23 ' A' ' 81' ' ' VAL . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.572 HG23 HG23 ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.73 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.479 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.483 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' C ' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.463 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.547 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.216 -0.596 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.625 ' HB2' HD22 ' A' ' 102' ' ' LEU . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.657 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.74 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.872 ' HG2' HG12 ' A' ' 18' ' ' VAL . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.452 HD12 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.501 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.872 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.568 HG22 HG23 ' A' ' 6' ' ' VAL . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.552 ' N ' HG12 ' A' ' 20' ' ' VAL . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.406 ' N ' HG12 ' A' ' 22' ' ' VAL . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.732 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.959 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.474 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.75 ' O ' HG23 ' A' ' 54' ' ' THR . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.654 ' OH ' HD13 ' A' ' 100' ' ' LEU . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.531 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.899 HG12 HD11 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.56 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.767 ' O ' HG23 ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' THR . . . . . 0.522 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.531 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.75 HG23 ' O ' ' A' ' 29' ' ' GLU . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' THR . . . . . 1.009 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.959 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 67' ' ' VAL . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 16' ' ' GLN . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.468 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.604 ' CE2' HG11 ' A' ' 84' ' ' VAL . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.979 HG23 HG21 ' A' ' 81' ' ' VAL . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 79' ' ' THR . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.979 HG21 HG23 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.604 HG11 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.899 HD11 HG12 ' A' ' 33' ' ' ILE . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.654 HD13 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.628 ' N ' HD23 ' A' ' 100' ' ' LEU . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.657 HG11 ' CG1' ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.765 HD11 ' HB2' ' A' ' 93' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.44 ' HG3' HD21 ' A' ' 100' ' ' LEU . 45.0 Cg_endo . . . . . 0 C--O 1.214 -0.703 0 N-CA-C 110.42 -0.646 . . . . 0.0 110.42 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.698 ' HB3' ' OG ' ' A' ' 23' ' ' SER . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 4' ' ' PHE . . . . . 0.823 ' HD1' HG22 ' A' ' 22' ' ' VAL . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.575 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.77 ' O ' HG22 ' A' ' 67' ' ' VAL . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.582 HG12 ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.486 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.823 HG22 ' HD1' ' A' ' 4' ' ' PHE . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.698 ' OG ' ' HB3' ' A' ' 3' ' ' ALA . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.578 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.486 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.831 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.446 HG23 ' OG1' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.585 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.655 ' C ' HD13 ' A' ' 33' ' ' ILE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.583 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 35' ' ' GLN . . . . . 0.707 ' NE2' ' CE1' ' A' ' 71' ' ' TYR . 8.8 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.569 ' O ' HG13 ' A' ' 39' ' ' VAL . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.796 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.446 ' OG1' HG23 ' A' ' 30' ' ' THR . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.578 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.831 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.507 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.707 ' CE1' ' NE2' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 72' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.796 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.543 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 75' ' ' THR . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' CE1' ' A' ' 71' ' ' TYR . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.658 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 34' ' ' ALA . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB1' HD12 ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.585 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.565 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.778 HD22 ' CG1' ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.575 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.559 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.507 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.485 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 120.745 0.307 . . . . 0.0 110.289 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 44.3 Cg_endo -73.32 -167.32 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.078 1.568 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.534 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.907 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.639 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.639 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.504 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.593 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 21' ' ' SER . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.41 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.819 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.835 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 29' ' ' GLU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 95' ' ' ALA . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.493 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.553 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.755 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.491 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.491 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.439 ' O ' HG22 ' A' ' 33' ' ' ILE . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 30' ' ' THR . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.819 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.835 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.769 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.708 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.477 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.755 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.548 HG23 ' CG2' ' A' ' 81' ' ' VAL . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.812 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.435 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.409 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.548 ' CG2' HG23 ' A' ' 75' ' ' THR . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.423 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.491 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.447 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.459 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.924 ' HB2' HD11 ' A' ' 107' ' ' LEU . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.71 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.458 ' O ' CL21 ' A' ' 111' ' ' ROM . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.58 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.534 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.907 HG11 ' CG1' ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.459 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.924 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.504 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.812 H7A2 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.837 0.351 . . . . 0.0 110.317 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.41 179.7 5.27 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.042 1.548 . . . . 0.0 110.127 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.53 ' CD1' HG22 ' A' ' 22' ' ' VAL . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.908 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.443 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.423 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG12 ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.569 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.822 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.764 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.669 ' O ' HG23 ' A' ' 54' ' ' THR . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.88 ' OH ' HD13 ' A' ' 100' ' ' LEU . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.858 HD12 ' HB2' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.484 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.571 ' OE1' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.415 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.429 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.423 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.453 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.769 ' O ' HG23 ' A' ' 30' ' ' THR . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 29' ' ' GLU . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.822 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.764 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.453 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.565 ' CA ' ' CE2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.702 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.708 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.436 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.708 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.702 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.732 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.564 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.732 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.449 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.484 HD12 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.858 ' HB2' HD12 ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.53 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.88 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.464 HD12 ' HA2' ' A' ' 96' ' ' GLY . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 7.7 p-80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.908 HG11 ' CG1' ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.515 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.571 HD12 ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.565 ' CE2' ' CA ' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.633 ' C23' ' C7 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.603 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.818 0.342 . . . . 0.0 110.197 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.603 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 41.9 Cg_endo -69.74 -168.28 0.26 Allowed 'Trans proline' 0 C--N 1.302 -1.891 0 O-C-N 124.07 1.563 . . . . 0.0 110.381 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.881 ' CD1' HG22 ' A' ' 22' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.76 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.77 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.77 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.45 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.496 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.472 ' HB3' ' HG2' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.951 ' O ' HG22 ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HB ' ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.554 HG12 ' N ' ' A' ' 21' ' ' SER . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.554 ' N ' HG12 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.881 HG22 ' CD1' ' A' ' 4' ' ' PHE . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.502 ' H ' HG12 ' A' ' 22' ' ' VAL . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.844 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.435 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HD21 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.507 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.738 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.517 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.647 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.844 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.584 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.46 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.738 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.444 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.571 HG23 ' CG2' ' A' ' 81' ' ' VAL . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.637 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' H11' ' A' ' 111' ' ' ROM . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.573 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.573 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 75' ' ' THR . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 33' ' ' ILE . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.567 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.812 HG23 ' CD2' ' A' ' 4' ' ' PHE . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.518 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 1.08 H6B2 H4B3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 120.722 0.296 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.473 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo -81.89 -177.74 3.73 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.924 1.486 . . . . 0.0 110.257 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.531 ' CD1' HG22 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.885 HG22 ' HD2' ' A' ' 8' ' ' PRO . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.665 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.885 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 107' ' ' LEU . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.408 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.57 HG12 ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.57 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.903 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.736 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.805 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.816 ' O ' HG23 ' A' ' 54' ' ' THR . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.797 ' CZ ' ' HB1' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.44 HG12 HD11 ' A' ' 93' ' ' LEU . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.787 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.417 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.417 HG23 ' C ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.416 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.521 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 29' ' ' GLU . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.903 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.805 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.772 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.432 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.588 HG23 ' CG2' ' A' ' 81' ' ' VAL . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.807 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.588 ' CG2' HG23 ' A' ' 75' ' ' THR . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.609 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.609 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.787 HD12 ' O ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.649 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.664 HD13 ' N ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.664 ' N ' HD13 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.649 HD12 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 2.5 m80 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.808 HG11 ' CG1' ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.415 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.807 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 120.778 0.323 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.553 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo -73.49 -159.06 0.08 OUTLIER 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.941 1.495 . . . . 0.0 110.323 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.575 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.918 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.629 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.459 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.855 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' H ' HG22 ' A' ' 18' ' ' VAL . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.601 HG12 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.601 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 4' ' ' PHE . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.791 ' OH ' HD13 ' A' ' 100' ' ' LEU . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.509 ' HB3' " O'2" ' A' ' 111' ' ' ROM . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 51' ' ' THR . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.521 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 81' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.583 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.507 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 3.4 t-20 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.858 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.592 ' O ' HG22 ' A' ' 33' ' ' ILE . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.598 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.855 HG22 ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.625 HG23 HG21 ' A' ' 81' ' ' VAL . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.516 HG23 ' OG1' ' A' ' 75' ' ' THR . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 39' ' ' VAL . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.512 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.552 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.791 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.705 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.918 HG11 ' CG1' ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.858 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.721 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.556 ' HG3' HD21 ' A' ' 100' ' ' LEU . 44.3 Cg_endo -73.61 -158.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.811 0 O-C-N 123.989 1.521 . . . . 0.0 110.218 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.874 ' CD2' HG22 ' A' ' 22' ' ' VAL . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.932 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.454 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.681 HG12 HE22 ' A' ' 16' ' ' GLN . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG12 ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.536 ' N ' HG12 ' A' ' 20' ' ' VAL . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.874 HG22 ' CD2' ' A' ' 4' ' ' PHE . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.576 ' O ' HG23 ' A' ' 54' ' ' THR . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.589 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.558 HD13 ' HZ ' ' A' ' 63' ' ' PHE . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.775 ' OE1' HG12 ' A' ' 67' ' ' VAL . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.427 ' CB ' HG11 ' A' ' 84' ' ' VAL . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.519 ' C ' HG23 ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.519 HG23 ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.669 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' ' 30' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.476 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 67' ' ' VAL . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.775 HG12 ' OE1' ' A' ' 35' ' ' GLN . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.497 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.669 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.443 HG23 ' CG2' ' A' ' 81' ' ' VAL . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.934 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.443 ' CG2' HG23 ' A' ' 75' ' ' THR . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.531 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.427 HG11 ' CB ' ' A' ' 37' ' ' ALA . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.751 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.463 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.786 ' HB2' HD11 ' A' ' 107' ' ' LEU . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.401 ' HA3' ' CE1' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.603 ' HB2' ' CE2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.536 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.453 ' HB2' " H2'" ' A' ' 111' ' ' ROM . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.556 HD21 ' HG3' ' A' ' 2' ' ' PRO . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.674 HD13 HG11 ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 66.3 m-70 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.932 HG11 ' CG1' ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.934 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -73.87 -166.49 0.32 Allowed 'Trans proline' 0 C--N 1.302 -1.88 0 O-C-N 124.031 1.542 . . . . 0.0 110.261 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.925 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.606 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.732 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.732 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.532 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.816 ' O ' HG22 ' A' ' 67' ' ' VAL . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 21' ' ' SER . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.506 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.605 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.888 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.519 ' O ' HG23 ' A' ' 54' ' ' THR . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 1.078 ' CE1' HD22 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.781 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.781 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.514 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.474 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.503 ' C ' HG23 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.503 HG23 ' C ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.493 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.514 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 63.1 t30 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.697 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' THR . . . . . 1.009 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.888 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.816 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.405 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.405 ' HB3' ' O ' ' A' ' 70' ' ' SER . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.797 HG23 HG23 ' A' ' 81' ' ' VAL . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.527 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.453 ' O ' HG23 ' A' ' 79' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.797 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' HB3' ' A' ' 37' ' ' ALA . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.758 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.758 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.481 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.557 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 1.078 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.481 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.421 ' CE1' HD22 ' A' ' 92' ' ' ASN . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.925 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.621 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.621 HD23 ' O ' ' A' ' 106' ' ' ALA . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.697 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.836 0.351 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.37 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.961 1.506 . . . . 0.0 110.224 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.899 ' HD1' HG22 ' A' ' 22' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.674 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.6 HG12 ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.6 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' HD1' ' A' ' 4' ' ' PHE . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.94 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.414 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.794 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CE1' HD13 ' A' ' 100' ' ' LEU . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.811 HD11 HD21 ' A' ' 93' ' ' LEU . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.569 ' C ' HG23 ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.569 HG23 ' C ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.453 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.574 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.596 ' HD3' H7A1 ' A' ' 111' ' ' ROM . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.574 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.522 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.94 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.794 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.633 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.403 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.819 ' CE2' HG11 ' A' ' 84' ' ' VAL . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.453 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 HG23 ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.588 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.495 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.495 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.55 HG23 HG23 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.819 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.767 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.636 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.4 OUTLIER -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.811 HD21 HD11 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.594 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.466 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 6' ' ' VAL . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 106' ' ' ALA . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.596 H7A1 ' HD3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.724 0.297 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.32 -159.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.982 1.517 . . . . 0.0 110.418 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.721 ' CD2' HG22 ' A' ' 22' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.525 HG11 HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.519 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.476 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.755 HD12 ' HB3' ' A' ' 107' ' ' LEU . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.793 ' O ' HG22 ' A' ' 67' ' ' VAL . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.555 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.61 HG12 ' N ' ' A' ' 21' ' ' SER . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.61 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.721 HG22 ' CD2' ' A' ' 4' ' ' PHE . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.447 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.802 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.976 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.087 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.794 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.576 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.791 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.636 ' HB2' HG13 ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.477 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.75 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.579 ' O ' HG22 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.454 ' OG ' H3A2 ' A' ' 111' ' ' ROM . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.802 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.976 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.474 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.507 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.517 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.527 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.513 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.546 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.546 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 1.087 HD11 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.525 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.49 ' HB2' ' O9 ' ' A' ' 111' ' ' ROM . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.446 ' OD1' CL21 ' A' ' 111' ' ' ROM . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.494 HD22 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.534 HG12 ' N ' ' A' ' 106' ' ' ALA . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.534 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.755 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.517 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.75 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.571 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 120.841 0.353 . . . . 0.0 110.47 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.571 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 44.6 Cg_endo -71.46 -153.26 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.163 1.612 . . . . 0.0 109.927 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.893 ' CD1' HG22 ' A' ' 22' ' ' VAL . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 8' ' ' PRO . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.682 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.54 HD12 ' HB3' ' A' ' 107' ' ' LEU . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.786 ' O ' HG22 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.564 HG12 ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.564 ' N ' HG12 ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.893 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.708 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.726 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.632 ' O ' HG23 ' A' ' 54' ' ' THR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.5 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.603 ' OH ' HD13 ' A' ' 100' ' ' LEU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.526 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.567 ' HB3' HD13 ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB2' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 1.046 HG12 ' O ' ' A' ' 42' ' ' GLN . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 1.046 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.6 mp0 -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.606 ' CG ' ' HG1' ' A' ' 49' ' ' THR . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.483 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.606 ' HG1' ' CG ' ' A' ' 46' ' ' ASN . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.632 HG23 ' O ' ' A' ' 29' ' ' GLU . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.708 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.726 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.536 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.585 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.745 ' O ' H7A1 ' A' ' 111' ' ' ROM . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.44 ' C ' H7A3 ' A' ' 111' ' ' ROM . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.792 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.55 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.55 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.439 HG23 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.509 HG11 ' CE1' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.685 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.685 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.476 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.603 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.597 ' N ' HD23 ' A' ' 100' ' ' LEU . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.428 HD22 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.494 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.606 HG11 HG11 ' A' ' 6' ' ' VAL . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.494 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.54 ' HB3' HD12 ' A' ' 12' ' ' LEU . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.585 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 1.128 H4A2 H6A3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 120.799 0.333 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.8 -167.21 0.29 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 O-C-N 124.087 1.572 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.872 ' CD1' HG22 ' A' ' 22' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.87 HG22 ' HD2' ' A' ' 8' ' ' PRO . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.669 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.87 ' HD2' HG22 ' A' ' 6' ' ' VAL . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.475 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.44 ' O ' HG13 ' A' ' 66' ' ' VAL . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.567 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.563 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.872 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 31' ' ' TYR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.459 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.413 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.436 ' O ' HG23 ' A' ' 54' ' ' THR . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CE1' HD13 ' A' ' 100' ' ' LEU . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.838 HD11 HD21 ' A' ' 93' ' ' LEU . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.603 ' C ' HG23 ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.603 HG23 ' C ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.648 ' CB ' H7A3 ' A' ' 111' ' ' ROM . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.485 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CD2' ' HB1' ' A' ' 61' ' ' ALA . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 29' ' ' GLU . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.452 HG23 ' CE2' ' A' ' 31' ' ' TYR . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.798 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.485 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.578 ' CE ' ' HB2' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.665 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.492 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.665 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.578 ' HB2' ' CE ' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HD11 ' A' ' 33' ' ' ILE . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 100' ' ' LEU . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.646 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.858 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.475 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.704 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 120.693 0.282 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo -73.96 154.41 47.88 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.013 1.533 . . . . 0.0 110.271 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.611 ' HB2' HD22 ' A' ' 102' ' ' LEU . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.644 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.512 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.502 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 1.014 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.513 ' O ' HG23 ' A' ' 54' ' ' THR . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.641 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.595 ' OH ' HD13 ' A' ' 100' ' ' LEU . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.89 HD11 HD21 ' A' ' 93' ' ' LEU . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.456 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.416 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.51 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.46 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 11.1 t-20 -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB1' " C'2" ' A' ' 111' ' ' ROM . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.641 ' OG1' HG23 ' A' ' 30' ' ' THR . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' THR . . . . . 1.014 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.494 ' O ' HG22 ' A' ' 18' ' ' VAL . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.509 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.51 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.774 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.488 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.452 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.774 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.55 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.89 HD21 HD11 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.595 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.611 HD22 ' HB2' ' A' ' 4' ' ' PHE . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.487 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.578 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB3' HD12 ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.509 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.604 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 120.72 0.295 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.28 -163.2 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.912 1.48 . . . . 0.0 109.935 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 1.034 ' CD1' HG22 ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.763 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.542 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.473 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.779 ' O ' HG22 ' A' ' 67' ' ' VAL . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.556 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 1.034 HG22 ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.446 ' N ' HG12 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.731 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.961 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.61 ' O ' HG23 ' A' ' 54' ' ' THR . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.664 ' OH ' HD22 ' A' ' 100' ' ' LEU . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.402 ' H ' HG22 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.573 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.495 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.795 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.415 ' C ' HG12 ' A' ' 39' ' ' VAL . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.899 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.495 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.479 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 51' ' ' THR . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.594 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.731 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.961 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.779 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.485 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.482 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.574 HG23 ' CG2' ' A' ' 81' ' ' VAL . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.814 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.899 HG11 ' HB2' ' A' ' 44' ' ' ALA . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.414 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.747 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.525 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.556 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.683 ' HB2' HD11 ' A' ' 107' ' ' LEU . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.455 ' HB3' ' HB2' ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.664 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' A' ' 31' ' ' TYR . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.556 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.763 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.488 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.683 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.814 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 120.667 0.27 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo -72.2 -159.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.919 1.484 . . . . 0.0 110.634 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.752 ' CD1' HG22 ' A' ' 22' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.828 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.554 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.596 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.707 HG22 ' O ' ' A' ' 65' ' ' PHE . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.549 ' N ' HG12 ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.752 HG22 ' CD1' ' A' ' 4' ' ' PHE . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.941 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.884 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.438 ' O ' HG23 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.752 ' OH ' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.502 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.502 HG23 ' C ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.941 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.884 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.647 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.493 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.707 ' O ' HG22 ' A' ' 18' ' ' VAL . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.551 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.77 HG23 HG21 ' A' ' 81' ' ' VAL . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.601 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.601 ' HD2' HG22 ' A' ' 79' ' ' THR . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.811 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.811 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.623 ' HB2' HD11 ' A' ' 107' ' ' LEU . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.421 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.483 ' C ' ' H8 ' ' A' ' 111' ' ' ROM . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.752 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.519 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 7.3 m-70 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.828 HG11 ' CG1' ' A' ' 6' ' ' VAL . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.586 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.623 HD11 ' HB2' ' A' ' 93' ' ' LEU . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.551 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 1.04 H6A3 H4B2 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 120.772 0.32 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.521 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo -73.37 -159.27 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.017 1.535 . . . . 0.0 110.262 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.625 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.594 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.437 HD12 ' HB3' ' A' ' 107' ' ' LEU . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.653 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.575 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.833 ' CG1' HD22 ' A' ' 102' ' ' LEU . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.521 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 1.041 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.628 ' O ' HG23 ' A' ' 54' ' ' THR . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.527 HG23 ' OG1' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.563 ' CE1' HD22 ' A' ' 100' ' ' LEU . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.027 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.926 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.596 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.483 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 39' ' ' VAL . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.483 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.508 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.409 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.471 ' HA ' " C'6" ' A' ' 111' ' ' ROM . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 33' ' ' ILE . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.628 HG23 ' O ' ' A' ' 29' ' ' GLU . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 1.041 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.528 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 82' ' ' GLY . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 75' ' ' THR . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.586 HG23 HG23 ' A' ' 81' ' ' VAL . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.58 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.586 HG23 HG23 ' A' ' 75' ' ' THR . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.596 HG11 ' HB3' ' A' ' 37' ' ' ALA . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.637 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 1.027 HD11 HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.409 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.543 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.563 HD22 ' CE1' ' A' ' 31' ' ' TYR . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.486 ' N ' HD23 ' A' ' 100' ' ' LEU . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.833 HD22 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.594 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.422 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.706 HD11 ' HB2' ' A' ' 93' ' ' LEU . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.63 H4A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 120.814 0.34 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.43 -173.48 1.33 Allowed 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.126 1.593 . . . . 0.0 110.519 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.922 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.69 HG11 HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.448 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.81 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 18' ' ' VAL . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 20' ' ' VAL . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.922 HG22 ' CD1' ' A' ' 4' ' ' PHE . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.717 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.42 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.482 ' O ' HG23 ' A' ' 54' ' ' THR . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.459 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.797 ' OH ' HD13 ' A' ' 100' ' ' LEU . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.468 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.049 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.65 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.65 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.436 ' SG ' H141 ' A' ' 111' ' ' ROM . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.468 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' GLU . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.717 HG21 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.793 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.81 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 14' ' ' ASP . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HG3' ' HB3' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.58 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.516 ' HB3' ' O13' ' A' ' 111' ' ' ROM . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.491 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 75' ' ' THR . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.418 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 1.049 HD11 HD11 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.628 ' HA3' ' CE1' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB3' HD12 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.524 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.595 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.452 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.797 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.643 HD12 ' HB3' ' A' ' 95' ' ' ALA . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.517 ' N ' HD13 ' A' ' 102' ' ' LEU . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.628 ' CE1' ' HA3' ' A' ' 94' ' ' GLY . 4.2 m-70 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.792 HG23 ' CD2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.481 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.515 HD11 ' HB2' ' A' ' 93' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.469 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 1.073 H6B2 H4A3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 120.799 0.333 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.67 154.5 54.53 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.985 1.518 . . . . 0.0 110.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.814 ' CD2' HG22 ' A' ' 22' ' ' VAL . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.748 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.604 HD12 ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.777 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.847 ' CG1' HD22 ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.71 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.642 ' O ' HG23 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.75 ' CE1' HD22 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.441 ' H ' HG22 ' A' ' 33' ' ' ILE . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.558 ' O ' HG12 ' A' ' 39' ' ' VAL . 12.0 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 1.08 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.494 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.477 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 33' ' ' ILE . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.642 HG23 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.71 HG21 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.654 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.519 ' O ' ' HB3' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.489 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.439 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 1.08 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.485 HG23 HG21 ' A' ' 81' ' ' VAL . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.803 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.485 HG21 HG23 ' A' ' 75' ' ' THR . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.461 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.655 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.531 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.44 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.421 ' HB2' ' HA ' ' A' ' 31' ' ' TYR . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.75 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.847 HD22 ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.531 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 29.5 m80 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.748 HG11 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.401 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.604 ' HB3' HD12 ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.803 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.552 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo -73.54 -158.16 0.07 OUTLIER 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.994 1.523 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.586 ' CD1' HG22 ' A' ' 22' ' ' VAL . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.861 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.621 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.664 HD12 ' HB3' ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.614 ' O ' HG22 ' A' ' 67' ' ' VAL . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.505 HG12 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 21' ' ' SER . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.841 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.783 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.986 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.766 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.664 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.754 ' OH ' ' HB1' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.495 ' CE1' " O2'" ' A' ' 111' ' ' ROM . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.025 HD13 ' HB2' ' A' ' 95' ' ' ALA . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.535 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.48 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.793 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.51 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.542 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.78 ' OG1' HG23 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.766 HG23 ' O ' ' A' ' 29' ' ' GLU . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.783 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.986 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.474 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' THR . . . . . 1.001 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.439 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.615 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.615 ' HD2' HG22 ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 1.001 ' CG2' HG23 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.691 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.479 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.691 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.804 ' CG ' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.806 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 1.025 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.413 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.597 HD13 ' C ' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.841 HD11 HG13 ' A' ' 22' ' ' VAL . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.861 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.664 ' HB3' HD12 ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.622 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.524 ' HG2' HD23 ' A' ' 102' ' ' LEU . 45.9 Cg_endo -72.88 -175.21 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.779 1.41 . . . . 0.0 110.081 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.97 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.855 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.532 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.636 HD12 ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.672 ' O ' HG22 ' A' ' 67' ' ' VAL . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.427 HG22 ' H ' ' A' ' 18' ' ' VAL . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.605 HG12 ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.605 ' N ' HG12 ' A' ' 20' ' ' VAL . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.97 HG22 ' CD1' ' A' ' 4' ' ' PHE . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.901 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.568 ' O ' HG23 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.45 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.603 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.611 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.925 ' OE1' HG12 ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.422 ' C ' HG23 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 39' ' ' VAL . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.9 HD22 ' H ' ' A' ' 35' ' ' GLN . 17.0 p30 -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.453 ' HB ' ' CE1' ' A' ' 65' ' ' PHE . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.901 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.719 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.925 HG12 ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.498 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.567 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 75' ' ' THR . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.751 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.611 HD12 ' O ' ' A' ' 34' ' ' ALA . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.55 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.552 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.515 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.603 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.489 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 96' ' ' GLY . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 3.6 p80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.855 HG11 ' CG1' ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.436 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.636 ' HB3' HD12 ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.688 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo -74.03 -166.81 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.031 1.542 . . . . 0.0 110.436 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.852 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.653 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.653 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.534 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.498 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.638 HE22 HG12 ' A' ' 18' ' ' VAL . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.638 HG12 HE22 ' A' ' 16' ' ' GLN . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.453 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.852 HG22 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.47 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.924 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.748 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.95 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.413 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.542 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.435 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.919 ' OH ' HD22 ' A' ' 100' ' ' LEU . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.966 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.863 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.621 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.619 HG11 ' CG1' ' A' ' 81' ' ' VAL . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.471 ' O ' HG21 ' A' ' 81' ' ' VAL . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.653 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.724 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.439 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.526 ' O ' HG22 ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.924 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.95 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' O ' HG22 ' A' ' 18' ' ' VAL . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.548 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.78 ' O ' H7A1 ' A' ' 111' ' ' ROM . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.927 HG23 HG23 ' A' ' 81' ' ' VAL . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.454 ' O ' ' OE2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.894 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.894 ' HD2' HG22 ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 75' ' ' THR . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.621 HG11 ' HB3' ' A' ' 37' ' ' ALA . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.71 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.71 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.465 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.966 HD11 HD11 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.919 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.418 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 106' ' ' ALA . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.663 HD11 ' HB2' ' A' ' 93' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.548 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.78 H7A1 ' O ' ' A' ' 74' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 120.816 0.341 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.482 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo -73.11 -162.15 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 124.023 1.538 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.946 ' CD1' HG22 ' A' ' 22' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.844 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.554 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.848 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.743 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 18' ' ' VAL . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.946 HG22 ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.594 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.841 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.612 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.404 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.432 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.471 HG23 ' CG2' ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.42 ' HG ' ' HD2' ' A' ' 32' ' ' TYR . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.626 ' HA ' ' HB2' ' A' ' 61' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.841 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.448 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.626 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.743 HG22 ' OG ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.848 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.668 ' CE1' HG11 ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.404 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.561 HG23 HG21 ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.578 ' HB3' " C'9" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.458 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.561 HG21 HG23 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG11 ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.795 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.795 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.478 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.522 ' O ' HD13 ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.612 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.522 HD13 ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.844 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.554 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.71 H4B2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.503 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo -75.81 165.99 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.965 1.508 . . . . 0.0 110.376 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.544 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.617 ' O ' HG22 ' A' ' 67' ' ' VAL . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.589 HG12 ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.589 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 1.021 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.846 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.631 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.638 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.5 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.546 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.49 ' CG ' HG23 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.599 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.625 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.429 HG21 ' HD2' ' A' ' 68' ' ' ARG . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.416 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' THR . . . . . 1.021 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.846 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.656 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.499 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.429 ' HD2' HG21 ' A' ' 49' ' ' THR . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.711 HG23 HG23 ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.51 ' HB3' " H'8" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.711 HG23 HG23 ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.559 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.561 HG22 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.726 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.726 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.832 ' HB2' HD11 ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.501 ' OG ' " H2'" ' A' ' 111' ' ' ROM . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' CE1' ' A' ' 31' ' ' TYR . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.638 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' A' ' 104' ' ' HIS . 1.5 m80 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.447 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.832 HD11 ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.544 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.489 ' HB2' ' O ' ' A' ' 86' ' ' CYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.625 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo -74.1 150.27 42.56 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.858 1.452 . . . . 0.0 110.121 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.741 ' CD2' HG22 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.718 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.508 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.53 ' O ' HG22 ' A' ' 67' ' ' VAL . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.593 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.522 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.741 HG22 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.756 ' O ' ' HB2' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.756 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.623 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.416 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.655 ' O ' HG23 ' A' ' 54' ' ' THR . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.5 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.434 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.644 ' O ' HG13 ' A' ' 39' ' ' VAL . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.541 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.657 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.493 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.465 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.857 ' HD2' ' HB1' ' A' ' 61' ' ' ALA . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.655 HG23 ' O ' ' A' ' 29' ' ' GLU . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.609 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.623 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' A' ' 55' ' ' THR . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.857 ' HB1' ' HD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' OG ' ' A' ' 17' ' ' SER . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.421 ' HG2' HG21 ' A' ' 49' ' ' THR . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.468 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.527 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.82 HG23 HG21 ' A' ' 81' ' ' VAL . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.554 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.578 HG22 ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.82 HG21 HG23 ' A' ' 75' ' ' THR . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.478 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.861 ' HB2' HD11 ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.5 ' HB3' ' O ' ' A' ' 30' ' ' THR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.6 ' C ' HD23 ' A' ' 100' ' ' LEU . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.672 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.508 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.427 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.752 ' C4D' H3A2 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 120.758 0.313 . . . . 0.0 110.365 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.71 -171.99 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 123.922 1.485 . . . . 0.0 109.933 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.779 ' CD1' HG22 ' A' ' 22' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 1.026 HG12 HG11 ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.572 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.74 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.584 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.464 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.779 HG22 ' CD1' ' A' ' 4' ' ' PHE . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.746 ' O ' ' HB3' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.746 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.589 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.59 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.69 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.413 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.503 ' NE2' HG12 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.661 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 39' ' ' VAL . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.4 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.725 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.69 ' OG1' HG23 ' A' ' 30' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.714 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.589 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.531 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.74 HG22 ' O ' ' A' ' 16' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.566 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.478 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.503 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.725 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' H ' ' A' ' 75' ' ' THR . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.662 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.485 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.485 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG2' HG23 ' A' ' 75' ' ' THR . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.661 HG11 ' HB3' ' A' ' 37' ' ' ALA . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.641 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.945 ' HB2' HD11 ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.643 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 46.1 t30 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.485 HD12 ' HG ' ' A' ' 102' ' ' LEU . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.701 HD22 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.488 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 1.026 HG11 HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.945 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.572 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.662 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.68 -158.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.42 0 O-C-N 123.816 1.43 . . . . 0.0 109.959 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.941 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.677 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.442 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.574 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.559 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.941 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.981 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.857 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.501 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 33' ' ' ILE . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.491 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.518 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.489 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.491 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.572 ' OG1' HG23 ' A' ' 30' ' ' THR . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.981 HG21 ' HB3' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.857 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.501 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.795 ' CE2' HG11 ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.436 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.439 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.721 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.636 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.431 ' OE2' H6B2 ' A' ' 111' ' ' ROM . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.441 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.721 ' CG2' HG23 ' A' ' 75' ' ' THR . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.587 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.795 HG11 ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.536 ' OD1' ' HB2' ' A' ' 89' ' ' ALA . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.441 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.536 ' HB2' ' OD1' ' A' ' 85' ' ' ASP . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.776 ' HB2' ' CE1' ' A' ' 104' ' ' HIS . 13.8 p30 -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.491 HD12 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.486 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.447 ' HA3' CL21 ' A' ' 111' ' ' ROM . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.573 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.53 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.501 ' N ' HD23 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.616 HD22 HG13 ' A' ' 22' ' ' VAL . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' HIS . . . . . 0.776 ' CE1' ' HB2' ' A' ' 92' ' ' ASN . 6.2 t-80 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 6' ' ' VAL . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 9' ' ' ALA . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.704 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 120.858 0.361 . . . . 0.0 110.395 . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 46.3 Cg_endo -72.48 -170.05 0.54 Allowed 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 124.167 1.614 . . . . 0.0 110.632 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.717 ' O ' HG13 ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.546 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.831 HG22 ' HD2' ' A' ' 8' ' ' PRO . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.642 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.831 ' HD2' HG22 ' A' ' 6' ' ' VAL . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.485 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.485 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.939 HG11 HD22 ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.62 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.404 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.62 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.842 ' O ' HG23 ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.773 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.591 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.426 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.947 HD11 HD21 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.522 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 107' ' ' LEU . 6.6 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.516 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.729 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.907 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.675 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.442 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.426 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.842 HG23 ' O ' ' A' ' 29' ' ' GLU . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.62 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.62 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.54 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.518 ' HB1' ' HD1' ' A' ' 53' ' ' PHE . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.489 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.597 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.426 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.907 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.474 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.526 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.488 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.488 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG23 ' HA ' ' A' ' 74' ' ' SER . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.516 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.947 HD21 HD11 ' A' ' 33' ' ' ILE . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.521 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.518 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.939 HD22 HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 3.2 t60 -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.596 HG12 ' N ' ' A' ' 106' ' ' ALA . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.596 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.522 HD12 ' HG3' ' A' ' 35' ' ' GLN . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.597 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.68 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.781 0.324 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HG3' HD21 ' A' ' 100' ' ' LEU . 43.0 Cg_endo -71.59 -169.28 0.41 Allowed 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.996 1.524 . . . . 0.0 110.386 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.899 ' CD1' HG22 ' A' ' 22' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.753 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.672 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.724 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.454 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.692 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.716 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.723 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 1.068 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.81 ' CE2' HD13 ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.96 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.96 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.573 ' HA ' HD12 ' A' ' 93' ' ' LEU . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.447 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.484 HG12 ' O ' ' A' ' 39' ' ' VAL . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.454 ' OE1' HG22 ' A' ' 81' ' ' VAL . 7.7 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.447 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.406 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.589 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.723 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 1.068 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.49 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.442 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.411 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.818 HG23 HG23 ' A' ' 81' ' ' VAL . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.586 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.818 HG23 HG23 ' A' ' 75' ' ' THR . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.483 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.49 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 35' ' ' GLN . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.512 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 100' ' ' LEU . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.863 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.753 HG11 ' CG1' ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 108' ' ' THR . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.421 ' HA3' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.608 ' C6 ' ' C21' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 43.3 Cg_endo -71.63 -159.65 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.844 1.444 . . . . 0.0 110.077 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 2' ' ' PRO . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.687 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 9' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.463 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.732 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.417 ' H ' HG22 ' A' ' 18' ' ' VAL . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.687 HG22 ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 1.066 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.753 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.833 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.405 ' O ' HG23 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.516 ' CE2' ' HB1' ' A' ' 25' ' ' ALA . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.438 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.479 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' GLN . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.683 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.581 ' N ' H7A3 ' A' ' 111' ' ' ROM . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.467 ' OG1' HG23 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' THR . . . . . 1.066 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.833 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.436 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.732 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.674 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.559 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.683 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.572 HG23 HG23 ' A' ' 81' ' ' VAL . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.548 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.572 HG23 HG23 ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.73 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.479 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.483 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' C ' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.463 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.547 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.608 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.71 -157.08 0.05 OUTLIER 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.952 1.501 . . . . 0.0 110.435 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.625 ' HB2' HD22 ' A' ' 102' ' ' LEU . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.657 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.74 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.872 ' HG2' HG12 ' A' ' 18' ' ' VAL . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.452 HD12 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.501 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.872 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.568 HG22 HG23 ' A' ' 6' ' ' VAL . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.552 ' N ' HG12 ' A' ' 20' ' ' VAL . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.406 ' N ' HG12 ' A' ' 22' ' ' VAL . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.732 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.959 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.474 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.75 ' O ' HG23 ' A' ' 54' ' ' THR . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.654 ' OH ' HD13 ' A' ' 100' ' ' LEU . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.531 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.899 HG12 HD11 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.56 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 3.7 tt0 -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.767 ' O ' HG23 ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.561 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.522 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.531 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.75 HG23 ' O ' ' A' ' 29' ' ' GLU . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' THR . . . . . 1.009 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.959 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 67' ' ' VAL . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 16' ' ' GLN . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.468 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.604 ' CE2' HG11 ' A' ' 84' ' ' VAL . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.979 HG23 HG21 ' A' ' 81' ' ' VAL . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.987 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 79' ' ' THR . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.979 HG21 HG23 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.604 HG11 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.899 HD11 HG12 ' A' ' 33' ' ' ILE . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.654 HD13 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.628 ' N ' HD23 ' A' ' 100' ' ' LEU . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.657 HG11 ' CG1' ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.765 HD11 ' HB2' ' A' ' 93' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.987 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.73 0.3 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.44 ' HG3' HD21 ' A' ' 100' ' ' LEU . 45.0 Cg_endo -71.83 -170.25 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.013 1.533 . . . . 0.0 110.42 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.698 ' HB3' ' OG ' ' A' ' 23' ' ' SER . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' PHE . . . . . 0.823 ' HD1' HG22 ' A' ' 22' ' ' VAL . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.575 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.77 ' O ' HG22 ' A' ' 67' ' ' VAL . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.582 HG12 ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.486 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.823 HG22 ' HD1' ' A' ' 4' ' ' PHE . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.698 ' OG ' ' HB3' ' A' ' 3' ' ' ALA . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.578 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.486 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.831 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.446 HG23 ' OG1' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.585 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.47 ' CD2' " O'2" ' A' ' 111' ' ' ROM . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.655 ' C ' HD13 ' A' ' 33' ' ' ILE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.583 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' GLN . . . . . 0.707 ' NE2' ' CE1' ' A' ' 71' ' ' TYR . 8.8 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.569 ' O ' HG13 ' A' ' 39' ' ' VAL . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.796 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' CYS . . . . . 0.488 ' SG ' H141 ' A' ' 111' ' ' ROM . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.653 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.446 ' OG1' HG23 ' A' ' 30' ' ' THR . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.578 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.831 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.507 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.707 ' CE1' ' NE2' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 72' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.796 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.543 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.53 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 75' ' ' THR . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' CE1' ' A' ' 71' ' ' TYR . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.658 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 34' ' ' ALA . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB1' HD12 ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.585 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.565 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD1' CL21 ' A' ' 111' ' ' ROM . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.778 HD22 ' CG1' ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.575 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.559 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.507 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 111' ' ' ROM . . . . . 0.653 H7A3 ' CA ' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.48 0.727 0 N-CA-C 110.39 -0.658 . . . . 0.0 110.39 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.534 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.907 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.639 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.639 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.504 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.593 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 21' ' ' SER . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.41 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.819 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.835 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 29' ' ' GLU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 95' ' ' ALA . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.493 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.553 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.755 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.491 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.491 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.439 ' O ' HG22 ' A' ' 33' ' ' ILE . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 30' ' ' THR . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.819 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.835 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.769 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.708 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.477 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.755 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.548 HG23 ' CG2' ' A' ' 81' ' ' VAL . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.435 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.409 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.548 ' CG2' HG23 ' A' ' 75' ' ' THR . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.423 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.491 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.447 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.459 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.924 ' HB2' HD11 ' A' ' 107' ' ' LEU . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.71 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.58 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.534 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.907 HG11 ' CG1' ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.459 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.924 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.504 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 C--O 1.215 -0.671 0 N-CA-C 110.127 -0.759 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.53 ' CD1' HG22 ' A' ' 22' ' ' VAL . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.908 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.443 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.423 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG12 ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.569 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.822 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.764 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.669 ' O ' HG23 ' A' ' 54' ' ' THR . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.88 ' OH ' HD13 ' A' ' 100' ' ' LEU . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.858 HD12 ' HB2' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.484 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.571 ' OE1' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.415 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.423 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.453 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.769 ' O ' HG23 ' A' ' 30' ' ' THR . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 29' ' ' GLU . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.822 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.764 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.453 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.565 ' CA ' ' CE2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.702 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.708 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.708 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.702 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.732 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.564 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.732 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.449 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.484 HD12 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.858 ' HB2' HD12 ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.485 ' C ' ' O ' ' A' ' 97' ' ' ASN . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.88 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.464 HD12 ' HA2' ' A' ' 96' ' ' GLY . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 1.6 p80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.908 HG11 ' CG1' ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.515 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.571 HD12 ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.565 ' CE2' ' CA ' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 41.9 Cg_endo . . . . . 0 C--O 1.214 -0.724 0 N-CA-C 110.381 -0.661 . . . . 0.0 110.381 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.881 ' CD1' HG22 ' A' ' 22' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.76 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.77 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.77 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.45 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.496 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.472 ' HB3' ' HG2' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.951 ' O ' HG22 ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HB ' ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.554 HG12 ' N ' ' A' ' 21' ' ' SER . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.554 ' N ' HG12 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.881 HG22 ' CD1' ' A' ' 4' ' ' PHE . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.502 ' H ' HG12 ' A' ' 22' ' ' VAL . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.844 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.435 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HD21 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.507 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.738 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.444 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.647 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.844 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.584 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.46 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.738 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.444 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.571 HG23 ' CG2' ' A' ' 81' ' ' VAL . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.573 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.573 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 75' ' ' THR . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.522 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 91' ' ' CYS . 30.5 m120 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 33' ' ' ILE . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.567 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.812 HG23 ' CD2' ' A' ' 4' ' ' PHE . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.518 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.473 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo . . . . . 0 C--O 1.216 -0.584 0 N-CA-C 110.257 -0.709 . . . . 0.0 110.257 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.531 ' CD1' HG22 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.885 HG22 ' HD2' ' A' ' 8' ' ' PRO . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.665 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.885 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 107' ' ' LEU . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.408 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.57 HG12 ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.57 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.903 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.736 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.805 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.816 ' O ' HG23 ' A' ' 54' ' ' THR . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.797 ' CZ ' ' HB1' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.44 HG12 HD11 ' A' ' 93' ' ' LEU . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.787 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.417 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.417 HG23 ' C ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.416 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.521 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 29' ' ' GLU . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.903 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.805 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.772 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.432 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.588 HG23 ' CG2' ' A' ' 81' ' ' VAL . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.484 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.588 ' CG2' HG23 ' A' ' 75' ' ' THR . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.609 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.609 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.787 HD12 ' O ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.649 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.664 HD13 ' N ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.664 ' N ' HD13 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.649 HD12 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.52 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.559 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 3.6 m-70 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.808 HG11 ' CG1' ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.415 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.553 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo . . . . . 0 C--O 1.215 -0.651 0 N-CA-C 110.323 -0.684 . . . . 0.0 110.323 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.575 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.918 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.629 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.459 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.855 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.419 ' H ' HG22 ' A' ' 18' ' ' VAL . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.601 HG12 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.601 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 4' ' ' PHE . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.791 ' OH ' HD13 ' A' ' 100' ' ' LEU . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 51' ' ' THR . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 81' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.583 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.514 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 29.4 t30 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 49' ' ' THR . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.592 ' O ' HG22 ' A' ' 33' ' ' ILE . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.598 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.855 HG22 ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.625 HG23 HG21 ' A' ' 81' ' ' VAL . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.516 HG23 ' OG1' ' A' ' 75' ' ' THR . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 39' ' ' VAL . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.512 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.444 ' OD1' ' HA ' ' A' ' 31' ' ' TYR . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.791 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.705 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.918 HG11 ' CG1' ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.451 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.556 ' HG3' HD21 ' A' ' 100' ' ' LEU . 44.3 Cg_endo . . . . . 0 C--O 1.217 -0.56 0 N-CA-C 110.218 -0.724 . . . . 0.0 110.218 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.874 ' CD2' HG22 ' A' ' 22' ' ' VAL . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.932 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.454 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.681 HG12 HE22 ' A' ' 16' ' ' GLN . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.536 HG12 ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.536 ' N ' HG12 ' A' ' 20' ' ' VAL . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.874 HG22 ' CD2' ' A' ' 4' ' ' PHE . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.576 ' O ' HG23 ' A' ' 54' ' ' THR . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.589 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.558 HD13 ' HZ ' ' A' ' 63' ' ' PHE . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.775 ' OE1' HG12 ' A' ' 67' ' ' VAL . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.427 ' CB ' HG11 ' A' ' 84' ' ' VAL . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.519 ' C ' HG23 ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.519 HG23 ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.669 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' ' 30' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.476 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 67' ' ' VAL . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.775 HG12 ' OE1' ' A' ' 35' ' ' GLN . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.497 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.669 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.443 HG23 ' CG2' ' A' ' 81' ' ' VAL . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.443 ' CG2' HG23 ' A' ' 75' ' ' THR . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.531 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.427 HG11 ' CB ' ' A' ' 37' ' ' ALA . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.751 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.463 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.786 ' HB2' HD11 ' A' ' 107' ' ' LEU . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.594 ' HA3' ' CD2' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.603 ' HB2' ' CE2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.556 HD21 ' HG3' ' A' ' 2' ' ' PRO . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.674 HD13 HG11 ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.594 ' CD2' ' HA3' ' A' ' 94' ' ' GLY . 64.0 m80 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.932 HG11 ' CG1' ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 C--O 1.215 -0.642 0 N-CA-C 110.261 -0.707 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.925 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.606 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.732 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.732 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.532 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.816 ' O ' HG22 ' A' ' 67' ' ' VAL . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 21' ' ' SER . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.506 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.605 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.888 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.519 ' O ' HG23 ' A' ' 54' ' ' THR . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 1.078 ' CE1' HD22 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.781 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.781 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.514 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.474 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.503 ' C ' HG23 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.503 HG23 ' C ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.493 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.514 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.428 ' ND2' ' CD2' ' A' ' 71' ' ' TYR . 5.1 t-20 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 1.009 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.888 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.816 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.405 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.428 ' CD2' ' ND2' ' A' ' 46' ' ' ASN . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.797 HG23 HG23 ' A' ' 81' ' ' VAL . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.453 ' O ' HG23 ' A' ' 79' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.797 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' HB3' ' A' ' 37' ' ' ALA . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.758 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.758 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.481 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 1.078 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.481 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.421 ' CE1' HD22 ' A' ' 92' ' ' ASN . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.925 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.621 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.621 HD23 ' O ' ' A' ' 106' ' ' ALA . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.48 0.709 0 N-CA-C 110.224 -0.721 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.899 ' HD1' HG22 ' A' ' 22' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.674 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.6 HG12 ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.6 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' HD1' ' A' ' 4' ' ' PHE . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.94 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.414 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.794 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.522 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CE1' HD13 ' A' ' 100' ' ' LEU . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.811 HD11 HD21 ' A' ' 93' ' ' LEU . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.515 ' NE2' HD12 ' A' ' 107' ' ' LEU . 0.6 OUTLIER -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.569 ' C ' HG23 ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.569 HG23 ' C ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.453 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.574 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.574 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.522 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.94 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.794 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.633 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.403 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.819 ' CE2' HG11 ' A' ' 84' ' ' VAL . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.453 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 HG23 ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.509 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.495 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.495 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.55 HG23 HG23 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.819 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.767 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.492 ' OD1' ' O ' ' A' ' 92' ' ' ASN . 12.3 p30 -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.811 HD21 HD11 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.594 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.473 ' O ' ' CD2' ' A' ' 104' ' ' HIS . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.473 ' CD2' ' O ' ' A' ' 103' ' ' GLY . 46.3 m170 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 6' ' ' VAL . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 106' ' ' ALA . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo . . . . . 0 N--CA 1.479 0.663 0 N-CA-C 110.418 -0.647 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.721 ' CD2' HG22 ' A' ' 22' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.525 HG11 HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.519 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.476 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.755 HD12 ' HB3' ' A' ' 107' ' ' LEU . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.793 ' O ' HG22 ' A' ' 67' ' ' VAL . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.555 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.61 HG12 ' N ' ' A' ' 21' ' ' SER . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.61 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.721 HG22 ' CD2' ' A' ' 4' ' ' PHE . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.447 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.802 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.976 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.087 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.794 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.576 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.791 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.636 ' HB2' HG13 ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.465 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.579 ' O ' HG22 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.802 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.976 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.474 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.507 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.517 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.527 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.546 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.546 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 1.087 HD11 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.494 HD22 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.534 HG12 ' N ' ' A' ' 106' ' ' ALA . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.534 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.755 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.517 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo . . . . . 0 N--CA 1.483 0.862 0 N-CA-C 109.927 -0.836 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.893 ' CD1' HG22 ' A' ' 22' ' ' VAL . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 8' ' ' PRO . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.682 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.54 HD12 ' HB3' ' A' ' 107' ' ' LEU . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.786 ' O ' HG22 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.564 HG12 ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.564 ' N ' HG12 ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.893 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.708 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.726 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.632 ' O ' HG23 ' A' ' 54' ' ' THR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.5 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.603 ' OH ' HD13 ' A' ' 100' ' ' LEU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.526 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.567 ' HB3' HD13 ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB2' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 1.046 HG12 ' O ' ' A' ' 42' ' ' GLN . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 1.046 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.606 ' CG ' ' HG1' ' A' ' 49' ' ' THR . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.606 ' HG1' ' CG ' ' A' ' 46' ' ' ASN . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.632 HG23 ' O ' ' A' ' 29' ' ' GLU . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.708 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.726 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.536 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.585 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.412 ' C ' ' O ' ' A' ' 74' ' ' SER . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.55 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.55 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.439 HG23 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.509 HG11 ' CE1' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.685 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.685 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.603 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.597 ' N ' HD23 ' A' ' 100' ' ' LEU . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.428 HD22 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.494 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.606 HG11 HG11 ' A' ' 6' ' ' VAL . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.494 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.54 ' HB3' HD12 ' A' ' 12' ' ' LEU . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.585 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.679 0 N-CA-C 110.226 -0.721 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.872 ' CD1' HG22 ' A' ' 22' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.87 HG22 ' HD2' ' A' ' 8' ' ' PRO . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.669 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.87 ' HD2' HG22 ' A' ' 6' ' ' VAL . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.475 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.44 ' O ' HG13 ' A' ' 66' ' ' VAL . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.567 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.563 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.872 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 31' ' ' TYR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.459 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.413 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.436 ' O ' HG23 ' A' ' 54' ' ' THR . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CE1' HD13 ' A' ' 100' ' ' LEU . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.838 HD11 HD21 ' A' ' 93' ' ' LEU . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.603 ' C ' HG23 ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.603 HG23 ' C ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.485 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CD2' ' HB1' ' A' ' 61' ' ' ALA . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 29' ' ' GLU . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.452 HG23 ' CE2' ' A' ' 31' ' ' TYR . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.798 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.485 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.578 ' CE ' ' HB2' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.665 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.665 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.578 ' HB2' ' CE ' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HD11 ' A' ' 33' ' ' ILE . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 100' ' ' LEU . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.646 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.858 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.475 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo . . . . . 0 C--O 1.215 -0.646 0 N-CA-C 110.271 -0.703 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.611 ' HB2' HD22 ' A' ' 102' ' ' LEU . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.644 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.512 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.502 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 1.014 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.513 ' O ' HG23 ' A' ' 54' ' ' THR . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.641 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.595 ' OH ' HD13 ' A' ' 100' ' ' LEU . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.89 HD11 HD21 ' A' ' 93' ' ' LEU . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.456 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.416 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.51 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.46 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 0.3 OUTLIER -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.641 ' OG1' HG23 ' A' ' 30' ' ' THR . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 1.014 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.494 ' O ' HG22 ' A' ' 18' ' ' VAL . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.509 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.51 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.774 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.452 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.774 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.55 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.89 HD21 HD11 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.595 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.611 HD22 ' HB2' ' A' ' 4' ' ' PHE . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.487 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.7 m170 -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.578 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB3' HD12 ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.509 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo . . . . . 0 C--O 1.215 -0.654 0 N-CA-C 109.935 -0.833 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 1.034 ' CD1' HG22 ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.763 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.542 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.473 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.779 ' O ' HG22 ' A' ' 67' ' ' VAL . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.556 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 1.034 HG22 ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.446 ' N ' HG12 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.731 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.961 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.61 ' O ' HG23 ' A' ' 54' ' ' THR . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.664 ' OH ' HD22 ' A' ' 100' ' ' LEU . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.402 ' H ' HG22 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.573 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.495 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.795 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.415 ' C ' HG12 ' A' ' 39' ' ' VAL . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.899 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.495 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 51' ' ' THR . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.594 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.731 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.961 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.779 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.485 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.482 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.574 HG23 ' CG2' ' A' ' 81' ' ' VAL . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.899 HG11 ' HB2' ' A' ' 44' ' ' ALA . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.414 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.747 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.525 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.556 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.683 ' HB2' HD11 ' A' ' 107' ' ' LEU . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.455 ' HB3' ' HB2' ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.664 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' A' ' 31' ' ' TYR . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.556 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.763 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.488 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.683 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 110.634 -0.564 . . . . 0.0 110.634 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.752 ' CD1' HG22 ' A' ' 22' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.828 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.554 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.596 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.707 HG22 ' O ' ' A' ' 65' ' ' PHE . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.549 ' N ' HG12 ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.752 HG22 ' CD1' ' A' ' 4' ' ' PHE . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.941 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.884 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.438 ' O ' HG23 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.752 ' OH ' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.502 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.502 HG23 ' C ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.941 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.884 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.647 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.493 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.707 ' O ' HG22 ' A' ' 18' ' ' VAL . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.551 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.77 HG23 HG21 ' A' ' 81' ' ' VAL . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.601 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.601 ' HD2' HG22 ' A' ' 79' ' ' THR . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.811 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.811 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.623 ' HB2' HD11 ' A' ' 107' ' ' LEU . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.421 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.424 ' OD1' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.752 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.519 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 3.4 m80 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.828 HG11 ' CG1' ' A' ' 6' ' ' VAL . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.586 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.623 HD11 ' HB2' ' A' ' 93' ' ' LEU . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.551 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.521 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo . . . . . 0 C--O 1.214 -0.696 0 N-CA-C 110.262 -0.707 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.625 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.594 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.437 HD12 ' HB3' ' A' ' 107' ' ' LEU . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.653 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.575 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.833 ' CG1' HD22 ' A' ' 102' ' ' LEU . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.521 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 1.041 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.628 ' O ' HG23 ' A' ' 54' ' ' THR . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.527 HG23 ' OG1' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.563 ' CE1' HD22 ' A' ' 100' ' ' LEU . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.027 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.926 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.596 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.483 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 39' ' ' VAL . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.483 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.508 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.409 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.402 ' O ' ' C ' ' A' ' 48' ' ' ALA . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 33' ' ' ILE . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.628 HG23 ' O ' ' A' ' 29' ' ' GLU . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 1.041 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.528 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 82' ' ' GLY . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 75' ' ' THR . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.586 HG23 HG23 ' A' ' 81' ' ' VAL . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.489 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.586 HG23 HG23 ' A' ' 75' ' ' THR . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.596 HG11 ' HB3' ' A' ' 37' ' ' ALA . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.637 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 1.027 HD11 HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.409 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.411 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.563 HD22 ' CE1' ' A' ' 31' ' ' TYR . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.486 ' N ' HD23 ' A' ' 100' ' ' LEU . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.833 HD22 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.594 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.422 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.706 HD11 ' HB2' ' A' ' 93' ' ' LEU . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo . . . . . 0 N--CA 1.48 0.687 0 N-CA-C 110.519 -0.608 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.922 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.69 HG11 HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.448 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.81 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 18' ' ' VAL . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 20' ' ' VAL . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.922 HG22 ' CD1' ' A' ' 4' ' ' PHE . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.717 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.42 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.482 ' O ' HG23 ' A' ' 54' ' ' THR . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.459 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.797 ' OH ' HD13 ' A' ' 100' ' ' LEU . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.468 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.049 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.65 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.65 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.468 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' GLU . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.717 HG21 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.793 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.81 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 14' ' ' ASP . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HG3' ' HB3' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.58 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.409 ' O ' ' C ' ' A' ' 77' ' ' GLU . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.491 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 75' ' ' THR . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.418 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 1.049 HD11 HD11 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.618 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB3' HD12 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.524 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.595 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.797 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.643 HD12 ' HB3' ' A' ' 95' ' ' ALA . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.517 ' N ' HD13 ' A' ' 102' ' ' LEU . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.618 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 1.3 m80 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.792 HG23 ' CD2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.481 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.515 HD11 ' HB2' ' A' ' 93' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.469 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo . . . . . 0 N--CA 1.48 0.715 0 N-CA-C 110.448 -0.635 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.814 ' CD2' HG22 ' A' ' 22' ' ' VAL . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.748 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.604 HD12 ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.777 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.847 ' CG1' HD22 ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.71 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.642 ' O ' HG23 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.75 ' CE1' HD22 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.441 ' H ' HG22 ' A' ' 33' ' ' ILE . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.558 ' O ' HG12 ' A' ' 39' ' ' VAL . 2.5 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 1.08 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.477 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 33' ' ' ILE . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.642 HG23 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.71 HG21 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.654 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.519 ' O ' ' HB3' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.489 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.439 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 1.08 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.485 HG23 HG21 ' A' ' 81' ' ' VAL . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.485 HG21 HG23 ' A' ' 75' ' ' THR . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.461 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.655 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.531 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.44 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.421 ' HB2' ' HA ' ' A' ' 31' ' ' TYR . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.75 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.847 HD22 ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.531 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 21.0 m-70 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.748 HG11 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.401 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.604 ' HB3' HD12 ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.552 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo . . . . . 0 N--CA 1.479 0.662 0 N-CA-C 110.237 -0.716 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.586 ' CD1' HG22 ' A' ' 22' ' ' VAL . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.861 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.621 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.664 HD12 ' HB3' ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.614 ' O ' HG22 ' A' ' 67' ' ' VAL . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.505 HG12 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 21' ' ' SER . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.841 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.783 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.986 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.766 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.664 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.754 ' OH ' ' HB1' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.477 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.025 HD13 ' HB2' ' A' ' 95' ' ' ALA . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.465 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.48 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.793 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.425 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.474 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.78 ' OG1' HG23 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.766 HG23 ' O ' ' A' ' 29' ' ' GLU . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.783 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.986 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.474 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 1.001 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.615 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.615 ' HD2' HG22 ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 1.001 ' CG2' HG23 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.691 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.479 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.691 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.804 ' CG ' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.806 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 1.025 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.597 HD13 ' C ' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.841 HD11 HG13 ' A' ' 22' ' ' VAL . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.861 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.432 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.664 ' HB3' HD12 ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.524 ' HG2' HD23 ' A' ' 102' ' ' LEU . 45.9 Cg_endo . . . . . 0 C--O 1.215 -0.641 0 N-CA-C 110.081 -0.777 . . . . 0.0 110.081 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.97 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.855 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.532 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.636 HD12 ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.672 ' O ' HG22 ' A' ' 67' ' ' VAL . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG22 ' H ' ' A' ' 18' ' ' VAL . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.605 HG12 ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.605 ' N ' HG12 ' A' ' 20' ' ' VAL . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.97 HG22 ' CD1' ' A' ' 4' ' ' PHE . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.901 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.568 ' O ' HG23 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.45 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.603 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.611 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.925 ' OE1' HG12 ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.422 ' C ' HG23 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 39' ' ' VAL . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.7 OUTLIER -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 46' ' ' ASN . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.549 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.901 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.719 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.925 HG12 ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.498 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.471 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 75' ' ' THR . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.751 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.611 HD12 ' O ' ' A' ' 34' ' ' ALA . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.55 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 100' ' ' LEU . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.603 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.489 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 96' ' ' GLY . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 1.4 p-80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.855 HG11 ' CG1' ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.436 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.636 ' HB3' HD12 ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo . . . . . 0 C--O 1.215 -0.668 0 N-CA-C 110.436 -0.64 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.852 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.653 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.653 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.534 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.498 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.638 HE22 HG12 ' A' ' 18' ' ' VAL . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.638 HG12 HE22 ' A' ' 16' ' ' GLN . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.453 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.852 HG22 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.47 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.924 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.748 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.95 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.413 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.542 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.435 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.919 ' OH ' HD22 ' A' ' 100' ' ' LEU . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.966 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.863 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.621 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.619 HG11 ' CG1' ' A' ' 81' ' ' VAL . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.471 ' O ' HG21 ' A' ' 81' ' ' VAL . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.653 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 46' ' ' ASN . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.439 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.526 ' O ' HG22 ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.924 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.95 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.462 ' O ' HG22 ' A' ' 18' ' ' VAL . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.548 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.653 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.927 HG23 HG23 ' A' ' 81' ' ' VAL . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.454 ' O ' ' OE2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.894 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.894 ' HD2' HG22 ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 75' ' ' THR . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.621 HG11 ' HB3' ' A' ' 37' ' ' ALA . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.71 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.71 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.465 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.966 HD11 HD11 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.919 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.418 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.1 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 106' ' ' ALA . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.663 HD11 ' HB2' ' A' ' 93' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.548 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.482 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo . . . . . 0 N--CA 1.482 0.82 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.946 ' CD1' HG22 ' A' ' 22' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.844 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.554 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.848 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.743 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 18' ' ' VAL . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.946 HG22 ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.594 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.841 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.612 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.404 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.432 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.471 HG23 ' CG2' ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.42 ' HG ' ' HD2' ' A' ' 32' ' ' TYR . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.626 ' HA ' ' HB2' ' A' ' 61' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.841 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.448 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.626 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.743 HG22 ' OG ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.848 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.668 ' CE1' HG11 ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.404 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.561 HG23 HG21 ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.458 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.561 HG21 HG23 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.668 HG11 ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.795 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.795 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.478 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.522 ' O ' HD13 ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.612 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.522 HD13 ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.844 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.554 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.503 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo . . . . . 0 C--O 1.214 -0.7 0 N-CA-C 110.376 -0.663 . . . . 0.0 110.376 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.544 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.617 ' O ' HG22 ' A' ' 67' ' ' VAL . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.589 HG12 ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.589 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 1.021 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.846 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.631 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.638 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.546 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.49 ' CG ' HG23 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.599 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.429 HG21 ' HD2' ' A' ' 68' ' ' ARG . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.416 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 1.021 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.846 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.656 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.499 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.429 ' HD2' HG21 ' A' ' 49' ' ' THR . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.711 HG23 HG23 ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.711 HG23 HG23 ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.559 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.561 HG22 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.726 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.726 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.832 ' HB2' HD11 ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' CE1' ' A' ' 31' ' ' TYR . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.638 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.533 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.616 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 2.4 m-70 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.447 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.832 HD11 ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.544 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.489 ' HB2' ' O ' ' A' ' 86' ' ' CYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo . . . . . 0 C--O 1.215 -0.653 0 N-CA-C 110.121 -0.761 . . . . 0.0 110.121 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.741 ' CD2' HG22 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.718 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.508 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.53 ' O ' HG22 ' A' ' 67' ' ' VAL . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.593 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.522 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.741 HG22 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.756 ' O ' ' HB2' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.756 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.623 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.416 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.655 ' O ' HG23 ' A' ' 54' ' ' THR . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.5 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.434 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.644 ' O ' HG13 ' A' ' 39' ' ' VAL . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.541 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.493 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.465 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.857 ' HD2' ' HB1' ' A' ' 61' ' ' ALA . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.655 HG23 ' O ' ' A' ' 29' ' ' GLU . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.609 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.623 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' A' ' 55' ' ' THR . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.857 ' HB1' ' HD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' OG ' ' A' ' 17' ' ' SER . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.421 ' HG2' HG21 ' A' ' 49' ' ' THR . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.468 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.527 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.82 HG23 HG21 ' A' ' 81' ' ' VAL . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.503 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.578 HG22 ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.82 HG21 HG23 ' A' ' 75' ' ' THR . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.488 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.478 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.861 ' HB2' HD11 ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.5 ' HB3' ' O ' ' A' ' 30' ' ' THR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.6 ' C ' HD23 ' A' ' 100' ' ' LEU . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.672 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.508 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.427 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 C--O 1.216 -0.618 0 N-CA-C 109.933 -0.833 . . . . 0.0 109.933 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.779 ' CD1' HG22 ' A' ' 22' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 1.026 HG12 HG11 ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.572 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.74 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.584 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.464 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.779 HG22 ' CD1' ' A' ' 4' ' ' PHE . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.746 ' O ' ' HB3' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.746 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.589 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.59 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.69 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.503 ' NE2' HG12 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.661 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 39' ' ' VAL . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 1.1 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.725 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.69 ' OG1' HG23 ' A' ' 30' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.714 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.589 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.531 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.74 HG22 ' O ' ' A' ' 16' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.566 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.478 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.503 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.725 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' H ' ' A' ' 75' ' ' THR . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HG2' ' A' ' 77' ' ' GLU . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.485 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.485 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG2' HG23 ' A' ' 75' ' ' THR . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.661 HG11 ' HB3' ' A' ' 37' ' ' ALA . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.641 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.945 ' HB2' HD11 ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.643 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 12.5 t-20 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.485 HD12 ' HG ' ' A' ' 102' ' ' LEU . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.701 HD22 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.488 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 1.026 HG11 HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.945 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.572 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.479 0.664 0 N-CA-C 109.959 -0.823 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.941 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.677 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.442 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.574 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.559 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.941 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.981 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.857 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.501 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 33' ' ' ILE . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.491 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.489 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.572 ' OG1' HG23 ' A' ' 30' ' ' THR . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.981 HG21 ' HB3' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.857 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.501 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.795 ' CE2' HG11 ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.436 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.439 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.721 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.441 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.721 ' CG2' HG23 ' A' ' 75' ' ' THR . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.587 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.795 HG11 ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.536 ' OD1' ' HB2' ' A' ' 89' ' ' ALA . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.441 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.536 ' HB2' ' OD1' ' A' ' 85' ' ' ASP . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.626 ' ND2' ' CE1' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.491 HD12 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.486 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.503 ' HB2' ' O ' ' A' ' 30' ' ' THR . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.53 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.501 ' N ' HD23 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.616 HD22 HG13 ' A' ' 22' ' ' VAL . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.626 ' CE1' ' ND2' ' A' ' 92' ' ' ASN . 4.7 t60 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 6' ' ' VAL . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 9' ' ' ALA . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 N--CA 1.481 0.762 0 N-CA-C 110.632 -0.565 . . . . 0.0 110.632 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.717 ' O ' HG13 ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.546 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.831 HG22 ' HD2' ' A' ' 8' ' ' PRO . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.642 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.831 ' HD2' HG22 ' A' ' 6' ' ' VAL . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.485 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.485 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.939 HG11 HD22 ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.62 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.404 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.62 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.842 ' O ' HG23 ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.773 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.591 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.426 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.947 HD11 HD21 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.47 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 107' ' ' LEU . 26.3 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.516 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.729 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.907 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.442 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.426 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.842 HG23 ' O ' ' A' ' 29' ' ' GLU . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.62 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.62 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.54 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.518 ' HB1' ' HD1' ' A' ' 53' ' ' PHE . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.489 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.597 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.426 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.907 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.474 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.474 ' HD2' ' HB ' ' A' ' 75' ' ' THR . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.488 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.488 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG23 ' HA ' ' A' ' 74' ' ' SER . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.516 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.947 HD21 HD11 ' A' ' 33' ' ' ILE . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.526 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.497 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.939 HD22 HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . 0.526 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 0.5 OUTLIER -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.596 HG12 ' N ' ' A' ' 106' ' ' ALA . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.596 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.522 HD12 ' HG3' ' A' ' 35' ' ' GLN . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.597 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HG3' HD21 ' A' ' 100' ' ' LEU . 43.0 Cg_endo . . . . . 0 N--CA 1.48 0.734 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.899 ' CD1' HG22 ' A' ' 22' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.753 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.672 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.724 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.454 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.692 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.716 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.723 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 1.068 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.81 ' CE2' HD13 ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.96 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.96 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.573 ' HA ' HD12 ' A' ' 93' ' ' LEU . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.447 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.484 HG12 ' O ' ' A' ' 39' ' ' VAL . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.604 ' NE2' HG22 ' A' ' 81' ' ' VAL . 19.2 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.447 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.406 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.406 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.723 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 1.068 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.49 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.442 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.411 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.818 HG23 HG23 ' A' ' 81' ' ' VAL . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.818 HG23 HG23 ' A' ' 75' ' ' THR . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.483 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.49 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 35' ' ' GLN . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 100' ' ' LEU . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.863 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.753 HG11 ' CG1' ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 108' ' ' THR . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.421 ' HA3' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 43.3 Cg_endo . . . . . 0 C--O 1.215 -0.644 0 N-CA-C 110.077 -0.778 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 2' ' ' PRO . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.687 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.463 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.732 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.417 ' H ' HG22 ' A' ' 18' ' ' VAL . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.687 HG22 ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 1.066 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.753 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.833 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.405 ' O ' HG23 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.516 ' CE2' ' HB1' ' A' ' 25' ' ' ALA . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.479 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.683 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 45' ' ' CYS . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.467 ' OG1' HG23 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 1.066 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.833 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.436 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.732 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.674 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.559 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.683 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.572 HG23 HG23 ' A' ' 81' ' ' VAL . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.572 HG23 HG23 ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.73 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.479 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.483 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' C ' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.463 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.547 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.216 -0.596 0 N-CA-C 110.435 -0.64 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.625 ' HB2' HD22 ' A' ' 102' ' ' LEU . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.657 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.74 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.872 ' HG2' HG12 ' A' ' 18' ' ' VAL . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.452 HD12 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.501 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.872 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.568 HG22 HG23 ' A' ' 6' ' ' VAL . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.552 ' N ' HG12 ' A' ' 20' ' ' VAL . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.406 ' N ' HG12 ' A' ' 22' ' ' VAL . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.732 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.959 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.474 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.75 ' O ' HG23 ' A' ' 54' ' ' THR . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.654 ' OH ' HD13 ' A' ' 100' ' ' LEU . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.531 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.899 HG12 HD11 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.56 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.767 ' O ' HG23 ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . 0.522 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.531 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.75 HG23 ' O ' ' A' ' 29' ' ' GLU . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 1.009 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.959 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 67' ' ' VAL . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 16' ' ' GLN . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.468 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.604 ' CE2' HG11 ' A' ' 84' ' ' VAL . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.979 HG23 HG21 ' A' ' 81' ' ' VAL . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 79' ' ' THR . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.979 HG21 HG23 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.604 HG11 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.899 HD11 HG12 ' A' ' 33' ' ' ILE . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.654 HD13 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.628 ' N ' HD23 ' A' ' 100' ' ' LEU . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.657 HG11 ' CG1' ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.765 HD11 ' HB2' ' A' ' 93' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.44 ' HG3' HD21 ' A' ' 100' ' ' LEU . 45.0 Cg_endo . . . . . 0 C--O 1.214 -0.703 0 N-CA-C 110.42 -0.646 . . . . 0.0 110.42 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.698 ' HB3' ' OG ' ' A' ' 23' ' ' SER . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . 0.823 ' HD1' HG22 ' A' ' 22' ' ' VAL . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.575 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.77 ' O ' HG22 ' A' ' 67' ' ' VAL . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.582 HG12 ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.486 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.823 HG22 ' HD1' ' A' ' 4' ' ' PHE . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.698 ' OG ' ' HB3' ' A' ' 3' ' ' ALA . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.578 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.486 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.831 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.446 HG23 ' OG1' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.585 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.655 ' C ' HD13 ' A' ' 33' ' ' ILE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.583 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' GLN . . . . . 0.564 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 7.5 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.569 ' O ' HG13 ' A' ' 39' ' ' VAL . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.796 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.446 ' OG1' HG23 ' A' ' 30' ' ' THR . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.578 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.831 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.507 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.564 ' CE1' ' OE1' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.796 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.543 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 75' ' ' THR . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' CE1' ' A' ' 71' ' ' TYR . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.658 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 34' ' ' ALA . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB1' HD12 ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.585 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.565 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.778 HD22 ' CG1' ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.575 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.559 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.507 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.485 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 120.745 0.307 . . . . 0.0 110.289 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.485 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 44.3 Cg_endo -73.32 -167.32 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.078 1.568 . . . . 0.0 110.39 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.534 ' O ' HD22 ' A' ' 102' ' ' LEU . . . -139.88 174.23 10.73 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.156 -0.965 . . . . 0.0 110.49 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.522 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 3.6 t80 -155.15 135.46 13.2 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.402 -0.811 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -146.59 158.56 43.92 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.83 -1.169 . . . . 0.0 111.482 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.907 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.3 p -127.1 147.97 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.639 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 3.7 t -59.81 -78.08 0.06 OUTLIER Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 120.515 -1.366 . . . . 0.0 109.339 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.639 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -81.42 166.19 18.13 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 N-CA-C 109.684 -0.929 . . . . 0.0 109.684 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -161.92 20.65 0.11 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.135 -0.978 . . . . 0.0 110.198 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.504 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -166.32 142.83 4.94 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.318 -0.864 . . . . 0.0 109.771 179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.57 31.6 65.27 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 71.8 mt -68.99 -155.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -1.068 . . . . 0.0 110.605 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.525 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -170.82 155.72 4.8 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.48 -0.762 . . . . 0.0 110.129 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.3 t0 -64.9 132.41 49.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.964 -1.085 . . . . 0.0 109.737 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.29 -28.69 5.56 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.1 tt0 -50.83 136.93 21.49 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.286 -1.126 . . . . 0.0 110.568 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 80.1 p -111.18 122.92 49.12 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.501 -0.75 . . . . 0.0 109.337 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.593 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 31.3 m -98.39 166.9 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 O-C-N 121.137 -0.977 . . . . 0.0 110.519 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.9 m -102.57 99.53 9.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.408 -0.807 . . . . 0.0 109.344 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 21' ' ' SER . 43.6 t -85.38 160.87 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 O-C-N 121.256 -0.902 . . . . 0.0 110.434 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.41 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -160.09 118.87 2.72 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.598 -0.689 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.9 t -107.64 169.53 2.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.283 -0.886 . . . . 0.0 110.146 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.4 p -165.38 143.42 6.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.308 -0.87 . . . . 0.0 110.207 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 117.89 -27.6 7.4 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.819 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -65.36 -154.37 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.253 -1.145 . . . . 0.0 110.152 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.19 139.89 24.91 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.016 -1.052 . . . . 0.0 110.696 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.835 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.12 131.18 31.84 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.333 -0.854 . . . . 0.0 110.423 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.18 -2.82 29.82 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.58 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 10.2 mm-40 -109.84 140.52 43.69 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.126 -1.22 . . . . 0.0 110.429 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 7.8 m -124.72 106.09 9.8 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.498 -0.752 . . . . 0.0 109.287 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CZ ' ' HB3' ' A' ' 29' ' ' GLU . 18.5 m-85 -97.66 164.68 12.31 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.309 -0.87 . . . . 0.0 110.597 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 5.8 m-85 -104.29 148.08 26.77 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.387 -0.82 . . . . 0.0 109.767 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 95' ' ' ALA . 1.5 tp -131.39 144.65 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.081 -1.012 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.493 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.2 154.81 6.13 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.348 -0.845 . . . . 0.0 110.187 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -97.51 164.64 12.35 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.309 -0.869 . . . . 0.0 109.44 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -145.45 -178.39 6.05 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.049 -1.032 . . . . 0.0 111.168 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.553 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -175.12 130.28 0.42 Allowed Pre-proline 0 C--N 1.302 -1.484 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -70.85 160.81 48.18 Favored 'Trans proline' 0 C--N 1.3 -2.006 0 O-C-N 123.814 1.429 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 39' ' ' VAL . 85.3 t -129.06 66.02 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.539 -0.725 . . . . 0.0 109.617 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 45.21 26.06 1.3 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.39 -80.05 0.04 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.54 -166.18 1.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.184 -1.186 . . . . 0.0 110.402 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.411 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 6.6 p-10 -114.74 113.6 24.5 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.896 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.755 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -101.85 153.66 19.63 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.353 -0.842 . . . . 0.0 110.466 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 66.9 m -126.92 156.66 41.12 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.864 -1.148 . . . . 0.0 110.008 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.491 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 27.8 t-20 -71.07 123.86 90.04 Favored Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.343 -0.848 . . . . 0.0 110.743 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.493 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -81.83 -23.79 4.49 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.874 1.46 . . . . 0.0 110.59 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.96 -43.52 13.12 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.327 -0.858 . . . . 0.0 110.784 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.491 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 81.6 p -87.91 87.34 7.32 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.027 -1.046 . . . . 0.0 110.329 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -163.52 99.15 0.91 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.414 -0.804 . . . . 0.0 109.833 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.439 ' O ' HG22 ' A' ' 33' ' ' ILE . 8.9 t -122.25 155.64 35.47 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.187 -0.946 . . . . 0.0 110.363 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.9 p -102.6 134.06 46.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 110.022 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 30' ' ' THR . 44.4 p90 -124.07 157.68 33.98 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.265 -0.897 . . . . 0.0 109.976 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 29' ' ' GLU . 30.4 m -109.34 156.61 19.78 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.869 . . . . 0.0 110.053 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.819 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.3 p -89.95 175.84 7.04 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.247 -0.908 . . . . 0.0 110.422 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.835 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.5 m-20 -96.95 -165.06 1.21 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.433 -0.792 . . . . 0.0 109.986 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.769 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.49 -29.03 70.36 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.218 -0.927 . . . . 0.0 110.151 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.9 t -93.67 21.15 6.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.247 -0.908 . . . . 0.0 109.843 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 54.56 18.75 11.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.25 130.86 55.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -1.114 . . . . 0.0 110.107 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.22 169.43 14.17 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.27 -0.894 . . . . 0.0 110.512 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -166.6 123.65 1.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.555 -0.715 . . . . 0.0 109.264 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -154.7 163.97 39.46 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.035 -1.041 . . . . 0.0 110.619 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 94.8 p -92.18 121.75 34.01 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.37 -0.831 . . . . 0.0 109.93 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -113.76 136.97 52.27 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.358 -0.839 . . . . 0.0 110.389 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 32.3 t -85.69 164.52 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 110.107 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.3 m -137.33 165.91 26.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.707 0 O-C-N 121.451 -0.78 . . . . 0.0 110.074 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 9.3 mtp85 -134.99 104.23 5.88 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.136 -0.978 . . . . 0.0 109.997 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.574 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 11.9 ttpp -43.55 -55.24 4.38 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.465 -0.772 . . . . 0.0 111.497 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.455 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 13.4 t -111.65 146.5 37.34 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 120.95 -1.094 . . . . 0.0 111.313 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.708 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 29.9 p90 -178.46 138.3 0.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.612 -0.68 . . . . 0.0 109.656 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.7 OUTLIER -58.18 127.9 34.41 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.98 -1.075 . . . . 0.0 110.027 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.477 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -86.06 153.11 26.43 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 120.114 -1.041 . . . . 0.0 110.633 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.755 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 0.2 OUTLIER -161.66 -155.43 0.39 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.589 -0.948 . . . . 0.0 109.391 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.548 HG23 ' CG2' ' A' ' 81' ' ' VAL . 19.0 p -124.93 144.13 46.03 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.0 -1.063 . . . . 0.0 110.321 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.812 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 41.1 Cg_endo -66.13 -9.63 24.24 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.186 1.624 . . . . 0.0 111.061 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -86.63 -48.94 7.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.27 -0.894 . . . . 0.0 110.308 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 145.4 54.27 0.02 OUTLIER Glycine 0 N--CA 1.493 2.446 0 N-CA-C 108.967 -1.653 . . . . 0.0 108.967 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.435 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.2 OUTLIER -151.71 137.46 11.14 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.411 -1.052 . . . . 0.0 110.202 -179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.409 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 49.2 Cg_endo -76.21 150.64 33.38 Favored 'Trans proline' 0 C--N 1.3 -1.989 0 O-C-N 123.84 1.442 . . . . 0.0 110.541 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.548 ' CG2' HG23 ' A' ' 75' ' ' THR . 70.6 t -131.79 -47.71 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.333 -0.854 . . . . 0.0 109.846 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.423 ' HA3' HG11 ' A' ' 39' ' ' VAL . . . 166.4 -179.96 40.09 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.305 -1.518 . . . . 0.0 109.305 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.6 OUTLIER -91.4 153.32 19.95 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.322 -1.105 . . . . 0.0 110.364 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 5.6 t -122.93 152.31 27.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.184 -0.948 . . . . 0.0 110.026 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -158.49 118.47 3.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 110.19 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.491 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -82.93 23.76 0.81 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.365 -0.835 . . . . 0.0 111.351 -179.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.447 ' O ' ' HB ' ' A' ' 88' ' ' THR . . . -76.78 5.06 8.35 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.894 -1.128 . . . . 0.0 109.182 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 87' ' ' ALA . 5.2 t 177.96 -30.72 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -59.52 175.03 0.37 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.779 -0.576 . . . . 0.0 110.291 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.85 89.08 3.0 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.329 -0.857 . . . . 0.0 109.484 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.453 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.4 m -79.29 163.17 25.14 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.193 -0.942 . . . . 0.0 110.655 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.459 ' OD1' ' HA ' ' A' ' 106' ' ' ALA . 5.8 m-20 -146.44 -177.67 5.75 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.507 -0.746 . . . . 0.0 109.805 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.924 ' HB2' HD11 ' A' ' 107' ' ' LEU . 55.6 tp -145.73 147.22 31.69 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.187 -0.945 . . . . 0.0 109.923 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -158.58 159.25 30.03 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.2 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.71 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -140.07 164.78 29.12 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.479 -1.013 . . . . 0.0 110.311 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 150.79 168.26 15.4 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.458 ' O ' CL21 ' A' ' 111' ' ' ROM . 9.7 t30 -116.98 179.52 4.0 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.015 -1.285 . . . . 0.0 110.504 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 38.0 m -41.76 -29.29 0.19 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.411 -0.806 . . . . 0.0 111.621 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.421 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.53 -85.07 0.73 Allowed Glycine 0 N--CA 1.493 2.496 0 C-N-CA 119.299 -1.429 . . . . 0.0 110.41 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.58 HD22 ' CE1' ' A' ' 31' ' ' TYR . 3.1 tt -38.05 128.18 1.28 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.529 -0.983 . . . . 0.0 111.147 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -117.51 153.18 33.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.346 -0.846 . . . . 0.0 109.654 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.534 HD22 ' O ' ' A' ' 3' ' ' ALA . 5.7 mt -121.02 -89.85 0.59 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.099 -1.001 . . . . 0.0 110.598 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -175.72 -177.11 44.51 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.522 ' CB ' ' O ' ' A' ' 93' ' ' LEU . 5.1 p-80 -142.63 137.33 29.92 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.288 -1.125 . . . . 0.0 110.451 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.907 HG11 ' CG1' ' A' ' 6' ' ' VAL . 49.5 t -102.02 136.99 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.297 -0.877 . . . . 0.0 109.561 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.459 ' HA ' ' OD1' ' A' ' 92' ' ' ASN . . . -81.44 129.75 34.77 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.986 -1.071 . . . . 0.0 109.959 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.924 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.5 mt -105.52 169.13 8.64 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.314 -0.866 . . . . 0.0 109.942 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.504 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.9 m -152.5 113.51 4.2 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.063 -1.023 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.574 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 27.2 m-85 -84.99 128.35 34.59 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.262 -0.899 . . . . 0.0 110.31 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' A' ' 109' ' ' PHE . . . . . . . . 0 N--CA 1.49 2.29 0 CA-C-O 117.993 -1.448 . . . . 0.0 109.507 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.812 H7A2 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.837 0.351 . . . . 0.0 110.317 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.41 179.7 5.27 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.042 1.548 . . . . 0.0 110.127 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -138.51 176.93 8.27 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -0.957 . . . . 0.0 110.647 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.53 ' CD1' HG22 ' A' ' 22' ' ' VAL . 14.8 t80 -166.36 127.08 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.471 -0.768 . . . . 0.0 109.273 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -152.47 163.97 38.48 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.847 -1.158 . . . . 0.0 111.818 -179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.908 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.1 p -124.73 155.37 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.631 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -66.65 -72.9 0.24 Allowed Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 120.68 -1.263 . . . . 0.0 109.516 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.631 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -76.25 175.67 11.04 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 N-CA-C 109.344 -1.06 . . . . 0.0 109.344 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.37 31.51 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.286 -0.884 . . . . 0.0 109.959 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 30.8 p -174.86 157.69 2.46 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.448 -0.782 . . . . 0.0 109.717 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.71 51.86 31.8 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.978 -1.649 . . . . 0.0 108.978 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.443 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 65.2 mt -89.49 -166.81 1.69 Allowed 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.376 -1.073 . . . . 0.0 110.793 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 4.6 m -157.75 148.8 21.28 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.364 -0.835 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -56.79 129.93 43.43 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.137 -0.977 . . . . 0.0 110.15 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 87.59 -29.57 5.29 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.276 -1.529 . . . . 0.0 109.276 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.423 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 2.9 tt0 -44.18 156.29 0.07 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -1.056 . . . . 0.0 110.04 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 63.2 m -129.73 140.35 51.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.165 -0.959 . . . . 0.0 110.188 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.587 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.6 m -121.46 164.8 17.8 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.375 -0.828 . . . . 0.0 110.138 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.5 t -96.52 105.11 17.15 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.181 -0.949 . . . . 0.0 110.471 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG12 ' N ' ' A' ' 21' ' ' SER . 55.9 t -96.33 168.96 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.151 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.569 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.1 t -167.47 125.5 1.25 Allowed 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.34 -0.85 . . . . 0.0 109.927 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -109.94 155.48 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 O-C-N 121.391 -0.818 . . . . 0.0 110.165 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 92.8 p -155.05 171.5 19.66 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 87.83 -28.47 5.96 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.822 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.04 -139.47 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.309 -1.113 . . . . 0.0 110.008 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -170.79 139.68 1.54 Allowed 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.726 -1.233 . . . . 0.0 111.147 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.764 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.6 132.6 35.84 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.542 -0.724 . . . . 0.0 110.469 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.17 17.75 11.22 Favored Glycine 0 N--CA 1.483 1.771 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.669 ' O ' HG23 ' A' ' 54' ' ' THR . 3.5 mm-40 -141.54 150.91 42.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.274 -1.133 . . . . 0.0 110.594 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 53' ' ' PHE . 41.5 m -128.42 138.74 52.47 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.491 -0.756 . . . . 0.0 109.801 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.88 ' OH ' HD13 ' A' ' 100' ' ' LEU . 42.1 m-85 -121.39 158.94 27.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.137 -0.977 . . . . 0.0 110.238 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 33.2 m-85 -117.88 128.29 54.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.948 . . . . 0.0 110.072 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.858 HD12 ' HB2' ' A' ' 95' ' ' ALA . 5.4 tt -115.63 148.44 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.905 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.484 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.32 156.61 21.65 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.11 -0.994 . . . . 0.0 110.507 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.571 ' OE1' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -88.62 140.67 29.21 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.449 -0.782 . . . . 0.0 110.173 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 64.8 m -143.06 147.17 34.61 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.441 -0.787 . . . . 0.0 109.901 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -129.87 150.92 77.22 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.056 -1.027 . . . . 0.0 110.087 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.01 160.96 44.79 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.838 1.441 . . . . 0.0 110.705 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 10.5 m -146.48 74.78 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.323 -0.86 . . . . 0.0 110.563 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.92 -63.44 3.18 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.88 21.24 0.18 Allowed Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -134.74 -169.94 2.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.743 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -124.53 131.55 53.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -119.38 150.04 40.84 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.569 -0.707 . . . . 0.0 109.159 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.415 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 12.2 m -123.48 179.61 4.69 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.817 -1.177 . . . . 0.0 110.534 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 56.2 t30 -125.78 120.78 24.35 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.404 -0.81 . . . . 0.0 110.397 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.429 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -73.89 -3.71 14.22 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 O-C-N 123.89 1.468 . . . . 0.0 110.416 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.423 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . . . -90.64 -26.86 19.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.219 -0.925 . . . . 0.0 110.49 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.453 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 25.3 p -108.54 29.41 7.42 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.234 -0.916 . . . . 0.0 110.647 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.08 97.26 10.82 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.079 -1.013 . . . . 0.0 110.175 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.469 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.7 p -99.35 168.32 10.09 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.188 -0.945 . . . . 0.0 110.481 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.2 p -138.09 133.74 33.83 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.545 -0.722 . . . . 0.0 109.577 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.769 ' O ' HG23 ' A' ' 30' ' ' THR . 27.0 p90 -140.11 177.28 8.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.055 -1.028 . . . . 0.0 110.775 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 29' ' ' GLU . 32.0 m -137.35 156.74 47.87 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.511 -0.743 . . . . 0.0 109.775 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.822 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.5 p -82.14 168.67 17.47 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.053 -1.029 . . . . 0.0 110.338 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.764 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 17.5 m-20 -91.77 -166.36 1.54 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.395 -0.815 . . . . 0.0 109.753 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.546 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -66.24 -30.16 70.54 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.838 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 32.0 m -89.8 11.57 19.73 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.415 -0.803 . . . . 0.0 109.986 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.0 58.09 14.36 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -157.5 130.01 7.37 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.262 -1.14 . . . . 0.0 109.762 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -125.98 165.9 17.92 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.089 -1.007 . . . . 0.0 110.953 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -163.5 127.78 2.86 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 14.2 p90 -162.7 168.7 21.19 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.93 -1.107 . . . . 0.0 110.324 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.4 m -92.91 116.07 28.71 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.375 -0.828 . . . . 0.0 110.096 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.561 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 43.5 t80 -99.43 145.23 27.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.229 -0.919 . . . . 0.0 110.041 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.561 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 10.7 t -94.08 160.96 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.06 -1.025 . . . . 0.0 110.866 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 16.3 m -131.58 145.61 34.84 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.453 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 11.2 mtt180 -126.49 102.21 7.02 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.922 -1.111 . . . . 0.0 110.626 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.565 ' CA ' ' CE2' ' A' ' 109' ' ' PHE . 6.9 ttmt -40.11 -60.3 1.08 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.746 -0.596 . . . . 0.0 110.762 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.2 t -100.43 148.58 24.58 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.179 -0.951 . . . . 0.0 110.967 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.702 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 11.5 p90 -177.41 152.54 0.85 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.432 -0.792 . . . . 0.0 109.95 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.8 m -69.82 127.41 32.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.023 -1.048 . . . . 0.0 110.37 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -87.69 149.79 21.96 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 5.1 p -179.15 116.2 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.335 -1.097 . . . . 0.0 110.125 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.708 HG23 ' CG2' ' A' ' 81' ' ' VAL . 44.3 p -42.13 142.06 1.26 Allowed Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.322 -0.861 . . . . 0.0 110.272 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.436 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.3 Cg_endo -71.18 -2.17 10.73 Favored 'Trans proline' 0 C--N 1.302 -1.874 0 O-C-N 124.116 1.587 . . . . 0.0 110.058 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -79.2 -70.98 0.47 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.197 -0.94 . . . . 0.0 110.727 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -166.03 -73.68 0.03 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.645 -1.264 . . . . 0.0 110.182 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -51.45 135.67 32.81 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.128 -1.219 . . . . 0.0 110.16 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.34 179.59 5.7 Favored 'Trans proline' 0 C--N 1.306 -1.686 0 O-C-N 123.962 1.506 . . . . 0.0 110.512 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.708 ' CG2' HG23 ' A' ' 75' ' ' THR . 41.7 t -134.92 -30.78 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.364 -0.835 . . . . 0.0 110.365 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 138.84 -179.46 18.5 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 17.6 m -81.95 163.37 22.23 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.399 -1.06 . . . . 0.0 110.102 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.702 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 20.4 t -135.16 156.61 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.171 -0.955 . . . . 0.0 110.56 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -151.28 91.62 1.7 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.373 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.732 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -79.87 25.17 0.37 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.365 -0.835 . . . . 0.0 111.62 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.564 ' CB ' ' HD3' ' A' ' 69' ' ' LYS . . . -58.92 -37.25 76.23 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.709 -1.244 . . . . 0.0 108.799 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.1 t -139.99 11.25 2.41 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.732 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -95.7 175.61 6.46 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 121.615 -0.678 . . . . 0.0 110.149 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.74 99.56 12.57 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.183 -0.948 . . . . 0.0 110.01 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.449 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -100.38 155.16 17.96 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.306 -0.871 . . . . 0.0 110.302 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -142.2 177.79 8.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.23 -0.919 . . . . 0.0 110.336 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.484 HD12 ' O ' ' A' ' 34' ' ' ALA . 30.4 tp -138.18 140.07 39.62 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.356 -0.84 . . . . 0.0 109.826 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -131.57 150.01 19.41 Favored Glycine 0 N--CA 1.495 2.587 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.051 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.858 ' HB2' HD12 ' A' ' 33' ' ' ILE . . . -147.66 135.3 20.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.268 -1.136 . . . . 0.0 110.453 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 172.51 -139.93 5.48 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.485 ' O ' ' C ' ' A' ' 98' ' ' SER . 24.0 t-20 -159.62 165.55 32.52 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.193 -1.18 . . . . 0.0 110.43 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.53 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 10.6 t -28.06 -45.43 0.03 OUTLIER 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.971 -0.456 . . . . 0.0 111.837 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -116.27 -74.45 0.55 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.879 -1.289 . . . . 0.0 109.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.88 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.3 tt -44.49 108.73 0.12 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.351 -1.087 . . . . 0.0 110.73 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD2' ' O ' ' A' ' 101' ' ' ASP . 4.9 p-10 -106.16 104.34 14.02 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.307 -0.871 . . . . 0.0 109.619 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.464 HD12 ' HA2' ' A' ' 96' ' ' GLY . 16.5 mt -69.25 -101.34 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.24 -0.912 . . . . 0.0 110.897 -179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -149.77 -176.92 23.34 Favored Glycine 0 N--CA 1.494 2.521 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.182 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 1.6 p80 -140.42 135.43 32.03 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.416 -1.05 . . . . 0.0 110.143 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.908 HG11 ' CG1' ' A' ' 6' ' ' VAL . 64.2 t -107.21 132.78 53.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.203 -0.935 . . . . 0.0 110.344 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.515 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -84.56 146.78 27.37 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.17 -0.956 . . . . 0.0 110.368 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.571 HD12 ' OE1' ' A' ' 35' ' ' GLN . 11.3 mt -124.68 173.83 8.27 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.235 -0.916 . . . . 0.0 110.071 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.2 m -153.66 120.88 5.77 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.263 -0.898 . . . . 0.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.565 ' CE2' ' CA ' ' A' ' 69' ' ' LYS . 16.3 m-85 -93.36 148.98 21.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.347 -0.846 . . . . 0.0 110.428 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.966 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.633 ' C23' ' C7 ' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.603 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.818 0.342 . . . . 0.0 110.197 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.603 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 41.9 Cg_endo -69.74 -168.28 0.26 Allowed 'Trans proline' 0 C--N 1.302 -1.891 0 O-C-N 124.07 1.563 . . . . 0.0 110.381 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -151.72 146.21 25.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.172 -0.955 . . . . 0.0 110.876 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.881 ' CD1' HG22 ' A' ' 22' ' ' VAL . 58.1 t80 -128.75 127.43 42.03 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -137.4 150.89 48.0 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.76 -1.212 . . . . 0.0 112.133 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.76 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.7 p -123.92 160.18 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.613 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 t -68.8 -69.44 0.46 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.494 -1.379 . . . . 0.0 108.845 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.77 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 53.6 Cg_endo -77.22 -157.49 0.07 OUTLIER 'Trans proline' 0 C--N 1.32 -0.951 0 N-CA-C 108.917 -1.224 . . . . 0.0 108.917 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.77 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 164.76 -23.38 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 121.225 -0.922 . . . . 0.0 110.082 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.45 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 5.5 p -131.87 160.64 35.08 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.356 -0.84 . . . . 0.0 109.912 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 55.73 52.97 44.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 85.0 mt -89.32 -163.85 1.06 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.257 -1.143 . . . . 0.0 110.206 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.496 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -155.65 154.65 31.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.201 -0.937 . . . . 0.0 109.99 179.998 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.472 ' HB3' ' HG2' ' A' ' 69' ' ' LYS . 1.0 OUTLIER -61.93 124.95 22.19 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.113 -0.992 . . . . 0.0 109.975 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.86 -21.25 24.19 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.951 ' O ' HG22 ' A' ' 67' ' ' VAL . 22.2 tt0 -49.53 138.2 14.06 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.325 -1.103 . . . . 0.0 110.521 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.1 m -107.83 126.06 52.19 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.4 -0.813 . . . . 0.0 109.745 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.406 ' HB ' ' HG2' ' A' ' 8' ' ' PRO . 30.5 m -111.07 155.7 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.126 -0.983 . . . . 0.0 109.87 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 62.8 m -88.36 137.29 32.46 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.027 -1.046 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.554 HG12 ' N ' ' A' ' 21' ' ' SER . 54.8 t -126.46 167.23 21.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.035 -1.041 . . . . 0.0 110.688 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.554 ' N ' HG12 ' A' ' 20' ' ' VAL . 4.4 p -166.75 112.99 0.81 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.442 -0.786 . . . . 0.0 109.602 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.881 HG22 ' CD1' ' A' ' 4' ' ' PHE . 6.3 t -93.19 174.59 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.285 -0.884 . . . . 0.0 110.732 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.502 ' H ' HG12 ' A' ' 22' ' ' VAL . 61.5 p -169.45 164.11 10.52 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.52 -0.738 . . . . 0.0 109.962 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.78 -20.76 22.44 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.801 -1.32 . . . . 0.0 109.801 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.647 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.41 -124.64 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.118 -1.225 . . . . 0.0 109.839 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . -175.39 130.57 0.28 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.763 -1.211 . . . . 0.0 111.227 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.844 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.02 139.05 42.41 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.636 -0.665 . . . . 0.0 110.821 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.435 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.13 16.4 25.53 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.435 ' HG2' ' C ' ' A' ' 28' ' ' GLY . 12.4 mm-40 -138.08 147.95 44.54 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.211 -1.17 . . . . 0.0 110.444 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.4 OUTLIER -116.94 121.43 41.4 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.493 -0.754 . . . . 0.0 109.469 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.457 ' C ' ' CD1' ' A' ' 32' ' ' TYR . 96.6 m-85 -104.65 165.93 10.73 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.136 -0.977 . . . . 0.0 110.384 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -125.48 121.53 34.02 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.338 -0.851 . . . . 0.0 109.667 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.495 HD11 HD21 ' A' ' 93' ' ' LEU . 8.7 tt -93.47 151.51 3.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.107 -0.996 . . . . 0.0 110.527 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.26 138.24 2.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.35 -0.844 . . . . 0.0 110.019 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 93' ' ' LEU . 10.8 pt20 -92.32 152.59 19.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.715 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 57.7 m -143.67 -179.01 6.18 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.26 -0.9 . . . . 0.0 110.694 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.43 142.38 14.1 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.535 -0.728 . . . . 0.0 109.324 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 41.0 Cg_endo -67.6 169.33 16.07 Favored 'Trans proline' 0 C--N 1.303 -1.857 0 O-C-N 123.736 1.387 . . . . 0.0 110.582 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.507 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.4 p -167.67 67.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.217 -0.927 . . . . 0.0 110.263 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.38 23.48 36.95 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 117.63 -43.18 1.67 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.1 tt0 -82.93 -168.63 2.14 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -1.185 . . . . 0.0 110.198 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.41 108.36 4.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.173 -0.954 . . . . 0.0 110.524 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.738 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -82.47 120.77 25.9 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.229 -0.919 . . . . 0.0 109.218 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 17.2 m -90.87 156.74 17.78 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.119 -0.988 . . . . 0.0 111.462 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.54 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -76.73 115.96 52.6 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.736 -0.603 . . . . 0.0 110.348 179.872 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.517 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 54.8 Cg_endo -88.53 -22.15 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.573 0 O-C-N 123.71 1.374 . . . . 0.0 111.663 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.72 7.86 39.72 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 120.942 -1.099 . . . . 0.0 112.069 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.494 ' O ' ' OD1' ' A' ' 46' ' ' ASN . 0.0 OUTLIER -146.44 83.59 1.61 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.756 -1.215 . . . . 0.0 110.825 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.88 141.09 34.64 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.191 -0.943 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.7 t -135.86 163.32 30.51 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.237 -0.914 . . . . 0.0 110.183 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.47 142.21 49.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.298 -0.876 . . . . 0.0 110.593 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.452 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 34.7 p90 -141.25 139.61 33.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.965 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 61.7 m -97.64 149.17 22.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.311 -0.868 . . . . 0.0 110.228 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.647 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.8 p -75.68 176.99 7.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.197 -0.939 . . . . 0.0 110.332 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.844 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -104.03 -167.6 1.39 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.426 -0.796 . . . . 0.0 108.963 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -61.92 -29.81 70.47 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.1 -1.0 . . . . 0.0 109.827 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 p -94.72 24.04 4.97 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.322 -0.861 . . . . 0.0 109.705 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.446 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.93 27.25 50.28 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -112.95 144.76 41.98 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.164 -1.197 . . . . 0.0 109.982 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -140.12 158.66 43.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.956 -1.09 . . . . 0.0 110.734 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 16.4 m -156.32 125.36 6.05 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.474 -0.766 . . . . 0.0 109.792 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.51 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -159.72 157.5 29.6 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 110.191 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.57 131.3 34.44 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.278 -0.889 . . . . 0.0 109.958 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -119.42 148.22 43.48 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.382 -0.824 . . . . 0.0 110.244 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 15.7 t -97.9 162.09 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.164 -0.96 . . . . 0.0 109.966 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.951 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.1 m -134.04 -178.09 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.198 -0.939 . . . . 0.0 110.196 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -162.45 91.73 0.78 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.47 -0.769 . . . . 0.0 109.233 179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.584 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 14.6 pttt -40.81 -22.78 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.719 -0.613 . . . . 0.0 112.226 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.469 ' N ' ' O ' ' A' ' 68' ' ' ARG . 15.3 m -132.24 133.84 44.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.587 -1.32 . . . . 0.0 110.731 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.46 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 32.5 p90 -174.76 160.9 3.03 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.324 -0.86 . . . . 0.0 110.196 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -80.96 124.22 28.97 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.253 -0.904 . . . . 0.0 110.128 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.738 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.17 155.91 33.36 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.444 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 68.4 m -164.85 118.58 1.29 Allowed 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.467 -1.02 . . . . 0.0 109.501 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.571 HG23 ' CG2' ' A' ' 81' ' ' VAL . 14.9 p -42.1 131.62 2.6 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.843 . . . . 0.0 110.389 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.637 ' HA ' H7A2 ' A' ' 111' ' ' ROM . 43.3 Cg_endo -69.61 -8.91 24.82 Favored 'Trans proline' 0 C--N 1.309 -1.501 0 O-C-N 123.987 1.519 . . . . 0.0 111.027 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.439 ' CD ' ' H11' ' A' ' 111' ' ' ROM . 28.3 mt-10 -143.15 38.03 1.41 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.046 -1.034 . . . . 0.0 111.024 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.46 -108.67 0.41 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.474 -1.346 . . . . 0.0 109.862 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.573 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -141.21 -179.57 1.01 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.476 -1.014 . . . . 0.0 109.289 -179.911 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.573 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.9 Cg_endo -68.06 119.32 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.377 1.198 . . . . 0.0 110.584 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 75' ' ' THR . 89.2 t -81.58 -79.97 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.428 -0.795 . . . . 0.0 110.443 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -162.5 -169.07 25.36 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -87.24 162.54 17.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.285 -1.126 . . . . 0.0 110.526 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 4.1 t -136.81 156.06 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.296 -0.878 . . . . 0.0 109.879 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -147.86 78.49 1.45 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.333 -0.854 . . . . 0.0 110.207 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' N ' ' O ' ' A' ' 69' ' ' LYS . 71.5 m -62.24 -8.54 5.88 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.317 -0.864 . . . . 0.0 110.682 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -51.24 -32.82 25.56 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.009 -1.057 . . . . 0.0 109.252 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.0 t -136.34 0.56 2.56 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.724 -0.61 . . . . 0.0 109.478 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -106.79 174.59 5.82 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.396 -0.815 . . . . 0.0 110.247 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.09 130.37 34.99 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.327 -0.858 . . . . 0.0 110.144 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.522 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -126.08 154.86 42.47 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.302 -0.874 . . . . 0.0 109.804 -179.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 91' ' ' CYS . 30.5 m120 -147.35 -178.03 6.01 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.187 -0.946 . . . . 0.0 110.73 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 33' ' ' ILE . 47.9 tp -144.79 147.05 32.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.448 -0.783 . . . . 0.0 109.843 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -152.6 157.21 27.15 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -127.01 176.55 7.25 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.325 -1.103 . . . . 0.0 110.275 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 153.89 155.16 7.08 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.477 ' O ' ' CB ' ' A' ' 98' ' ' SER . 31.3 t30 -117.3 -24.55 7.39 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -1.157 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER 170.72 -47.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.214 -0.929 . . . . 0.0 110.077 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -133.22 35.13 2.33 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -130.1 113.85 15.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.292 -1.123 . . . . 0.0 110.243 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 103' ' ' GLY . 4.3 m-20 -69.34 -29.05 66.78 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.195 -0.941 . . . . 0.0 110.103 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.567 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 1.2 mt 47.12 -88.91 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.515 -0.741 . . . . 0.0 110.487 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 101' ' ' ASP . . . 174.58 -179.4 45.92 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.454 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.3 p-80 -149.27 133.83 17.66 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.547 -0.973 . . . . 0.0 109.686 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.812 HG23 ' CD2' ' A' ' 4' ' ' PHE . 45.0 t -105.41 130.62 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.155 -0.966 . . . . 0.0 110.182 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.29 140.78 31.41 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.125 -0.984 . . . . 0.0 110.351 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.518 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -114.48 172.14 7.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.372 -0.83 . . . . 0.0 109.808 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 2.3 m -155.4 121.51 5.15 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.152 -0.968 . . . . 0.0 110.434 -179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.584 ' CD1' ' HB3' ' A' ' 69' ' ' LYS . 62.5 m-85 -100.89 76.09 1.74 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.378 -0.826 . . . . 0.0 109.894 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.435 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.984 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 1.08 H6B2 H4B3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 120.722 0.296 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.473 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 44.1 Cg_endo -81.89 -177.74 3.73 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.924 1.486 . . . . 0.0 110.257 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -150.89 179.4 8.27 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.206 -0.934 . . . . 0.0 110.268 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.531 ' CD1' HG22 ' A' ' 22' ' ' VAL . 20.4 t80 -160.81 131.51 5.35 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.414 -0.804 . . . . 0.0 109.846 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.9 t -151.06 163.2 39.33 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.912 -1.117 . . . . 0.0 111.281 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.885 HG22 ' HD2' ' A' ' 8' ' ' PRO . 8.5 p -132.21 164.73 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.665 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.89 -59.01 0.58 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.793 -1.192 . . . . 0.0 109.646 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.885 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.4 Cg_endo -93.29 175.72 1.54 Allowed 'Trans proline' 0 C--N 1.322 -0.826 0 O-C-N 123.434 1.228 . . . . 0.0 109.787 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.503 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.67 30.98 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.246 -0.909 . . . . 0.0 109.881 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 11' ' ' GLY . 1.0 OUTLIER -177.96 163.33 1.76 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.441 -0.787 . . . . 0.0 109.628 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.5 27.36 1.24 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.194 -1.562 . . . . 0.0 109.194 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 107' ' ' LEU . 83.7 mt -62.93 -161.28 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.382 -1.07 . . . . 0.0 110.502 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.408 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 6.9 m -161.08 149.11 15.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.223 -0.923 . . . . 0.0 110.379 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -63.77 134.48 55.37 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.309 -0.869 . . . . 0.0 110.28 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.64 -23.35 13.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 67' ' ' VAL . 54.6 tt0 -63.74 140.19 58.85 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.296 -1.12 . . . . 0.0 110.707 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 16.7 t -108.48 117.86 35.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.525 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 13.0 m -87.05 153.5 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.866 . . . . 0.0 110.095 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 6.6 p -91.2 103.19 15.89 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.026 -1.046 . . . . 0.0 109.715 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.57 HG12 ' N ' ' A' ' 21' ' ' SER . 68.8 t -93.99 168.81 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 110.398 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.57 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.2 p -164.98 116.39 1.16 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.325 -0.859 . . . . 0.0 110.479 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.531 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.0 t -109.01 142.86 20.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 O-C-N 121.555 -0.715 . . . . 0.0 109.108 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 64.2 p -149.97 137.02 19.53 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.83 -1.169 . . . . 0.0 110.884 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.473 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 126.25 -32.77 3.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.903 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -58.82 -25.07 62.85 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.192 -1.181 . . . . 0.0 110.665 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.736 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.68 133.18 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.303 0 O-C-N 121.228 -0.92 . . . . 0.0 111.03 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.805 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.31 133.2 24.34 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.632 -0.667 . . . . 0.0 110.547 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.459 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 115.0 18.9 6.15 Favored Glycine 0 N--CA 1.486 2.033 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.816 ' O ' HG23 ' A' ' 54' ' ' THR . 67.9 mm-40 -143.37 144.66 32.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.148 -1.207 . . . . 0.0 110.252 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 m -112.0 145.97 38.7 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 110.389 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.797 ' CZ ' ' HB1' ' A' ' 25' ' ' ALA . 85.3 m-85 -135.37 169.41 17.53 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.29 -0.881 . . . . 0.0 109.81 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.592 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.2 m-85 -127.74 123.74 36.08 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.116 -0.99 . . . . 0.0 110.349 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.44 HG12 HD11 ' A' ' 93' ' ' LEU . 13.5 tt -115.06 130.71 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.232 -0.917 . . . . 0.0 109.734 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.787 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.71 147.73 26.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.167 -0.958 . . . . 0.0 110.919 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -88.11 129.7 35.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.552 -0.717 . . . . 0.0 109.186 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.4 m -134.33 173.6 11.44 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.94 -1.1 . . . . 0.0 110.278 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -152.31 151.59 27.71 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.421 -0.799 . . . . 0.0 109.848 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.417 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.7 Cg_endo -69.68 158.17 58.0 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 O-C-N 123.913 1.481 . . . . 0.0 110.935 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.417 HG23 ' C ' ' A' ' 38' ' ' PRO . 23.1 t -145.92 72.76 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.629 -0.67 . . . . 0.0 109.91 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 87.93 -31.06 4.8 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.4 -42.24 0.09 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -79.12 -165.06 0.69 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.246 -1.149 . . . . 0.0 110.18 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -136.91 103.01 5.03 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.303 -0.873 . . . . 0.0 110.091 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -88.34 114.88 25.41 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -0.94 . . . . 0.0 109.934 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 7.0 t -96.54 173.47 7.33 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.167 -0.958 . . . . 0.0 110.259 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.497 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 26.2 t-20 -106.66 122.9 40.35 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.535 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.416 ' HD2' ' OD1' ' A' ' 46' ' ' ASN . 50.3 Cg_endo -76.95 -29.05 5.57 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.939 1.494 . . . . 0.0 110.448 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.0 -56.74 17.57 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.35 -0.844 . . . . 0.0 110.498 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.4 p -89.05 49.8 1.84 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.272 -0.892 . . . . 0.0 110.377 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.19 112.06 11.96 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.256 -0.903 . . . . 0.0 110.032 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.6 t -134.28 158.26 44.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -0.923 . . . . 0.0 110.335 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 71.0 p -101.4 139.33 37.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.356 -0.84 . . . . 0.0 109.856 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.521 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 52.1 p90 -135.04 131.13 36.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.121 -0.987 . . . . 0.0 110.554 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.816 HG23 ' O ' ' A' ' 29' ' ' GLU . 95.2 m -90.99 140.56 29.72 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.197 -0.939 . . . . 0.0 109.657 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.903 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -48.77 170.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.102 -0.998 . . . . 0.0 110.126 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.805 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 2.6 t70 -89.86 -168.92 2.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.162 -0.962 . . . . 0.0 109.605 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.54 -24.43 67.11 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.083 -1.01 . . . . 0.0 109.909 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -97.3 17.63 16.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.369 -0.832 . . . . 0.0 109.345 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 65.55 19.25 66.7 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -132.28 120.26 21.9 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.355 -1.085 . . . . 0.0 109.808 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.53 122.79 38.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.196 -0.94 . . . . 0.0 110.968 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.7 m -121.68 137.6 54.68 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.572 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 20.0 p90 -158.62 177.28 11.38 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.884 -1.135 . . . . 0.0 111.118 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 p -100.22 119.62 38.65 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.559 -0.713 . . . . 0.0 110.14 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.5 t80 -109.68 132.65 53.95 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.394 -0.816 . . . . 0.0 109.798 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 14.6 t -81.91 161.56 3.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.975 -1.078 . . . . 0.0 110.349 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.772 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.5 m -135.02 157.4 40.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 121.599 -0.688 . . . . 0.0 109.196 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.43 ' O ' ' C ' ' A' ' 69' ' ' LYS . 67.5 mtp180 -130.49 101.31 5.67 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.939 -1.1 . . . . 0.0 110.399 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.43 ' C ' ' O ' ' A' ' 68' ' ' ARG . 2.3 tttm -39.34 -48.44 1.88 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.69 -0.631 . . . . 0.0 110.962 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.1 t -122.25 145.82 47.86 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.997 -1.064 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.497 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 9.5 p90 -177.02 145.18 0.47 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.436 -0.79 . . . . 0.0 110.172 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 2.0 m -75.61 124.0 26.48 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.096 -1.002 . . . . 0.0 110.14 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.432 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -92.75 177.15 38.54 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.524 ' O ' ' O ' ' A' ' 75' ' ' THR . 77.5 p -179.65 40.47 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.317 -1.108 . . . . 0.0 110.19 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.588 HG23 ' CG2' ' A' ' 81' ' ' VAL . 22.5 p 49.66 165.79 0.03 OUTLIER Pre-proline 0 N--CA 1.508 2.427 0 O-C-N 121.831 -0.543 . . . . 0.0 110.511 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.807 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.9 Cg_endo -72.94 -54.67 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.443 1.233 . . . . 0.0 110.726 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.7 103.46 2.09 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.221 -0.924 . . . . 0.0 110.282 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 171.97 -94.5 0.1 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -125.95 153.96 73.74 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.251 -1.147 . . . . 0.0 110.208 179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.0 154.33 62.87 Favored 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 123.933 1.491 . . . . 0.0 110.482 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.588 ' CG2' HG23 ' A' ' 75' ' ' THR . 76.4 t -117.43 -86.06 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.298 -0.876 . . . . 0.0 110.12 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.412 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -174.74 -157.37 16.02 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.5 OUTLIER -94.52 163.19 13.5 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.136 -1.214 . . . . 0.0 110.217 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.4 t -129.78 153.45 38.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 110.379 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.609 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.2 p-10 -155.79 109.1 2.73 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.361 -0.837 . . . . 0.0 110.286 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 36.3 m -67.3 -6.42 18.51 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.254 -0.904 . . . . 0.0 110.31 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.18 -43.04 66.82 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.07 -1.019 . . . . 0.0 109.282 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -135.31 4.8 3.2 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.687 -0.633 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.609 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -108.09 134.23 51.27 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.467 -0.77 . . . . 0.0 110.101 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.97 101.94 0.91 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.15 -0.969 . . . . 0.0 110.193 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 19.1 m -89.91 164.25 14.66 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.263 -0.898 . . . . 0.0 110.267 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.444 ' OD1' ' N ' ' A' ' 92' ' ' ASN . 11.4 p-10 -162.13 -176.28 5.07 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.248 -0.907 . . . . 0.0 110.584 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.787 HD12 ' O ' ' A' ' 34' ' ' ALA . 14.7 tp -147.07 148.17 31.36 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.408 -0.807 . . . . 0.0 109.514 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.62 149.45 21.6 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.467 -1.349 . . . . 0.0 110.165 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -140.56 152.25 45.36 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.367 -1.078 . . . . 0.0 110.136 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.649 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 148.08 162.29 10.05 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -94.98 179.43 5.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.145 . . . . 0.0 110.179 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 1.4 p -65.4 -31.26 72.28 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.294 -0.878 . . . . 0.0 110.367 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -107.31 -47.02 1.02 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.394 -1.483 . . . . 0.0 109.394 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.664 HD13 ' N ' ' A' ' 101' ' ' ASP . 3.0 tm? -77.27 131.19 38.04 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.372 -1.075 . . . . 0.0 109.923 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.664 ' N ' HD13 ' A' ' 100' ' ' LEU . 2.7 p-10 -104.79 160.63 14.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.216 -0.927 . . . . 0.0 110.266 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.649 HD12 ' HA2' ' A' ' 96' ' ' GLY . 12.6 mt -136.79 -91.61 0.25 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.098 -1.001 . . . . 0.0 110.354 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.52 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -169.19 -179.53 41.22 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.559 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 3.6 m-70 -140.45 129.1 22.92 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.451 -1.029 . . . . 0.0 109.692 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.808 HG11 ' CG1' ' A' ' 6' ' ' VAL . 21.8 t -111.02 129.48 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.275 -0.891 . . . . 0.0 110.476 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' C ' ' HG ' ' A' ' 107' ' ' LEU . . . -83.12 158.02 22.58 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.289 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.522 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.5 mt -132.2 172.99 11.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.288 -0.882 . . . . 0.0 109.946 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.517 ' O ' ' N ' ' A' ' 11' ' ' GLY . 5.9 m -168.69 113.54 0.6 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.149 -0.969 . . . . 0.0 110.219 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.415 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 88.7 m-85 -85.68 69.08 10.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.192 -0.942 . . . . 0.0 110.16 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.807 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 120.778 0.323 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.553 ' HG3' ' CD2' ' A' ' 100' ' ' LEU . 42.6 Cg_endo -73.49 -159.06 0.08 OUTLIER 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.941 1.495 . . . . 0.0 110.323 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -155.55 146.86 22.71 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.177 -0.952 . . . . 0.0 110.591 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.575 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.0 t80 -132.14 128.66 38.57 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.372 -0.83 . . . . 0.0 109.341 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.09 164.61 34.17 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 120.852 -1.155 . . . . 0.0 111.533 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.918 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.9 p -129.64 162.48 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.681 -0.637 . . . . 0.0 109.421 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.629 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.8 m -71.74 -74.17 0.15 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.887 -1.133 . . . . 0.0 109.204 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.0 Cg_endo -79.63 179.82 5.99 Favored 'Trans proline' 0 N--CA 1.482 0.822 0 N-CA-C 109.533 -0.987 . . . . 0.0 109.533 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.527 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.3 32.04 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.284 -0.885 . . . . 0.0 110.132 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 9' ' ' ALA . 54.8 m -167.9 158.23 10.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.293 -0.879 . . . . 0.0 109.789 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 47.4 54.42 10.49 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.5 -1.84 . . . . 0.0 108.5 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.6 mt -88.86 -161.95 0.81 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.491 -1.005 . . . . 0.0 110.683 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.459 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 7.8 t -161.63 153.29 18.98 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.395 -0.816 . . . . 0.0 110.056 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -61.28 129.67 42.41 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.226 -0.922 . . . . 0.0 110.135 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.47 -27.48 8.59 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.855 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.3 tt0 -50.4 136.1 21.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.4 -1.059 . . . . 0.0 110.46 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.9 p -108.14 129.04 55.19 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.501 -0.75 . . . . 0.0 110.166 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.419 ' H ' HG22 ' A' ' 18' ' ' VAL . 23.7 m -102.04 155.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 110.42 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.65 104.96 17.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 109.687 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.601 HG12 ' N ' ' A' ' 21' ' ' SER . 72.3 t -96.67 169.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.028 -1.045 . . . . 0.0 110.821 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.601 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.5 p -165.48 119.2 1.2 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.712 -0.617 . . . . 0.0 109.444 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.575 HG22 ' CD2' ' A' ' 4' ' ' PHE . 10.7 t -109.81 151.97 11.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.297 -0.877 . . . . 0.0 110.058 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.1 t -147.85 178.68 8.3 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.445 -0.784 . . . . 0.0 109.862 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.46 -39.5 3.12 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.2 -163.66 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.291 -1.123 . . . . 0.0 109.741 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.2 148.16 24.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.967 -1.083 . . . . 0.0 110.932 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -45.5 132.81 7.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.474 -0.766 . . . . 0.0 110.543 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 104.73 20.38 10.09 Favored Glycine 0 N--CA 1.486 1.998 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' O ' HG23 ' A' ' 54' ' ' THR . 6.8 mm-40 -137.43 139.47 40.69 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.159 -1.2 . . . . 0.0 110.244 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.0 m -124.3 117.17 23.92 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.497 -0.752 . . . . 0.0 110.002 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.791 ' OH ' HD13 ' A' ' 100' ' ' LEU . 96.5 m-85 -101.51 168.6 9.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.307 -0.871 . . . . 0.0 110.277 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.509 ' HB3' " O'2" ' A' ' 111' ' ' ROM . 14.7 m-85 -125.67 116.94 22.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.143 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.592 HG22 ' O ' ' A' ' 51' ' ' THR . 3.8 tp -97.62 135.29 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.955 . . . . 0.0 110.124 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.521 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -150.04 147.74 28.18 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 110.41 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.458 ' OE1' ' CD1' ' A' ' 107' ' ' LEU . 1.7 tt0 -83.7 157.96 21.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.33 -0.856 . . . . 0.0 109.255 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -149.69 177.67 9.56 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.934 -1.104 . . . . 0.0 111.387 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.81 150.62 4.67 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.56 161.81 44.44 Favored 'Trans proline' 0 C--N 1.302 -1.915 0 O-C-N 123.708 1.373 . . . . 0.0 110.519 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 81' ' ' VAL . 10.8 p -158.76 73.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.358 -0.838 . . . . 0.0 110.335 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.25 30.85 29.69 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 92.59 -21.74 36.99 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 13.2 mm-40 -86.61 -179.65 6.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.323 -1.104 . . . . 0.0 110.183 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -118.31 136.09 53.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -0.887 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.583 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -134.83 123.23 23.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -0.885 . . . . 0.0 110.211 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -107.45 168.87 8.94 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.222 -0.924 . . . . 0.0 109.932 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.514 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 29.4 t30 -115.85 119.97 36.44 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.184 -0.948 . . . . 0.0 110.296 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.858 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 47.5 Cg_endo -73.19 -48.22 0.28 Allowed 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.873 1.46 . . . . 0.0 110.315 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.405 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.89 -28.17 0.15 Allowed 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.395 -0.815 . . . . 0.0 110.603 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.41 ' N ' ' O ' ' A' ' 47' ' ' PRO . 34.7 p -115.82 76.52 1.02 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.18 -0.95 . . . . 0.0 110.48 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -144.49 130.45 19.37 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.119 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.592 ' O ' HG22 ' A' ' 33' ' ' ILE . 65.8 p -126.69 131.93 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.159 -0.963 . . . . 0.0 110.656 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.3 p -97.69 118.81 35.07 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.208 -0.933 . . . . 0.0 109.748 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.598 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 40.7 p90 -119.6 165.21 14.74 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.133 -0.979 . . . . 0.0 110.819 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 30' ' ' THR . 6.1 m -131.32 151.92 51.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.201 -0.937 . . . . 0.0 110.144 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -78.97 152.5 31.0 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.086 -1.009 . . . . 0.0 110.143 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.3 OUTLIER -84.34 -163.1 0.75 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.358 -0.839 . . . . 0.0 109.886 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.13 -25.39 66.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.915 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.7 t -86.02 4.53 37.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.436 -0.79 . . . . 0.0 110.164 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 57.01 58.77 12.85 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -167.73 131.94 1.78 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -1.095 . . . . 0.0 109.611 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.69 162.91 30.17 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.03 -1.044 . . . . 0.0 111.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.3 m -156.89 128.81 7.22 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 9.9 p90 -160.0 177.83 10.34 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.937 -1.102 . . . . 0.0 110.612 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.4 p -102.17 127.6 49.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.511 -0.743 . . . . 0.0 110.555 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -113.29 131.42 55.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.443 -0.786 . . . . 0.0 109.499 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.03 160.39 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.004 -1.06 . . . . 0.0 111.063 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.855 HG22 ' O ' ' A' ' 16' ' ' GLN . 12.0 m -132.84 176.39 9.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.495 -0.753 . . . . 0.0 109.891 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 70' ' ' SER . 0.0 OUTLIER -148.15 100.37 3.16 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.286 -0.884 . . . . 0.0 110.061 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.435 ' C ' ' O ' ' A' ' 68' ' ' ARG . 8.4 ttpt -38.94 -27.33 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.56 -0.713 . . . . 0.0 111.065 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 68' ' ' ARG . 2.2 p -135.45 139.1 43.83 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.969 -1.082 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 5.6 p90 -167.65 156.72 9.82 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.271 -0.893 . . . . 0.0 109.608 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 25.2 m -80.87 130.0 34.82 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.202 -0.937 . . . . 0.0 110.367 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.583 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.58 154.98 38.88 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 2.1 m -175.39 107.04 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.318 -1.107 . . . . 0.0 110.041 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.625 HG23 HG21 ' A' ' 81' ' ' VAL . 71.9 p -47.18 164.33 0.23 Allowed Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.423 -0.798 . . . . 0.0 110.289 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.567 ' O ' ' C ' ' A' ' 77' ' ' GLU . 43.4 Cg_endo -71.9 -90.44 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.901 1.474 . . . . 0.0 110.147 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.567 ' C ' ' O ' ' A' ' 76' ' ' PRO . 0.1 OUTLIER 5.7 -95.42 0.0 OUTLIER 'General case' 0 N--CA 1.52 3.074 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.43 66.02 0.13 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.516 HG23 ' OG1' ' A' ' 75' ' ' THR . 7.0 t -167.64 127.17 1.07 Allowed Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -1.158 . . . . 0.0 110.08 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 166.22 30.29 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.924 1.486 . . . . 0.0 110.468 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.797 HG11 HG11 ' A' ' 39' ' ' VAL . 81.5 t -128.98 -67.45 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.21 -0.931 . . . . 0.0 110.091 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.02 -172.02 41.18 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.8 p -92.19 159.42 15.66 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.163 -1.198 . . . . 0.0 109.931 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 2.8 t -133.4 147.96 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 110.156 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 85' ' ' ASP . 0.8 OUTLIER -142.4 92.65 2.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.925 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.512 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 58.8 m -75.65 27.27 0.11 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.404 -0.81 . . . . 0.0 112.001 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.75 81.71 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.409 -1.432 . . . . 0.0 108.075 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.3 t -149.34 18.18 0.94 Allowed 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -98.49 -176.25 3.33 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-O 121.458 0.647 . . . . 0.0 110.66 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.34 85.72 5.07 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 0.0 110.433 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -87.71 162.35 17.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.282 -0.887 . . . . 0.0 109.957 -179.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.427 ' CG ' ' O ' ' A' ' 91' ' ' CYS . 14.8 m120 -156.44 -178.5 7.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.116 -0.99 . . . . 0.0 110.693 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.421 ' O ' ' HB2' ' A' ' 104' ' ' HIS . 16.7 tp -144.87 140.9 28.66 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.554 -0.716 . . . . 0.0 109.302 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -148.63 161.5 28.67 Favored Glycine 0 N--CA 1.496 2.657 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.765 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -147.6 -158.71 0.94 Allowed 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.591 -0.946 . . . . 0.0 109.593 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 113.1 -176.35 17.38 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.552 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -134.17 -156.21 0.72 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.281 -1.129 . . . . 0.0 110.672 -179.912 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 49.0 m -81.98 -3.39 54.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.48 -0.763 . . . . 0.0 110.792 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -162.57 66.62 0.24 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.791 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.4 OUTLIER -179.32 -32.89 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -1.2 . . . . 0.0 110.291 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.9 p30 35.94 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 O-C-N 121.602 -0.686 . . . . 0.0 110.643 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.705 HD11 ' CG ' ' A' ' 31' ' ' TYR . 69.5 mt -69.66 -92.19 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.175 -0.953 . . . . 0.0 110.473 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -161.0 -178.18 34.76 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 28.4 p80 -146.46 140.04 25.95 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.259 -1.142 . . . . 0.0 110.255 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.918 HG11 ' CG1' ' A' ' 6' ' ' VAL . 71.5 t -113.72 135.55 53.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.315 -0.865 . . . . 0.0 110.331 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.451 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.44 142.85 31.6 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.28 -0.887 . . . . 0.0 109.761 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.458 ' CD1' ' OE1' ' A' ' 35' ' ' GLN . 39.7 mt -117.8 168.04 10.84 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.115 -0.99 . . . . 0.0 110.372 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.452 ' O ' ' N ' ' A' ' 11' ' ' GLY . 16.5 m -159.6 117.33 2.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.244 -0.91 . . . . 0.0 109.999 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -92.73 159.11 15.57 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.309 -0.869 . . . . 0.0 110.379 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.926 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.858 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.721 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.556 ' HG3' HD21 ' A' ' 100' ' ' LEU . 44.3 Cg_endo -73.61 -158.03 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.811 0 O-C-N 123.989 1.521 . . . . 0.0 110.218 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.92 -179.58 7.99 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.156 -0.965 . . . . 0.0 110.332 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.874 ' CD2' HG22 ' A' ' 22' ' ' VAL . 47.3 t80 -155.36 133.13 11.31 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.348 -0.845 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.3 m -149.59 152.03 34.79 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.839 -1.163 . . . . 0.0 111.555 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.932 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.3 p -123.96 160.88 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.647 -0.658 . . . . 0.0 109.26 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.7 m -69.25 -78.14 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.784 -1.197 . . . . 0.0 109.112 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.644 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.1 Cg_endo -78.13 168.15 22.29 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 N-CA-C 109.334 -1.064 . . . . 0.0 109.334 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -170.63 24.87 0.02 OUTLIER 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.07 -1.019 . . . . 0.0 110.319 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -168.26 155.6 7.99 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.344 -0.847 . . . . 0.0 109.741 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.46 51.76 54.34 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.8 mt -91.36 -163.37 1.03 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.465 -1.021 . . . . 0.0 110.512 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.454 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -156.36 158.46 37.43 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.418 -0.802 . . . . 0.0 110.377 179.919 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t0 -60.08 122.39 14.25 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.471 -0.768 . . . . 0.0 110.154 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.47 -24.04 21.88 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 17.9 tm0? -45.96 139.17 4.51 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.665 -0.903 . . . . 0.0 110.363 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 p -113.05 139.34 48.77 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.311 -0.868 . . . . 0.0 110.013 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.681 HG12 HE22 ' A' ' 16' ' ' GLN . 25.1 m -115.59 161.81 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 110.222 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 m -100.44 103.61 14.98 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.19 -0.943 . . . . 0.0 109.653 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG12 ' N ' ' A' ' 21' ' ' SER . 85.5 t -86.81 165.2 2.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.144 -0.973 . . . . 0.0 110.744 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.536 ' N ' HG12 ' A' ' 20' ' ' VAL . 11.4 p -165.67 108.1 0.78 Allowed 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.61 -0.682 . . . . 0.0 109.676 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.874 HG22 ' CD2' ' A' ' 4' ' ' PHE . 9.3 t -95.94 149.6 4.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.384 -0.823 . . . . 0.0 109.942 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 37.6 t -144.12 146.42 32.77 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.168 -0.958 . . . . 0.0 110.315 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 120.96 -36.44 3.33 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.31 -137.7 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.365 -1.08 . . . . 0.0 109.922 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -166.05 133.63 2.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.896 -1.128 . . . . 0.0 110.993 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.849 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.12 133.16 11.9 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.561 -0.712 . . . . 0.0 110.47 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.5 11.66 12.87 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.576 ' O ' HG23 ' A' ' 54' ' ' THR . 31.7 mm-40 -143.97 159.34 42.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.14 -1.212 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.589 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -123.54 167.31 14.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 110.197 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD1' ' O ' ' A' ' 30' ' ' THR . 43.6 m-85 -151.56 156.21 40.02 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.771 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 80.4 m-85 -103.08 164.43 11.62 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.65 -1.281 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.558 HD13 ' HZ ' ' A' ' 63' ' ' PHE . 3.4 tt -149.0 138.11 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.214 -0.929 . . . . 0.0 109.979 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.11 164.59 38.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.191 -0.943 . . . . 0.0 110.772 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.775 ' OE1' HG12 ' A' ' 67' ' ' VAL . 5.3 tt0 -99.22 153.27 19.06 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.417 -0.802 . . . . 0.0 110.018 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -146.73 -179.64 6.93 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.33 -0.856 . . . . 0.0 110.447 -179.949 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.427 ' CB ' HG11 ' A' ' 84' ' ' VAL . . . -158.68 123.65 2.26 Favored Pre-proline 0 C--N 1.3 -1.547 0 O-C-N 121.465 -0.772 . . . . 0.0 109.721 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.519 ' C ' HG23 ' A' ' 39' ' ' VAL . 40.4 Cg_endo -68.13 157.59 61.16 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.923 1.486 . . . . 0.0 110.654 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.519 HG23 ' C ' ' A' ' 38' ' ' PRO . 5.2 t -151.95 68.4 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.496 -0.753 . . . . 0.0 110.24 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.15 -9.88 72.1 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.43 ' C ' ' OE1' ' A' ' 42' ' ' GLN . . . 143.62 -15.06 2.23 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 3.7 mm100 -92.97 160.67 14.78 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.313 -1.11 . . . . 0.0 109.816 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -115.03 97.93 6.51 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 110.571 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.669 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -85.76 113.62 22.07 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.412 -0.805 . . . . 0.0 109.847 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.5 m -100.59 162.93 12.6 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.96 . . . . 0.0 110.632 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -97.56 120.03 61.5 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.392 -0.817 . . . . 0.0 110.16 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -77.25 -0.54 10.71 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.917 1.483 . . . . 0.0 110.667 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.89 -10.98 45.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.118 -0.989 . . . . 0.0 110.496 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 71.2 p -129.0 91.15 3.15 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.205 -0.934 . . . . 0.0 110.273 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -137.66 87.23 2.24 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.191 -0.943 . . . . 0.0 110.316 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 3.1 t -118.08 171.17 8.28 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.193 -0.942 . . . . 0.0 110.072 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.2 p -125.99 168.48 13.87 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.14 -0.975 . . . . 0.0 110.712 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -154.86 143.0 20.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.542 -0.724 . . . . 0.0 109.705 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.589 ' OG1' HG23 ' A' ' 30' ' ' THR . 92.1 m -103.12 156.16 17.89 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.158 -0.964 . . . . 0.0 110.388 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.476 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -72.89 -179.15 3.04 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.404 -0.81 . . . . 0.0 110.129 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.849 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -110.65 -160.46 0.71 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.402 -0.811 . . . . 0.0 109.86 179.947 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.18 -28.07 69.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.109 -0.994 . . . . 0.0 110.045 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.3 p -93.55 15.94 14.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.213 -0.929 . . . . 0.0 109.512 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 64.59 12.13 51.23 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.2 122.13 45.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.24 -1.153 . . . . 0.0 109.909 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 21' ' ' SER . . . -99.66 149.4 23.34 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.139 -0.976 . . . . 0.0 110.585 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 15.3 m -155.53 119.77 4.61 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.519 -0.738 . . . . 0.0 109.303 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.616 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.9 p90 -151.92 -179.94 7.91 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.014 -1.054 . . . . 0.0 110.85 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.05 129.76 46.96 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.503 -0.748 . . . . 0.0 110.536 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 68.6 t80 -124.82 128.18 48.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.414 -0.804 . . . . 0.0 109.593 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.411 HG12 ' N ' ' A' ' 67' ' ' VAL . 22.0 t -83.35 164.05 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.056 -1.028 . . . . 0.0 110.786 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.775 HG12 ' OE1' ' A' ' 35' ' ' GLN . 11.8 m -134.16 178.78 5.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.527 -0.733 . . . . 0.0 109.494 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.89 112.33 6.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.115 -0.991 . . . . 0.0 110.464 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.497 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 87.5 tttt -55.99 -16.66 5.16 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.548 -0.72 . . . . 0.0 110.423 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 60.2 p -151.23 123.1 8.09 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.247 -0.908 . . . . 0.0 109.88 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.539 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 8.1 p90 -159.61 145.25 15.8 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.281 -0.887 . . . . 0.0 109.915 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.13 121.31 12.75 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.166 -0.959 . . . . 0.0 110.159 179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.669 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -81.19 152.51 32.78 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 79.0 p -179.99 125.48 0.08 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -1.033 . . . . 0.0 109.961 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.443 HG23 ' CG2' ' A' ' 81' ' ' VAL . 43.3 p -44.7 143.21 2.25 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.323 -0.861 . . . . 0.0 110.377 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.934 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 39.6 Cg_endo -63.57 -30.55 70.94 Favored 'Trans proline' 0 C--N 1.312 -1.35 0 O-C-N 124.043 1.549 . . . . 0.0 111.112 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.468 ' CA ' ' OE1' ' A' ' 77' ' ' GLU . 4.1 tp10 -156.33 101.17 2.03 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.08 -1.012 . . . . 0.0 110.477 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 159.57 -91.79 0.12 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 p -140.62 151.43 63.41 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.366 -1.079 . . . . 0.0 110.187 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.23 149.32 51.32 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.003 1.528 . . . . 0.0 110.157 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.443 ' CG2' HG23 ' A' ' 75' ' ' THR . 5.9 t -110.44 -70.88 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.488 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -179.13 -161.4 26.62 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.531 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -91.28 159.65 15.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -1.189 . . . . 0.0 110.286 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.427 HG11 ' CB ' ' A' ' 37' ' ' ALA . 15.1 t -132.98 154.95 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 110.578 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.751 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -156.03 111.73 3.01 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.331 -0.856 . . . . 0.0 110.313 -179.973 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.543 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 85.9 m -65.06 -5.68 7.03 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.322 -0.861 . . . . 0.0 111.117 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.87 -56.54 8.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.896 -1.128 . . . . 0.0 108.706 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -127.12 -7.49 5.96 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-O 121.45 0.643 . . . . 0.0 109.361 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -89.62 -179.45 5.79 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.396 -0.815 . . . . 0.0 110.079 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.463 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -113.2 139.94 48.35 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.395 -0.816 . . . . 0.0 110.383 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.04 139.46 43.1 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.395 -0.816 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 26.5 p30 -124.13 -176.0 3.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.291 -0.881 . . . . 0.0 110.475 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.786 ' HB2' HD11 ' A' ' 107' ' ' LEU . 29.7 tp -135.45 143.8 46.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.531 -0.731 . . . . 0.0 109.448 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.594 ' HA3' ' CD2' ' A' ' 104' ' ' HIS . . . -138.92 145.73 17.15 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 119.317 -1.421 . . . . 0.0 110.236 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.603 ' HB2' ' CE2' ' A' ' 4' ' ' PHE . . . -131.51 119.25 21.28 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.492 -1.004 . . . . 0.0 110.094 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 175.72 156.69 15.3 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.536 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 33.7 p-10 -109.51 -144.31 0.39 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.233 -1.157 . . . . 0.0 110.286 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.453 ' HB2' " H2'" ' A' ' 111' ' ' ROM . 38.5 t -99.18 60.0 1.17 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.225 -0.922 . . . . 0.0 110.336 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 172.95 -69.93 0.1 Allowed Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.691 -1.242 . . . . 0.0 110.047 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.556 HD21 ' HG3' ' A' ' 2' ' ' PRO . 0.5 OUTLIER -86.21 154.46 21.29 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.136 -1.214 . . . . 0.0 110.803 -179.906 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 2' ' ' PRO . 25.9 m-20 -124.46 137.16 54.46 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.454 -0.778 . . . . 0.0 109.632 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.674 HD13 HG11 ' A' ' 22' ' ' VAL . 23.9 mt -102.09 -79.95 0.51 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.16 -0.962 . . . . 0.0 110.73 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.28 -179.67 47.68 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.594 ' CD2' ' HA3' ' A' ' 94' ' ' GLY . 64.0 m80 -134.27 131.23 38.19 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.242 -1.152 . . . . 0.0 110.396 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.932 HG11 ' CG1' ' A' ' 6' ' ' VAL . 53.2 t -109.37 129.58 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.303 -0.873 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.05 35.33 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.065 -1.022 . . . . 0.0 110.628 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.8 mt -114.1 167.14 10.93 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.415 -0.803 . . . . 0.0 109.821 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.0 m -153.03 130.48 11.39 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.015 . . . . 0.0 110.158 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.543 ' CD1' ' CB ' ' A' ' 86' ' ' CYS . 32.1 m-85 -94.42 73.53 3.84 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.34 -0.85 . . . . 0.0 110.522 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 CA-C-O 117.902 -1.499 . . . . 0.0 109.621 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.934 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -73.87 -166.49 0.32 Allowed 'Trans proline' 0 C--N 1.302 -1.88 0 O-C-N 124.031 1.542 . . . . 0.0 110.261 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.38 -179.33 8.06 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.326 -0.859 . . . . 0.0 110.402 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 22' ' ' VAL . 11.9 t80 -158.37 134.86 9.48 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.336 -0.853 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -148.74 153.69 38.55 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.919 -1.113 . . . . 0.0 111.335 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.925 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.3 p -121.58 167.45 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.702 -0.624 . . . . 0.0 109.525 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.606 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.3 t -79.72 -70.14 0.18 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 120.918 -1.114 . . . . 0.0 109.302 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.732 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 54.5 Cg_endo -78.21 -159.83 0.11 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.383 -1.045 . . . . 0.0 109.383 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.732 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 167.12 -24.13 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.1 -1.0 . . . . 0.0 110.528 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 58.5 p -132.82 159.9 38.45 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.152 -0.967 . . . . 0.0 110.279 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 52.96 52.84 36.88 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.532 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.5 mt -90.96 -159.71 0.65 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.422 -1.046 . . . . 0.0 110.583 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 2.1 m -166.62 151.22 7.56 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.468 -0.77 . . . . 0.0 109.948 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -62.76 131.24 48.21 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.997 -1.064 . . . . 0.0 110.169 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.89 22.81 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.816 ' O ' HG22 ' A' ' 67' ' ' VAL . 10.8 tp60 -55.38 144.65 24.63 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.313 -1.11 . . . . 0.0 110.411 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -116.24 116.08 27.13 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.39 -0.818 . . . . 0.0 109.274 179.897 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.57 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 14.4 m -92.89 150.68 3.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.194 -0.941 . . . . 0.0 110.212 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.492 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 32.6 p -88.92 103.88 16.44 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.043 . . . . 0.0 109.939 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 21' ' ' SER . 93.4 t -90.39 164.53 2.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.219 -0.926 . . . . 0.0 110.347 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.506 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -162.67 115.45 1.65 Allowed 'General case' 0 C--N 1.294 -1.82 0 O-C-N 121.495 -0.753 . . . . 0.0 109.999 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.605 HG22 ' CD2' ' A' ' 4' ' ' PHE . 24.7 t -103.76 155.21 5.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.644 -0.66 . . . . 0.0 109.645 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 t -153.78 161.27 42.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.052 -1.03 . . . . 0.0 110.243 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.22 5.57 87.2 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -87.39 -25.13 23.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.211 -1.17 . . . . 0.0 110.272 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.74 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 71.94 129.8 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.159 -0.963 . . . . 0.0 111.162 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.888 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.36 141.87 18.54 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.378 0.609 . . . . 0.0 110.345 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.45 ' O ' ' OE1' ' A' ' 29' ' ' GLU . . . 104.63 19.58 11.02 Favored Glycine 0 N--CA 1.484 1.887 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.519 ' O ' HG23 ' A' ' 54' ' ' THR . 4.8 mm-40 -134.92 136.77 42.56 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.308 -1.113 . . . . 0.0 110.375 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.495 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.7 OUTLIER -115.44 119.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.608 -0.682 . . . . 0.0 109.393 179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 1.078 ' CE1' HD22 ' A' ' 100' ' ' LEU . 53.3 m-85 -110.81 165.85 11.51 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 10.3 m-85 -119.2 102.96 9.09 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.31 -0.869 . . . . 0.0 110.008 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.781 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -88.12 142.68 12.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.67 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.781 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -162.49 150.48 14.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.081 -1.012 . . . . 0.0 110.592 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -96.36 144.91 26.07 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.393 -0.817 . . . . 0.0 109.548 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.514 ' CB ' ' HA ' ' A' ' 45' ' ' CYS . 32.8 m -139.12 -179.79 6.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.064 -1.023 . . . . 0.0 110.525 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.474 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -157.35 131.82 5.17 Favored Pre-proline 0 C--N 1.302 -1.484 0 O-C-N 121.473 -0.767 . . . . 0.0 109.922 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.503 ' C ' HG23 ' A' ' 39' ' ' VAL . 50.4 Cg_endo -77.87 166.28 25.39 Favored 'Trans proline' 0 C--N 1.303 -1.847 0 O-C-N 123.918 1.483 . . . . 0.0 110.672 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.503 HG23 ' C ' ' A' ' 38' ' ' PRO . 99.4 t -150.76 68.13 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.429 -0.794 . . . . 0.0 109.906 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.73 13.68 77.42 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 127.27 -45.6 1.14 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -58.5 143.85 44.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.248 -1.148 . . . . 0.0 110.225 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 47.6 m-20 -103.94 117.62 34.75 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.286 -0.884 . . . . 0.0 110.346 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.493 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -121.69 103.89 9.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -0.967 . . . . 0.0 110.158 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.514 ' HA ' ' CB ' ' A' ' 36' ' ' CYS . 1.4 m -82.0 -179.0 7.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.154 -0.966 . . . . 0.0 110.214 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.428 ' ND2' ' CD2' ' A' ' 71' ' ' TYR . 5.1 t-20 -113.14 117.22 46.07 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.125 -0.985 . . . . 0.0 110.802 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.697 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.2 Cg_endo -85.45 -16.64 4.69 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.997 1.525 . . . . 0.0 109.96 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.8 -40.51 80.09 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -0.794 . . . . 0.0 110.769 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.408 ' O ' ' O ' ' A' ' 50' ' ' ALA . 4.4 p -89.84 -83.95 0.24 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.503 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.408 ' O ' ' O ' ' A' ' 49' ' ' THR . . . 52.73 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.219 -0.926 . . . . 0.0 110.05 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.492 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 46.2 p -126.5 114.43 18.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.573 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.37 111.65 23.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.443 -0.785 . . . . 0.0 109.349 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -118.74 179.99 3.97 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.219 -0.926 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.519 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.1 m -134.77 143.69 47.26 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.441 -0.787 . . . . 0.0 109.713 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 1.009 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -60.17 175.15 0.44 Allowed 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.052 -1.03 . . . . 0.0 110.489 -179.951 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.888 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 8.3 t70 -98.34 -165.71 1.28 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.317 -0.865 . . . . 0.0 109.5 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.69 -29.46 70.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.096 -1.002 . . . . 0.0 110.612 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 13.9 m -94.1 19.07 9.68 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.192 -0.943 . . . . 0.0 109.737 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 58.29 37.85 88.42 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -145.01 128.52 17.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.193 -1.181 . . . . 0.0 109.937 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -132.71 157.15 45.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.196 -0.94 . . . . 0.0 110.858 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 m -151.29 123.44 8.23 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -145.21 175.51 10.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.995 -1.065 . . . . 0.0 111.178 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 70.1 p -96.13 123.15 39.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.493 -0.754 . . . . 0.0 110.205 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -117.02 135.86 53.39 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.485 -0.759 . . . . 0.0 109.838 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.5 t -86.82 162.44 2.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.011 -1.056 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.816 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.6 m -130.96 170.49 19.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 37.6 mtt180 -148.52 103.8 3.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.958 -1.089 . . . . 0.0 111.022 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.587 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 27.8 ttpt -43.97 -60.63 1.76 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 110.332 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.405 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.5 p -104.4 136.86 43.2 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.311 -0.868 . . . . 0.0 110.328 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.428 ' CD2' ' ND2' ' A' ' 46' ' ' ASN . 41.4 p90 -175.86 161.59 2.52 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.324 -0.86 . . . . 0.0 110.142 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.7 138.95 38.52 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.823 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.493 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -114.51 176.7 17.1 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.1 OUTLIER 177.19 123.38 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.339 -1.095 . . . . 0.0 109.695 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.797 HG23 HG23 ' A' ' 81' ' ' VAL . 29.0 p -40.0 143.79 0.58 Allowed Pre-proline 0 N--CA 1.499 1.979 0 O-C-N 121.378 -0.827 . . . . 0.0 110.463 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.527 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 46.9 Cg_endo -76.47 6.05 4.29 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.021 1.537 . . . . 0.0 110.555 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -102.16 -78.91 0.53 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.126 -0.984 . . . . 0.0 110.766 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -144.96 -94.3 0.17 Allowed Glycine 0 N--CA 1.496 2.681 0 C-N-CA 119.6 -1.286 . . . . 0.0 110.4 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.453 ' O ' HG23 ' A' ' 79' ' ' THR . 6.0 t -36.87 132.78 0.68 Allowed Pre-proline 0 N--CA 1.501 2.11 0 O-C-N 121.525 -0.985 . . . . 0.0 110.892 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -76.21 -166.78 0.39 Allowed 'Trans proline' 0 C--N 1.309 -1.544 0 O-C-N 124.071 1.564 . . . . 0.0 110.34 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.797 HG23 HG23 ' A' ' 75' ' ' THR . 53.1 t -140.2 -38.7 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 137.46 -172.3 22.81 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 87.3 p -79.34 172.6 13.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.259 -1.142 . . . . 0.0 109.898 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG11 ' HB3' ' A' ' 37' ' ' ALA . 9.9 t -140.89 160.68 23.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.234 -0.916 . . . . 0.0 110.21 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.758 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.3 m-20 -157.14 118.76 3.74 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.347 -0.846 . . . . 0.0 110.233 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -80.23 4.18 18.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.514 179.983 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.08 -47.88 83.62 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.024 -1.047 . . . . 0.0 108.95 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 t -126.44 10.79 7.35 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.758 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.95 178.22 4.39 Favored 'General case' 0 N--CA 1.484 1.271 0 O-C-N 121.691 -0.63 . . . . 0.0 109.86 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -105.8 163.49 12.67 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.3 -0.875 . . . . 0.0 109.786 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 63.2 m -137.54 167.16 22.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 110.061 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 9.6 p-10 -157.29 -177.35 6.54 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.125 -0.984 . . . . 0.0 110.743 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.653 HD11 HD11 ' A' ' 33' ' ' ILE . 13.6 tp -151.45 143.54 23.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.546 -0.721 . . . . 0.0 109.183 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -157.51 159.19 29.62 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.237 -1.458 . . . . 0.0 110.196 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.481 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -148.32 168.45 22.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.422 -1.046 . . . . 0.0 110.167 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.85 161.38 8.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.557 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 32.8 t30 -102.58 -169.38 1.66 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.216 -1.167 . . . . 0.0 110.256 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.2 t -72.17 -38.95 69.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.237 -0.914 . . . . 0.0 110.554 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -103.33 12.96 55.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 1.078 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.2 tt -142.48 141.14 32.1 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.046 -1.267 . . . . 0.0 110.59 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -119.08 144.9 46.33 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.481 ' HB2' ' O ' ' A' ' 95' ' ' ALA . 25.6 mt -117.07 -92.63 0.52 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.116 -0.99 . . . . 0.0 110.517 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.424 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -157.18 174.44 34.73 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.432 -1.366 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.421 ' CE1' HD22 ' A' ' 92' ' ' ASN . 4.8 t-80 -134.63 98.62 4.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.708 -0.878 . . . . 0.0 109.381 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.925 HG11 ' CG1' ' A' ' 6' ' ' VAL . 39.5 t -92.15 124.86 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.101 -1.0 . . . . 0.0 110.741 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.621 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.34 164.25 21.21 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.287 -0.883 . . . . 0.0 109.759 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.621 HD23 ' O ' ' A' ' 106' ' ' ALA . 41.0 mt -136.45 174.47 10.58 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.167 -0.958 . . . . 0.0 110.161 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 7.3 m -154.64 109.89 3.1 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.187 -0.945 . . . . 0.0 110.502 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.587 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 40.8 m-85 -81.72 153.19 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.424 -0.797 . . . . 0.0 109.975 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 CA-C-O 117.986 -1.452 . . . . 0.0 109.535 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.697 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 120.836 0.351 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.37 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.961 1.506 . . . . 0.0 110.224 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -156.07 136.86 13.43 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.033 -1.042 . . . . 0.0 110.318 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.899 ' HD1' HG22 ' A' ' 22' ' ' VAL . 61.6 t80 -130.11 126.07 36.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 0.0 109.667 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.5 m -140.23 158.42 44.07 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.909 -1.119 . . . . 0.0 111.546 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 105' ' ' VAL . 11.5 p -123.93 155.11 30.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -64.88 -68.99 0.64 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 120.852 -1.155 . . . . 0.0 109.345 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.674 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 55.3 Cg_endo -82.71 175.47 8.71 Favored 'Trans proline' 0 C--N 1.324 -0.72 0 O-C-N 123.047 1.025 . . . . 0.0 109.682 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.82 31.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.242 -0.911 . . . . 0.0 109.357 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.433 ' O ' ' C ' ' A' ' 11' ' ' GLY . 9.8 p -174.8 157.99 2.54 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.525 -0.735 . . . . 0.0 109.882 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.46 45.57 6.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.1 mt -77.81 -159.03 0.13 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.519 -0.989 . . . . 0.0 111.043 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.489 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 1.3 t -160.8 152.29 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.672 -0.642 . . . . 0.0 109.497 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -66.29 133.33 50.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.11 -0.994 . . . . 0.0 110.64 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.91 -23.26 14.43 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.628 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.3 tt0 -53.0 145.4 13.01 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.396 -1.061 . . . . 0.0 110.775 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 25.1 t -114.45 121.41 43.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.529 -0.732 . . . . 0.0 109.446 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 18.5 m -97.83 152.53 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.222 -0.924 . . . . 0.0 110.694 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.17 106.15 18.25 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.232 -0.918 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.6 HG12 ' N ' ' A' ' 21' ' ' SER . 54.2 t -94.57 169.07 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.085 -1.009 . . . . 0.0 110.881 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.6 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.9 OUTLIER -163.31 119.39 1.76 Allowed 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.608 -0.683 . . . . 0.0 109.689 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' HD1' ' A' ' 4' ' ' PHE . 14.0 t -108.27 148.07 12.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 121.283 -0.886 . . . . 0.0 110.263 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.9 t -155.26 144.01 20.62 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.139 -0.976 . . . . 0.0 110.166 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 113.63 -32.92 5.77 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.94 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.92 -154.92 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.365 -1.079 . . . . 0.0 109.901 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.414 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . -151.33 139.56 20.27 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.861 -1.149 . . . . 0.0 111.026 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.794 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.35 135.76 32.37 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.578 -0.701 . . . . 0.0 110.327 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.87 8.61 34.07 Favored Glycine 0 N--CA 1.485 1.915 0 N-CA-C 109.359 -1.497 . . . . 0.0 109.359 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.522 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 mm-40 -123.51 135.32 53.97 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.193 -1.181 . . . . 0.0 110.502 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.6 m -114.99 113.19 23.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.646 -0.658 . . . . 0.0 109.45 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CE1' HD13 ' A' ' 100' ' ' LEU . 77.8 m-85 -102.56 149.11 24.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.171 -0.955 . . . . 0.0 110.627 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.2 m-85 -112.26 118.3 34.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.417 -0.802 . . . . 0.0 109.261 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.811 HD11 HD21 ' A' ' 93' ' ' LEU . 14.9 tt -95.24 161.7 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 111.049 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -169.9 144.22 2.73 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.517 -0.74 . . . . 0.0 109.971 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.515 ' NE2' HD12 ' A' ' 107' ' ' LEU . 0.6 OUTLIER -84.01 114.44 21.72 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.209 -0.932 . . . . 0.0 109.897 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 25.8 m -114.82 167.94 10.34 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.086 -1.009 . . . . 0.0 111.382 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.54 145.89 15.19 Favored Pre-proline 0 N--CA 1.493 1.713 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.569 ' C ' HG23 ' A' ' 39' ' ' VAL . 45.6 Cg_endo -71.77 161.38 45.29 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.686 1.361 . . . . 0.0 110.606 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.569 HG23 ' C ' ' A' ' 38' ' ' PRO . 42.3 t -154.92 86.95 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.499 -0.751 . . . . 0.0 110.131 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.77 17.26 78.99 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.41 -22.83 25.99 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -84.73 -166.64 1.53 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.236 -1.155 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.94 153.8 49.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.279 -0.888 . . . . 0.0 110.477 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.453 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -150.53 109.04 3.8 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.251 -0.906 . . . . 0.0 110.251 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 35.2 m -92.84 155.51 17.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.198 -0.939 . . . . 0.0 110.24 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.574 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 9.2 t-20 -102.26 115.66 64.21 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.305 -0.872 . . . . 0.0 110.18 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.596 ' HD3' H7A1 ' A' ' 111' ' ' ROM . 46.3 Cg_endo -80.84 -18.01 9.31 Favored 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.996 1.524 . . . . 0.0 110.528 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.89 -62.35 1.72 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 18.2 p -92.04 63.11 4.36 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.325 -0.86 . . . . 0.0 110.663 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.65 152.69 20.15 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.19 -0.944 . . . . 0.0 109.822 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.499 ' CG2' ' CG2' ' A' ' 33' ' ' ILE . 6.6 t -158.84 131.95 7.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.099 -1.0 . . . . 0.0 110.682 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.574 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.0 OUTLIER -103.75 132.99 49.5 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.392 -0.818 . . . . 0.0 109.954 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.485 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 23.3 p90 -138.87 142.14 38.59 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.274 -0.891 . . . . 0.0 110.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.522 HG23 ' O ' ' A' ' 29' ' ' GLU . 59.3 m -102.31 144.99 30.11 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.414 -0.804 . . . . 0.0 109.868 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.94 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -68.33 175.77 3.15 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.067 -1.021 . . . . 0.0 110.429 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.794 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -92.73 -168.38 1.94 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.401 -0.812 . . . . 0.0 109.987 -179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.633 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.12 -32.86 74.59 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.239 -0.913 . . . . 0.0 109.75 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -89.45 12.88 15.15 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.28 -0.888 . . . . 0.0 109.738 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.467 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 62.35 30.36 75.95 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.403 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -127.4 126.68 42.87 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -1.101 . . . . 0.0 110.413 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.42 170.82 14.14 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.296 -0.877 . . . . 0.0 110.622 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -167.88 138.0 2.7 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.4 p90 -172.41 -177.55 1.8 Allowed 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.883 -1.136 . . . . 0.0 110.575 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 16.5 p -102.7 139.1 38.72 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-O 121.583 0.706 . . . . 0.0 110.761 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.478 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 66.7 t80 -129.02 132.37 47.49 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.515 -0.741 . . . . 0.0 109.191 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.478 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 21.6 t -82.62 167.57 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.109 -0.994 . . . . 0.0 110.574 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.628 HG22 ' O ' ' A' ' 16' ' ' GLN . 18.4 m -142.6 173.13 7.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 121.57 -0.706 . . . . 0.0 109.813 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -144.48 109.15 4.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.15 -0.969 . . . . 0.0 110.264 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.615 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -40.93 -54.72 2.67 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.647 -0.658 . . . . 0.0 111.496 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.508 ' CB ' ' OD1' ' A' ' 85' ' ' ASP . 78.9 p -114.77 148.41 38.42 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.97 -1.081 . . . . 0.0 111.678 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.819 ' CE2' HG11 ' A' ' 84' ' ' VAL . 1.4 p90 -173.57 137.0 0.61 Allowed 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.64 -0.662 . . . . 0.0 109.287 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.53 129.43 39.84 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.203 -0.936 . . . . 0.0 110.338 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.453 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.26 157.53 40.85 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.439 ' O ' ' O ' ' A' ' 75' ' ' THR . 0.0 OUTLIER 179.45 117.46 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.292 -1.123 . . . . 0.0 110.23 179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 HG23 ' A' ' 81' ' ' VAL . 66.9 p -42.98 166.13 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.426 -0.796 . . . . 0.0 110.191 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.588 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 40.9 Cg_endo -69.48 -20.03 36.67 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 O-C-N 123.745 1.392 . . . . 0.0 109.977 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.0 OUTLIER 177.5 110.21 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.462 -0.774 . . . . 0.0 110.032 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 161.36 -81.59 0.14 Allowed Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.661 -1.256 . . . . 0.0 110.289 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.495 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 2.3 t -147.09 155.12 47.12 Favored Pre-proline 0 N--CA 1.495 1.797 0 O-C-N 121.129 -1.218 . . . . 0.0 110.408 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.495 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 44.3 Cg_endo -71.93 118.4 5.62 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.983 1.517 . . . . 0.0 110.205 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.55 HG23 HG23 ' A' ' 75' ' ' THR . 86.2 t -78.53 -68.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.477 -0.764 . . . . 0.0 110.502 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 176.39 178.51 46.22 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 1.3 m -78.15 166.09 23.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.439 -1.036 . . . . 0.0 110.203 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.819 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.2 t -136.44 152.42 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.369 -0.832 . . . . 0.0 110.298 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.767 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -161.43 111.97 1.68 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.273 -0.892 . . . . 0.0 110.578 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.533 ' CB ' ' CD1' ' A' ' 109' ' ' PHE . 21.8 m -65.17 -9.83 26.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.386 -0.821 . . . . 0.0 109.572 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -66.15 -40.94 90.94 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.447 -0.783 . . . . 0.0 109.684 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.9 t -134.58 16.38 3.65 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.52 -0.737 . . . . 0.0 109.602 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.767 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.09 165.35 20.52 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.21 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.47 95.93 9.58 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.152 -0.968 . . . . 0.0 110.037 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 40.8 m -80.99 164.32 22.62 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.136 -0.977 . . . . 0.0 109.999 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.492 ' OD1' ' O ' ' A' ' 92' ' ' ASN . 12.3 p30 -168.19 119.85 0.83 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.226 -0.921 . . . . 0.0 110.491 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.811 HD21 HD11 ' A' ' 33' ' ' ILE . 18.4 tp -83.19 137.51 34.01 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.215 -0.928 . . . . 0.0 109.465 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -141.01 154.16 24.29 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.569 -1.301 . . . . 0.0 110.353 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.42 179.87 6.41 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.441 -1.035 . . . . 0.0 109.837 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.36 -178.44 23.12 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.528 ' O ' ' N ' ' A' ' 99' ' ' GLY . 35.6 t30 -156.73 146.52 20.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.474 -1.015 . . . . 0.0 109.779 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 97' ' ' ASN . 3.2 p 41.86 -93.83 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.339 -0.85 . . . . 0.0 110.063 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -145.72 54.24 0.55 Allowed Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' CE1' ' A' ' 31' ' ' TYR . 8.9 tt -111.21 -23.79 10.65 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.068 -1.254 . . . . 0.0 110.109 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.4 OUTLIER 47.64 100.64 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.342 -0.849 . . . . 0.0 110.413 179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.594 HD21 ' CG1' ' A' ' 22' ' ' VAL . 0.4 OUTLIER -82.92 -71.34 0.5 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.152 -0.968 . . . . 0.0 110.314 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.473 ' O ' ' CD2' ' A' ' 104' ' ' HIS . . . -167.0 168.1 40.15 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.473 ' CD2' ' O ' ' A' ' 103' ' ' GLY . 46.3 m170 -136.13 99.5 4.15 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.412 -1.052 . . . . 0.0 110.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.759 HG11 HG11 ' A' ' 6' ' ' VAL . 67.3 t -83.83 151.66 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.186 -0.947 . . . . 0.0 110.256 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -105.24 139.26 40.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 109.871 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 106' ' ' ALA . 21.3 mt -118.96 164.95 14.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.186 -0.946 . . . . 0.0 110.356 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.497 ' O ' ' N ' ' A' ' 11' ' ' GLY . 25.2 m -161.54 111.19 1.59 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.261 -0.899 . . . . 0.0 109.8 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.615 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 6.0 m-85 -86.73 156.59 19.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.261 -0.899 . . . . 0.0 109.641 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.262 0 CA-C-O 117.921 -1.488 . . . . 0.0 109.531 -179.971 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.596 H7A1 ' HD3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.724 0.297 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.447 ' HB3' ' HA3' ' A' ' 24' ' ' GLY . 44.2 Cg_endo -73.32 -159.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 123.982 1.517 . . . . 0.0 110.418 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.93 152.07 13.0 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.092 -1.005 . . . . 0.0 110.687 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.721 ' CD2' HG22 ' A' ' 22' ' ' VAL . 42.8 t80 -142.22 125.5 16.5 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.568 -0.708 . . . . 0.0 109.104 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 66.1 m -147.94 164.59 33.27 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.875 -1.141 . . . . 0.0 111.46 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.525 HG11 HG11 ' A' ' 105' ' ' VAL . 10.8 p -128.16 161.81 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.647 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.2 m -69.94 -76.21 0.1 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.858 -1.151 . . . . 0.0 109.076 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.647 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -76.11 175.07 11.8 Favored 'Trans proline' 0 C--O 1.208 -0.986 0 N-CA-C 109.345 -1.06 . . . . 0.0 109.345 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.519 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 176.84 32.29 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 O-C-N 121.424 -0.797 . . . . 0.0 109.607 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.476 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 61.5 m -168.53 164.02 12.48 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.488 -0.757 . . . . 0.0 109.274 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 42.97 43.15 5.34 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.051 -1.62 . . . . 0.0 109.051 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.755 HD12 ' HB3' ' A' ' 107' ' ' LEU . 70.4 mt -83.27 -167.94 1.89 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.478 -1.013 . . . . 0.0 110.448 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 75.2 m -156.75 155.31 31.41 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 110.247 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 25.5 p-10 -65.61 125.43 25.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -0.912 . . . . 0.0 109.818 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 97.99 -25.46 27.46 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.793 ' O ' HG22 ' A' ' 67' ' ' VAL . 5.4 tt0 -57.55 142.0 45.97 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.573 -0.957 . . . . 0.0 110.309 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 28.9 p -115.09 133.23 56.22 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 110.163 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.555 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.1 m -108.79 175.75 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.498 -0.751 . . . . 0.0 110.244 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -111.18 110.27 20.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.251 -0.906 . . . . 0.0 109.752 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.61 HG12 ' N ' ' A' ' 21' ' ' SER . 76.4 t -100.68 170.86 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.136 -0.977 . . . . 0.0 110.731 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.61 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.7 p -161.77 128.86 3.91 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.455 -0.778 . . . . 0.0 110.229 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.721 HG22 ' CD2' ' A' ' 4' ' ' PHE . 11.0 t -112.48 135.72 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.341 -0.85 . . . . 0.0 109.985 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 p -148.17 130.96 16.04 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.876 -1.14 . . . . 0.0 110.362 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.447 ' HA3' ' HB3' ' A' ' 2' ' ' PRO . . . 126.74 -31.08 4.03 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.802 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.23 -156.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.334 -1.098 . . . . 0.0 109.742 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' C ' ' A' ' 27' ' ' ALA . . . -161.84 133.07 5.26 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.844 -1.16 . . . . 0.0 111.118 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.976 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -40.73 137.71 1.13 Allowed 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.722 -0.611 . . . . 0.0 110.465 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 119.14 2.4 13.75 Favored Glycine 0 N--CA 1.484 1.841 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.444 ' O ' HG23 ' A' ' 54' ' ' THR . 5.0 mt-10 -143.0 141.93 31.48 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.014 -1.286 . . . . 0.0 110.754 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 34.3 m -114.67 122.05 45.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.66 -0.65 . . . . 0.0 109.531 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -102.94 147.14 27.29 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.227 -0.921 . . . . 0.0 110.583 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 14.3 m-85 -107.46 100.28 9.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.338 -0.851 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.087 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.55 134.78 26.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 110.306 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.794 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -155.39 165.26 37.17 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.275 -0.891 . . . . 0.0 110.209 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.576 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 49.7 tt0 -96.24 128.74 43.43 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.336 -0.852 . . . . 0.0 109.171 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 78.8 m -132.82 178.98 6.45 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.068 -1.02 . . . . 0.0 110.893 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -151.28 155.73 34.73 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.531 -0.73 . . . . 0.0 109.7 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -71.01 159.54 52.12 Favored 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.81 1.427 . . . . 0.0 110.586 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.791 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -158.34 69.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.332 -0.855 . . . . 0.0 110.377 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.64 28.38 67.46 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 110.48 -40.68 2.46 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.636 ' HB2' HG13 ' A' ' 39' ' ' VAL . 17.1 mt-30 -72.66 -176.37 1.94 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -1.085 . . . . 0.0 109.758 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -140.56 107.77 5.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.461 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -81.51 158.13 24.6 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 108.541 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.477 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 17.4 m -138.46 171.06 14.93 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 120.53 -1.356 . . . . 0.0 111.141 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 44.2 p-10 -112.26 128.21 25.81 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.458 -0.776 . . . . 0.0 110.586 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.75 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.0 Cg_endo -83.92 -63.9 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.671 1.353 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.465 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -33.83 -59.48 0.41 Allowed 'General case' 0 N--CA 1.504 2.262 0 CA-C-O 121.303 0.573 . . . . 0.0 111.196 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 4.8 p -90.94 107.12 18.99 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.336 -0.853 . . . . 0.0 110.389 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -179.62 141.07 0.15 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.329 -0.857 . . . . 0.0 109.569 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.579 ' O ' HG22 ' A' ' 33' ' ' ILE . 31.0 p -130.56 135.02 47.49 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.012 -1.055 . . . . 0.0 111.162 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.454 ' OG ' H3A2 ' A' ' 111' ' ' ROM . 50.7 m -105.09 123.71 48.29 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.503 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.0 p90 -137.93 153.35 49.51 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 120.956 -1.09 . . . . 0.0 111.523 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.444 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.3 m -109.09 145.69 35.25 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.741 . . . . 0.0 109.497 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.802 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -76.23 151.33 36.87 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.951 -1.093 . . . . 0.0 110.41 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.976 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 13.4 p-10 -83.06 -165.38 1.06 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.447 -0.783 . . . . 0.0 110.078 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.401 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -63.67 -26.2 68.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.3 -0.875 . . . . 0.0 110.475 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.5 m -86.86 10.67 15.39 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.233 -0.917 . . . . 0.0 110.301 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.474 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 47.19 49.49 18.75 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -142.28 165.71 26.69 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.362 -1.081 . . . . 0.0 110.893 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -168.41 169.5 10.52 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.402 -0.811 . . . . 0.0 110.313 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 35.6 p -168.0 128.49 1.35 Allowed 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -167.79 152.3 6.61 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.827 -1.17 . . . . 0.0 110.804 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.2 p -84.86 141.21 30.59 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.309 -0.869 . . . . 0.0 109.616 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.453 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 39.6 t80 -126.51 135.12 50.91 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 110.438 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.4 t -81.22 163.36 3.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.141 -0.975 . . . . 0.0 110.365 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.8 m -133.49 -179.38 3.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 O-C-N 121.529 -0.732 . . . . 0.0 109.283 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.507 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 13.8 mtp180 -159.66 99.96 1.44 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.239 -0.913 . . . . 0.0 110.064 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.517 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.6 ttmm -37.25 -51.41 1.04 Allowed 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.732 -0.605 . . . . 0.0 110.692 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -108.54 145.08 35.33 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.147 -0.971 . . . . 0.0 110.492 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 34.8 p90 -174.14 131.4 0.39 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.294 -0.879 . . . . 0.0 109.987 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -55.83 119.43 5.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.313 -0.867 . . . . 0.0 110.25 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.82 151.27 35.4 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 t -169.63 128.82 0.98 Allowed 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.379 -1.071 . . . . 0.0 109.962 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.527 HG23 ' CG2' ' A' ' 81' ' ' VAL . 26.7 p -55.69 158.94 5.61 Favored Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.221 -0.924 . . . . 0.0 110.171 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.513 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 49.5 Cg_endo -75.67 23.23 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.682 0 O-C-N 124.014 1.534 . . . . 0.0 111.475 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -112.87 -81.37 0.59 Allowed 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.792 -1.192 . . . . 0.0 110.484 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -173.51 30.81 0.1 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.3 m -130.13 127.45 22.62 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.167 -1.196 . . . . 0.0 110.085 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.37 111.84 3.34 Favored 'Trans proline' 0 C--N 1.308 -1.555 0 O-C-N 123.801 1.422 . . . . 0.0 110.517 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.527 ' CG2' HG23 ' A' ' 75' ' ' THR . 67.4 t -74.19 -21.15 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.207 -0.933 . . . . 0.0 109.851 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.05 -169.91 21.94 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 4.6 m -94.84 143.06 26.76 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.166 -1.196 . . . . 0.0 110.162 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -114.2 147.77 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.102 -0.999 . . . . 0.0 110.236 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.546 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.9 p30 -141.87 116.19 9.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.553 -0.717 . . . . 0.0 109.991 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -79.12 5.08 12.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -0.859 . . . . 0.0 110.622 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -57.7 -45.22 85.98 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.95 -1.094 . . . . 0.0 108.685 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.8 t -124.39 -2.78 7.98 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.546 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -99.17 172.84 7.12 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.47 -0.769 . . . . 0.0 110.051 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -113.99 127.59 56.02 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.299 -0.875 . . . . 0.0 109.806 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 32.6 m -114.16 161.54 17.66 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.165 -0.959 . . . . 0.0 110.515 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -153.02 142.34 21.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.273 -0.892 . . . . 0.0 110.041 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 1.087 HD11 HD11 ' A' ' 33' ' ' ILE . 37.0 tp -83.83 149.91 26.09 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.313 -0.867 . . . . 0.0 110.208 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.12 140.47 7.76 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -137.34 168.24 20.03 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.218 -1.166 . . . . 0.0 110.171 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 127.66 154.94 8.6 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.525 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 11.0 p-10 -92.5 -163.1 1.0 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.294 -1.121 . . . . 0.0 110.208 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.49 ' HB2' ' O9 ' ' A' ' 111' ' ' ROM . 19.5 t -80.45 14.33 2.07 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.266 -0.896 . . . . 0.0 110.824 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -140.2 -75.94 0.05 OUTLIER Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 5.0 tt -74.32 118.37 17.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.265 -1.138 . . . . 0.0 109.912 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.446 ' OD1' CL21 ' A' ' 111' ' ' ROM . 0.1 OUTLIER -98.68 129.38 45.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.258 -0.902 . . . . 0.0 110.521 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.494 HD22 ' CG1' ' A' ' 22' ' ' VAL . 51.8 mt -83.24 -89.75 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.254 -0.904 . . . . 0.0 110.218 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -160.66 -179.09 35.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 104' ' ' HIS . 16.9 p80 -139.52 110.74 6.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.536 -0.979 . . . . 0.0 109.927 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.534 HG12 ' N ' ' A' ' 106' ' ' ALA . 98.7 t -86.37 170.99 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.26 -0.9 . . . . 0.0 110.115 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.534 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.82 143.22 50.46 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.139 -0.976 . . . . 0.0 110.293 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.755 ' HB3' HD12 ' A' ' 12' ' ' LEU . 8.3 mt -115.32 163.35 15.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.261 -0.9 . . . . 0.0 109.777 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.476 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.8 OUTLIER -141.88 101.78 4.02 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.139 -0.976 . . . . 0.0 110.306 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.517 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 55.3 m-85 -83.84 120.09 25.64 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 110.451 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.166 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.75 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.571 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 120.841 0.353 . . . . 0.0 110.47 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.571 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 44.6 Cg_endo -71.46 -153.26 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.163 1.612 . . . . 0.0 109.927 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -153.57 -179.43 7.77 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.796 -1.19 . . . . 0.0 111.253 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.893 ' CD1' HG22 ' A' ' 22' ' ' VAL . 46.8 t80 -166.45 126.03 1.57 Allowed 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.7 t -145.19 154.66 42.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.666 -1.271 . . . . 0.0 111.78 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 8' ' ' PRO . 9.5 p -121.26 147.84 24.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.656 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.2 m -51.01 -77.98 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.635 -1.291 . . . . 0.0 109.181 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.682 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.5 Cg_endo -79.99 -175.11 2.55 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 O-C-N 122.778 0.883 . . . . 0.0 109.928 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 178.31 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.487 -0.758 . . . . 0.0 109.691 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.442 ' O ' ' C ' ' A' ' 11' ' ' GLY . 7.3 p -174.14 163.58 3.93 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.456 -0.778 . . . . 0.0 109.459 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.527 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 43.34 42.58 5.64 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.54 HD12 ' HB3' ' A' ' 107' ' ' LEU . 45.5 mt -80.61 -170.54 2.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.504 -0.997 . . . . 0.0 110.851 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 18.5 m -156.66 144.06 19.03 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.407 -0.808 . . . . 0.0 110.116 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -60.29 135.49 57.75 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.245 -0.91 . . . . 0.0 110.333 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.67 -28.52 8.33 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.786 ' O ' HG22 ' A' ' 67' ' ' VAL . 36.1 tt0 -61.11 134.78 57.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.31 -1.112 . . . . 0.0 110.247 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -106.56 123.26 47.84 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.44 -0.788 . . . . 0.0 109.936 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -101.12 164.68 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.953 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 42.4 m -95.73 100.17 11.92 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.053 -1.03 . . . . 0.0 110.115 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.564 HG12 ' N ' ' A' ' 21' ' ' SER . 54.4 t -85.03 168.29 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.179 -0.95 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.564 ' N ' HG12 ' A' ' 20' ' ' VAL . 52.2 p -169.72 114.51 0.53 Allowed 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.284 -0.885 . . . . 0.0 110.148 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.893 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.8 t -100.34 153.45 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.134 -0.979 . . . . 0.0 109.882 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.74 -177.24 5.68 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 83.53 -39.83 2.83 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.708 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -56.53 -160.28 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.053 -1.263 . . . . 0.0 110.122 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.75 30.85 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.05 -1.031 . . . . 0.0 111.133 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.726 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.49 131.59 24.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.411 -0.805 . . . . 0.0 110.329 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.48 22.44 7.77 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.632 ' O ' HG23 ' A' ' 54' ' ' THR . 5.3 mm-40 -133.98 141.79 47.41 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.158 -1.201 . . . . 0.0 110.865 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.5 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.6 OUTLIER -118.84 124.19 46.56 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.615 -0.678 . . . . 0.0 109.337 179.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.603 ' OH ' HD13 ' A' ' 100' ' ' LEU . 65.4 m-85 -116.07 172.72 6.99 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.968 . . . . 0.0 110.966 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.5 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 41.0 m-85 -121.39 133.24 55.08 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.8 tt -118.45 140.79 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.099 -1.0 . . . . 0.0 110.826 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.526 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -172.22 146.26 1.85 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.411 -0.805 . . . . 0.0 109.995 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.567 ' HB3' HD13 ' A' ' 93' ' ' LEU . 4.4 pt20 -97.84 145.71 26.15 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -0.967 . . . . 0.0 110.655 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.7 m -138.27 178.43 7.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.293 -0.879 . . . . 0.0 109.926 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB2' ' SG ' ' A' ' 91' ' ' CYS . . . -157.08 159.19 31.31 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.341 -0.85 . . . . 0.0 109.737 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.39 167.41 24.02 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.818 1.431 . . . . 0.0 110.48 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 1.046 HG12 ' O ' ' A' ' 42' ' ' GLN . 7.6 p -153.93 62.16 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.187 -0.946 . . . . 0.0 110.638 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.79 34.25 82.39 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 118.45 -44.73 1.36 Allowed Glycine 0 N--CA 1.493 2.482 0 O-C-N 120.96 -1.317 . . . . 0.0 109.915 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 1.046 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -86.47 160.82 18.89 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.197 -1.178 . . . . 0.0 110.12 -179.953 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.86 113.95 25.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.159 -0.963 . . . . 0.0 109.648 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.477 ' O ' ' OH ' ' A' ' 71' ' ' TYR . . . -108.58 120.48 42.56 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.319 -0.863 . . . . 0.0 110.786 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 8.6 t -99.92 177.06 5.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.355 -0.841 . . . . 0.0 109.637 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.606 ' CG ' ' HG1' ' A' ' 49' ' ' THR . 2.5 p30 -91.52 123.5 63.58 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.039 -1.038 . . . . 0.0 110.838 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.483 ' HB3' " O'7" ' A' ' 111' ' ' ROM . 53.7 Cg_endo -88.29 -20.78 1.68 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.91 1.479 . . . . 0.0 109.842 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.27 -57.09 4.18 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.392 -0.818 . . . . 0.0 111.015 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.606 ' HG1' ' CG ' ' A' ' 46' ' ' ASN . 4.9 p -87.64 74.06 9.28 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.226 -0.921 . . . . 0.0 110.493 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -132.04 101.76 5.54 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.411 -0.806 . . . . 0.0 109.726 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -127.48 161.65 28.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.27 -0.894 . . . . 0.0 110.273 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 99.3 p -110.2 151.22 27.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.296 -0.877 . . . . 0.0 110.399 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.498 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 41.7 p90 -142.2 138.78 31.74 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.27 -0.894 . . . . 0.0 110.366 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.632 HG23 ' O ' ' A' ' 29' ' ' GLU . 63.1 m -98.54 159.45 14.94 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.341 -0.849 . . . . 0.0 110.141 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.708 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.6 p -82.78 177.15 8.81 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.293 -0.88 . . . . 0.0 110.456 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.726 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.0 OUTLIER -101.74 -163.44 1.01 Allowed 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.351 -0.843 . . . . 0.0 110.169 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.37 -30.02 70.32 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -0.914 . . . . 0.0 109.664 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.3 15.31 15.88 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.331 -0.855 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.45 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.79 40.85 98.75 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.39 124.49 16.36 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.28 -1.129 . . . . 0.0 110.079 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.536 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -125.76 156.01 40.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.2 -0.938 . . . . 0.0 110.826 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.4 t -150.64 144.64 25.36 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.413 ' CD1' ' C ' ' A' ' 63' ' ' PHE . 7.8 p90 -167.53 174.94 7.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.941 -1.1 . . . . 0.0 110.743 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 22.7 p -94.76 120.62 35.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.431 -0.793 . . . . 0.0 110.305 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -117.95 142.01 47.82 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.248 -0.907 . . . . 0.0 109.509 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 22.7 t -94.01 162.26 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.032 -1.043 . . . . 0.0 110.738 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -126.85 166.49 23.29 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 121.597 -0.689 . . . . 0.0 109.203 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 7.1 mtp85 -144.03 92.0 2.28 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.915 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.585 ' HB2' ' CD1' ' A' ' 109' ' ' PHE . 0.0 OUTLIER -47.52 -26.42 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.414 -0.804 . . . . 0.0 111.051 -179.988 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.7 p -132.81 137.77 46.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.907 -1.12 . . . . 0.0 110.647 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 72' ' ' THR . 6.1 p90 -173.75 159.8 3.55 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.155 -0.966 . . . . 0.0 109.619 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.571 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -65.27 -161.41 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.093 -1.005 . . . . 0.0 109.666 179.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -142.18 150.68 22.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.745 ' O ' H7A1 ' A' ' 111' ' ' ROM . 9.2 t 179.97 107.49 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.53 -0.982 . . . . 0.0 110.102 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.44 ' C ' H7A3 ' A' ' 111' ' ' ROM . 77.3 p -43.07 151.68 0.4 Allowed Pre-proline 0 N--CA 1.495 1.798 0 O-C-N 121.135 -0.978 . . . . 0.0 110.101 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.792 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 39.1 Cg_endo -63.23 -50.6 3.46 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.795 1.418 . . . . 0.0 110.898 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -122.65 83.13 2.07 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.129 -0.982 . . . . 0.0 110.126 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -175.15 -102.11 0.15 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.55 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 0.5 OUTLIER -151.32 178.88 1.38 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.347 -1.09 . . . . 0.0 109.592 -179.922 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.55 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 43.2 Cg_endo -70.65 150.34 62.66 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.522 1.275 . . . . 0.0 109.84 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.439 HG23 ' HA ' ' A' ' 74' ' ' SER . 48.2 t -118.47 -98.89 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.198 -0.939 . . . . 0.0 110.703 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' N ' ' A' ' 73' ' ' GLY . . . -147.01 -162.56 10.0 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 27.6 p -88.3 164.64 15.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.218 -1.166 . . . . 0.0 110.436 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.509 HG11 ' CE1' ' A' ' 71' ' ' TYR . 24.3 t -144.33 158.4 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.126 -0.984 . . . . 0.0 110.599 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -152.62 91.86 1.61 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.414 -0.804 . . . . 0.0 110.024 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.685 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 94.0 m -81.01 21.08 0.73 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.406 -0.809 . . . . 0.0 111.28 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HA ' ' CG ' ' A' ' 69' ' ' LYS . . . -55.53 -50.83 68.96 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.804 -1.185 . . . . 0.0 108.99 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.5 t -129.67 9.19 5.43 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 121.538 0.685 . . . . 0.0 109.168 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.685 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -85.59 -171.19 3.47 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-O 121.544 0.687 . . . . 0.0 110.678 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.11 93.16 5.58 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.683 -0.635 . . . . 0.0 110.068 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.554 ' SG ' ' HB2' ' A' ' 37' ' ' ALA . 0.1 OUTLIER -105.32 147.61 27.95 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.176 -0.953 . . . . 0.0 110.165 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -146.58 133.81 20.56 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.171 -0.956 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.567 HD13 ' HB3' ' A' ' 35' ' ' GLN . 67.2 tp -89.3 146.17 24.89 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.359 -0.838 . . . . 0.0 110.114 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -146.2 154.78 26.17 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.689 -1.243 . . . . 0.0 110.193 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -134.21 -178.87 5.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.366 -1.079 . . . . 0.0 109.976 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 126.79 155.44 8.88 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.998 -1.241 . . . . 0.0 109.998 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 52.7 p30 -107.52 -162.25 0.83 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.435 -1.038 . . . . 0.0 110.396 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.476 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 16.5 m -70.35 -16.4 62.98 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.395 -0.815 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.13 -85.36 1.34 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.603 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.9 tt -66.49 140.33 58.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.291 -1.123 . . . . 0.0 110.407 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.597 ' N ' HD23 ' A' ' 100' ' ' LEU . 2.9 p30 -122.15 118.44 28.66 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.131 -0.981 . . . . 0.0 110.065 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.428 HD22 ' CG1' ' A' ' 22' ' ' VAL . 13.4 mt -71.69 -139.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.31 -0.869 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -119.04 -177.87 16.61 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.494 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 22.5 p80 -132.28 124.46 28.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.413 -1.051 . . . . 0.0 110.232 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.606 HG11 HG11 ' A' ' 6' ' ' VAL . 14.8 t -89.48 169.21 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.765 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.494 ' N ' ' CG1' ' A' ' 105' ' ' VAL . . . -117.94 140.05 50.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.994 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.54 ' HB3' HD12 ' A' ' 12' ' ' LEU . 11.8 mt -116.05 167.3 11.1 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 109.958 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.527 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.3 m -159.71 110.45 1.95 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.084 -1.01 . . . . 0.0 110.109 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.585 ' CD1' ' HB2' ' A' ' 69' ' ' LYS . 95.6 m-85 -89.0 77.61 7.63 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.21 -0.931 . . . . 0.0 110.524 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.393 0 CA-C-O 118.03 -1.428 . . . . 0.0 109.611 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 1.128 H4A2 H6A3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 120.799 0.333 . . . . 0.0 110.295 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -71.8 -167.21 0.29 Allowed 'Trans proline' 0 C--N 1.303 -1.82 0 O-C-N 124.087 1.572 . . . . 0.0 110.226 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -158.67 179.58 8.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.175 -0.953 . . . . 0.0 110.643 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.872 ' CD1' HG22 ' A' ' 22' ' ' VAL . 69.0 t80 -150.71 132.93 15.41 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.516 -0.74 . . . . 0.0 109.202 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.1 p -140.89 158.17 44.33 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.764 -1.21 . . . . 0.0 111.555 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.87 HG22 ' HD2' ' A' ' 8' ' ' PRO . 12.6 p -131.82 157.04 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.651 -0.656 . . . . 0.0 109.409 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.669 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -67.26 -62.69 3.36 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 120.732 -1.23 . . . . 0.0 109.709 179.945 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.87 ' HD2' HG22 ' A' ' 6' ' ' VAL . 56.0 Cg_endo -88.26 176.36 3.71 Favored 'Trans proline' 0 C--N 1.322 -0.828 0 O-C-N 123.106 1.056 . . . . 0.0 109.437 179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.03 30.2 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.039 -1.038 . . . . 0.0 110.465 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.475 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 47.2 t -179.6 155.54 0.66 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.296 -0.878 . . . . 0.0 109.892 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 51.5 50.73 40.71 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 47.9 mt -90.59 -149.45 0.22 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.444 -1.033 . . . . 0.0 110.545 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 3.2 t -170.65 150.21 3.3 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.444 -0.785 . . . . 0.0 110.229 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 18.6 p30 -61.09 131.73 51.49 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.34 -0.85 . . . . 0.0 110.13 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.44 ' O ' HG13 ' A' ' 66' ' ' VAL . . . 90.23 -26.3 10.48 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 1.6 tt0 -56.34 137.66 52.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.375 -1.074 . . . . 0.0 110.339 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.8 p -108.92 141.22 41.32 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.35 -0.844 . . . . 0.0 110.066 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.567 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 33.7 m -117.41 159.68 17.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.322 -0.861 . . . . 0.0 110.242 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.1 m -95.79 100.31 12.03 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.598 ' CG1' ' CE1' ' A' ' 4' ' ' PHE . 91.9 t -86.72 168.47 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 110.773 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.563 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -166.56 111.39 0.78 Allowed 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.596 -0.69 . . . . 0.0 109.681 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.872 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -96.66 161.11 2.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.342 -0.849 . . . . 0.0 110.042 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.4 p -160.04 148.76 17.27 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.187 -0.946 . . . . 0.0 110.158 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 114.18 -38.8 3.03 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.461 ' HB1' ' OH ' ' A' ' 31' ' ' TYR . . . -60.03 -144.74 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.245 -1.15 . . . . 0.0 110.091 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.459 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -157.21 138.3 13.54 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.85 -1.156 . . . . 0.0 111.316 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.56 143.93 8.6 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.435 0.636 . . . . 0.0 110.458 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.413 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 101.22 13.57 33.03 Favored Glycine 0 N--CA 1.485 1.96 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.436 ' O ' HG23 ' A' ' 54' ' ' THR . 59.2 mt-10 -138.82 145.34 39.96 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.281 -1.129 . . . . 0.0 110.285 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.558 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 2.7 m -96.81 173.76 7.14 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.907 . . . . 0.0 110.266 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' CE1' HD13 ' A' ' 100' ' ' LEU . 51.2 m-85 -157.48 122.07 4.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.258 -0.901 . . . . 0.0 110.108 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 22.8 m-85 -95.0 115.27 27.21 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.317 -0.864 . . . . 0.0 110.074 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.838 HD11 HD21 ' A' ' 93' ' ' LEU . 1.0 OUTLIER -94.94 140.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.287 -0.883 . . . . 0.0 110.033 -179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.814 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -154.87 146.58 23.31 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.255 -0.903 . . . . 0.0 110.506 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -87.48 123.62 32.59 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.35 -0.844 . . . . 0.0 109.842 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 20.9 m -119.19 -178.66 3.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.192 -0.943 . . . . 0.0 110.62 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -154.48 137.81 10.55 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.373 -0.83 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.603 ' C ' HG23 ' A' ' 39' ' ' VAL . 46.3 Cg_endo -74.45 164.71 33.37 Favored 'Trans proline' 0 C--N 1.305 -1.715 0 O-C-N 123.835 1.439 . . . . 0.0 110.748 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.603 HG23 ' C ' ' A' ' 38' ' ' PRO . 60.6 t -155.5 79.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.509 -0.744 . . . . 0.0 110.352 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.44 -13.14 53.08 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 146.61 -36.9 1.23 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.03 169.93 15.94 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.29 -1.124 . . . . 0.0 110.133 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 3.7 p30 -111.04 147.89 33.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.236 -0.915 . . . . 0.0 110.383 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -140.92 98.32 3.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.361 -0.837 . . . . 0.0 109.77 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 17.2 m -81.83 162.24 22.92 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.119 -0.988 . . . . 0.0 110.458 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.534 ' ND2' ' CG ' ' A' ' 71' ' ' TYR . 49.0 t-20 -101.29 122.14 49.3 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.386 -0.821 . . . . 0.0 110.395 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.648 ' CB ' H7A3 ' A' ' 111' ' ' ROM . 46.3 Cg_endo -73.1 -13.81 26.01 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 O-C-N 123.854 1.449 . . . . 0.0 110.099 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -67.3 -59.68 3.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.376 -0.827 . . . . 0.0 110.323 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.485 ' CG2' ' HD2' ' A' ' 68' ' ' ARG . 5.8 p -89.68 116.85 28.12 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.381 -0.824 . . . . 0.0 110.422 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -157.14 87.71 0.99 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.303 -0.873 . . . . 0.0 110.156 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.525 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 63.8 p -96.24 154.24 17.36 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 p -118.6 123.52 45.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.383 -0.823 . . . . 0.0 110.067 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.416 ' CD2' ' HB1' ' A' ' 61' ' ' ALA . 39.9 p90 -134.16 141.48 47.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.436 HG23 ' O ' ' A' ' 29' ' ' GLU . 28.2 m -99.12 152.32 20.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.328 -0.858 . . . . 0.0 109.735 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.452 HG23 ' CE2' ' A' ' 31' ' ' TYR . 1.3 p -67.68 177.35 2.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.12 -0.987 . . . . 0.0 110.523 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.798 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 48.7 m-20 -98.92 -164.89 1.17 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.416 -0.802 . . . . 0.0 109.825 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.09 69.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.274 -0.891 . . . . 0.0 109.955 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.4 p -93.93 16.35 14.56 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.378 -0.827 . . . . 0.0 109.588 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 68.54 13.68 65.92 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -103.3 128.8 50.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.146 -1.208 . . . . 0.0 110.141 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.432 ' O ' ' OG ' ' A' ' 62' ' ' SER . . . -108.59 157.55 18.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.123 -0.986 . . . . 0.0 110.41 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 61' ' ' ALA . 20.3 m -165.08 126.11 2.0 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.412 -0.805 . . . . 0.0 109.484 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 44.7 p90 -166.23 177.37 6.93 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.993 -1.067 . . . . 0.0 110.809 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -100.54 138.29 37.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.587 -0.696 . . . . 0.0 110.091 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.552 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 37.1 t80 -138.24 135.34 35.46 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.157 -0.965 . . . . 0.0 110.12 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.552 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 38.5 t -83.06 164.86 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.142 -0.974 . . . . 0.0 110.405 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.1 m -130.49 160.49 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.442 -0.786 . . . . 0.0 110.264 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.485 ' HD2' ' CG2' ' A' ' 49' ' ' THR . 0.2 OUTLIER -123.65 109.83 14.22 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.155 -0.965 . . . . 0.0 109.856 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.578 ' CE ' ' HB2' ' A' ' 87' ' ' ALA . 75.1 tttt -44.93 -42.11 7.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.588 -0.695 . . . . 0.0 112.129 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.446 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 30.8 m -133.83 155.27 50.14 Favored 'General case' 0 N--CA 1.507 2.42 0 O-C-N 120.688 -1.257 . . . . 0.0 111.335 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.534 ' CG ' ' ND2' ' A' ' 46' ' ' ASN . 19.6 p90 -177.36 163.24 1.99 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.202 -0.936 . . . . 0.0 109.938 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.428 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -81.49 131.51 35.28 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.085 -1.009 . . . . 0.0 110.293 -179.914 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.464 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -79.98 144.19 25.99 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 2.0 m -167.28 126.79 1.4 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.596 -0.944 . . . . 0.0 109.6 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.665 HG23 ' CG2' ' A' ' 81' ' ' VAL . 50.5 p -57.56 145.28 69.72 Favored Pre-proline 0 N--CA 1.495 1.817 0 O-C-N 121.137 -0.977 . . . . 0.0 110.514 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.492 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 45.3 Cg_endo -71.64 -5.8 17.82 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.035 1.545 . . . . 0.0 110.424 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -83.19 -94.78 0.06 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.329 -0.857 . . . . 0.0 110.199 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -160.17 54.55 0.34 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -159.4 136.34 6.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.326 -1.102 . . . . 0.0 110.191 -179.978 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.86 160.05 37.66 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.279 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.665 ' CG2' HG23 ' A' ' 75' ' ' THR . 22.9 t -132.64 -38.86 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.223 -0.923 . . . . 0.0 110.311 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.49 -170.02 29.72 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 1.4 m -94.19 164.75 12.92 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.284 -1.127 . . . . 0.0 110.071 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 23.6 t -141.4 155.32 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 O-C-N 121.015 -1.053 . . . . 0.0 110.276 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.473 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 44.6 m-20 -153.53 99.21 2.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.531 -0.73 . . . . 0.0 109.548 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 11.9 m -63.75 -9.0 12.08 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.556 -0.715 . . . . 0.0 110.345 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.578 ' HB2' ' CE ' ' A' ' 69' ' ' LYS . . . -58.85 -46.1 88.55 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.098 -1.001 . . . . 0.0 109.975 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 t -123.63 5.26 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.47 -0.769 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -111.53 165.34 12.08 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.432 -0.793 . . . . 0.0 110.443 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.68 91.19 7.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.331 -0.856 . . . . 0.0 109.877 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -83.53 165.54 19.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.292 -0.88 . . . . 0.0 110.692 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 17.5 p-10 -151.97 -176.73 5.77 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.338 -0.851 . . . . 0.0 110.24 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HD11 ' A' ' 33' ' ' ILE . 17.8 tp -143.19 152.08 41.36 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.591 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.48 159.68 28.54 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.85 -174.89 2.66 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.454 -1.027 . . . . 0.0 110.252 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.51 140.43 3.8 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.684 -1.367 . . . . 0.0 109.684 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 30' ' ' THR . 43.6 t30 -111.05 -32.7 6.71 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.206 -1.173 . . . . 0.0 110.274 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -170.98 -54.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.249 -0.907 . . . . 0.0 110.52 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -145.03 59.22 0.51 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 100' ' ' LEU . 2.7 tt -138.58 -51.48 0.57 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.263 -1.139 . . . . 0.0 110.37 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 100' ' ' LEU . 0.2 OUTLIER 54.51 108.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.313 -0.867 . . . . 0.0 110.35 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.646 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.2 mp -95.77 -60.33 1.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.234 -0.916 . . . . 0.0 110.14 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.24 179.48 48.88 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.49 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 23.3 p80 -141.39 137.28 32.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.287 -1.125 . . . . 0.0 110.267 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.858 HG11 ' CG1' ' A' ' 6' ' ' VAL . 97.6 t -105.82 129.18 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.157 -0.964 . . . . 0.0 110.15 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -81.76 122.75 28.08 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.094 -1.004 . . . . 0.0 110.271 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 13.1 mt -105.93 170.23 8.03 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.349 -0.845 . . . . 0.0 110.094 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.475 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 1.3 m -148.8 141.42 24.44 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.248 -0.907 . . . . 0.0 109.694 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -109.9 74.52 0.89 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.127 -0.983 . . . . 0.0 110.265 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 CA-C-O 117.95 -1.472 . . . . 0.0 109.558 -179.994 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.704 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 120.693 0.282 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.4 Cg_endo -73.96 154.41 47.88 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.013 1.533 . . . . 0.0 110.271 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -136.06 158.11 45.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 110.546 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.611 ' HB2' HD22 ' A' ' 102' ' ' LEU . 5.9 t80 -128.1 130.7 48.59 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.427 -0.796 . . . . 0.0 109.363 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.2 162.38 35.39 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.839 -1.163 . . . . 0.0 111.718 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 105' ' ' VAL . 11.8 p -133.25 154.94 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.644 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.1 t -69.48 -69.57 0.42 Allowed Pre-proline 0 C--N 1.304 -1.388 0 O-C-N 120.866 -1.147 . . . . 0.0 109.146 179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.644 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -82.4 172.88 11.14 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 N-CA-C 109.261 -1.092 . . . . 0.0 109.261 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -172.26 27.09 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.101 -0.999 . . . . 0.0 109.793 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.458 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 9.3 t -179.88 173.21 1.01 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.514 -0.741 . . . . 0.0 109.579 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.31 35.27 3.71 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.379 -1.489 . . . . 0.0 109.379 -179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.512 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.3 mt -77.72 -163.54 0.41 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.293 -1.121 . . . . 0.0 110.382 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.502 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 46.4 m -157.13 159.89 38.27 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.353 -0.842 . . . . 0.0 110.117 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -64.88 125.6 25.36 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.203 -0.935 . . . . 0.0 110.61 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.09 -21.46 27.64 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.738 ' O ' HG22 ' A' ' 67' ' ' VAL . 2.9 tt0 -53.16 142.48 20.43 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.384 -1.068 . . . . 0.0 110.528 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 100.0 p -110.25 143.34 40.56 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.463 -0.773 . . . . 0.0 109.844 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.628 HG12 ' HG2' ' A' ' 8' ' ' PRO . 30.9 m -116.97 153.91 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.264 -0.897 . . . . 0.0 110.468 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.96 105.13 17.16 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.255 -0.903 . . . . 0.0 109.475 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 21' ' ' SER . 47.6 t -99.9 164.93 2.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.06 -1.025 . . . . 0.0 110.499 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 20' ' ' VAL . 19.0 p -164.13 125.31 2.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.583 -0.698 . . . . 0.0 109.513 179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.496 HG13 HD22 ' A' ' 102' ' ' LEU . 6.7 t -108.01 155.8 8.74 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 O-C-N 121.441 -0.787 . . . . 0.0 109.695 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.09 166.0 30.06 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.131 -0.981 . . . . 0.0 110.367 179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 94.5 -44.72 2.24 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 1.014 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -50.14 -176.1 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.385 -1.067 . . . . 0.0 110.084 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -128.1 146.11 50.8 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.143 -0.973 . . . . 0.0 110.454 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.62 130.94 17.68 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.385 -0.822 . . . . 0.0 110.708 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.66 -5.76 40.71 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.513 ' O ' HG23 ' A' ' 54' ' ' THR . 2.8 mt-10 -98.48 144.56 27.69 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.248 -1.148 . . . . 0.0 110.11 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.641 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.9 m -131.27 126.76 36.27 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.36 -0.838 . . . . 0.0 110.119 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.595 ' OH ' HD13 ' A' ' 100' ' ' LEU . 69.9 m-85 -111.6 149.89 30.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.265 -0.897 . . . . 0.0 110.39 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.5 m-85 -103.41 131.74 50.25 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 108.878 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.89 HD11 HD21 ' A' ' 93' ' ' LEU . 10.7 tt -122.05 147.08 26.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 120.968 -1.082 . . . . 0.0 111.089 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.43 143.12 13.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.681 -0.637 . . . . 0.0 109.337 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.456 ' HG3' ' O ' ' A' ' 35' ' ' GLN . 0.0 OUTLIER -82.91 120.83 26.18 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.044 -1.035 . . . . 0.0 110.558 -179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 1.6 m -126.65 138.16 53.39 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.404 -0.81 . . . . 0.0 109.809 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -122.29 140.74 33.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.18 -0.95 . . . . 0.0 109.817 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.5 163.55 38.65 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.876 1.461 . . . . 0.0 110.649 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.749 ' O ' HG13 ' A' ' 39' ' ' VAL . 8.8 p -148.56 63.59 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 110.4 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.33 50.62 2.93 Favored Glycine 0 N--CA 1.495 2.629 0 N-CA-C 110.176 -1.169 . . . . 0.0 110.176 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 177.97 -74.27 0.07 OUTLIER Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.416 ' HA ' ' OE1' ' A' ' 42' ' ' GLN . 17.3 mm-40 -135.12 -158.24 0.86 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.347 -1.09 . . . . 0.0 109.693 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -119.53 120.35 36.5 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.312 -0.867 . . . . 0.0 110.346 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.51 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -103.67 137.57 41.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.252 -0.905 . . . . 0.0 109.373 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 3.7 t -127.95 158.22 38.44 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.793 -1.192 . . . . 0.0 110.895 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.46 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 0.3 OUTLIER -88.49 132.22 39.68 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.327 -0.858 . . . . 0.0 110.067 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.47 ' O ' ' N ' ' A' ' 49' ' ' THR . 53.0 Cg_endo -79.66 -57.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.917 1.483 . . . . 0.0 111.056 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -38.66 -28.15 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.466 -0.771 . . . . 0.0 111.114 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.47 ' N ' ' O ' ' A' ' 47' ' ' PRO . 17.5 p -97.33 48.56 1.04 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.008 -1.058 . . . . 0.0 110.199 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB1' " C'2" ' A' ' 111' ' ' ROM . . . -100.1 80.66 2.31 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.339 -0.851 . . . . 0.0 109.886 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 13.6 t -100.94 138.31 38.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.261 -0.899 . . . . 0.0 110.632 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.94 120.76 41.78 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.341 -0.85 . . . . 0.0 109.548 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 20.1 p90 -111.32 161.53 15.95 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.181 -0.949 . . . . 0.0 110.837 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.641 ' OG1' HG23 ' A' ' 30' ' ' THR . 10.4 m -126.19 158.23 36.13 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.277 -0.89 . . . . 0.0 110.357 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 1.014 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.0 p -82.46 -178.63 7.13 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.274 -0.891 . . . . 0.0 110.159 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 47.1 m-20 -107.03 -161.53 0.79 Allowed 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.47 -0.769 . . . . 0.0 109.806 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.568 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.0 -30.52 71.52 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.923 . . . . 0.0 110.076 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.1 t -90.2 12.04 19.25 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.349 -0.845 . . . . 0.0 109.736 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 25' ' ' ALA . . . 62.84 43.62 98.66 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.824 -1.311 . . . . 0.0 109.824 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -136.67 121.04 18.09 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.213 -1.169 . . . . 0.0 109.929 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.52 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -111.46 164.79 12.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.131 -0.98 . . . . 0.0 111.123 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -163.71 121.6 1.86 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.572 -0.705 . . . . 0.0 109.189 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 6.2 p90 -157.42 164.7 37.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.966 -1.084 . . . . 0.0 110.714 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.8 m -97.0 129.47 44.46 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.147 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.494 ' O ' HG22 ' A' ' 18' ' ' VAL . 38.4 t80 -115.72 130.66 56.94 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.404 -0.81 . . . . 0.0 109.935 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 14.8 t -82.14 162.32 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.019 -1.051 . . . . 0.0 110.48 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.4 m -135.58 167.77 24.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.493 -0.754 . . . . 0.0 110.055 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.7 mtp85 -138.07 106.56 5.84 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.326 -0.859 . . . . 0.0 110.299 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.509 ' CB ' ' CD2' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -43.75 -53.2 6.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.369 -0.832 . . . . 0.0 110.7 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.39 143.58 43.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 120.998 -1.064 . . . . 0.0 110.882 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.488 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 13.3 p90 -175.16 139.91 0.49 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.409 -0.807 . . . . 0.0 109.96 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.14 128.19 34.94 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.149 -0.969 . . . . 0.0 109.876 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.51 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -76.51 161.38 51.49 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 20.8 t 179.33 141.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.4 -1.059 . . . . 0.0 109.714 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.774 HG23 ' CG2' ' A' ' 81' ' ' VAL . 71.0 p -78.86 163.55 59.97 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.127 -0.983 . . . . 0.0 110.516 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.488 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -74.46 -19.47 19.23 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.094 1.576 . . . . 0.0 110.589 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -62.23 -71.47 0.15 Allowed 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 163.31 36.24 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.452 HG22 ' OG1' ' A' ' 75' ' ' THR . 11.3 t -138.55 137.71 20.77 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.166 -1.196 . . . . 0.0 110.022 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.25 137.89 26.74 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 124.074 1.565 . . . . 0.0 110.768 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.774 ' CG2' HG23 ' A' ' 75' ' ' THR . 88.0 t -109.22 -26.1 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.417 -0.802 . . . . 0.0 109.731 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.9 -179.38 21.3 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 6.5 m -93.99 157.66 16.0 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.345 -1.091 . . . . 0.0 110.13 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.414 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 6.7 t -126.25 151.16 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.162 -0.961 . . . . 0.0 110.156 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.55 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 23.9 p-10 -149.2 106.74 3.64 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.293 -0.879 . . . . 0.0 110.076 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -75.58 -4.64 41.11 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.299 -0.875 . . . . 0.0 110.59 -179.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.54 -39.44 23.51 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.147 -0.97 . . . . 0.0 109.116 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -139.66 9.2 2.41 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.55 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -107.2 173.75 6.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.439 -0.788 . . . . 0.0 110.389 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -109.9 110.71 21.76 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.327 -0.858 . . . . 0.0 110.2 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 11.0 m -101.38 169.41 8.9 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.233 -0.917 . . . . 0.0 110.173 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 73.7 m-20 -152.58 162.03 41.78 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.192 -0.942 . . . . 0.0 110.256 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.89 HD21 HD11 ' A' ' 33' ' ' ILE . 21.8 tp -112.22 146.9 37.32 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.341 -0.85 . . . . 0.0 109.446 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -141.85 150.88 22.37 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.21 175.24 9.91 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.285 -1.126 . . . . 0.0 110.298 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . 131.52 145.49 5.6 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 100' ' ' LEU . 14.9 p-10 -89.69 -163.92 1.08 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.109 -1.23 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.8 p -58.22 -22.77 53.35 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.227 -0.921 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.496 ' O ' ' N ' ' A' ' 101' ' ' ASP . . . -132.98 -84.15 0.24 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.595 HD13 ' OH ' ' A' ' 31' ' ' TYR . 0.9 OUTLIER -40.15 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.419 -1.047 . . . . 0.0 110.654 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.496 ' N ' ' O ' ' A' ' 99' ' ' GLY . 2.5 t70 -97.56 137.22 36.82 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.154 -0.966 . . . . 0.0 110.26 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.611 HD22 ' HB2' ' A' ' 4' ' ' PHE . 0.4 OUTLIER -92.39 -84.93 0.27 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.202 -0.936 . . . . 0.0 110.25 -179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -168.49 -178.23 40.04 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.487 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 6.7 m170 -122.91 115.89 22.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -1.013 . . . . 0.0 110.199 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 HG11 ' A' ' 6' ' ' VAL . 50.0 t -79.73 175.96 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.578 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -129.19 135.43 48.82 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.026 -1.046 . . . . 0.0 110.447 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB3' HD12 ' A' ' 12' ' ' LEU . 50.2 mt -115.8 173.5 6.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.429 -0.795 . . . . 0.0 110.075 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.512 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.1 m -162.22 108.26 1.26 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.041 -1.037 . . . . 0.0 110.516 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.509 ' CD2' ' CB ' ' A' ' 69' ' ' LYS . 32.3 m-85 -83.84 132.88 34.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.183 -0.948 . . . . 0.0 110.291 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 CA-C-O 117.961 -1.466 . . . . 0.0 109.506 -179.976 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.604 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 120.72 0.295 . . . . 0.0 110.379 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.28 -163.2 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.912 1.48 . . . . 0.0 109.935 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -137.99 167.52 21.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.059 -1.026 . . . . 0.0 110.479 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 1.034 ' CD1' HG22 ' A' ' 22' ' ' VAL . 11.4 t80 -169.81 133.95 1.29 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.419 -0.801 . . . . 0.0 109.674 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.8 t -160.79 169.56 22.48 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.894 -1.129 . . . . 0.0 111.673 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.763 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -125.27 152.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.617 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 t -53.81 -78.63 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 120.617 -1.302 . . . . 0.0 109.28 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' O ' HG13 ' A' ' 6' ' ' VAL . 56.3 Cg_endo -79.49 -176.86 3.48 Favored 'Trans proline' 0 C--O 1.213 -0.771 0 N-CA-C 109.327 -1.066 . . . . 0.0 109.327 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.542 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.42 30.6 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.235 -0.916 . . . . 0.0 110.007 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.473 ' HA ' ' OG1' ' A' ' 108' ' ' THR . 27.3 p -172.18 152.82 2.91 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.412 -0.805 . . . . 0.0 109.676 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 49.18 51.55 25.43 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.878 -1.689 . . . . 0.0 108.878 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.9 mt -89.4 -160.39 0.67 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.485 -1.009 . . . . 0.0 110.79 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.538 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 1.6 m -158.37 151.76 23.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.38 -0.825 . . . . 0.0 110.546 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -61.08 134.86 57.5 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.301 -0.874 . . . . 0.0 110.214 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.58 -29.89 5.15 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.779 ' O ' HG22 ' A' ' 67' ' ' VAL . 61.1 tt0 -50.47 140.58 13.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.372 -1.075 . . . . 0.0 110.457 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -116.19 134.02 55.38 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.655 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.545 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 28.2 m -112.77 154.75 14.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.312 -0.867 . . . . 0.0 110.428 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.3 t -88.39 110.18 20.6 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.204 -0.935 . . . . 0.0 109.823 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 21' ' ' SER . 98.3 t -93.32 168.63 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.183 -0.948 . . . . 0.0 110.796 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.556 ' N ' HG12 ' A' ' 20' ' ' VAL . 0.1 OUTLIER -170.14 129.46 0.91 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.675 -0.64 . . . . 0.0 109.772 179.96 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 1.034 HG22 ' CD1' ' A' ' 4' ' ' PHE . 26.6 t -121.04 166.44 15.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.281 -0.887 . . . . 0.0 110.398 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.446 ' N ' HG12 ' A' ' 22' ' ' VAL . 0.1 OUTLIER -163.78 172.69 13.77 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.366 -0.834 . . . . 0.0 109.813 179.993 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 89.76 -34.53 4.03 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.731 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.41 -157.37 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.232 -1.158 . . . . 0.0 109.759 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.68 141.18 25.41 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.903 -1.123 . . . . 0.0 111.12 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.961 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.48 137.6 48.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.566 -0.709 . . . . 0.0 110.532 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.77 11.34 28.74 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.61 ' O ' HG23 ' A' ' 54' ' ' THR . 14.7 mt-10 -137.86 141.17 40.73 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.127 -1.219 . . . . 0.0 110.462 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.564 ' O ' ' CG ' ' A' ' 31' ' ' TYR . 5.2 m -102.5 177.55 4.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.425 -0.797 . . . . 0.0 109.708 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.664 ' OH ' HD22 ' A' ' 100' ' ' LEU . 38.7 m-85 -159.95 123.7 3.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.012 -1.055 . . . . 0.0 110.85 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 71.5 m-85 -91.38 123.18 34.61 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.201 -0.937 . . . . 0.0 109.653 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.402 ' H ' HG22 ' A' ' 33' ' ' ILE . 6.6 tt -113.87 144.88 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.234 -0.916 . . . . 0.0 110.163 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.573 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -165.18 160.8 18.95 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.141 -0.974 . . . . 0.0 110.826 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.495 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 23.6 tt0 -87.56 127.63 35.26 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.424 -0.798 . . . . 0.0 109.632 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.5 OUTLIER -126.09 152.77 45.43 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.131 -0.981 . . . . 0.0 110.68 -179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -133.28 158.86 74.68 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.149 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.06 166.04 30.46 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.637 1.335 . . . . 0.0 110.757 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.795 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.3 p -162.95 84.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.335 -0.853 . . . . 0.0 110.549 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.04 5.57 48.27 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 133.79 -41.27 1.49 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.415 ' C ' HG12 ' A' ' 39' ' ' VAL . 4.7 mp0 -80.0 -162.66 0.46 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.204 -1.174 . . . . 0.0 109.8 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 43' ' ' ASP . 2.8 p30 -147.15 117.2 7.26 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.143 -0.973 . . . . 0.0 110.573 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.899 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -97.77 128.2 44.25 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.287 -0.883 . . . . 0.0 109.924 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.438 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 44.7 m -95.35 173.98 7.26 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.144 -0.972 . . . . 0.0 110.612 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.495 ' ND2' ' HB3' ' A' ' 35' ' ' GLN . 50.5 p-10 -104.39 123.23 41.21 Favored Pre-proline 0 N--CA 1.492 1.632 0 C-N-CA 119.726 -0.79 . . . . 0.0 111.242 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.479 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 49.6 Cg_endo -86.08 4.53 6.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.762 1.401 . . . . 0.0 109.931 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -67.21 0.75 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.326 -0.858 . . . . 0.0 110.315 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 30.9 p -92.88 36.04 1.04 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 110.244 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.02 93.62 5.14 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.206 -0.934 . . . . 0.0 110.097 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 51' ' ' THR . 2.8 t -110.38 167.39 10.24 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.297 -0.877 . . . . 0.0 110.565 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.594 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.1 OUTLIER -124.92 149.2 47.85 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.485 -0.759 . . . . 0.0 110.139 179.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.8 p90 -144.56 145.6 31.9 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.284 -0.885 . . . . 0.0 110.46 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 29' ' ' GLU . 43.0 m -115.38 154.82 28.5 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.323 -0.861 . . . . 0.0 109.963 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.731 HG21 ' HB3' ' A' ' 25' ' ' ALA . 2.2 p -80.83 177.15 9.23 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.188 -0.945 . . . . 0.0 110.556 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.961 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 5.8 t70 -119.43 -156.55 0.66 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.473 -0.767 . . . . 0.0 109.76 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.36 -20.03 65.86 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 110.09 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.8 t -100.73 20.21 15.64 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.417 -0.802 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.484 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 46.63 26.09 2.46 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -114.69 135.78 53.78 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.143 -1.21 . . . . 0.0 110.298 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -129.11 104.45 7.56 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.239 -0.913 . . . . 0.0 110.577 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 2.7 t -107.23 146.79 30.99 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.504 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.419 ' HB3' ' O ' ' A' ' 62' ' ' SER . 52.3 p90 -175.71 170.58 2.85 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 110.124 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -96.19 158.35 15.48 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.322 -0.861 . . . . 0.0 109.991 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -152.76 140.37 19.83 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.289 -0.882 . . . . 0.0 110.046 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.492 HG12 ' N ' ' A' ' 67' ' ' VAL . 43.2 t -93.09 166.34 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.011 -1.056 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.779 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.2 m -133.9 149.86 30.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 O-C-N 121.572 -0.705 . . . . 0.0 109.611 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' O ' ' C ' ' A' ' 69' ' ' LYS . 8.2 mmt180 -124.37 106.91 10.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.219 -0.926 . . . . 0.0 110.01 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.485 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.5 ttmt -41.07 -34.68 0.46 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.372 -0.83 . . . . 0.0 110.96 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 27.9 t -138.77 153.44 48.44 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.042 -1.037 . . . . 0.0 110.187 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' HG11 ' A' ' 84' ' ' VAL . 20.9 p90 -174.94 153.86 1.75 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.24 -0.913 . . . . 0.0 110.239 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.406 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.33 128.35 33.54 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.133 -0.98 . . . . 0.0 110.149 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.482 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -78.19 152.17 37.77 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 43.4 m -172.55 119.69 0.38 Allowed 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.86 -0.788 . . . . 0.0 109.229 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.574 HG23 ' CG2' ' A' ' 81' ' ' VAL . 63.8 p -46.97 155.82 0.6 Allowed Pre-proline 0 N--CA 1.501 2.08 0 O-C-N 121.118 -0.989 . . . . 0.0 110.928 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.814 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.6 Cg_endo -69.37 -27.6 28.14 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 124.218 1.641 . . . . 0.0 110.804 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -69.6 -75.71 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.111 -0.993 . . . . 0.0 110.387 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.431 ' O ' ' C ' ' A' ' 79' ' ' THR . . . -168.89 -50.7 0.03 OUTLIER Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.431 ' C ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -43.0 124.23 3.19 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.278 -1.13 . . . . 0.0 109.958 -180.0 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -69.97 -176.95 1.72 Allowed 'Trans proline' 0 C--N 1.305 -1.722 0 O-C-N 123.834 1.439 . . . . 0.0 109.937 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.899 HG11 ' HB2' ' A' ' 44' ' ' ALA . 70.6 t -145.62 -84.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 110.176 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.414 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -170.1 -167.0 29.94 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -94.88 163.52 13.3 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.268 -1.137 . . . . 0.0 110.219 179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.747 HG11 ' CE2' ' A' ' 71' ' ' TYR . 4.8 t -133.46 149.36 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.23 -0.919 . . . . 0.0 109.908 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.525 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 7.7 p30 -149.03 103.74 3.37 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.36 -0.838 . . . . 0.0 110.069 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 69' ' ' LYS . 20.8 m -61.34 -10.18 6.69 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.514 -0.741 . . . . 0.0 110.58 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.77 -40.36 72.67 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.267 -0.896 . . . . 0.0 109.896 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.1 t -125.21 12.12 8.21 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.444 -0.785 . . . . 0.0 109.83 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -128.25 163.06 25.57 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.286 -0.884 . . . . 0.0 110.487 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.6 95.2 9.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.998 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 1.3 m -86.63 144.26 27.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.261 -0.9 . . . . 0.0 110.307 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.556 ' HB3' ' NE2' ' A' ' 104' ' ' HIS . 8.8 m120 -145.87 -178.34 6.06 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.153 -0.967 . . . . 0.0 110.288 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.683 ' HB2' HD11 ' A' ' 107' ' ' LEU . 51.7 tp -137.46 131.22 31.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.469 -0.769 . . . . 0.0 109.436 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -135.75 156.38 22.78 Favored Glycine 0 N--CA 1.489 2.231 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.308 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.455 ' HB3' ' HB2' ' A' ' 102' ' ' LEU . . . -131.45 169.72 15.66 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.555 -0.968 . . . . 0.0 109.67 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 163.6 -160.85 33.63 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.522 ' N ' ' OD1' ' A' ' 97' ' ' ASN . 11.9 p-10 -159.51 -33.58 0.06 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.238 -1.154 . . . . 0.0 110.96 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.435 ' CB ' ' O ' ' A' ' 97' ' ' ASN . 0.1 OUTLIER 172.37 -61.2 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.918 -1.113 . . . . 0.0 110.928 -179.996 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.28 -15.44 8.34 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.17 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.664 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.8 tt -116.26 121.51 42.23 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.049 -1.266 . . . . 0.0 110.284 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -94.88 152.21 18.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.932 . . . . 0.0 109.92 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.496 HD11 ' CG ' ' A' ' 31' ' ' TYR . 33.7 mt -99.41 -83.11 0.43 Allowed 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.177 -0.952 . . . . 0.0 110.303 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -155.6 179.98 31.15 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.556 ' NE2' ' HB3' ' A' ' 92' ' ' ASN . 68.1 t60 -140.36 90.72 2.38 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.479 -1.013 . . . . 0.0 109.908 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.763 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.4 t -83.6 122.53 37.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.31 -0.869 . . . . 0.0 110.322 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.488 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -80.25 143.45 33.69 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.163 -0.961 . . . . 0.0 109.143 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.683 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.2 mt -121.86 165.96 15.11 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.107 -0.996 . . . . 0.0 110.962 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -142.04 166.87 23.53 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.372 -0.83 . . . . 0.0 109.604 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.485 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 29.6 m-85 -135.85 109.17 7.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.09 -1.006 . . . . 0.0 110.286 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 CA-C-O 118.046 -1.419 . . . . 0.0 109.569 -179.985 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.814 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.732 0 CA-C-O 120.667 0.27 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.475 ' HG2' ' HA ' ' A' ' 102' ' ' LEU . 46.3 Cg_endo -72.2 -159.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.919 1.484 . . . . 0.0 110.634 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -127.6 179.11 5.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.216 -0.927 . . . . 0.0 110.389 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.752 ' CD1' HG22 ' A' ' 22' ' ' VAL . 61.4 t80 -175.66 124.22 0.21 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 109.205 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.89 157.41 44.16 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.867 -1.146 . . . . 0.0 111.516 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.828 ' CG1' HG11 ' A' ' 105' ' ' VAL . 13.7 p -126.26 164.19 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.627 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -76.74 -69.18 0.24 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.752 -1.218 . . . . 0.0 108.913 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.627 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 52.8 Cg_endo -76.83 172.31 16.42 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 O-C-N 123.346 1.182 . . . . 0.0 109.487 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.554 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 177.93 28.14 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.155 -0.966 . . . . 0.0 110.46 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 24.1 p -179.14 160.87 1.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.335 -0.853 . . . . 0.0 109.567 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 42.81 41.67 4.54 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 64.9 mt -76.87 -158.58 0.11 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -1.048 . . . . 0.0 110.678 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -161.51 146.12 13.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.023 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -60.58 130.1 44.85 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.361 -0.837 . . . . 0.0 110.141 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.58 -26.44 10.61 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.596 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.8 tt0 -56.78 153.67 10.37 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.363 -1.081 . . . . 0.0 110.224 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.2 m -111.49 163.85 13.59 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.918 . . . . 0.0 110.328 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.707 HG22 ' O ' ' A' ' 65' ' ' PHE . 28.2 m -137.23 152.29 27.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 121.408 -0.808 . . . . 0.0 110.208 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -93.28 103.42 15.67 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.075 -1.016 . . . . 0.0 109.598 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 21' ' ' SER . 90.2 t -95.82 168.31 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.08 -1.013 . . . . 0.0 110.587 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.549 ' N ' HG12 ' A' ' 20' ' ' VAL . 84.2 p -171.11 109.78 0.32 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.547 -0.721 . . . . 0.0 110.083 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.752 HG22 ' CD1' ' A' ' 4' ' ' PHE . 7.9 t -95.11 165.67 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 O-C-N 121.346 -0.846 . . . . 0.0 109.665 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.94 172.66 10.05 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.265 -0.897 . . . . 0.0 110.053 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.86 -3.98 54.55 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.941 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -73.84 -138.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.098 -1.236 . . . . 0.0 110.002 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -167.31 127.02 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 120.879 -1.138 . . . . 0.0 111.154 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.884 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -47.81 135.7 11.74 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.56 -0.712 . . . . 0.0 110.415 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 106.32 12.03 26.14 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.438 ' O ' HG23 ' A' ' 54' ' ' THR . 11.8 mt-10 -135.7 141.89 45.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.104 -1.233 . . . . 0.0 110.775 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.0 m -116.17 125.72 52.69 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.563 -0.71 . . . . 0.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.752 ' OH ' HD22 ' A' ' 100' ' ' LEU . 68.8 m-85 -110.42 158.4 18.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.98 . . . . 0.0 110.429 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.424 ' CE2' ' OD1' ' A' ' 97' ' ' ASN . 19.0 m-85 -117.09 115.13 24.77 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.509 -0.744 . . . . 0.0 110.031 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.434 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 0.3 OUTLIER -92.54 142.09 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.273 -0.892 . . . . 0.0 110.272 -179.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -162.55 152.03 15.68 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.272 -0.893 . . . . 0.0 110.547 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -91.34 137.78 32.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.492 -0.755 . . . . 0.0 109.177 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 33.0 m -133.24 177.79 7.4 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.983 -1.073 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -156.08 140.21 11.62 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.638 -0.664 . . . . 0.0 109.215 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.502 ' C ' HG23 ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.71 160.14 49.52 Favored 'Trans proline' 0 C--N 1.301 -1.954 0 O-C-N 123.843 1.444 . . . . 0.0 110.992 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.502 HG23 ' C ' ' A' ' 38' ' ' PRO . 62.9 t -150.85 69.02 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.565 -0.709 . . . . 0.0 110.321 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 73.9 0.91 57.76 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 142.5 -38.43 1.45 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -73.32 159.73 32.92 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.282 -1.128 . . . . 0.0 110.298 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -112.12 110.53 20.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -0.792 . . . . 0.0 110.156 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.79 108.01 20.2 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.255 -0.903 . . . . 0.0 110.247 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 8.5 m -95.2 175.52 6.57 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 110.394 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -107.4 118.71 52.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.284 -0.885 . . . . 0.0 110.168 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 45.6 Cg_endo -79.71 -35.73 0.72 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.883 1.465 . . . . 0.0 110.631 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.64 71.53 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.384 -0.823 . . . . 0.0 110.41 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.9 p -89.72 47.91 1.53 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.282 -0.886 . . . . 0.0 110.294 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.33 85.75 2.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.249 -0.907 . . . . 0.0 109.89 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.434 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 80.6 p -82.82 147.59 28.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 110.488 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.8 t -117.3 133.59 55.8 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.368 -0.833 . . . . 0.0 109.628 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 13.9 p90 -140.25 173.93 11.02 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.151 -0.968 . . . . 0.0 110.54 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 29' ' ' GLU . 54.6 m -130.73 149.63 52.29 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.456 -0.777 . . . . 0.0 109.801 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.941 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.1 p -78.29 172.79 13.07 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.088 -1.008 . . . . 0.0 110.339 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.884 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -101.92 -164.11 1.07 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.374 -0.829 . . . . 0.0 109.814 -179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.647 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.8 -25.92 67.46 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.083 -1.011 . . . . 0.0 109.997 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.7 p -93.34 11.98 26.35 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.295 -0.878 . . . . 0.0 109.596 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.493 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 55.43 58.43 13.9 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -150.49 153.53 36.03 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.194 -1.18 . . . . 0.0 110.613 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -156.83 144.66 19.26 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.306 -0.871 . . . . 0.0 110.317 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 p -142.2 133.32 26.09 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.437 -0.789 . . . . 0.0 109.405 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -167.21 169.57 12.48 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.952 -1.093 . . . . 0.0 110.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.93 147.35 23.47 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.411 -0.806 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.707 ' O ' HG22 ' A' ' 18' ' ' VAL . 49.7 t80 -139.52 129.72 25.25 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.423 -0.798 . . . . 0.0 109.758 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.475 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 3.2 t -81.11 158.87 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.03 -1.044 . . . . 0.0 110.268 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.596 HG22 ' O ' ' A' ' 16' ' ' GLN . 3.6 m -127.09 173.81 11.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 O-C-N 121.537 -0.727 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.446 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.2 OUTLIER -147.05 105.19 3.76 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.297 -0.877 . . . . 0.0 110.226 -179.93 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.551 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.8 tttt -39.24 -53.29 1.92 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.591 -0.693 . . . . 0.0 110.478 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.18 145.59 41.48 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.249 -0.907 . . . . 0.0 110.374 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 17.3 p90 -172.58 147.35 1.82 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.243 -0.91 . . . . 0.0 110.091 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -64.03 125.85 25.78 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.132 -0.98 . . . . 0.0 109.811 179.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -97.32 160.07 21.28 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 73' ' ' GLY . 39.2 m -168.98 128.74 1.09 Allowed 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.475 -1.015 . . . . 0.0 109.805 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.77 HG23 HG21 ' A' ' 81' ' ' VAL . 34.7 p -56.75 142.19 72.43 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.101 -0.999 . . . . 0.0 110.049 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.31 0.84 7.43 Favored 'Trans proline' 0 C--N 1.304 -1.765 0 O-C-N 124.081 1.569 . . . . 0.0 110.616 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -76.85 3.18 12.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.212 -0.93 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 102.57 -27.06 21.94 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.601 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -89.53 146.54 35.98 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.275 -1.132 . . . . 0.0 110.004 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.601 ' HD2' HG22 ' A' ' 79' ' ' THR . 49.7 Cg_endo -84.07 178.79 5.07 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.928 1.489 . . . . 0.0 110.501 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 75' ' ' THR . 23.2 t -140.0 -70.31 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.357 -0.839 . . . . 0.0 109.959 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 178.28 -173.75 46.15 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 30.6 p -82.92 153.42 25.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.207 -1.172 . . . . 0.0 110.189 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 17.6 t -124.75 154.21 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.298 -0.876 . . . . 0.0 110.069 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.811 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 6.1 m-20 -155.39 117.06 4.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 110.33 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.404 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.3 OUTLIER -62.82 -10.83 14.47 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.865 . . . . 0.0 110.364 179.985 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.01 -54.45 46.97 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.09 -1.006 . . . . 0.0 109.471 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.6 t -122.46 15.65 10.42 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.587 -0.696 . . . . 0.0 109.345 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.811 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -127.19 153.38 46.14 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.442 -0.786 . . . . 0.0 110.556 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.414 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -76.3 160.99 29.11 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 109.623 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.414 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 30.4 m -143.14 149.36 37.98 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.023 -1.048 . . . . 0.0 110.664 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -153.29 -177.09 6.1 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.379 -0.825 . . . . 0.0 110.089 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.623 ' HB2' HD11 ' A' ' 107' ' ' LEU . 60.7 tp -143.85 139.54 29.33 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.296 -0.877 . . . . 0.0 109.247 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -146.05 154.86 26.22 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.213 -1.47 . . . . 0.0 110.383 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.61 156.67 42.31 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.495 -1.003 . . . . 0.0 109.919 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.421 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 148.43 -159.04 27.9 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.483 ' C ' ' H8 ' ' A' ' 111' ' ' ROM . 0.7 OUTLIER -145.78 175.16 10.61 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -1.122 . . . . 0.0 110.262 179.964 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 t -57.58 -38.53 75.01 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.29 -0.882 . . . . 0.0 110.608 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.21 -78.32 1.31 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.752 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.3 tt -90.02 125.95 35.58 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -1.098 . . . . 0.0 110.331 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 56.3 p30 -107.02 -174.19 2.47 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.291 -0.881 . . . . 0.0 110.102 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HG2' ' A' ' 2' ' ' PRO . 17.8 mt -130.16 -111.97 0.26 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.074 -1.016 . . . . 0.0 110.512 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -141.45 -177.03 16.22 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.519 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 3.4 m80 -137.36 124.21 21.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.388 -1.066 . . . . 0.0 110.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.828 HG11 ' CG1' ' A' ' 6' ' ' VAL . 99.5 t -100.86 134.11 41.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.943 0 O-C-N 121.145 -0.972 . . . . 0.0 110.086 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.586 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.36 154.66 25.14 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.105 -0.997 . . . . 0.0 110.139 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.623 HD11 ' HB2' ' A' ' 93' ' ' LEU . 18.7 mt -134.05 166.18 23.33 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.324 -0.86 . . . . 0.0 110.09 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.494 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER -153.96 118.82 4.99 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.077 -1.015 . . . . 0.0 110.561 -180.0 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.551 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 22.5 m-85 -93.34 113.66 25.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.43 -0.794 . . . . 0.0 109.931 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.954 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 1.04 H6A3 H4B2 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 120.772 0.32 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.521 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.6 Cg_endo -73.37 -159.27 0.08 OUTLIER 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.017 1.535 . . . . 0.0 110.262 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -160.92 158.8 28.76 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.108 -0.995 . . . . 0.0 110.756 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.625 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.5 t80 -150.95 125.52 9.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 109.117 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.52 165.98 30.56 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.059 -1.057 . . . . 0.0 111.387 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.594 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.99 162.43 36.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.635 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.3 m -73.94 -72.2 0.2 Allowed Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.583 -1.323 . . . . 0.0 108.859 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.635 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -76.71 168.97 22.66 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 O-C-N 123.151 1.079 . . . . 0.0 109.505 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.96 31.44 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.158 -0.963 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.432 ' HB3' ' O ' ' A' ' 9' ' ' ALA . 79.9 p -178.71 145.84 0.32 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.707 -0.621 . . . . 0.0 109.551 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 61.47 41.72 99.61 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.437 HD12 ' HB3' ' A' ' 107' ' ' LEU . 57.0 mt -81.8 -154.24 0.12 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.326 -1.102 . . . . 0.0 110.634 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 2.1 t -167.4 157.66 11.01 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.556 -0.715 . . . . 0.0 110.307 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -61.25 124.7 21.32 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.327 -0.858 . . . . 0.0 110.668 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.4 ' O ' ' C ' ' A' ' 16' ' ' GLN . . . 89.0 -25.21 10.3 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.653 ' O ' HG22 ' A' ' 67' ' ' VAL . 4.4 tm0? -42.08 152.25 0.08 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.512 -0.993 . . . . 0.0 109.972 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -122.9 134.23 54.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.131 -0.981 . . . . 0.0 110.493 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.575 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 15.0 m -114.1 160.31 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.368 -0.832 . . . . 0.0 110.245 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.5 m -100.23 111.37 23.65 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.221 -0.925 . . . . 0.0 109.67 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 78.0 t -101.31 168.12 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.102 -0.999 . . . . 0.0 111.146 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -168.63 131.99 1.45 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.662 -0.649 . . . . 0.0 109.863 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.833 ' CG1' HD22 ' A' ' 102' ' ' LEU . 20.1 t -119.92 126.26 75.12 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 O-C-N 121.216 -0.927 . . . . 0.0 110.125 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.7 t -134.09 148.27 50.99 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.94 -1.1 . . . . 0.0 110.641 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.521 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 113.26 -21.79 16.81 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -64.81 -157.65 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.11 -1.23 . . . . 0.0 110.103 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -150.3 136.28 18.52 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.069 -1.019 . . . . 0.0 111.069 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 1.041 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.46 135.65 17.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.527 -0.733 . . . . 0.0 110.651 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.13 8.54 10.41 Favored Glycine 0 N--CA 1.485 1.948 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.628 ' O ' HG23 ' A' ' 54' ' ' THR . 1.9 mp0 -145.5 148.39 33.18 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.88 -1.365 . . . . 0.0 111.135 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.527 HG23 ' OG1' ' A' ' 54' ' ' THR . 20.9 m -120.69 122.47 40.52 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.563 ' CE1' HD22 ' A' ' 100' ' ' LEU . 76.7 m-85 -103.65 150.48 23.96 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.127 -0.983 . . . . 0.0 110.883 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 14.2 m-85 -112.07 124.96 53.53 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.406 -0.809 . . . . 0.0 109.91 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.027 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -112.02 142.61 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.897 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.926 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.65 161.52 34.99 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.281 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -86.11 152.73 22.62 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.359 -0.838 . . . . 0.0 109.714 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -142.66 177.22 8.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.957 -1.089 . . . . 0.0 111.088 -179.99 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.596 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -172.4 130.27 0.63 Allowed Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.483 ' HA ' ' O ' ' A' ' 42' ' ' GLN . 42.1 Cg_endo -69.61 161.33 46.32 Favored 'Trans proline' 0 C--N 1.301 -1.956 0 O-C-N 123.701 1.369 . . . . 0.0 111.326 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 39' ' ' VAL . 61.5 t -144.51 68.06 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 50.17 23.13 5.49 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.51 -81.7 0.04 OUTLIER Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.483 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 2.0 pt20 -128.36 -161.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.325 -1.103 . . . . 0.0 110.164 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -103.2 108.59 19.86 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.313 -0.867 . . . . 0.0 110.647 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.508 ' HB2' HG11 ' A' ' 81' ' ' VAL . . . -91.18 127.1 36.47 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.244 -0.91 . . . . 0.0 109.909 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.5 m -100.67 171.93 7.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.234 -0.916 . . . . 0.0 110.007 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.409 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 46.0 t-20 -109.53 129.27 24.11 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.957 . . . . 0.0 110.401 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.471 ' HA ' " C'6" ' A' ' 111' ' ' ROM . 50.3 Cg_endo -79.5 -46.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.122 1.59 . . . . 0.0 110.55 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.402 ' C ' ' O ' ' A' ' 47' ' ' PRO . . . -41.17 -58.83 1.68 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.442 -0.786 . . . . 0.0 110.629 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 25.1 p -91.27 113.45 25.72 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -164.05 141.91 7.15 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.422 -0.799 . . . . 0.0 109.616 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.41 ' O ' HG22 ' A' ' 33' ' ' ILE . 63.3 p -137.86 126.73 23.99 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.087 -1.008 . . . . 0.0 110.884 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 p -101.37 121.48 41.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.424 -0.797 . . . . 0.0 109.056 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 53.1 p90 -125.76 136.41 53.13 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.969 -1.082 . . . . 0.0 111.293 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.628 HG23 ' O ' ' A' ' 29' ' ' GLU . 61.1 m -103.89 156.6 17.71 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.527 -0.733 . . . . 0.0 109.223 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.4 p -94.77 161.26 14.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.029 -1.045 . . . . 0.0 110.452 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 1.041 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.2 t0 -107.74 -158.57 0.66 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.418 -0.801 . . . . 0.0 109.103 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -66.46 -22.28 66.2 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.068 -1.02 . . . . 0.0 109.923 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.3 p -86.72 -3.45 59.05 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.422 -0.799 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 49.71 55.9 12.95 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -154.08 140.04 18.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.245 -1.15 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -143.75 164.17 31.23 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.438 -0.789 . . . . 0.0 110.085 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.4 t -162.22 142.75 10.19 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.495 -0.753 . . . . 0.0 109.056 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -169.86 153.47 4.85 Favored 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.849 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.66 122.44 28.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.404 -0.81 . . . . 0.0 109.866 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.54 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 62.5 t80 -108.79 156.77 19.25 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.467 -0.771 . . . . 0.0 110.117 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.54 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 23.0 t -108.48 166.91 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.979 -1.076 . . . . 0.0 109.959 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.653 HG22 ' O ' ' A' ' 16' ' ' GLN . 10.5 m -137.76 168.6 20.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.233 -0.917 . . . . 0.0 110.135 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -146.6 109.03 4.49 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.251 -0.906 . . . . 0.0 110.149 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.9 tmmt? -47.88 -20.17 0.29 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.573 -0.704 . . . . 0.0 111.16 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.8 p -147.78 143.97 27.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.855 -1.153 . . . . 0.0 110.461 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.528 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 7.4 p90 -175.09 161.49 2.9 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.202 -0.936 . . . . 0.0 109.845 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -77.07 128.42 34.42 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.242 -0.911 . . . . 0.0 109.969 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 82' ' ' GLY . . . -97.13 152.3 20.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.472 ' O ' ' O ' ' A' ' 75' ' ' THR . 8.3 m -173.05 120.66 0.36 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.488 -1.007 . . . . 0.0 109.522 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.586 HG23 HG23 ' A' ' 81' ' ' VAL . 52.2 p -40.33 163.67 0.08 OUTLIER Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.449 -0.782 . . . . 0.0 110.504 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.58 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 43.1 Cg_endo -68.3 -27.14 34.83 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 O-C-N 123.992 1.522 . . . . 0.0 110.367 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.523 ' O ' ' CG ' ' A' ' 77' ' ' GLU . 10.2 pt-20 -177.45 121.34 0.12 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.281 -0.887 . . . . 0.0 110.246 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 144.48 -85.11 0.19 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -134.71 141.52 39.0 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.298 -1.119 . . . . 0.0 110.237 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.77 134.05 21.24 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.998 1.525 . . . . 0.0 110.085 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.586 HG23 HG23 ' A' ' 75' ' ' THR . 21.6 t -87.99 -35.55 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.865 . . . . 0.0 110.326 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 73' ' ' GLY . . . 127.61 -158.79 21.38 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.8 OUTLIER -83.55 171.49 13.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.159 -1.201 . . . . 0.0 110.305 179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.596 HG11 ' HB3' ' A' ' 37' ' ' ALA . 5.7 t -139.47 152.34 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.207 -0.933 . . . . 0.0 110.07 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.637 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 5.6 p-10 -146.86 103.28 3.61 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.38 -0.825 . . . . 0.0 109.886 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 71.6 m -70.05 -2.06 11.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.43 -0.793 . . . . 0.0 110.616 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -63.85 -55.93 19.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.128 -0.983 . . . . 0.0 109.82 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -109.1 -9.75 15.04 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.545 -0.722 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.637 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -91.19 179.55 5.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.522 -0.737 . . . . 0.0 110.466 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.47 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -99.06 99.32 10.32 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.481 -0.762 . . . . 0.0 109.888 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -83.27 140.51 32.46 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.332 -0.855 . . . . 0.0 110.437 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -156.73 144.97 19.61 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.161 -0.962 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 1.027 HD11 HD11 ' A' ' 33' ' ' ILE . 58.5 tp -98.06 147.06 24.91 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.32 -0.863 . . . . 0.0 109.651 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -152.89 151.94 23.68 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.288 -1.434 . . . . 0.0 110.182 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.409 ' HB2' HG12 ' A' ' 33' ' ' ILE . . . -142.33 -173.75 3.93 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.465 -1.021 . . . . 0.0 109.961 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.62 -166.25 25.63 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.543 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 2.6 t30 -145.28 -154.4 0.54 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.283 -1.128 . . . . 0.0 110.397 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.6 p -72.87 -36.07 67.32 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.334 -0.854 . . . . 0.0 110.864 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -122.41 -83.47 0.66 Allowed Glycine 0 N--CA 1.492 2.394 0 C-N-CA 119.765 -1.207 . . . . 0.0 110.106 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.563 HD22 ' CE1' ' A' ' 31' ' ' TYR . 5.6 tt -39.4 152.95 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.385 -1.068 . . . . 0.0 110.618 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.486 ' N ' HD23 ' A' ' 100' ' ' LEU . 3.7 p-10 -127.95 134.35 49.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.366 -0.834 . . . . 0.0 110.256 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.833 HD22 ' CG1' ' A' ' 22' ' ' VAL . 32.6 mt -92.91 -79.63 0.39 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.224 -0.923 . . . . 0.0 110.126 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.32 -179.54 48.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.706 -1.357 . . . . 0.0 109.706 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.412 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 5.8 p80 -141.83 122.75 14.48 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.338 -1.095 . . . . 0.0 110.065 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.594 HG11 ' CG1' ' A' ' 6' ' ' VAL . 89.5 t -100.49 164.08 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.271 -0.893 . . . . 0.0 110.216 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.422 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -118.06 141.93 47.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.229 -0.92 . . . . 0.0 109.936 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.706 HD11 ' HB2' ' A' ' 93' ' ' LEU . 12.9 mt -119.86 170.34 9.33 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 110.019 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.5 m -150.62 136.92 18.64 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.249 -0.907 . . . . 0.0 109.748 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -112.57 89.72 3.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 0.0 110.2 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 CA-C-O 118.041 -1.422 . . . . 0.0 109.549 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.63 H4A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 120.814 0.34 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.43 -173.48 1.33 Allowed 'Trans proline' 0 C--N 1.305 -1.76 0 O-C-N 124.126 1.593 . . . . 0.0 110.519 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -116.98 -178.87 3.54 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.353 -0.842 . . . . 0.0 110.651 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.922 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.1 t80 -170.89 131.2 0.82 Allowed 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.336 -0.853 . . . . 0.0 109.883 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -149.92 154.24 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.96 -1.087 . . . . 0.0 111.267 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.69 HG11 HG11 ' A' ' 105' ' ' VAL . 7.8 p -124.95 155.09 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.674 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 6.1 m -60.25 -88.38 0.01 OUTLIER Pre-proline 0 N--CA 1.488 1.448 0 O-C-N 120.692 -1.255 . . . . 0.0 108.575 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.674 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -79.69 162.12 24.43 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 N-CA-C 109.02 -1.185 . . . . 0.0 109.02 179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -147.17 5.31 0.84 Allowed 'General case' 0 C--N 1.289 -2.029 0 O-C-N 121.048 -1.032 . . . . 0.0 110.665 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.1 p -148.18 173.5 12.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.14 -0.975 . . . . 0.0 109.622 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 48.12 44.38 26.24 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.448 HD12 ' HB3' ' A' ' 107' ' ' LEU . 64.3 mt -86.76 -167.24 1.81 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.415 -1.05 . . . . 0.0 110.27 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.4 m -159.25 155.09 26.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.326 -0.859 . . . . 0.0 110.235 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 2.1 p30 -65.02 124.53 22.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.329 -0.857 . . . . 0.0 110.061 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 98.15 -22.99 38.02 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.894 -1.683 . . . . 0.0 108.894 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.81 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -60.01 133.07 55.74 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.602 -0.94 . . . . 0.0 110.286 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.422 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 6.7 p -106.34 122.89 47.17 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.337 -0.852 . . . . 0.0 109.985 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 18' ' ' VAL . 35.7 m -98.68 170.54 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.22 -0.925 . . . . 0.0 110.085 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.2 105.16 15.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.133 -0.979 . . . . 0.0 109.788 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.595 HG12 ' N ' ' A' ' 21' ' ' SER . 95.1 t -89.41 169.79 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.057 -1.027 . . . . 0.0 110.562 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.595 ' N ' HG12 ' A' ' 20' ' ' VAL . 51.4 p -167.86 111.79 0.65 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.476 -0.765 . . . . 0.0 110.035 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.922 HG22 ' CD1' ' A' ' 4' ' ' PHE . 22.0 t -96.89 157.14 3.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.445 -0.784 . . . . 0.0 110.004 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' A' ' 22' ' ' VAL . 3.9 m -164.58 119.7 1.44 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.139 -0.976 . . . . 0.0 110.249 179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.44 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 144.01 -31.19 1.87 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.717 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -61.26 -130.31 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.302 -1.117 . . . . 0.0 109.99 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -164.63 143.98 7.21 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.906 -1.121 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.98 133.33 43.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.65 -0.656 . . . . 0.0 110.61 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.42 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 101.06 22.29 10.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.482 ' O ' HG23 ' A' ' 54' ' ' THR . 10.0 mm-40 -137.32 142.06 41.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.205 -1.174 . . . . 0.0 110.596 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.459 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.2 m -116.44 132.4 56.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.562 -0.711 . . . . 0.0 109.727 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.797 ' OH ' HD13 ' A' ' 100' ' ' LEU . 12.9 m-85 -115.34 164.92 13.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.172 -0.955 . . . . 0.0 110.471 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.468 ' CD2' ' HB3' ' A' ' 52' ' ' SER . 76.7 m-85 -118.2 139.25 51.56 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.092 -1.005 . . . . 0.0 109.66 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.049 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -130.24 146.05 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.081 -1.012 . . . . 0.0 110.566 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.51 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -163.4 159.57 22.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.373 -0.83 . . . . 0.0 109.895 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -84.01 122.61 29.01 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.109 -0.994 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 63.6 m -128.91 178.08 6.64 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.231 -0.918 . . . . 0.0 110.386 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -168.29 151.62 5.58 Favored Pre-proline 0 N--CA 1.489 1.478 0 O-C-N 121.336 -0.853 . . . . 0.0 109.727 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.39 162.04 41.16 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 O-C-N 124.019 1.536 . . . . 0.0 110.779 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.65 HG22 ' O ' ' A' ' 42' ' ' GLN . 16.6 m -145.73 59.58 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.378 -0.826 . . . . 0.0 109.942 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.32 41.15 1.46 Allowed Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 178.92 -74.64 0.07 OUTLIER Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.65 ' O ' HG22 ' A' ' 39' ' ' VAL . 1.8 mp0 -124.73 -165.07 1.34 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.333 -1.098 . . . . 0.0 110.401 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -112.14 106.46 15.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.324 -0.86 . . . . 0.0 109.977 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -89.25 117.66 28.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 0.0 110.03 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.436 ' SG ' H141 ' A' ' 111' ' ' ROM . 2.9 m -90.5 178.72 6.03 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.151 -0.968 . . . . 0.0 110.376 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.401 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 61.9 t30 -107.04 121.0 46.19 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.201 -0.937 . . . . 0.0 110.338 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -81.0 -7.63 13.18 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 O-C-N 123.896 1.471 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.81 -67.75 0.57 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.35 -0.843 . . . . 0.0 110.349 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.0 p -91.52 100.17 12.97 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -140.54 104.75 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -0.893 . . . . 0.0 110.387 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 6.2 t -128.19 178.45 6.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.189 -0.945 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.468 ' HB3' ' CD2' ' A' ' 32' ' ' TYR . 5.0 p -135.11 157.19 47.57 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.206 -0.934 . . . . 0.0 110.647 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.587 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 13.4 p90 -140.42 -177.78 5.19 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.424 -0.798 . . . . 0.0 109.916 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 29' ' ' GLU . 25.0 m -144.76 156.78 44.23 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.019 -1.05 . . . . 0.0 110.208 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.717 HG21 ' HB3' ' A' ' 25' ' ' ALA . 6.1 p -84.33 176.15 8.9 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.185 -0.947 . . . . 0.0 110.53 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.793 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 27.6 p-10 -111.59 -158.33 0.64 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.384 -0.823 . . . . 0.0 109.47 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.13 -27.66 69.23 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.08 -1.012 . . . . 0.0 110.263 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 65.4 m -92.06 17.49 9.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.212 -0.93 . . . . 0.0 109.961 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.436 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.14 51.09 43.09 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -151.65 141.62 22.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.415 -1.05 . . . . 0.0 110.003 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.96 162.43 32.87 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.185 -0.947 . . . . 0.0 110.689 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.4 OUTLIER -153.32 133.05 13.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.529 -0.732 . . . . 0.0 109.088 179.898 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.9 p90 -162.58 165.67 25.66 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.044 . . . . 0.0 110.556 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 38.7 m -92.43 137.68 32.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.306 -0.871 . . . . 0.0 110.268 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -129.97 133.09 46.57 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.392 -0.817 . . . . 0.0 110.102 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.5 t -83.94 161.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.077 -1.015 . . . . 0.0 110.617 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.81 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.4 m -134.8 -177.24 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 O-C-N 121.534 -0.728 . . . . 0.0 109.566 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 14' ' ' ASP . 0.0 OUTLIER -157.28 107.02 2.2 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.041 -1.037 . . . . 0.0 110.736 179.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HG3' ' HB3' ' A' ' 109' ' ' PHE . 0.9 OUTLIER -38.9 -28.75 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.47 -0.769 . . . . 0.0 110.826 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 68' ' ' ARG . 28.9 t -136.95 148.66 47.09 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.232 -0.918 . . . . 0.0 110.032 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.58 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 12.7 p90 -173.74 147.43 1.37 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.19 -0.944 . . . . 0.0 110.319 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -69.82 132.13 45.57 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.272 -0.893 . . . . 0.0 109.899 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -83.02 165.41 43.47 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.363 -1.095 . . . . 0.0 110.363 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 73' ' ' GLY . 29.9 t 179.57 126.35 0.07 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.573 -0.957 . . . . 0.0 109.338 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.55 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.5 p -53.21 144.84 27.71 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.09 -1.006 . . . . 0.0 110.744 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.516 ' HB3' ' O13' ' A' ' 111' ' ' ROM . 47.5 Cg_endo -71.5 -42.19 1.97 Allowed 'Trans proline' 0 C--N 1.31 -1.466 0 O-C-N 124.155 1.608 . . . . 0.0 111.166 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.491 ' OE2' ' HB ' ' A' ' 75' ' ' THR . 0.0 OUTLIER -43.11 -70.04 0.12 Allowed 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.981 -1.075 . . . . 0.0 110.473 -179.954 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.91 52.5 0.05 OUTLIER Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.474 ' O ' ' OG1' ' A' ' 75' ' ' THR . 0.0 OUTLIER -151.23 155.15 34.59 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.236 -1.155 . . . . 0.0 110.186 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -87.26 174.75 5.08 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 O-C-N 123.926 1.487 . . . . 0.0 109.846 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 75' ' ' THR . 38.5 t -150.83 -73.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.212 -0.93 . . . . 0.0 110.046 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.418 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -176.89 -160.07 23.3 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 20.0 m -106.56 157.1 17.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.097 -1.237 . . . . 0.0 110.476 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 3.5 t -124.69 154.9 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.048 0 O-C-N 121.364 -0.835 . . . . 0.0 109.969 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 9.8 p30 -147.3 97.48 2.87 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.257 -0.902 . . . . 0.0 110.447 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -64.01 -7.26 8.01 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.485 -0.76 . . . . 0.0 110.954 179.921 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.45 50.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.007 -1.058 . . . . 0.0 109.266 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.4 t -135.88 1.78 2.8 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.765 -0.584 . . . . 0.0 109.774 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -109.42 156.43 20.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.292 -0.88 . . . . 0.0 110.316 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.6 117.11 29.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.935 . . . . 0.0 109.839 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.2 m -107.9 174.45 5.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.273 -0.892 . . . . 0.0 110.322 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 15.9 p30 -161.52 149.17 14.93 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.462 -0.774 . . . . 0.0 109.996 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 1.049 HD11 HD11 ' A' ' 33' ' ' ILE . 37.3 tp -83.06 127.53 33.66 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.248 -0.908 . . . . 0.0 109.757 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.618 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -122.37 138.38 11.96 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.612 -1.28 . . . . 0.0 110.099 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.643 ' HB3' HD12 ' A' ' 102' ' ' LEU . . . -130.76 -166.45 1.69 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.434 -1.039 . . . . 0.0 109.819 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.524 ' HA2' ' HB2' ' A' ' 102' ' ' LEU . . . 125.03 130.12 3.46 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.595 ' HB3' ' CG ' ' A' ' 31' ' ' TYR . 1.0 OUTLIER -89.41 174.44 7.8 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.343 -1.093 . . . . 0.0 110.284 179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.452 ' OG ' ' O9 ' ' A' ' 111' ' ' ROM . 0.2 OUTLIER -79.63 78.44 6.19 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.184 -0.948 . . . . 0.0 110.428 -179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 149.95 -12.94 0.98 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.661 -1.257 . . . . 0.0 110.21 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.797 HD13 ' OH ' ' A' ' 31' ' ' TYR . 3.9 tt -155.81 106.9 2.5 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.938 -1.331 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -55.74 144.6 26.76 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.207 -0.933 . . . . 0.0 109.54 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.643 HD12 ' HB3' ' A' ' 95' ' ' ALA . 0.3 OUTLIER -108.3 -88.44 0.48 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.052 -1.03 . . . . 0.0 110.694 -179.949 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.517 ' N ' HD13 ' A' ' 102' ' ' LEU . . . -158.99 -179.63 33.96 Favored Glycine 0 N--CA 1.495 2.613 0 C-N-CA 119.616 -1.278 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.618 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 1.3 m80 -146.26 104.16 3.77 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.331 -1.099 . . . . 0.0 110.413 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.792 HG23 ' CD2' ' A' ' 4' ' ' PHE . 17.2 t -85.52 168.4 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.143 -0.973 . . . . 0.0 109.631 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.481 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -116.69 152.62 33.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.038 -1.038 . . . . 0.0 110.614 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.515 HD11 ' HB2' ' A' ' 93' ' ' LEU . 7.7 mt -130.94 156.02 45.79 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.34 -0.85 . . . . 0.0 109.913 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.67 110.65 5.21 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.102 -0.999 . . . . 0.0 110.226 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.469 ' HB3' ' HG3' ' A' ' 69' ' ' LYS . 52.5 m-85 -86.02 75.32 9.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.399 -0.813 . . . . 0.0 110.456 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 CA-C-O 118.007 -1.441 . . . . 0.0 109.536 -179.975 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 1.073 H6B2 H4A3 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 120.799 0.333 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.67 154.5 54.53 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.985 1.518 . . . . 0.0 110.448 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -106.37 -178.83 3.76 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.241 -0.912 . . . . 0.0 110.627 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.814 ' CD2' HG22 ' A' ' 22' ' ' VAL . 6.1 t80 -168.43 122.28 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.403 -0.811 . . . . 0.0 109.356 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.2 157.16 44.75 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 120.985 -1.072 . . . . 0.0 111.392 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.748 ' CG1' HG11 ' A' ' 105' ' ' VAL . 8.2 p -123.6 150.51 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.4 m -59.42 -71.75 0.3 Allowed Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 120.764 -1.21 . . . . 0.0 109.803 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.626 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.9 Cg_endo -77.85 176.26 10.22 Favored 'Trans proline' 0 C--N 1.323 -0.808 0 O-C-N 123.137 1.072 . . . . 0.0 109.725 179.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.497 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 179.26 29.97 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.258 -0.901 . . . . 0.0 110.265 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -173.59 162.22 4.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.173 -0.954 . . . . 0.0 109.993 179.918 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 44.32 38.73 5.21 Favored Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.604 HD12 ' HB3' ' A' ' 107' ' ' LEU . 43.6 mt -74.14 -161.38 0.12 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.25 -1.147 . . . . 0.0 110.758 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB3' ' HB2' ' A' ' 16' ' ' GLN . 47.3 t -159.4 154.64 25.32 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.492 -0.755 . . . . 0.0 110.069 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -62.29 130.6 46.08 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.199 -0.938 . . . . 0.0 110.401 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.98 -27.27 6.81 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.777 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.5 tm0? -49.09 135.09 16.74 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.381 -1.07 . . . . 0.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.46 123.17 48.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.073 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 21.4 m -98.79 156.97 3.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.203 -0.936 . . . . 0.0 109.888 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 67.9 m -91.55 103.29 15.91 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.98 -1.075 . . . . 0.0 109.663 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 93.7 t -90.38 169.78 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.926 . . . . 0.0 110.811 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 5.0 p -167.03 115.82 0.84 Allowed 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.577 -0.702 . . . . 0.0 109.589 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.847 ' CG1' HD22 ' A' ' 102' ' ' LEU . 21.1 t -104.41 147.36 10.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.318 -0.864 . . . . 0.0 110.392 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -144.13 171.55 14.12 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.011 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.43 -8.88 52.1 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.896 -1.281 . . . . 0.0 109.896 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.71 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -74.14 -132.55 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.176 -1.19 . . . . 0.0 109.729 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -169.88 130.46 1.0 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.95 -1.093 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.97 134.01 37.94 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.549 -0.72 . . . . 0.0 110.373 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.67 26.94 7.36 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.642 ' O ' HG23 ' A' ' 54' ' ' THR . 4.5 mm-40 -140.49 145.99 37.6 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.044 -1.268 . . . . 0.0 110.734 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.0 OUTLIER -119.5 121.12 38.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.416 -0.802 . . . . 0.0 109.716 179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.75 ' CE1' HD22 ' A' ' 100' ' ' LEU . 21.3 m-85 -104.44 152.38 22.39 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 110.625 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -104.54 116.66 32.48 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.548 -0.72 . . . . 0.0 109.597 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.441 ' H ' HG22 ' A' ' 33' ' ' ILE . 9.5 tt -109.68 149.4 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.077 -1.015 . . . . 0.0 110.243 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.529 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -166.55 157.35 12.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.249 -0.907 . . . . 0.0 110.196 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -91.64 134.75 34.43 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.361 -0.837 . . . . 0.0 110.148 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 73.7 m -137.37 179.82 6.17 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.35 -0.844 . . . . 0.0 110.344 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.12 117.7 0.82 Allowed Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.329 -0.857 . . . . 0.0 109.759 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -73.97 164.33 34.74 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.93 1.49 . . . . 0.0 110.678 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.598 ' O ' HG22 ' A' ' 39' ' ' VAL . 7.3 p -143.06 57.07 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.478 -0.764 . . . . 0.0 109.753 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 39.12 51.85 2.73 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 170.42 -65.1 0.16 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.558 ' O ' HG12 ' A' ' 39' ' ' VAL . 2.5 mt-30 -127.15 166.94 16.73 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.266 -1.138 . . . . 0.0 110.437 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -106.15 107.89 19.12 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.299 -0.876 . . . . 0.0 110.079 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 1.08 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -89.71 110.27 21.18 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.192 -0.942 . . . . 0.0 110.594 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.6 m -95.91 -178.83 4.49 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 109.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.555 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -118.03 112.15 38.4 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.074 -1.016 . . . . 0.0 110.611 -179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.494 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 47.3 Cg_endo -73.02 -32.31 8.83 Favored 'Trans proline' 0 C--N 1.309 -1.5 0 O-C-N 123.964 1.507 . . . . 0.0 110.459 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.57 -43.47 98.73 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.348 -0.845 . . . . 0.0 110.377 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.477 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 4.2 p -96.51 74.68 2.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.211 -0.931 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -123.54 97.57 5.45 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.268 -0.895 . . . . 0.0 109.773 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 33' ' ' ILE . 3.8 t -120.41 134.2 55.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.279 -0.888 . . . . 0.0 110.679 -179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.8 p -107.36 133.62 51.63 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.351 -0.843 . . . . 0.0 109.565 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 38.5 p90 -124.13 -176.8 3.59 Favored 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.101 -1.0 . . . . 0.0 111.111 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.642 HG23 ' O ' ' A' ' 29' ' ' GLU . 97.5 m -133.91 155.28 50.18 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.443 -0.786 . . . . 0.0 110.257 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.71 HG21 ' CB ' ' A' ' 25' ' ' ALA . 1.8 p -75.73 -177.37 3.72 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.085 -1.009 . . . . 0.0 110.361 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.654 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -104.58 -160.25 0.75 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.525 -0.734 . . . . 0.0 109.749 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.24 -42.05 93.75 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.124 -0.985 . . . . 0.0 110.188 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -82.39 9.49 8.96 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.365 -0.834 . . . . 0.0 109.902 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.519 ' O ' ' HB3' ' A' ' 25' ' ' ALA . . . 74.61 14.26 81.34 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.489 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -109.78 116.61 32.0 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.167 -1.196 . . . . 0.0 110.023 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.694 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -99.15 171.76 7.81 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.35 -0.844 . . . . 0.0 110.612 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 26.9 p -175.03 135.49 0.36 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.48 -0.763 . . . . 0.0 109.404 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.522 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 27.9 p90 -173.53 179.04 2.18 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.037 -1.039 . . . . 0.0 110.531 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.1 p -98.03 120.6 38.72 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.409 -0.807 . . . . 0.0 110.288 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.6 t80 -107.39 151.13 25.94 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.273 -0.892 . . . . 0.0 109.972 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.572 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 2.0 t -103.67 156.44 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.101 -0.999 . . . . 0.0 110.087 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.7 m -126.19 168.75 18.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.262 -0.899 . . . . 0.0 110.316 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -138.53 107.93 6.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.296 -0.877 . . . . 0.0 109.905 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.57 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 2.1 tttm -47.43 -59.9 2.9 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.272 -0.892 . . . . 0.0 110.709 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.439 ' OG ' ' OD2' ' A' ' 85' ' ' ASP . 73.6 m -113.06 149.55 33.27 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.23 -0.919 . . . . 0.0 110.551 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.555 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 19.9 p90 -175.56 138.11 0.38 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.9 . . . . 0.0 109.913 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -62.1 123.55 18.43 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.235 -0.916 . . . . 0.0 109.897 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 1.08 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.29 146.19 28.82 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.7 OUTLIER -164.62 111.45 1.03 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.58 -0.953 . . . . 0.0 109.785 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.485 HG23 HG21 ' A' ' 81' ' ' VAL . 46.5 p -41.33 156.38 0.21 Allowed Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.305 -0.872 . . . . 0.0 110.357 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.803 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 33.5 Cg_endo -55.03 -13.54 6.71 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 124.3 1.684 . . . . 0.0 110.906 -179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -83.08 -178.66 7.19 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.085 -1.01 . . . . 0.0 109.666 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -85.77 42.36 3.14 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 22.3 p -126.8 115.08 22.43 Favored Pre-proline 0 C--N 1.307 -1.27 0 O-C-N 121.292 -1.122 . . . . 0.0 110.444 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -76.06 119.07 5.21 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.852 1.448 . . . . 0.0 110.181 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.485 HG21 HG23 ' A' ' 75' ' ' THR . 88.8 t -83.1 -89.67 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.248 -0.907 . . . . 0.0 110.439 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.461 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -145.71 -172.28 15.95 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -93.45 152.36 19.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -1.126 . . . . 0.0 110.268 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.8 t -128.04 156.11 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.176 -0.952 . . . . 0.0 110.2 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.655 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.6 OUTLIER -155.9 131.8 9.86 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.333 -0.854 . . . . 0.0 110.057 -179.948 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -89.79 8.81 29.95 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 110.699 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -56.86 -33.53 66.91 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.957 -1.089 . . . . 0.0 108.74 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.2 t -151.6 15.92 0.69 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -104.61 179.82 4.16 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.548 -0.72 . . . . 0.0 110.683 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.92 88.48 2.89 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.489 -0.757 . . . . 0.0 109.72 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.9 m -81.99 166.93 19.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.236 -0.915 . . . . 0.0 110.278 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 -150.86 -178.95 6.88 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.215 -0.928 . . . . 0.0 110.27 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.531 ' O ' ' HA ' ' A' ' 104' ' ' HIS . 28.6 tp -140.11 125.68 19.16 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.414 -0.804 . . . . 0.0 109.331 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -125.45 150.9 17.45 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 119.344 -1.408 . . . . 0.0 110.68 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -132.19 -176.76 4.18 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.494 -1.004 . . . . 0.0 109.937 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.44 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 121.47 156.67 9.82 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 119.752 -1.213 . . . . 0.0 110.305 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.421 ' HB2' ' HA ' ' A' ' 31' ' ' TYR . 14.6 t-20 -114.94 175.21 5.6 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.506 -0.996 . . . . 0.0 109.507 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.414 ' N ' ' CG ' ' A' ' 97' ' ' ASN . 8.5 t -53.51 -13.33 0.59 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.081 -1.012 . . . . 0.0 111.372 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 100' ' ' LEU . . . -133.75 37.91 1.92 Allowed Glycine 0 N--CA 1.496 2.68 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.345 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.75 HD22 ' CE1' ' A' ' 31' ' ' TYR . 2.6 tt -178.66 108.15 0.05 OUTLIER 'General case' 0 N--CA 1.501 2.11 0 O-C-N 120.767 -1.431 . . . . 0.0 110.912 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -93.07 134.08 35.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 109.877 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.847 HD22 ' CG1' ' A' ' 22' ' ' VAL . 7.1 mt -101.38 -84.06 0.44 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.148 -0.97 . . . . 0.0 110.558 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -169.99 -178.26 40.86 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.746 -1.342 . . . . 0.0 109.746 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.531 ' HA ' ' O ' ' A' ' 93' ' ' LEU . 21.0 m-70 -134.19 105.18 6.52 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.515 -0.991 . . . . 0.0 110.265 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.748 HG11 ' CG1' ' A' ' 6' ' ' VAL . 37.3 t -84.3 122.72 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 O-C-N 121.284 -0.885 . . . . 0.0 109.954 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.401 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -82.86 136.21 34.69 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.122 -0.986 . . . . 0.0 110.742 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.604 ' HB3' HD12 ' A' ' 12' ' ' LEU . 15.1 mt -117.99 171.46 8.07 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.415 -0.803 . . . . 0.0 109.721 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.472 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.9 m -154.88 117.12 4.22 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.063 -1.023 . . . . 0.0 110.431 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.57 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 24.1 m-85 -84.61 71.54 10.77 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.973 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.803 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.552 ' CB ' ' HA3' ' A' ' 24' ' ' GLY . 44.3 Cg_endo -73.54 -158.16 0.07 OUTLIER 'Trans proline' 0 C--N 1.307 -1.606 0 O-C-N 123.994 1.523 . . . . 0.0 110.237 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.81 127.16 1.05 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.937 -1.102 . . . . 0.0 110.929 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.586 ' CD1' HG22 ' A' ' 22' ' ' VAL . 34.8 t80 -124.35 130.91 53.33 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.367 -0.833 . . . . 0.0 109.379 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 t -153.59 163.96 39.07 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.77 -1.206 . . . . 0.0 111.981 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.861 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.4 p -121.59 163.98 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -68.47 -71.34 0.31 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 120.543 -1.348 . . . . 0.0 109.409 179.979 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 56.1 Cg_endo -88.38 -158.46 0.08 OUTLIER 'Trans proline' 0 CA--C 1.539 0.758 0 N-CA-C 109.176 -1.125 . . . . 0.0 109.176 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.621 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 173.63 -28.24 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.107 -0.996 . . . . 0.0 110.256 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -119.57 167.74 11.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.078 -1.014 . . . . 0.0 109.977 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 50.33 48.71 40.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.628 . . . . 0.0 109.031 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.664 HD12 ' HB3' ' A' ' 107' ' ' LEU . 63.0 mt -88.14 -173.01 4.05 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.402 -1.058 . . . . 0.0 110.638 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.463 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 56.6 p -162.4 145.16 11.23 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.531 -0.731 . . . . 0.0 110.009 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -57.61 136.9 56.84 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.298 -0.876 . . . . 0.0 110.42 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.95 -28.3 9.67 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.614 ' O ' HG22 ' A' ' 67' ' ' VAL . 53.9 tt0 -61.01 148.1 41.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.36 -1.082 . . . . 0.0 110.528 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.0 OUTLIER -117.34 127.74 54.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.169 -0.957 . . . . 0.0 110.087 -179.936 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.505 HG12 ' HG2' ' A' ' 8' ' ' PRO . 20.4 m -103.06 152.03 6.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.317 -0.864 . . . . 0.0 109.961 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.24 109.8 21.07 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.16 -0.963 . . . . 0.0 109.797 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.469 HG12 ' N ' ' A' ' 21' ' ' SER . 60.5 t -96.24 164.46 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 110.623 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.469 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.4 p -166.78 124.57 1.33 Allowed 'General case' 0 N--CA 1.493 1.682 0 C-N-CA 119.843 -0.743 . . . . 0.0 110.414 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.841 HG13 HD11 ' A' ' 102' ' ' LEU . 7.8 t -108.68 139.31 31.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.437 -0.789 . . . . 0.0 109.35 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 30.6 p -151.6 117.95 5.64 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.948 -1.095 . . . . 0.0 110.296 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.552 ' HA3' ' CB ' ' A' ' 2' ' ' PRO . . . 139.02 -34.56 2.07 Favored Glycine 0 N--CA 1.485 1.965 0 N-CA-C 109.309 -1.517 . . . . 0.0 109.309 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.783 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.09 -159.67 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.36 -1.082 . . . . 0.0 109.375 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.35 144.3 20.73 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.835 -1.166 . . . . 0.0 111.313 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.986 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -48.28 135.42 13.57 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.447 -0.783 . . . . 0.0 110.275 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.35 1.83 24.75 Favored Glycine 0 N--CA 1.485 1.958 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.766 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -130.3 142.65 50.53 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.192 -1.181 . . . . 0.0 110.498 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.664 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.8 m -108.33 150.0 27.92 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.553 -0.717 . . . . 0.0 109.339 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.754 ' OH ' ' HB1' ' A' ' 25' ' ' ALA . 92.1 m-85 -125.81 167.33 15.35 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.228 -0.92 . . . . 0.0 110.229 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.495 ' CE1' " O2'" ' A' ' 111' ' ' ROM . 3.3 m-85 -143.05 95.43 2.77 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.322 -0.861 . . . . 0.0 109.709 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.025 HD13 ' HB2' ' A' ' 95' ' ' ALA . 4.7 tp -84.17 141.35 14.84 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.344 -0.847 . . . . 0.0 110.107 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.535 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -165.8 149.11 7.73 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.252 -0.905 . . . . 0.0 110.39 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.48 ' O ' ' HB2' ' A' ' 46' ' ' ASN . 33.1 tt0 -86.79 121.46 29.31 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.225 -0.922 . . . . 0.0 109.593 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 34.7 m -119.79 179.4 4.25 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.239 -0.913 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -167.51 142.44 3.18 Favored Pre-proline 0 N--CA 1.489 1.507 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.68 160.2 49.21 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 O-C-N 123.657 1.346 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.793 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.0 p -159.72 77.62 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.515 -0.74 . . . . 0.0 110.189 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.82 0.59 68.7 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.77 3.62 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 6.2 mp0 -79.13 167.96 20.29 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.225 -1.162 . . . . 0.0 110.192 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -107.26 112.55 25.46 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.362 -0.836 . . . . 0.0 110.272 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.12 110.08 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 109.862 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.51 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 3.2 m -90.0 169.98 10.74 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.123 -0.985 . . . . 0.0 110.733 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 35' ' ' GLN . 24.6 t-20 -92.56 111.76 52.37 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.437 -0.789 . . . . 0.0 110.502 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.542 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.5 Cg_endo -81.87 -14.35 9.99 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.892 1.47 . . . . 0.0 110.277 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.19 -48.65 19.67 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.1 p -97.49 83.32 3.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.261 -0.899 . . . . 0.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -106.41 131.77 53.23 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.242 -0.911 . . . . 0.0 110.106 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.78 ' OG1' HG23 ' A' ' 33' ' ' ILE . 0.7 OUTLIER -136.22 91.36 2.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 110.673 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 31' ' ' TYR . 11.3 t -89.22 128.74 35.85 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.228 -0.92 . . . . 0.0 109.47 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 47.4 p90 -139.94 132.29 28.39 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.908 -1.12 . . . . 0.0 111.393 -179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.766 HG23 ' O ' ' A' ' 29' ' ' GLU . 55.0 m -97.16 149.02 22.46 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.282 -0.886 . . . . 0.0 109.233 179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.783 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -78.3 158.5 28.84 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.955 -1.091 . . . . 0.0 109.901 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.986 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.6 OUTLIER -94.93 -161.8 0.89 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.259 -0.901 . . . . 0.0 109.953 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.37 -26.37 67.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.261 -0.899 . . . . 0.0 109.834 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.3 m -82.08 -2.53 52.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.401 -0.812 . . . . 0.0 109.688 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.476 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 52.82 57.34 14.65 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -158.0 159.6 36.59 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.266 -1.137 . . . . 0.0 110.64 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -162.32 170.28 19.16 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.282 -0.886 . . . . 0.0 110.629 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 84.4 p -172.04 132.84 0.68 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.452 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 10.6 p90 -165.74 160.3 17.09 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.795 -1.191 . . . . 0.0 111.041 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.3 p -87.57 147.66 25.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.416 -0.803 . . . . 0.0 109.55 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -143.83 126.49 16.04 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.264 -0.897 . . . . 0.0 110.347 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.6 t -81.53 164.57 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.245 -0.909 . . . . 0.0 110.38 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -129.41 177.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.22 -0.925 . . . . 0.0 110.261 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' O ' ' C ' ' A' ' 69' ' ' LYS . 4.4 mtp85 -152.52 93.18 1.75 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 110.035 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.486 ' HG3' ' CG ' ' A' ' 109' ' ' PHE . 19.8 ttpt -31.8 -44.41 0.08 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-O 121.124 0.487 . . . . 0.0 111.63 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.58 141.79 48.24 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 120.938 -1.101 . . . . 0.0 110.467 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 10.3 p90 -173.85 143.21 0.95 Allowed 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.193 -0.942 . . . . 0.0 110.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.7 m -59.17 118.1 5.5 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.169 -0.957 . . . . 0.0 109.921 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -86.37 161.39 34.03 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.474 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.6 m -166.51 151.24 7.75 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.314 -1.109 . . . . 0.0 109.938 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 1.001 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.7 p -70.47 147.66 95.0 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.257 -0.902 . . . . 0.0 110.136 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.439 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 45.8 Cg_endo -71.51 -7.85 22.07 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 124.106 1.582 . . . . 0.0 110.78 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -156.7 119.56 4.08 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.938 -1.101 . . . . 0.0 110.742 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.402 ' C ' ' OG1' ' A' ' 79' ' ' THR . . . 127.45 -77.83 0.39 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.615 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.0 OUTLIER -170.4 -175.37 0.33 Allowed Pre-proline 0 N--CA 1.493 1.721 0 O-C-N 121.428 -1.042 . . . . 0.0 109.528 179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.615 ' HD2' HG22 ' A' ' 79' ' ' THR . 43.9 Cg_endo -71.99 167.3 27.09 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 O-C-N 123.418 1.22 . . . . 0.0 110.079 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 1.001 ' CG2' HG23 ' A' ' 75' ' ' THR . 56.1 t -122.12 -28.1 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.274 -0.891 . . . . 0.0 110.741 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.84 -159.59 27.63 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.8 m -100.57 149.37 23.8 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.169 -1.195 . . . . 0.0 110.466 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 10.6 t -123.43 155.47 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.357 -0.839 . . . . 0.0 110.301 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -143.99 90.59 2.14 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.932 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.691 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 86.1 m -74.05 3.53 6.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.35 -0.844 . . . . 0.0 110.752 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.479 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -51.03 -43.14 60.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.06 -1.025 . . . . 0.0 109.2 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 t -121.41 -9.41 9.03 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.505 0.669 . . . . 0.0 109.335 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.691 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -86.05 171.12 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.308 -0.87 . . . . 0.0 110.181 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.41 95.63 9.42 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.264 -0.898 . . . . 0.0 110.227 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.43 ' HB2' ' HB3' ' A' ' 86' ' ' CYS . 0.1 OUTLIER -81.97 169.29 16.94 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.328 -0.857 . . . . 0.0 109.942 -179.986 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -166.71 129.96 1.91 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.117 -0.989 . . . . 0.0 110.814 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.804 ' CG ' HD11 ' A' ' 33' ' ' ILE . 55.6 tp -84.24 142.62 30.15 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.345 -0.847 . . . . 0.0 110.131 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.806 ' O ' HD12 ' A' ' 33' ' ' ILE . . . -133.52 149.18 19.62 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 1.025 ' HB2' HD13 ' A' ' 33' ' ' ILE . . . -151.89 84.56 1.28 Allowed 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.416 -1.049 . . . . 0.0 110.145 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.413 ' O ' ' H6 ' ' A' ' 111' ' ' ROM . . . -149.18 148.29 19.52 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -77.54 -179.61 5.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -1.168 . . . . 0.0 110.03 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 t -63.3 -22.54 66.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 110.325 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.09 -42.56 0.18 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.597 HD13 ' C ' ' A' ' 100' ' ' LEU . 1.3 tm? -61.5 95.82 0.05 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -1.169 . . . . 0.0 110.432 -179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -70.89 89.69 0.78 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.25 -0.907 . . . . 0.0 109.878 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.841 HD11 HG13 ' A' ' 22' ' ' VAL . 0.2 OUTLIER -80.01 -75.7 0.25 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.342 -0.849 . . . . 0.0 110.518 -179.938 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 177.24 172.16 41.51 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.609 -1.281 . . . . 0.0 109.987 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 12.3 p80 -150.67 136.75 18.45 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.394 -1.062 . . . . 0.0 109.977 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.861 HG11 ' CG1' ' A' ' 6' ' ' VAL . 57.8 t -110.74 154.99 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.183 -0.948 . . . . 0.0 110.078 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.432 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -106.35 155.33 19.64 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 0.0 110.28 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.664 ' HB3' HD12 ' A' ' 12' ' ' LEU . 45.2 mt -123.69 170.82 10.11 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.172 -0.955 . . . . 0.0 110.121 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -159.39 102.59 1.57 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.24 -0.913 . . . . 0.0 110.267 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.486 ' CG ' ' HG3' ' A' ' 69' ' ' LYS . 85.4 m-85 -79.89 93.14 5.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.284 -0.885 . . . . 0.0 110.266 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.622 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.524 ' HG2' HD23 ' A' ' 102' ' ' LEU . 45.9 Cg_endo -72.88 -175.21 1.8 Allowed 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.779 1.41 . . . . 0.0 110.081 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.66 161.62 32.33 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 110.352 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.97 ' CD1' HG22 ' A' ' 22' ' ' VAL . 60.8 t80 -154.17 125.86 7.61 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.472 -0.768 . . . . 0.0 109.696 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -152.33 165.89 33.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.01 -1.056 . . . . 0.0 111.378 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.855 ' CG1' HG11 ' A' ' 105' ' ' VAL . 12.1 p -128.37 152.83 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.651 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.9 m -58.61 -79.13 0.04 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 120.713 -1.242 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.651 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.1 Cg_endo -79.37 163.36 24.75 Favored 'Trans proline' 0 C--O 1.211 -0.85 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.07 28.72 0.06 Allowed 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.02 -1.05 . . . . 0.0 110.449 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.532 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 29.2 m -167.45 154.83 8.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.395 -0.815 . . . . 0.0 109.587 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 58.36 44.35 95.22 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.756 -1.738 . . . . 0.0 108.756 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.636 HD12 ' HB3' ' A' ' 107' ' ' LEU . 58.5 mt -84.8 -161.57 0.59 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.443 -1.033 . . . . 0.0 110.641 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 12' ' ' LEU . 20.4 m -163.73 148.07 10.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.549 -0.719 . . . . 0.0 109.768 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 28.0 p-10 -60.67 131.01 49.36 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.072 -1.018 . . . . 0.0 109.903 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 93.96 -27.5 12.77 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.937 -1.665 . . . . 0.0 108.937 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.672 ' O ' HG22 ' A' ' 67' ' ' VAL . 42.0 tt0 -59.6 148.46 33.49 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.575 -0.956 . . . . 0.0 110.246 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 1.7 p -120.48 131.2 54.63 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 110.343 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.427 HG22 ' H ' ' A' ' 18' ' ' VAL . 26.9 m -105.51 166.77 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.321 -0.862 . . . . 0.0 109.931 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.1 m -99.86 100.56 11.5 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.128 -0.983 . . . . 0.0 109.531 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.605 HG12 ' N ' ' A' ' 21' ' ' SER . 71.2 t -83.45 170.58 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.02 -1.05 . . . . 0.0 110.692 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.605 ' N ' HG12 ' A' ' 20' ' ' VAL . 7.8 p -164.07 138.03 5.53 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.559 -0.713 . . . . 0.0 109.861 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.97 HG22 ' CD1' ' A' ' 4' ' ' PHE . 34.5 t -124.52 163.66 24.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.341 -0.849 . . . . 0.0 109.918 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 59' ' ' GLY . 1.5 m -164.02 172.01 14.43 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.373 -0.83 . . . . 0.0 110.14 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 87.04 -32.79 3.95 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.977 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -59.86 -131.71 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.273 -1.133 . . . . 0.0 110.366 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -168.6 133.2 1.6 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.923 -1.111 . . . . 0.0 110.772 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.901 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.93 132.12 46.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.265 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' C ' ' HG2' ' A' ' 29' ' ' GLU . . . 106.06 9.71 31.55 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.568 ' O ' HG23 ' A' ' 54' ' ' THR . 3.8 mm-40 -129.08 149.41 50.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.167 . . . . 0.0 110.087 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.45 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -123.58 136.67 54.66 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.296 -0.878 . . . . 0.0 110.998 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.603 ' CE1' ' HG ' ' A' ' 100' ' ' LEU . 50.2 m-85 -122.86 170.33 10.21 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.609 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 9.3 m-85 -114.83 137.59 51.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.731 -1.23 . . . . 0.0 110.526 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.6 tt -125.94 153.83 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 110.289 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.611 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -169.61 155.36 5.98 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.106 -0.996 . . . . 0.0 110.44 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.925 ' OE1' HG12 ' A' ' 67' ' ' VAL . 32.4 tt0 -95.77 133.59 39.72 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.081 -1.012 . . . . 0.0 109.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.8 OUTLIER -136.56 169.07 18.3 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.036 -1.04 . . . . 0.0 110.248 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.18 148.47 24.66 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.537 -0.727 . . . . 0.0 109.102 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.422 ' C ' HG23 ' A' ' 39' ' ' VAL . 42.0 Cg_endo -69.45 162.09 43.28 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.646 1.34 . . . . 0.0 110.277 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.464 HG12 ' O ' ' A' ' 39' ' ' VAL . 67.7 t -145.09 68.89 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 0.0 110.54 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.66 -9.74 21.34 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 161.72 -44.42 0.38 Allowed Glycine 0 N--CA 1.49 2.25 0 O-C-N 120.889 -1.359 . . . . 0.0 109.9 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.96 157.69 21.81 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.0 -1.294 . . . . 0.0 110.502 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.8 OUTLIER -108.25 110.73 22.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.292 -0.88 . . . . 0.0 110.23 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.01 120.84 43.16 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 110.038 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.517 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 4.7 t -98.67 178.79 4.88 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.138 -0.976 . . . . 0.0 110.388 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.558 ' O ' ' ND2' ' A' ' 46' ' ' ASN . 0.7 OUTLIER -99.8 138.33 20.35 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 111.186 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 53.8 Cg_endo -92.74 1.46 3.76 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 123.76 1.4 . . . . 0.0 109.413 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -91.68 -55.68 3.39 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.4 -0.812 . . . . 0.0 111.788 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.549 ' OG1' ' ND2' ' A' ' 46' ' ' ASN . 43.5 p -86.62 50.57 2.03 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.966 -1.084 . . . . 0.0 111.054 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.05 98.39 8.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.352 -0.843 . . . . 0.0 108.969 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.07 148.01 44.75 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.097 -1.002 . . . . 0.0 111.273 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -102.59 126.7 49.76 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -124.35 154.01 40.97 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.728 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 29' ' ' GLU . 85.9 m -108.28 144.94 35.09 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.553 -0.717 . . . . 0.0 109.174 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.977 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.2 p -69.63 175.79 3.95 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.002 -1.061 . . . . 0.0 111.316 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.901 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 22.3 t0 -100.2 -167.13 1.41 Allowed 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.536 -0.728 . . . . 0.0 109.516 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.503 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -60.96 -34.45 74.77 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.154 -0.966 . . . . 0.0 109.996 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.82 25.59 2.7 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.319 -0.863 . . . . 0.0 109.67 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 23' ' ' SER . . . 57.49 25.82 55.78 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' VAL . . . -112.58 120.59 42.12 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.325 -1.103 . . . . 0.0 110.571 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.719 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -116.19 101.83 9.05 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.36 -0.838 . . . . 0.0 110.242 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.518 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.5 m -111.75 139.84 46.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.223 -0.923 . . . . 0.0 110.204 -179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -167.44 174.0 8.3 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.484 -0.886 . . . . 0.0 110.445 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 p -91.25 142.41 27.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.303 -0.873 . . . . 0.0 110.738 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 64.7 t80 -138.69 128.01 24.36 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.507 -0.746 . . . . 0.0 109.521 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.48 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 20.4 t -83.44 166.92 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.156 -0.965 . . . . 0.0 110.207 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.925 HG12 ' OE1' ' A' ' 35' ' ' GLN . 3.0 m -135.99 -177.57 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.362 -0.836 . . . . 0.0 110.303 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 67' ' ' VAL . 4.0 mtt180 -155.45 102.61 2.26 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.302 -0.874 . . . . 0.0 110.023 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' C ' ' O ' ' A' ' 68' ' ' ARG . 9.5 ttpt -40.22 -56.1 2.01 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.366 -0.834 . . . . 0.0 110.49 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 37.9 m -116.77 141.05 48.71 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.259 -0.901 . . . . 0.0 110.311 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.498 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 39.6 p90 -168.97 147.27 3.89 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.242 -0.911 . . . . 0.0 109.994 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.6 OUTLIER -60.06 124.19 19.46 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.144 -0.972 . . . . 0.0 110.193 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -83.84 165.1 41.61 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 75' ' ' THR . 12.7 p 179.87 118.17 0.05 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.249 -1.148 . . . . 0.0 110.354 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.526 HG23 ' CG2' ' A' ' 81' ' ' VAL . 16.8 p -42.65 166.25 0.09 OUTLIER Pre-proline 0 N--CA 1.496 1.833 0 O-C-N 121.256 -0.902 . . . . 0.0 110.101 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.567 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 40.8 Cg_endo -67.08 -5.73 14.35 Favored 'Trans proline' 0 C--N 1.31 -1.465 0 O-C-N 123.748 1.394 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -98.12 -150.71 0.36 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.175 -0.953 . . . . 0.0 109.928 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -101.55 11.27 58.0 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -93.26 122.72 62.57 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.239 -1.154 . . . . 0.0 110.254 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.61 148.66 29.47 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.865 1.455 . . . . 0.0 110.369 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 75' ' ' THR . 90.5 t -115.5 -23.36 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.201 -0.937 . . . . 0.0 110.031 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 130.09 -177.53 18.13 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.9 OUTLIER -84.1 148.04 27.03 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.33 -1.1 . . . . 0.0 109.874 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 19.3 t -119.36 156.13 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.111 -0.993 . . . . 0.0 110.572 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 30.9 t0 -152.41 105.61 3.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.632 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.751 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 100.0 m -80.8 15.08 1.88 Allowed 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.34 -0.85 . . . . 0.0 111.139 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.41 -59.36 4.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.869 -1.145 . . . . 0.0 108.361 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 t -109.06 -8.44 15.18 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.751 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -82.65 -176.02 6.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.632 -0.667 . . . . 0.0 110.3 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -111.91 102.01 10.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.501 -0.749 . . . . 0.0 110.51 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -77.72 167.4 21.62 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.342 -0.849 . . . . 0.0 109.31 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.436 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 1.9 p-10 -162.92 -179.29 6.66 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.941 -1.099 . . . . 0.0 111.095 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.611 HD12 ' O ' ' A' ' 34' ' ' ALA . 63.1 tp -145.4 140.48 27.67 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.561 -0.712 . . . . 0.0 109.303 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA2' ' HB3' ' A' ' 104' ' ' HIS . . . -132.97 157.74 22.79 Favored Glycine 0 N--CA 1.494 2.548 0 C-N-CA 119.5 -1.333 . . . . 0.0 110.247 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -140.47 -166.82 2.2 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.449 -1.03 . . . . 0.0 110.077 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.55 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 91.69 176.48 42.82 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.552 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 46.4 p-10 -122.11 -136.05 0.31 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.195 -1.179 . . . . 0.0 110.436 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.515 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 0.1 OUTLIER -93.37 -47.87 6.68 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.007 -1.058 . . . . 0.0 111.59 -179.887 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -110.42 37.68 3.64 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.981 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.603 ' HG ' ' CE1' ' A' ' 31' ' ' TYR . 3.0 tm? -136.47 -49.37 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.005 -1.291 . . . . 0.0 109.754 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.489 ' O ' HD13 ' A' ' 100' ' ' LEU . 8.2 t0 61.44 132.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.431 -0.793 . . . . 0.0 110.118 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.55 HD12 ' N ' ' A' ' 96' ' ' GLY . 20.0 mt -127.96 -85.68 0.58 Allowed 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.343 -0.848 . . . . 0.0 110.411 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.98 162.83 29.55 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.535 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 1.4 p-80 -130.73 134.42 46.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -1.108 . . . . 0.0 109.979 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.855 HG11 ' CG1' ' A' ' 6' ' ' VAL . 66.4 t -101.45 128.0 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.264 -0.897 . . . . 0.0 110.562 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.436 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -82.94 135.02 35.04 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.201 -0.937 . . . . 0.0 109.899 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.636 ' HB3' HD12 ' A' ' 12' ' ' LEU . 17.7 mt -109.67 172.47 6.83 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -0.88 . . . . 0.0 110.397 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 6.0 m -138.04 140.6 40.16 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.391 -0.818 . . . . 0.0 109.737 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -116.76 121.77 42.56 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.077 -1.014 . . . . 0.0 110.184 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.202 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.953 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.688 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.47 ' HB3' ' C ' ' A' ' 24' ' ' GLY . 45.3 Cg_endo -74.03 -166.81 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.031 1.542 . . . . 0.0 110.436 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -157.3 -179.18 7.94 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.275 -0.891 . . . . 0.0 110.273 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.852 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.9 t80 -161.86 138.86 8.38 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.316 -0.865 . . . . 0.0 109.685 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 t -154.9 164.49 38.79 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 120.876 -1.14 . . . . 0.0 111.262 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' A' ' 105' ' ' VAL . 10.0 p -132.89 142.48 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.762 -0.586 . . . . 0.0 109.472 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.653 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.9 m -57.51 -74.87 0.12 Allowed Pre-proline 0 C--N 1.304 -1.38 0 O-C-N 120.64 -1.288 . . . . 0.0 108.706 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.653 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -80.67 159.95 21.88 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 N-CA-C 109.531 -0.988 . . . . 0.0 109.531 179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -159.55 20.01 0.18 Allowed 'General case' 0 C--N 1.295 -1.779 0 O-C-N 121.276 -0.89 . . . . 0.0 110.204 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.534 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 4.5 m -164.53 173.13 12.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.851 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 46.21 43.04 13.37 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 108.756 -1.737 . . . . 0.0 108.756 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.498 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 86.2 mt -85.3 -158.75 0.39 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.567 -0.961 . . . . 0.0 110.38 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 12' ' ' LEU . 41.1 t -178.82 156.71 0.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.408 -0.808 . . . . 0.0 110.3 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -61.7 129.9 43.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.25 -0.906 . . . . 0.0 109.852 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.76 -27.05 9.3 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.638 HE22 HG12 ' A' ' 18' ' ' VAL . 13.0 tm0? -51.8 153.1 2.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.345 -1.091 . . . . 0.0 110.015 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 m -121.3 147.24 45.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.087 -1.008 . . . . 0.0 110.489 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.638 HG12 HE22 ' A' ' 16' ' ' GLN . 15.0 m -128.96 159.93 40.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.304 -0.872 . . . . 0.0 109.895 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.453 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 15.6 p -101.93 99.42 9.61 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.115 -0.991 . . . . 0.0 109.942 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 76.9 t -87.95 167.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 O-C-N 121.106 -0.996 . . . . 0.0 110.319 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.2 p -163.77 121.88 1.88 Allowed 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.386 -0.822 . . . . 0.0 110.028 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.852 HG22 ' CD2' ' A' ' 4' ' ' PHE . 67.7 t -113.18 156.47 14.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.511 -0.743 . . . . 0.0 109.869 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -161.57 164.05 29.71 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.92 -1.113 . . . . 0.0 110.692 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.47 ' C ' ' HB3' ' A' ' 2' ' ' PRO . . . 91.19 3.46 69.78 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.841 -1.303 . . . . 0.0 109.841 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.924 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -95.03 -21.29 18.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.096 -1.238 . . . . 0.0 110.222 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.748 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.22 129.78 0.04 OUTLIER 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.406 -0.809 . . . . 0.0 111.173 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.95 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -50.17 136.78 18.89 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.734 -0.604 . . . . 0.0 110.477 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.413 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 122.33 16.79 3.77 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.542 ' O ' HG23 ' A' ' 54' ' ' THR . 0.6 OUTLIER -150.85 146.82 26.59 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -1.189 . . . . 0.0 110.624 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.435 HG23 ' OG1' ' A' ' 54' ' ' THR . 3.3 m -112.19 160.1 17.92 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.607 -0.683 . . . . 0.0 109.843 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.919 ' OH ' HD22 ' A' ' 100' ' ' LEU . 66.8 m-85 -146.42 145.6 30.3 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.177 -0.952 . . . . 0.0 110.485 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.443 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 24.4 m-85 -109.63 103.55 12.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.408 -0.808 . . . . 0.0 109.783 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.966 HD11 HD11 ' A' ' 93' ' ' LEU . 0.0 OUTLIER -83.24 140.21 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.052 -1.03 . . . . 0.0 109.956 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.863 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -154.68 151.72 29.09 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.263 -0.898 . . . . 0.0 110.171 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -88.36 126.92 35.44 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 109.928 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 99.1 m -112.26 172.33 6.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.118 -0.989 . . . . 0.0 110.571 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.621 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -174.73 140.48 0.69 Allowed Pre-proline 0 N--CA 1.494 1.742 0 O-C-N 121.408 -0.807 . . . . 0.0 109.878 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 43' ' ' ASP . 46.7 Cg_endo -72.52 167.16 27.8 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.002 1.527 . . . . 0.0 110.752 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.619 HG11 ' CG1' ' A' ' 81' ' ' VAL . 9.1 p -122.05 56.04 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.942 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 18.41 61.27 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -176.01 -75.47 0.05 OUTLIER Glycine 0 N--CA 1.495 2.569 0 C-N-CA 119.429 -1.367 . . . . 0.0 110.242 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -92.95 -169.34 2.15 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.276 -1.132 . . . . 0.0 110.572 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.471 ' O ' HG21 ' A' ' 81' ' ' VAL . 1.7 p30 -114.86 140.6 48.82 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.433 -0.792 . . . . 0.0 110.14 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.653 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -142.76 125.38 15.85 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.229 -0.919 . . . . 0.0 110.256 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 11.4 m -90.54 167.76 12.33 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.178 -0.951 . . . . 0.0 110.212 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.513 ' HB2' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.38 118.3 66.34 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.277 -0.889 . . . . 0.0 110.501 -179.971 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.724 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 50.4 Cg_endo -88.23 5.81 5.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.743 1.391 . . . . 0.0 109.978 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.13 -70.3 0.61 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.384 -0.823 . . . . 0.0 111.012 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.439 ' OG1' ' OD1' ' A' ' 46' ' ' ASN . 12.5 p -88.8 117.25 27.65 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.888 . . . . 0.0 110.786 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -149.11 93.29 2.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 109.551 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.526 ' O ' HG22 ' A' ' 33' ' ' ILE . 2.8 p -82.09 121.27 26.35 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.307 -0.87 . . . . 0.0 110.832 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 p -93.59 113.67 25.83 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.528 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 36.9 p90 -122.92 147.32 46.73 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.168 -0.957 . . . . 0.0 111.179 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 29' ' ' GLU . 91.6 m -107.72 155.05 20.62 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.465 -0.772 . . . . 0.0 109.34 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.924 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.9 OUTLIER -66.19 165.33 13.95 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.005 -1.06 . . . . 0.0 110.245 -179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.95 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 19.2 t0 -91.45 -167.03 1.7 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 0.0 109.631 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -64.96 -29.75 70.7 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.12 -0.988 . . . . 0.0 110.032 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 31.4 t -94.25 16.77 14.07 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.286 -0.884 . . . . 0.0 109.707 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.501 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 64.58 42.58 97.32 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -151.86 117.61 5.43 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.27 -1.135 . . . . 0.0 109.856 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -118.2 162.5 18.14 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 111.189 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.8 m -155.23 128.25 8.17 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -150.08 175.69 11.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.906 -1.121 . . . . 0.0 111.298 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.3 p -99.3 116.22 30.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.521 -0.737 . . . . 0.0 109.67 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' O ' HG22 ' A' ' 18' ' ' VAL . 42.3 t80 -112.31 132.24 55.08 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.313 -0.867 . . . . 0.0 110.459 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 16.6 t -82.55 164.36 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 110.043 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 16' ' ' GLN . 15.7 m -131.64 155.15 41.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.275 -0.89 . . . . 0.0 110.278 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -127.53 103.63 7.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.891 . . . . 0.0 109.555 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.548 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 53.1 tttt -36.3 -55.82 0.79 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.711 -0.618 . . . . 0.0 111.452 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 70.4 p -111.4 150.23 30.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.051 -1.03 . . . . 0.0 110.996 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.574 ' O ' ' CD1' ' A' ' 71' ' ' TYR . 11.2 p90 -175.23 139.89 0.48 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.463 -0.773 . . . . 0.0 109.861 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.475 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.8 m -58.9 130.26 46.13 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.16 -0.962 . . . . 0.0 109.972 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 74' ' ' SER . . . -90.69 169.6 34.2 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.78 ' O ' H7A1 ' A' ' 111' ' ' ROM . 6.7 t 172.28 119.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.351 -1.087 . . . . 0.0 109.773 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.927 HG23 HG23 ' A' ' 81' ' ' VAL . 51.4 p -43.65 143.63 1.56 Allowed Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.287 -0.883 . . . . 0.0 110.207 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.454 ' O ' ' OE2' ' A' ' 77' ' ' GLU . 42.4 Cg_endo -69.2 -25.48 31.12 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 124.001 1.527 . . . . 0.0 109.984 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.454 ' OE2' ' O ' ' A' ' 76' ' ' PRO . 61.2 mm-40 -156.77 103.07 2.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 110.176 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 155.28 -89.5 0.12 Allowed Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.894 HG22 ' HD2' ' A' ' 80' ' ' PRO . 0.2 OUTLIER -145.04 151.57 49.06 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.267 -1.137 . . . . 0.0 110.298 -179.958 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.894 ' HD2' HG22 ' A' ' 79' ' ' THR . 42.8 Cg_endo -70.96 116.12 4.55 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 124.066 1.561 . . . . 0.0 110.066 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.927 HG23 HG23 ' A' ' 75' ' ' THR . 99.3 t -74.5 -94.17 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.389 -0.819 . . . . 0.0 110.649 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.502 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -159.69 -157.02 8.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 2.9 m -90.58 163.98 14.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.212 -1.169 . . . . 0.0 110.351 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.621 HG11 ' HB3' ' A' ' 37' ' ' ALA . 8.2 t -133.5 161.03 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.245 -0.909 . . . . 0.0 110.085 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.71 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 3.3 t70 -164.33 117.24 1.36 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.426 ' SG ' ' CD1' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -65.89 -10.32 37.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.308 -0.87 . . . . 0.0 110.499 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -59.62 -34.57 72.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.235 -0.916 . . . . 0.0 109.42 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 t -143.14 12.83 1.81 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 121.421 0.629 . . . . 0.0 109.409 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.71 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -122.37 149.11 44.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.572 -0.705 . . . . 0.0 110.361 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.465 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -82.84 122.19 27.9 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.228 -0.92 . . . . 0.0 110.016 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 4.2 m -109.64 152.9 24.97 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.18 -0.95 . . . . 0.0 110.181 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.495 ' N ' ' OD1' ' A' ' 92' ' ' ASN . 18.2 p-10 -153.24 139.1 18.04 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.43 -0.794 . . . . 0.0 109.614 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.966 HD11 HD11 ' A' ' 33' ' ' ILE . 15.5 tp -79.45 142.51 35.82 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.218 -0.926 . . . . 0.0 110.767 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 104' ' ' HIS . . . -149.99 132.53 4.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -118.7 -175.46 2.89 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.168 -1.195 . . . . 0.0 110.246 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.73 157.06 7.12 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.576 ' HB3' ' CD2' ' A' ' 31' ' ' TYR . 46.8 p-10 -132.79 -179.79 5.69 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.101 -1.235 . . . . 0.0 110.386 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.553 ' C ' ' O ' ' A' ' 97' ' ' ASN . 1.5 t -4.2 -66.34 0.0 OUTLIER 'General case' 0 N--CA 1.517 2.885 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 97' ' ' ASN . . . -132.08 -65.38 0.09 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.272 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.919 HD22 ' OH ' ' A' ' 31' ' ' TYR . 8.1 tt -40.72 130.19 2.5 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.251 -1.146 . . . . 0.0 110.713 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 102' ' ' LEU . 60.9 t0 -116.94 145.85 43.36 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.33 -0.856 . . . . 0.0 110.184 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' N ' ' OD1' ' A' ' 101' ' ' ASP . 45.9 mt -100.72 -96.57 0.26 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.143 -0.973 . . . . 0.0 110.512 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -157.9 -178.63 32.12 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.601 -1.399 . . . . 0.0 109.601 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.418 ' HA ' ' HA2' ' A' ' 94' ' ' GLY . 0.1 OUTLIER -136.58 124.25 22.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.243 -1.151 . . . . 0.0 110.667 -179.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.613 HG12 ' N ' ' A' ' 106' ' ' ALA . 74.5 t -88.73 175.12 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.517 -0.739 . . . . 0.0 109.815 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.613 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -114.78 146.57 40.85 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.09 -1.006 . . . . 0.0 109.689 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.663 HD11 ' HB2' ' A' ' 93' ' ' LEU . 11.7 mt -132.01 161.39 33.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.082 -1.011 . . . . 0.0 110.821 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.534 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 21.8 m -138.67 154.25 48.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.514 -0.741 . . . . 0.0 109.088 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.548 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 18.5 m-85 -127.14 131.46 50.76 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.942 -1.099 . . . . 0.0 110.475 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 CA-C-O 117.916 -1.491 . . . . 0.0 109.445 179.96 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.78 H7A1 ' O ' ' A' ' 74' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 120.816 0.341 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.482 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 46.7 Cg_endo -73.11 -162.15 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.647 0 O-C-N 124.023 1.538 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -175.48 121.79 0.2 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.271 -0.893 . . . . 0.0 110.711 -179.923 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.946 ' CD1' HG22 ' A' ' 22' ' ' VAL . 17.9 t80 -88.22 139.18 30.76 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.55 -0.719 . . . . 0.0 109.76 179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.98 147.54 32.78 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 120.911 -1.118 . . . . 0.0 111.502 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.844 ' CG1' HG11 ' A' ' 105' ' ' VAL . 7.3 p -127.96 148.29 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.574 -0.703 . . . . 0.0 109.501 179.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.662 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 3.4 m -55.4 -81.58 0.03 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 120.746 -1.221 . . . . 0.0 109.451 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 51.6 Cg_endo -77.63 -161.07 0.13 Allowed 'Trans proline' 0 C--O 1.212 -0.813 0 N-CA-C 109.063 -1.168 . . . . 0.0 109.063 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.471 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -179.8 -30.83 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.2 p -128.03 156.17 43.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 110.209 -179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.44 44.87 89.34 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.918 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.554 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 61.6 mt -88.42 -151.76 0.21 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.486 -1.008 . . . . 0.0 110.269 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 16' ' ' GLN . 0.1 OUTLIER -177.51 153.72 0.93 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.409 -0.807 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -60.71 132.6 54.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.211 -0.93 . . . . 0.0 110.068 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.27 -28.29 7.59 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.149 -1.58 . . . . 0.0 109.149 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.848 ' O ' HG22 ' A' ' 67' ' ' VAL . 44.0 tt0 -57.63 123.45 15.67 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.539 -0.977 . . . . 0.0 110.233 -179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.743 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.6 OUTLIER -102.07 133.32 47.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.227 -0.921 . . . . 0.0 110.171 179.998 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.464 ' HB ' ' HD2' ' A' ' 8' ' ' PRO . 22.9 m -111.25 157.13 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.146 -0.971 . . . . 0.0 110.167 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -89.98 98.75 11.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.225 -0.922 . . . . 0.0 109.494 -179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 18' ' ' VAL . 43.8 t -87.44 160.95 2.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.105 -0.997 . . . . 0.0 110.282 -179.891 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.7 p -165.34 121.81 1.43 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.332 -0.855 . . . . 0.0 110.325 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.946 HG22 ' CD1' ' A' ' 4' ' ' PHE . 13.8 t -106.55 141.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.372 -0.83 . . . . 0.0 109.354 179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 39.0 p -142.68 137.4 29.88 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 120.86 -1.15 . . . . 0.0 110.562 -179.952 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 127.25 -29.04 4.41 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.594 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -60.95 -137.3 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.374 -1.074 . . . . 0.0 109.771 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -157.43 135.02 10.59 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.775 -1.203 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.841 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -53.58 125.74 19.21 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.385 -0.822 . . . . 0.0 110.117 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.61 8.07 12.84 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 62.6 mt-10 -126.92 140.72 52.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.137 -1.213 . . . . 0.0 110.062 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' ' CD2' ' A' ' 31' ' ' TYR . 8.8 m -106.4 166.83 10.25 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.292 -0.88 . . . . 0.0 110.019 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.612 ' CD1' ' HB2' ' A' ' 97' ' ' ASN . 43.4 m-85 -153.39 175.75 12.78 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.219 -0.926 . . . . 0.0 110.279 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.432 ' CD1' ' N ' ' A' ' 32' ' ' TYR . 14.2 m-85 -134.67 124.13 24.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.233 -0.917 . . . . 0.0 110.208 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 63' ' ' PHE . 3.6 tt -101.87 131.29 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.15 -0.968 . . . . 0.0 109.847 -179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.48 144.31 23.63 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.07 -1.019 . . . . 0.0 111.071 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 31.1 tt0 -86.55 128.98 35.02 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.493 -0.755 . . . . 0.0 109.085 179.877 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.1 OUTLIER -122.17 179.15 4.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.021 -1.05 . . . . 0.0 111.347 -179.941 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -166.59 150.13 6.53 Favored Pre-proline 0 N--CA 1.49 1.574 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.38 156.16 65.13 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.572 1.301 . . . . 0.0 110.595 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.3 p -143.9 69.7 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.424 -0.798 . . . . 0.0 110.18 -179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.75 -15.35 31.77 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 168.75 -48.99 0.22 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.62 -158.27 0.16 Allowed 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -1.166 . . . . 0.0 110.105 179.969 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.18 106.54 4.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.88 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.404 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -83.24 134.71 34.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.943 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 1.2 m -104.29 177.47 4.84 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.213 -0.93 . . . . 0.0 110.503 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.432 ' HB3' ' OG1' ' A' ' 49' ' ' THR . 7.4 t-20 -88.72 120.63 70.2 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.371 -0.831 . . . . 0.0 110.573 -179.894 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.445 ' HG3' ' HB2' ' A' ' 74' ' ' SER . 54.3 Cg_endo -85.52 -15.95 4.93 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.953 1.502 . . . . 0.0 110.752 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.2 -29.74 22.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 111.068 -179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.432 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 1.3 p -103.45 59.35 0.75 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.111 -0.993 . . . . 0.0 110.893 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -94.19 72.94 3.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.216 -0.927 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.471 HG23 ' CG2' ' A' ' 33' ' ' ILE . 8.8 t -101.48 138.89 37.89 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.275 -0.891 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.42 ' HG ' ' HD2' ' A' ' 32' ' ' TYR . 21.4 m -110.35 153.72 24.52 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.451 -0.78 . . . . 0.0 109.625 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 35.4 p90 -149.05 143.61 26.17 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.059 -1.026 . . . . 0.0 110.637 -179.938 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 48.0 m -104.35 157.6 17.03 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.375 -0.828 . . . . 0.0 109.753 179.898 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.626 ' HA ' ' HB2' ' A' ' 61' ' ' ALA . 2.2 p -74.82 -175.52 2.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.212 -0.93 . . . . 0.0 110.629 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.841 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.9 OUTLIER -116.39 -162.74 0.86 Allowed 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.624 -0.673 . . . . 0.0 109.321 179.977 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.43 -26.79 68.9 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.07 -1.019 . . . . 0.0 109.811 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 17.2 t -96.59 22.78 7.6 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.519 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.448 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 51.38 23.69 9.39 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -121.98 117.53 26.61 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.243 -1.151 . . . . 0.0 109.942 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.626 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -105.08 164.21 11.98 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.321 -0.862 . . . . 0.0 110.693 -179.995 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -157.8 137.95 12.56 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.456 -0.778 . . . . 0.0 109.454 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 p90 -166.11 164.23 18.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.123 -0.985 . . . . 0.0 110.028 -179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 p -91.11 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.194 -0.941 . . . . 0.0 110.16 179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -108.96 128.77 55.23 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.346 -0.846 . . . . 0.0 110.139 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.743 HG22 ' OG ' ' A' ' 17' ' ' SER . 2.6 t -82.36 158.13 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.232 -0.918 . . . . 0.0 110.299 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.848 HG22 ' O ' ' A' ' 16' ' ' GLN . 17.1 m -126.5 144.6 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.49 -0.756 . . . . 0.0 109.584 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 69' ' ' LYS . 9.9 mmt180 -117.03 103.6 10.42 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.139 -0.976 . . . . 0.0 110.664 -179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.496 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 24.6 ttpp -43.8 -55.74 4.29 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.137 -0.977 . . . . 0.0 109.362 179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 2.2 p -113.72 114.77 26.82 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.444 -0.785 . . . . 0.0 109.152 179.834 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.668 ' CE1' HG11 ' A' ' 84' ' ' VAL . 19.8 p90 -144.39 149.4 36.05 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.1 -1.0 . . . . 0.0 110.728 -179.856 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -73.39 117.52 15.24 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -0.905 . . . . 0.0 110.204 -179.999 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.404 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -79.84 163.3 47.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HG3' ' A' ' 47' ' ' PRO . 3.5 m -175.18 128.2 0.28 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -1.109 . . . . 0.0 109.826 -179.979 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.561 HG23 HG21 ' A' ' 81' ' ' VAL . 25.5 p -54.5 157.52 4.97 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.255 -0.903 . . . . 0.0 109.961 -179.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.578 ' HB3' " C'9" ' A' ' 111' ' ' ROM . 45.1 Cg_endo -72.97 -6.38 18.9 Favored 'Trans proline' 0 C--N 1.298 -2.111 0 O-C-N 124.038 1.546 . . . . 0.0 110.524 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.14 39.64 0.87 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.214 -0.929 . . . . 0.0 110.744 -179.903 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 48.34 45.39 28.4 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.458 ' HB ' ' OG1' ' A' ' 75' ' ' THR . 98.6 m -137.26 116.47 10.26 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.278 -1.131 . . . . 0.0 109.905 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.49 125.35 11.15 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.809 1.426 . . . . 0.0 110.938 -179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.561 HG21 HG23 ' A' ' 75' ' ' THR . 76.9 t -96.52 -54.2 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.363 -0.836 . . . . 0.0 109.846 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 177.09 -168.54 40.43 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 24.4 m -96.27 159.91 14.7 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.238 -1.154 . . . . 0.0 110.201 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.668 HG11 ' CE1' ' A' ' 71' ' ' TYR . 15.9 t -128.38 152.08 36.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.219 -0.926 . . . . 0.0 110.151 -179.923 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.795 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -154.31 110.55 3.26 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.384 -0.822 . . . . 0.0 110.197 179.978 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 7.6 t -80.75 -9.2 59.82 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.34 -0.85 . . . . 0.0 110.827 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.88 -47.57 21.37 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.077 -1.014 . . . . 0.0 109.335 179.929 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -123.58 6.58 8.88 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.908 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.795 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -115.69 175.07 5.69 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.557 -0.714 . . . . 0.0 110.441 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.27 112.94 26.17 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.409 -0.807 . . . . 0.0 110.039 179.999 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 22.7 p -108.98 149.19 29.59 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.353 -0.842 . . . . 0.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 22.2 p30 -134.49 -177.93 4.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.058 -1.026 . . . . 0.0 110.714 179.981 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.478 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 37.7 tp -132.75 127.29 34.35 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.534 -0.729 . . . . 0.0 109.385 179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -118.95 145.07 18.15 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.263 -179.904 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.522 ' O ' HD13 ' A' ' 102' ' ' LEU . . . -144.36 91.73 2.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.472 -1.017 . . . . 0.0 110.056 179.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.44 170.45 29.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.612 ' HB2' ' CD1' ' A' ' 31' ' ' TYR . 58.0 t30 -113.69 173.96 6.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.33 -1.1 . . . . 0.0 110.199 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 t -54.53 -23.66 17.47 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.166 -0.959 . . . . 0.0 110.038 -179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -101.28 -73.89 1.05 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.15 147.1 53.07 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.308 -1.113 . . . . 0.0 109.993 179.928 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 102' ' ' LEU . 3.5 t70 -103.57 -16.77 15.43 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.172 -0.955 . . . . 0.0 110.189 179.977 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.522 HD13 ' O ' ' A' ' 95' ' ' ALA . 2.7 mt 42.86 -156.13 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.354 -0.841 . . . . 0.0 109.929 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -123.76 -178.56 15.46 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.721 -1.228 . . . . 0.0 110.561 -179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -134.28 114.15 12.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.714 -0.874 . . . . 0.0 109.414 179.901 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.844 HG11 ' CG1' ' A' ' 6' ' ' VAL . 98.4 t -85.55 120.36 35.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.228 -0.92 . . . . 0.0 110.337 -179.919 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -80.16 140.09 36.51 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.94 . . . . 0.0 110.08 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.554 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 12.6 mt -112.86 169.73 8.7 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.403 -0.811 . . . . 0.0 110.118 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.49 123.69 13.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.201 -0.937 . . . . 0.0 109.762 179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 39.0 m-85 -95.12 145.5 24.96 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.374 -0.829 . . . . 0.0 110.317 -179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 CA-C-O 117.977 -1.457 . . . . 0.0 109.68 179.994 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.71 H4B2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.672 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.503 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 45.2 Cg_endo -75.81 165.99 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.965 1.508 . . . . 0.0 110.376 179.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.71 136.89 29.43 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.265 -0.897 . . . . 0.0 110.561 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 4' ' ' PHE . 4.0 t80 -128.76 130.84 47.6 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.454 -0.779 . . . . 0.0 109.346 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 39.0 t -152.09 160.01 43.53 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 120.865 -1.147 . . . . 0.0 111.639 -179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 105' ' ' VAL . 14.9 p -125.06 158.4 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 179.924 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.686 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -69.72 -66.78 0.82 Allowed Pre-proline 0 N--CA 1.489 1.479 0 O-C-N 120.599 -1.313 . . . . 0.0 109.363 179.917 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.686 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.5 Cg_endo -88.38 166.58 6.52 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 O-C-N 123.049 1.026 . . . . 0.0 109.493 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.54 25.66 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.983 -1.073 . . . . 0.0 110.444 179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.544 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 56.6 m -163.4 168.16 20.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.936 179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.44 33.04 4.17 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.523 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.4 mt -69.07 -165.62 0.07 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.308 -1.113 . . . . 0.0 110.521 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.531 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.7 OUTLIER -159.85 158.69 31.42 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.339 -0.851 . . . . 0.0 110.379 179.981 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.7 127.63 33.47 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.313 -0.867 . . . . 0.0 110.196 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.18 -25.38 12.52 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.617 ' O ' HG22 ' A' ' 67' ' ' VAL . 49.3 tt0 -54.66 150.86 8.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.455 -1.027 . . . . 0.0 110.091 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.0 t -121.13 128.14 52.25 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.23 -0.919 . . . . 0.0 110.841 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.5 154.34 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -0.867 . . . . 0.0 109.728 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.4 m -91.38 114.72 27.32 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.947 -1.095 . . . . 0.0 110.433 -179.89 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.589 HG12 ' N ' ' A' ' 21' ' ' SER . 97.6 t -101.18 168.61 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.005 -1.059 . . . . 0.0 110.22 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.589 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.3 p -165.77 120.41 1.22 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.561 -0.712 . . . . 0.0 109.813 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 4' ' ' PHE . 3.4 t -111.06 148.11 14.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.213 -0.929 . . . . 0.0 109.631 -179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 32.5 p -157.67 125.65 5.39 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.976 -1.078 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 131.37 -30.09 3.36 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 1.021 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -57.6 -157.24 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.188 -1.183 . . . . 0.0 109.732 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -147.36 137.82 23.34 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.784 -1.197 . . . . 0.0 111.056 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.846 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -49.5 136.23 16.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.548 -0.72 . . . . 0.0 110.5 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.45 -0.28 40.16 Favored Glycine 0 N--CA 1.485 1.952 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.952 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.631 ' O ' HG23 ' A' ' 54' ' ' THR . 6.6 mm-40 -114.79 140.27 49.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.167 -1.196 . . . . 0.0 110.175 -179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 53' ' ' PHE . 3.7 m -119.75 113.21 20.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.545 -0.722 . . . . 0.0 109.778 179.976 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.638 ' CG ' HD11 ' A' ' 102' ' ' LEU . 72.4 m-85 -95.77 159.72 14.84 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.208 -0.932 . . . . 0.0 110.326 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.623 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 2.1 m-85 -119.9 96.88 5.36 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.444 -0.785 . . . . 0.0 109.418 -179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' OG1' ' A' ' 51' ' ' THR . 2.9 tt -83.86 150.89 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.256 -0.902 . . . . 0.0 110.109 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -170.38 151.56 3.79 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.177 -0.952 . . . . 0.0 110.613 179.961 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 5.3 tt0 -90.94 128.87 36.95 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.345 -0.847 . . . . 0.0 109.285 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 21.6 m -122.96 176.91 5.75 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.091 -1.005 . . . . 0.0 111.284 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -164.51 142.58 5.53 Favored Pre-proline 0 N--CA 1.489 1.518 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 -179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.546 ' O ' HG13 ' A' ' 39' ' ' VAL . 44.0 Cg_endo -71.35 165.13 33.41 Favored 'Trans proline' 0 C--N 1.301 -1.952 0 O-C-N 123.759 1.399 . . . . 0.0 110.687 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.561 ' CG1' HG22 ' A' ' 84' ' ' VAL . 0.0 OUTLIER -158.69 88.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.438 -0.789 . . . . 0.0 110.011 -179.986 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.59 -5.31 82.44 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 130.52 -28.3 3.81 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.49 ' CG ' HG23 ' A' ' 39' ' ' VAL . 20.6 pt20 -86.14 -177.04 6.17 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -1.111 . . . . 0.0 110.557 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -110.01 152.36 26.01 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.384 -0.823 . . . . 0.0 110.133 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -145.9 100.97 3.48 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.206 -0.934 . . . . 0.0 110.189 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 36' ' ' CYS . 10.1 m -83.17 167.72 17.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.227 -0.92 . . . . 0.0 110.247 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.599 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 58.0 t-20 -104.72 121.64 46.22 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.258 -0.901 . . . . 0.0 110.36 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.625 ' HB3' H7A3 ' A' ' 111' ' ' ROM . 49.2 Cg_endo -76.4 -38.83 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.838 1.441 . . . . 0.0 110.369 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.34 -44.61 76.07 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.349 -0.845 . . . . 0.0 110.561 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.429 HG21 ' HD2' ' A' ' 68' ' ' ARG . 17.8 p -91.68 35.14 0.96 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.224 -0.922 . . . . 0.0 110.422 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -88.1 97.17 10.83 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.229 -0.92 . . . . 0.0 110.038 -179.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.535 ' OG1' ' CG2' ' A' ' 33' ' ' ILE . 41.2 p -101.19 117.69 35.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.16 -0.962 . . . . 0.0 110.793 -179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.416 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 1.6 t -100.59 118.98 37.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.396 -0.815 . . . . 0.0 108.91 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 30' ' ' THR . 43.5 p90 -130.74 167.42 18.87 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.124 -0.985 . . . . 0.0 110.896 -179.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.631 HG23 ' O ' ' A' ' 29' ' ' GLU . 89.9 m -121.66 153.49 38.08 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.573 -0.705 . . . . 0.0 109.363 179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 1.021 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.6 OUTLIER -78.94 177.58 8.66 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.059 -1.026 . . . . 0.0 110.325 -179.974 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.846 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.2 OUTLIER -95.13 -167.37 1.61 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.344 -0.848 . . . . 0.0 110.033 -179.995 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.656 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.04 -37.66 88.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.273 -0.892 . . . . 0.0 110.015 179.939 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.7 p -84.64 9.03 14.85 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.351 -0.843 . . . . 0.0 109.672 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.499 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 60.37 49.18 81.45 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -141.05 124.31 16.54 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.217 -1.167 . . . . 0.0 110.48 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -126.18 172.93 9.63 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.283 -0.886 . . . . 0.0 110.634 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.5 OUTLIER -173.04 133.56 0.53 Allowed 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -179.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.0 p90 -175.14 169.31 3.32 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.99 -1.069 . . . . 0.0 110.311 -179.816 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.8 m -88.6 160.05 17.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.274 -0.891 . . . . 0.0 110.362 -179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.442 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 53.6 t80 -143.67 126.34 16.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.426 -0.796 . . . . 0.0 109.531 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.442 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 3.2 t -81.77 159.18 3.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.097 -1.002 . . . . 0.0 109.979 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.617 HG22 ' O ' ' A' ' 16' ' ' GLN . 6.6 m -127.19 168.82 19.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.367 -0.833 . . . . 0.0 109.981 -179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.429 ' HD2' HG21 ' A' ' 49' ' ' THR . 0.2 OUTLIER -140.29 105.86 5.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.916 . . . . 0.0 110.448 -179.992 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.469 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 9.7 ttpt -47.31 -52.24 16.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.448 -0.783 . . . . 0.0 110.325 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -113.41 141.62 46.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.21 -0.931 . . . . 0.0 110.056 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 46' ' ' ASN . 27.8 p90 -175.97 144.25 0.6 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.033 -1.042 . . . . 0.0 110.672 -179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 15.4 m -63.68 134.62 55.71 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.0 -1.063 . . . . 0.0 108.897 179.805 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.17 165.98 13.3 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.684 -1.246 . . . . 0.0 110.871 -179.902 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.3 p -165.42 155.2 12.83 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.642 -0.916 . . . . 0.0 109.357 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.711 HG23 HG23 ' A' ' 81' ' ' VAL . 2.8 p -78.12 133.03 65.43 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.001 -1.062 . . . . 0.0 109.95 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.51 ' HB3' " H'8" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.28 -5.08 15.03 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 123.943 1.496 . . . . 0.0 110.482 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -69.44 -34.84 75.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.952 . . . . 0.0 109.711 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 149.86 -24.26 1.16 Allowed Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.471 ' O ' ' OG1' ' A' ' 75' ' ' THR . 71.6 p -99.2 142.65 24.99 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.211 -1.17 . . . . 0.0 110.29 -180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -76.29 -176.47 3.09 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.86 1.453 . . . . 0.0 110.448 -179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.711 HG23 HG23 ' A' ' 75' ' ' THR . 73.0 t -138.73 -85.73 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.441 ' N ' HG12 ' A' ' 81' ' ' VAL . . . -167.56 -159.14 12.62 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.559 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 99.6 p -92.97 150.08 20.8 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.194 -1.18 . . . . 0.0 110.221 -179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.561 HG22 ' CG1' ' A' ' 39' ' ' VAL . 20.8 t -125.32 157.53 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.081 -1.012 . . . . 0.0 110.337 -179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 85' ' ' ASP . 3.4 t70 -150.58 88.75 1.51 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.384 -0.822 . . . . 0.0 109.611 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.726 ' HA ' ' HB3' ' A' ' 89' ' ' ALA . 55.0 m -79.07 27.62 0.23 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.472 -0.767 . . . . 0.0 111.543 -179.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 69' ' ' LYS . . . -53.13 -34.3 56.12 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.678 -1.264 . . . . 0.0 108.335 179.937 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 t -152.01 18.33 0.67 Allowed 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.726 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -93.58 -179.89 5.17 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.558 -0.714 . . . . 0.0 110.766 -179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.4 94.57 9.94 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.447 -0.783 . . . . 0.0 109.828 179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.463 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -95.89 162.81 13.42 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.21 -0.931 . . . . 0.0 110.214 -179.976 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.463 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 28.4 m-80 -148.52 -178.54 6.39 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.946 . . . . 0.0 110.844 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.832 ' HB2' HD11 ' A' ' 107' ' ' LEU . 15.5 tp -150.88 132.87 15.18 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.927 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.9 160.82 28.44 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.122 -1.513 . . . . 0.0 110.532 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -152.61 170.56 19.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.544 -0.974 . . . . 0.0 109.704 179.935 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA2' ' HG ' ' A' ' 102' ' ' LEU . . . 143.15 -168.62 26.04 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -120.18 -165.21 1.16 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.339 -1.095 . . . . 0.0 110.354 -179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.501 ' OG ' " H2'" ' A' ' 111' ' ' ROM . 9.5 m -86.42 1.3 51.8 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.273 -0.892 . . . . 0.0 110.42 180.0 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -158.4 61.07 0.32 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' CE1' ' A' ' 31' ' ' TYR . 8.0 tt -171.11 -48.75 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -1.138 . . . . 0.0 110.28 -179.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 100' ' ' LEU . 4.3 m-20 62.59 124.95 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.284 -0.885 . . . . 0.0 109.945 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.638 HD11 ' CG ' ' A' ' 31' ' ' TYR . 34.0 mt -105.48 -70.49 0.78 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 110.41 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.533 ' C ' ' CD2' ' A' ' 104' ' ' HIS . . . -171.75 168.67 41.79 Favored Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.616 ' CD2' ' N ' ' A' ' 104' ' ' HIS . 2.4 m-70 -133.62 95.52 3.5 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -1.036 . . . . 0.0 109.65 179.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 6' ' ' VAL . 80.2 t -85.12 126.43 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.298 -0.876 . . . . 0.0 110.133 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.447 ' O ' HD23 ' A' ' 107' ' ' LEU . . . -81.47 143.54 32.01 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.119 -179.951 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.832 HD11 ' HB2' ' A' ' 93' ' ' LEU . 36.9 mt -120.64 169.42 10.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.172 -0.955 . . . . 0.0 110.458 -179.957 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.544 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 19.2 m -147.93 158.42 44.03 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.414 -0.803 . . . . 0.0 109.534 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.489 ' HB2' ' O ' ' A' ' 86' ' ' CYS . 29.9 m-85 -131.4 110.47 11.06 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.013 -1.055 . . . . 0.0 109.992 179.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 CA-C-O 117.991 -1.449 . . . . 0.0 109.524 -179.957 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.625 H7A3 ' HB3' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 24' ' ' GLY . 43.9 Cg_endo -74.1 150.27 42.56 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.858 1.452 . . . . 0.0 110.121 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.51 160.7 43.22 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.213 -0.93 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.741 ' CD2' HG22 ' A' ' 22' ' ' VAL . 1.8 t80 -129.77 126.76 38.91 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 t -145.54 166.5 25.54 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.777 -1.202 . . . . 0.0 111.653 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 8' ' ' PRO . 14.4 p -131.37 156.1 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.689 -0.632 . . . . 0.0 109.519 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -64.61 -72.08 0.3 Allowed Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 120.797 -1.189 . . . . 0.0 109.577 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.718 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 52.6 Cg_endo -76.59 -176.01 2.9 Favored 'Trans proline' 0 C--O 1.212 -0.801 0 N-CA-C 108.868 -1.243 . . . . 0.0 108.868 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 171.24 32.67 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.792 -1.192 . . . . 0.0 110.768 179.877 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.508 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 1.3 m 175.09 165.27 0.28 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.4 -0.813 . . . . 0.0 109.546 179.967 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.6 44.21 11.7 Favored Glycine 0 N--CA 1.487 2.053 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 53.9 mt -85.83 -155.6 0.25 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.511 -0.993 . . . . 0.0 110.63 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.497 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 3.1 t -158.24 153.0 24.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.491 -0.756 . . . . 0.0 109.983 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -61.48 130.55 46.56 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.212 -0.93 . . . . 0.0 109.932 179.981 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.06 -23.93 15.57 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.53 ' O ' HG22 ' A' ' 67' ' ' VAL . 50.6 tt0 -54.68 150.01 10.13 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.405 -1.056 . . . . 0.0 110.215 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.593 ' OG ' HG22 ' A' ' 66' ' ' VAL . 0.3 OUTLIER -121.5 128.16 51.78 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.296 -0.877 . . . . 0.0 110.171 179.98 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 25.1 m -99.72 155.69 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.32 -0.862 . . . . 0.0 110.161 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.0 m -97.52 106.83 19.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.132 -0.98 . . . . 0.0 109.616 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.522 HG12 ' N ' ' A' ' 21' ' ' SER . 54.5 t -94.52 166.07 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.096 -1.003 . . . . 0.0 110.79 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.522 ' N ' HG12 ' A' ' 20' ' ' VAL . 2.3 p -164.21 117.81 1.42 Allowed 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.59 -0.694 . . . . 0.0 110.006 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.741 HG22 ' CD2' ' A' ' 4' ' ' PHE . 8.4 t -111.76 150.01 14.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.37 -0.831 . . . . 0.0 109.591 179.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.1 p -151.73 153.29 34.04 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.175 -0.953 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 25' ' ' ALA . . . 102.05 -26.16 25.28 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.756 ' O ' ' HB2' ' A' ' 26' ' ' ALA . . . -53.12 -107.2 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.416 -1.05 . . . . 0.0 110.013 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.756 ' HB2' ' O ' ' A' ' 25' ' ' ALA . . . 167.78 131.5 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.904 -1.122 . . . . 0.0 111.309 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.623 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.79 134.58 51.76 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.651 -0.656 . . . . 0.0 110.226 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.416 ' C ' ' HG3' ' A' ' 29' ' ' GLU . . . 104.52 17.76 14.48 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.655 ' O ' HG23 ' A' ' 54' ' ' THR . 58.7 mt-10 -137.58 144.25 41.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -1.169 . . . . 0.0 110.186 179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.5 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 22.6 m -120.89 159.05 26.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.273 -0.892 . . . . 0.0 109.989 -179.917 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 65.3 m-85 -143.64 130.18 20.09 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -0.93 . . . . 0.0 110.214 179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.503 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 21.8 m-85 -93.2 102.58 14.88 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.094 -1.004 . . . . 0.0 109.392 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.434 HG12 HD11 ' A' ' 93' ' ' LEU . 11.4 tt -88.83 157.73 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.351 -0.843 . . . . 0.0 110.58 -179.88 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.8 148.48 8.87 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.32 -0.862 . . . . 0.0 110.656 179.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.46 ' O ' ' SG ' ' A' ' 45' ' ' CYS . 47.2 tt0 -90.75 129.16 36.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.429 -0.794 . . . . 0.0 109.429 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 1.3 m -145.8 162.59 37.32 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.101 -0.999 . . . . 0.0 110.652 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.67 140.36 35.19 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.416 -0.803 . . . . 0.0 109.351 -179.991 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -70.0 165.36 31.48 Favored 'Trans proline' 0 C--N 1.304 -1.794 0 O-C-N 123.769 1.405 . . . . 0.0 110.676 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.644 ' O ' HG13 ' A' ' 39' ' ' VAL . 14.8 p -135.15 64.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.328 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.68 2.14 27.28 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 163.82 -54.7 0.28 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 120.828 -1.395 . . . . 0.0 110.054 179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.541 ' HB3' ' CG1' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -73.8 -166.76 0.4 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.096 -1.238 . . . . 0.0 109.961 -179.973 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -148.34 121.05 8.63 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.143 -0.973 . . . . 0.0 110.817 -179.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 73' ' ' GLY . . . -112.13 151.96 28.85 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.516 -0.74 . . . . 0.0 109.252 179.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 11.2 t -144.08 170.3 16.2 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.939 -1.101 . . . . 0.0 110.689 -179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.572 ' OD1' ' CG ' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -98.64 127.82 34.61 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.186 -0.946 . . . . 0.0 110.174 179.995 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.657 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.9 Cg_endo -82.15 -13.98 9.85 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.891 1.469 . . . . 0.0 110.136 179.915 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -82.4 -34.93 28.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.422 -0.799 . . . . 0.0 110.393 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.493 ' OG1' ' HB3' ' A' ' 46' ' ' ASN . 34.5 p -93.26 40.42 1.06 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 110.175 -179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.2 30.14 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.285 -0.884 . . . . 0.0 110.04 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 10.1 t -132.67 149.69 52.26 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.246 -0.908 . . . . 0.0 110.492 179.986 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.465 ' HB2' ' CD2' ' A' ' 32' ' ' TYR . 20.1 t -110.07 130.77 55.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.278 -0.889 . . . . 0.0 109.831 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.857 ' HD2' ' HB1' ' A' ' 61' ' ' ALA . 26.8 p90 -127.61 127.83 44.51 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.222 -0.924 . . . . 0.0 110.556 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.655 HG23 ' O ' ' A' ' 29' ' ' GLU . 50.5 m -101.51 147.11 26.77 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.287 -0.883 . . . . 0.0 110.137 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.609 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.3 p -61.39 -172.54 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.114 -0.991 . . . . 0.0 110.537 -179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.623 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 25.3 m-20 -113.91 -160.14 0.72 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.602 -0.686 . . . . 0.0 109.717 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.89 -23.44 65.12 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.154 -0.966 . . . . 0.0 109.728 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.73 6.88 46.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.416 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 73.0 34.86 58.33 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' A' ' 55' ' ' THR . . . -120.25 144.69 47.63 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.154 -1.204 . . . . 0.0 109.855 179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.857 ' HB1' ' HD2' ' A' ' 53' ' ' PHE . . . -132.63 92.83 3.12 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.151 -0.968 . . . . 0.0 110.951 -179.945 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 3.9 m -106.54 145.81 31.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 108.898 179.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.439 ' C ' ' CD1' ' A' ' 63' ' ' PHE . 18.5 p90 -175.2 173.61 2.55 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.782 -1.198 . . . . 0.0 111.1 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.26 132.12 48.41 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.492 -0.755 . . . . 0.0 109.755 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.562 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 57.3 t80 -124.72 130.55 52.63 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.259 -0.901 . . . . 0.0 110.454 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' OG ' ' A' ' 17' ' ' SER . 15.4 t -82.26 167.28 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.989 0 O-C-N 121.099 -1.0 . . . . 0.0 110.028 -179.957 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 16' ' ' GLN . 5.3 m -138.36 156.38 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.103 -0.998 . . . . 0.0 111.097 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.421 ' HG2' HG21 ' A' ' 49' ' ' THR . 6.8 mmt85 -119.73 112.7 19.6 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.478 -0.764 . . . . 0.0 110.067 179.942 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.427 ' HA ' ' CZ ' ' A' ' 109' ' ' PHE . 2.5 tttt -52.56 -60.99 2.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.349 -0.844 . . . . 0.0 111.401 -179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.468 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 80.3 p -121.7 151.41 40.52 Favored 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.994 -1.066 . . . . 0.0 111.326 -179.811 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.572 ' CG ' ' OD1' ' A' ' 46' ' ' ASN . 13.6 p90 -178.81 156.08 0.82 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.453 -0.779 . . . . 0.0 109.556 179.975 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.416 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 0.2 OUTLIER -69.86 130.94 43.63 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.722 -1.236 . . . . 0.0 109.213 179.899 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 44' ' ' ALA . . . -76.1 152.3 41.76 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 120.001 -1.095 . . . . 0.0 110.542 -179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.527 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 4.3 t -170.43 125.63 0.74 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.614 -0.933 . . . . 0.0 109.595 -179.974 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.82 HG23 HG21 ' A' ' 81' ' ' VAL . 13.2 p -60.58 168.36 2.54 Favored Pre-proline 0 N--CA 1.499 2.017 0 O-C-N 121.164 -0.96 . . . . 0.0 110.407 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.554 ' HB3' " C'8" ' A' ' 111' ' ' ROM . 45.0 Cg_endo -72.83 2.49 5.3 Favored 'Trans proline' 0 C--N 1.318 -1.05 0 O-C-N 123.794 1.418 . . . . 0.0 111.126 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.17 8.66 42.36 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.08 -1.013 . . . . 0.0 110.477 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.42 78.38 0.51 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.578 HG22 ' OG1' ' A' ' 75' ' ' THR . 12.8 t -173.42 136.84 0.71 Allowed Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.332 -1.099 . . . . 0.0 109.548 179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.41 116.02 4.39 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 O-C-N 123.944 1.497 . . . . 0.0 111.277 -179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.82 HG21 HG23 ' A' ' 75' ' ' THR . 55.9 t -96.3 -20.61 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 CA-C-O 121.8 0.81 . . . . 0.0 108.982 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.33 175.11 23.58 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 53.8 p -84.96 159.78 20.21 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.404 -1.057 . . . . 0.0 109.832 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' HB ' ' O ' ' A' ' 71' ' ' TYR . 12.9 t -138.33 150.06 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.04 -1.037 . . . . 0.0 110.802 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -153.61 96.81 2.05 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.604 -0.685 . . . . 0.0 109.377 179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . . . . . . . . . 62.2 m -73.63 13.05 0.53 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.555 -0.716 . . . . 0.0 112.133 -179.84 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -52.05 -48.56 64.53 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.49 -1.381 . . . . 0.0 108.802 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 t -137.72 4.66 2.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.394 0.616 . . . . 0.0 109.504 179.855 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -80.52 -173.56 4.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.454 -0.779 . . . . 0.0 110.441 179.995 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.63 77.82 2.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.503 -0.748 . . . . 0.0 110.658 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.464 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.5 OUTLIER -77.77 156.38 30.58 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.141 -0.974 . . . . 0.0 109.265 179.941 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.478 ' HA ' ' HA ' ' A' ' 106' ' ' ALA . 7.0 m120 -151.05 -177.75 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.876 -1.14 . . . . 0.0 111.407 -179.906 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.861 ' HB2' HD11 ' A' ' 107' ' ' LEU . 44.0 tp -143.33 129.93 20.2 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -127.04 149.17 17.64 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 118.981 -1.58 . . . . 0.0 110.85 -179.837 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -121.09 147.1 46.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.622 -0.928 . . . . 0.0 109.72 179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 173.14 149.91 7.12 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.5 ' HB3' ' O ' ' A' ' 30' ' ' THR . 2.4 p30 -117.82 -37.99 3.34 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.124 -1.221 . . . . 0.0 110.85 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -173.25 -35.54 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.212 -0.93 . . . . 0.0 110.521 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -134.98 -75.38 0.08 OUTLIER Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.6 ' C ' HD23 ' A' ' 100' ' ' LEU . 8.9 tt -55.32 127.95 31.84 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.407 -1.055 . . . . 0.0 110.432 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.443 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 1.0 OUTLIER -124.24 102.88 7.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.375 -0.828 . . . . 0.0 109.899 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.672 HD22 ' CG1' ' A' ' 22' ' ' VAL . 1.3 mt -53.51 -73.7 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 110.303 179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.67 -177.82 48.09 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.712 -1.233 . . . . 0.0 110.1 179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.425 ' CA ' ' O ' ' A' ' 93' ' ' LEU . 15.3 p80 -129.42 130.77 46.38 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.431 -1.04 . . . . 0.0 110.103 179.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 6' ' ' VAL . 33.9 t -96.23 132.15 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.183 -0.948 . . . . 0.0 110.211 -179.97 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.478 ' HA ' ' HA ' ' A' ' 92' ' ' ASN . . . -81.71 135.73 35.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.32 -0.863 . . . . 0.0 110.056 -179.986 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.3 mt -120.5 161.32 21.47 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.246 -0.909 . . . . 0.0 110.623 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.508 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 0.2 OUTLIER -139.75 171.18 14.59 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.284 -0.885 . . . . 0.0 109.968 179.9 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.427 ' CZ ' ' HA ' ' A' ' 69' ' ' LYS . 34.2 m-85 -134.44 159.24 41.69 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.163 -0.961 . . . . 0.0 110.069 179.937 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.378 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 179.975 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.752 ' C4D' H3A2 ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 120.758 0.313 . . . . 0.0 110.365 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.71 -171.99 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 123.922 1.485 . . . . 0.0 109.933 179.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -162.54 147.18 12.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.097 -1.002 . . . . 0.0 110.786 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.779 ' CD1' HG22 ' A' ' 22' ' ' VAL . 65.9 t80 -119.51 133.09 55.84 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 109.196 179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 161.42 40.56 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.993 -1.067 . . . . 0.0 111.371 -179.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 1.026 HG12 HG11 ' A' ' 105' ' ' VAL . 11.4 p -129.89 145.99 34.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.619 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.4 m -56.81 -73.09 0.2 Allowed Pre-proline 0 C--N 1.304 -1.379 0 O-C-N 120.758 -1.214 . . . . 0.0 109.171 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -78.69 162.76 26.98 Favored 'Trans proline' 0 C--O 1.208 -1.003 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 179.756 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -165.45 25.3 0.05 Allowed 'General case' 0 C--N 1.287 -2.116 0 O-C-N 120.798 -1.189 . . . . 0.0 110.364 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.572 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 3.3 t -177.28 160.61 1.72 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.339 -0.851 . . . . 0.0 110.233 179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 56.98 25.61 53.8 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 -179.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.0 mt -68.51 -166.0 0.07 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.54 -0.976 . . . . 0.0 110.764 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 16' ' ' GLN . 0.4 OUTLIER -155.69 156.91 35.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.51 -0.744 . . . . 0.0 110.11 179.909 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -65.11 130.45 43.4 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.231 -0.918 . . . . 0.0 110.584 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.82 -25.36 9.87 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.74 ' O ' HG22 ' A' ' 67' ' ' VAL . 3.7 tt0 -53.49 137.81 35.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.465 -1.021 . . . . 0.0 110.301 -179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 43.5 t -110.87 110.61 21.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.425 -0.797 . . . . 0.0 109.868 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.584 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.1 m -84.24 -177.76 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.34 -0.85 . . . . 0.0 110.219 -179.982 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.464 ' OG ' ' HB2' ' A' ' 7' ' ' SER . 52.9 p -122.46 99.8 6.6 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.252 179.874 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG12 ' N ' ' A' ' 21' ' ' SER . 78.3 t -81.52 168.04 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.303 -0.873 . . . . 0.0 110.687 -179.845 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.545 ' N ' HG12 ' A' ' 20' ' ' VAL . 21.4 p -163.13 116.1 1.57 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.54 -0.725 . . . . 0.0 109.713 -179.918 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.779 HG22 ' CD1' ' A' ' 4' ' ' PHE . 2.9 t -105.03 145.6 13.2 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.263 -0.898 . . . . 0.0 109.631 -179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.6 t -144.56 149.0 35.1 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.946 -1.097 . . . . 0.0 110.431 -179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 109.9 -38.56 3.26 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.746 ' O ' ' HB3' ' A' ' 26' ' ' ALA . . . -53.13 -31.88 44.57 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.286 -1.126 . . . . 0.0 110.38 179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.746 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.36 133.03 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.34 0 O-C-N 121.437 -0.789 . . . . 0.0 110.982 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.589 ' N ' ' HA2' ' A' ' 59' ' ' GLY . . . -50.65 135.16 23.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.644 -0.66 . . . . 0.0 110.524 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.427 ' O ' ' CD ' ' A' ' 29' ' ' GLU . . . 120.07 15.31 5.22 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.94 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.59 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -149.57 156.88 42.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.163 -1.198 . . . . 0.0 110.824 179.955 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.69 HG23 ' OG1' ' A' ' 54' ' ' THR . 0.2 OUTLIER -111.79 170.82 7.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.546 -0.721 . . . . 0.0 110.133 -179.94 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 30' ' ' THR . 96.8 m-85 -157.73 156.17 31.17 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.913 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.643 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 6.9 m-85 -118.62 127.03 53.21 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.141 -0.974 . . . . 0.0 109.742 179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.11 147.91 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.134 -0.979 . . . . 0.0 110.728 -179.954 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.413 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -163.15 161.64 25.18 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.483 -0.761 . . . . 0.0 110.001 179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.503 ' NE2' HG12 ' A' ' 67' ' ' VAL . 35.7 mt-30 -98.0 163.6 12.7 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 109.94 -179.96 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.465 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 0.1 OUTLIER -160.02 143.5 14.06 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.199 -0.938 . . . . 0.0 110.277 -179.927 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.661 ' HB3' HG11 ' A' ' 84' ' ' VAL . . . -137.34 147.08 56.63 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.169 -0.957 . . . . 0.0 110.004 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.5 Cg_endo -72.95 161.45 43.55 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.909 1.479 . . . . 0.0 110.636 -179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 39' ' ' VAL . 76.7 t -145.29 74.45 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.738 -0.601 . . . . 0.0 109.71 -179.903 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.64 -27.96 6.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.256 -1.538 . . . . 0.0 109.256 -179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 171.11 -32.23 0.14 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 38' ' ' PRO . 1.1 mp0 -83.18 173.11 11.96 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.192 -1.181 . . . . 0.0 110.583 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.485 ' N ' ' OD1' ' A' ' 43' ' ' ASP . 0.7 OUTLIER -127.71 106.43 9.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.339 -0.85 . . . . 0.0 110.113 -179.949 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.725 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -98.73 147.89 24.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.257 -0.902 . . . . 0.0 109.994 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 1.3 m -110.9 173.5 6.3 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.083 -1.011 . . . . 0.0 110.972 -179.942 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.499 ' OD1' ' O ' ' A' ' 46' ' ' ASN . 49.3 p-10 -93.91 114.83 64.13 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.599 -0.688 . . . . 0.0 110.929 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.55 ' HB3' ' C7X' ' A' ' 111' ' ' ROM . 48.8 Cg_endo -83.36 -24.71 2.92 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.799 1.42 . . . . 0.0 110.59 179.938 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.02 -47.38 52.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.262 -0.899 . . . . 0.0 110.808 -179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.5 110.02 21.85 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -146.01 130.69 17.96 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.352 -0.843 . . . . 0.0 109.58 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 8.3 p -140.38 137.84 34.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.017 -1.052 . . . . 0.0 110.944 -179.913 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.488 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -110.3 135.42 51.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.44 -0.788 . . . . 0.0 108.984 179.801 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.571 ' CZ ' HG21 ' A' ' 22' ' ' VAL . 24.8 p90 -140.32 154.41 46.77 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.944 -1.098 . . . . 0.0 111.625 -179.799 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.69 ' OG1' HG23 ' A' ' 30' ' ' THR . 15.2 m -109.6 145.87 35.7 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 179.751 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.714 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -47.86 173.28 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.779 0 O-C-N 120.943 -1.098 . . . . 0.0 110.12 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.441 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.8 m-20 -91.08 -166.52 1.6 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.228 -0.92 . . . . 0.0 109.863 -179.972 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -67.04 -31.04 71.29 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.183 -0.948 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -89.75 4.73 48.77 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.481 -0.762 . . . . 0.0 109.442 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.589 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 81.46 18.8 67.81 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -125.66 110.48 13.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -1.109 . . . . 0.0 110.085 -179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.531 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -85.49 154.75 21.58 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.383 -0.823 . . . . 0.0 110.705 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 73.5 m -166.39 117.01 0.97 Allowed 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 26.6 p90 -153.61 175.46 13.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.148 -0.97 . . . . 0.0 110.762 -179.873 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 0.5 OUTLIER -97.52 129.04 44.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.474 -0.766 . . . . 0.0 109.964 -179.996 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -119.23 134.2 55.34 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.439 -0.788 . . . . 0.0 110.193 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 15.1 t -82.28 160.12 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.092 -1.005 . . . . 0.0 109.869 -179.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.74 HG22 ' O ' ' A' ' 16' ' ' GLN . 13.2 m -136.07 176.18 8.82 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 O-C-N 121.318 -0.864 . . . . 0.0 109.435 179.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.478 ' O ' ' C ' ' A' ' 69' ' ' LYS . 73.6 mtm180 -152.3 101.58 2.7 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.178 -0.951 . . . . 0.0 110.158 -179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.566 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 4.3 ttpt -35.66 -51.11 0.65 Allowed 'General case' 0 N--CA 1.493 1.715 0 CA-C-O 121.469 0.652 . . . . 0.0 110.423 179.913 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 t -110.33 144.93 38.33 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.336 -0.853 . . . . 0.0 109.951 -179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.478 ' O ' ' HB ' ' A' ' 84' ' ' VAL . 25.0 p90 -174.58 136.76 0.45 Allowed 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.371 -0.831 . . . . 0.0 110.075 179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -60.45 110.28 1.22 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.105 -0.997 . . . . 0.0 109.729 -179.907 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.503 ' C ' ' HB1' ' A' ' 44' ' ' ALA . . . -79.12 160.66 46.51 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.725 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 47.8 t -179.28 121.6 0.08 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.529 -0.983 . . . . 0.0 109.567 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.469 HG23 ' H ' ' A' ' 75' ' ' THR . 44.2 p -40.33 151.65 0.24 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.353 -0.842 . . . . 0.0 110.547 -179.883 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.662 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.2 Cg_endo -61.72 -45.32 17.64 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 124.258 1.662 . . . . 0.0 110.694 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 76' ' ' PRO . 8.2 mm-40 -149.67 94.51 2.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.262 -0.899 . . . . 0.0 110.295 179.962 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.22 -96.85 0.11 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.976 -1.249 . . . . 0.0 109.976 179.98 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.485 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 5.7 t -134.29 154.59 80.03 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.285 -1.127 . . . . 0.0 110.252 -179.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.485 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 42.6 Cg_endo -68.93 152.81 73.4 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.793 1.417 . . . . 0.0 109.955 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.408 ' CG2' HG23 ' A' ' 75' ' ' THR . 16.2 t -112.8 -40.71 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.211 -0.93 . . . . 0.0 110.482 -179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.08 -160.68 26.32 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 0.7 OUTLIER -94.76 145.58 24.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.16 -1.2 . . . . 0.0 110.343 179.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.661 HG11 ' HB3' ' A' ' 37' ' ' ALA . 18.9 t -112.44 157.6 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.27 -0.894 . . . . 0.0 110.151 179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.641 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 9.4 p-10 -152.9 115.46 4.49 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.34 -0.85 . . . . 0.0 109.943 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.5 -2.22 37.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.159 -0.963 . . . . 0.0 110.214 179.981 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -53.83 -36.02 62.08 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 108.896 -179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 t -141.07 10.31 2.15 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.8 169.63 8.63 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.371 -0.831 . . . . 0.0 110.088 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -108.71 105.63 15.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.122 -0.986 . . . . 0.0 110.374 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 61.8 m -83.48 172.18 12.67 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.233 -0.917 . . . . 0.0 110.487 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.465 ' OD1' ' O ' ' A' ' 36' ' ' CYS . 36.7 p30 -154.64 -174.94 5.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.224 -0.922 . . . . 0.0 110.342 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.945 ' HB2' HD11 ' A' ' 107' ' ' LEU . 19.7 tp -145.12 142.15 29.41 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.309 -0.869 . . . . 0.0 110.082 -179.956 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -143.65 146.61 17.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.431 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -149.58 138.24 20.92 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.407 -1.055 . . . . 0.0 110.156 179.946 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.643 ' HA2' HD12 ' A' ' 102' ' ' LEU . . . 168.22 166.04 26.64 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 98' ' ' SER . 12.5 t-20 -97.81 173.71 6.96 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -1.102 . . . . 0.0 110.091 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 97' ' ' ASN . 92.9 p -42.5 -41.03 2.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.274 -0.892 . . . . 0.0 110.912 -179.964 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 100' ' ' LEU . . . -110.5 -61.73 0.5 Allowed Glycine 0 N--CA 1.493 2.463 0 C-N-CA 119.776 -1.202 . . . . 0.0 110.137 -179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.485 HD12 ' HG ' ' A' ' 102' ' ' LEU . 0.3 OUTLIER -39.92 114.98 0.48 Allowed 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.326 -1.102 . . . . 0.0 110.63 -179.899 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -100.62 89.65 3.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.28 -0.888 . . . . 0.0 109.99 179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.701 HD22 ' CG1' ' A' ' 22' ' ' VAL . 5.1 mt -71.07 -94.88 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.223 -0.923 . . . . 0.0 110.524 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.43 -178.64 46.37 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.488 ' HB2' ' O ' ' A' ' 93' ' ' LEU . 0.4 OUTLIER -139.93 147.68 40.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.331 -1.099 . . . . 0.0 110.335 179.936 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 1.026 HG11 HG12 ' A' ' 6' ' ' VAL . 44.8 t -114.97 139.56 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.278 -0.889 . . . . 0.0 110.391 -179.967 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -82.72 147.41 28.48 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.123 -0.985 . . . . 0.0 110.155 -180.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.945 HD11 ' HB2' ' A' ' 93' ' ' LEU . 10.4 mt -129.46 163.89 24.88 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.194 -0.941 . . . . 0.0 110.487 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.572 ' HB ' ' HA ' ' A' ' 10' ' ' SER . 25.5 m -147.84 164.99 31.96 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.37 -0.832 . . . . 0.0 109.194 179.923 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.566 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 32.2 m-85 -132.4 114.11 13.96 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.983 -1.073 . . . . 0.0 110.741 -179.942 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.225 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.982 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.662 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.714 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.68 -158.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.42 0 O-C-N 123.816 1.43 . . . . 0.0 109.959 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.13 118.61 2.33 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.941 ' CD2' HG22 ' A' ' 22' ' ' VAL . 4.3 t80 -111.31 124.75 52.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.443 -0.786 . . . . 0.0 108.952 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 p -142.48 155.24 45.04 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 120.797 -1.189 . . . . 0.0 111.875 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 105' ' ' VAL . 4.6 p -117.74 163.72 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.774 -0.579 . . . . 0.0 109.671 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.626 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 1.6 t -72.66 -71.41 0.23 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 120.778 -1.201 . . . . 0.0 108.917 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.677 ' O ' ' HB2' ' A' ' 9' ' ' ALA . 55.4 Cg_endo -77.5 -161.03 0.13 Allowed 'Trans proline' 0 N--CA 1.483 0.869 0 O-C-N 123.143 1.075 . . . . 0.0 109.77 179.831 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 169.78 -25.51 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.425 -0.797 . . . . 0.0 110.172 179.904 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.409 ' O ' ' C ' ' A' ' 11' ' ' GLY . 86.7 p -126.0 170.8 11.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 110.059 179.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 45.5 43.77 10.91 Favored Glycine 0 N--CA 1.488 2.126 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.442 HD12 ' HB3' ' A' ' 107' ' ' LEU . 53.7 mt -78.55 -169.22 1.62 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.407 -1.055 . . . . 0.0 110.555 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.41 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 0.0 OUTLIER -154.65 149.91 27.1 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.336 -0.852 . . . . 0.0 110.235 179.938 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -62.15 129.26 39.98 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.346 -0.846 . . . . 0.0 110.677 -179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.03 -27.24 7.59 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.764 ' O ' HG22 ' A' ' 67' ' ' VAL . 24.0 tt0 -51.54 145.24 9.16 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.349 -1.089 . . . . 0.0 110.193 -179.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.3 t -115.61 119.89 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.261 -0.899 . . . . 0.0 109.719 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.574 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -91.98 155.29 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.225 -0.922 . . . . 0.0 110.308 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.4 t -90.27 104.37 16.96 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.079 -1.013 . . . . 0.0 109.735 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 21' ' ' SER . 77.5 t -93.32 167.75 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.334 -0.854 . . . . 0.0 110.769 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.559 ' N ' HG12 ' A' ' 20' ' ' VAL . 54.6 p -166.44 114.54 0.89 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.501 -0.749 . . . . 0.0 109.955 179.935 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.941 HG22 ' CD2' ' A' ' 4' ' ' PHE . 21.3 t -106.21 153.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.368 -0.833 . . . . 0.0 110.153 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t -159.59 152.11 21.29 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.329 -0.857 . . . . 0.0 109.973 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 97.68 3.32 58.36 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.981 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -89.37 -25.53 21.53 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.12 -1.223 . . . . 0.0 110.176 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 73.33 135.37 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.422 -0.798 . . . . 0.0 110.959 179.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.857 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -55.13 132.27 47.05 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.418 -0.801 . . . . 0.0 109.911 179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.451 ' O ' ' OE2' ' A' ' 29' ' ' GLU . . . 118.69 3.31 14.1 Favored Glycine 0 N--CA 1.482 1.73 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 179.922 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.501 ' O ' HG23 ' A' ' 54' ' ' THR . 2.9 mp0 -122.94 146.01 47.97 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.171 -1.193 . . . . 0.0 110.563 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.581 ' O ' ' CD1' ' A' ' 31' ' ' TYR . 0.6 OUTLIER -117.48 166.0 12.86 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.532 -0.73 . . . . 0.0 109.074 179.92 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.581 ' CD1' ' O ' ' A' ' 30' ' ' THR . 70.5 m-85 -156.14 124.75 5.9 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.107 -0.996 . . . . 0.0 110.796 -179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.408 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 26.6 m-85 -84.98 105.85 16.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.878 . . . . 0.0 109.39 179.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.431 HG22 ' H ' ' A' ' 33' ' ' ILE . 16.9 tt -92.17 141.45 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.107 -0.996 . . . . 0.0 110.732 -179.877 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.491 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -167.51 161.19 13.66 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.397 -0.814 . . . . 0.0 110.262 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -94.35 130.86 40.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.379 -0.826 . . . . 0.0 110.194 179.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -127.65 157.06 41.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.35 -0.844 . . . . 0.0 110.625 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.97 138.62 9.23 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.459 -0.776 . . . . 0.0 109.428 179.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.49 ' C ' ' CG2' ' A' ' 39' ' ' VAL . 41.4 Cg_endo -67.6 161.63 42.74 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.848 1.446 . . . . 0.0 111.108 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.49 ' CG2' ' C ' ' A' ' 38' ' ' PRO . 1.7 t -151.2 73.82 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.452 -0.78 . . . . 0.0 110.069 -179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 110.52 -53.22 0.59 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.69 -33.03 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.839 -1.305 . . . . 0.0 109.839 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -94.82 -170.82 2.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -1.206 . . . . 0.0 110.253 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 8.4 m-20 -117.86 125.41 50.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.38 -0.825 . . . . 0.0 110.375 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -112.11 122.95 49.19 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.75 . . . . 0.0 109.562 179.905 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.518 ' SG ' ' C14' ' A' ' 111' ' ' ROM . 0.8 OUTLIER -92.48 173.45 7.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.134 -0.979 . . . . 0.0 111.252 -179.873 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.489 ' ND2' ' HB2' ' A' ' 71' ' ' TYR . 49.1 t-20 -102.08 115.66 64.32 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.405 -0.809 . . . . 0.0 110.578 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.491 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 45.3 Cg_endo -73.67 -9.74 22.89 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.898 1.473 . . . . 0.0 110.529 179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.59 -62.42 1.68 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.276 -0.89 . . . . 0.0 110.389 179.999 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 68' ' ' ARG . 27.6 p -90.05 81.07 6.26 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.35 -0.844 . . . . 0.0 110.405 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -136.1 96.76 3.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.416 -0.803 . . . . 0.0 109.964 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 7.1 t -122.43 157.4 31.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.322 -0.861 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -118.16 147.63 43.15 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.313 -0.867 . . . . 0.0 109.864 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 17.3 p90 -144.89 158.76 43.69 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.108 -0.995 . . . . 0.0 110.909 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.572 ' OG1' HG23 ' A' ' 30' ' ' THR . 62.4 m -116.05 159.51 21.58 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.372 -0.83 . . . . 0.0 109.999 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.981 HG21 ' HB3' ' A' ' 25' ' ' ALA . 3.4 p -75.59 -178.39 4.12 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.149 -0.97 . . . . 0.0 110.856 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.857 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -105.06 -161.95 0.85 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.503 -0.748 . . . . 0.0 109.722 179.968 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -30.18 71.1 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.177 -0.952 . . . . 0.0 110.317 -179.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.29 15.81 12.95 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.197 -0.94 . . . . 0.0 109.71 -179.964 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 57.36 22.63 45.3 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -130.92 126.36 35.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.138 -1.213 . . . . 0.0 110.183 179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.96 154.01 46.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.312 -0.867 . . . . 0.0 110.531 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -144.19 135.39 25.48 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.499 -0.75 . . . . 0.0 109.129 179.864 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.49 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 30.2 p90 -163.22 175.19 11.21 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.903 -1.123 . . . . 0.0 110.828 -179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.6 p -99.14 123.15 43.22 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.349 -0.844 . . . . 0.0 110.313 179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 56.6 t80 -109.37 135.15 50.89 Favored 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.287 -0.883 . . . . 0.0 109.79 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 17.6 t -85.33 164.01 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 110.247 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.764 HG22 ' O ' ' A' ' 16' ' ' GLN . 4.8 m -138.02 177.09 5.85 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 O-C-N 121.381 -0.824 . . . . 0.0 109.935 179.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -149.3 97.46 2.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.246 -0.909 . . . . 0.0 110.457 -179.956 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.501 ' HB2' ' CD2' ' A' ' 109' ' ' PHE . 16.5 ttpt -40.22 -33.1 0.21 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.526 -0.734 . . . . 0.0 110.692 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 54.7 p -125.19 144.13 50.6 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.05 -1.031 . . . . 0.0 110.597 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.795 ' CE2' HG11 ' A' ' 84' ' ' VAL . 10.7 p90 -176.02 131.38 0.24 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.777 179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.5 OUTLIER -57.31 126.06 25.55 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.076 -1.015 . . . . 0.0 110.358 -179.876 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.436 ' O ' ' OG ' ' A' ' 74' ' ' SER . . . -76.17 153.2 42.94 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.439 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 8.0 m -170.5 147.85 3.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.281 -1.129 . . . . 0.0 110.281 -179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.721 HG23 ' CG2' ' A' ' 81' ' ' VAL . 40.3 p -69.1 151.51 97.13 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.222 -0.924 . . . . 0.0 110.606 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.636 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.7 Cg_endo -64.19 -6.44 11.5 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.705 1.603 . . . . 0.0 111.584 -179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.431 ' OE2' H6B2 ' A' ' 111' ' ' ROM . 4.5 tt0 178.95 82.53 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.919 -1.113 . . . . 0.0 110.665 -179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 179.57 -101.63 0.15 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.441 ' HB ' ' HD2' ' A' ' 80' ' ' PRO . 0.6 OUTLIER -137.36 171.08 9.11 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.238 -1.154 . . . . 0.0 110.042 -179.974 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 79' ' ' THR . 45.4 Cg_endo -71.29 129.81 16.55 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.96 1.505 . . . . 0.0 109.91 179.923 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.721 ' CG2' HG23 ' A' ' 75' ' ' THR . 21.4 t -94.09 -39.68 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.258 -0.901 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.74 -163.89 36.58 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.844 -1.302 . . . . 0.0 109.844 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.587 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 93.8 p -110.18 145.38 37.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 110.798 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.795 HG11 ' CE2' ' A' ' 71' ' ' TYR . 7.3 t -110.09 153.63 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.307 -0.871 . . . . 0.0 109.664 179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.536 ' OD1' ' HB2' ' A' ' 89' ' ' ALA . 53.3 p-10 -149.33 81.05 1.41 Allowed 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.096 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.441 ' HB3' ' CD1' ' A' ' 109' ' ' PHE . 81.6 m -44.81 -23.84 0.16 Allowed 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.434 -0.791 . . . . 0.0 110.664 -179.991 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -49.21 -50.51 37.91 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.233 -0.917 . . . . 0.0 109.752 179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 t -117.94 5.37 12.14 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.564 -0.71 . . . . 0.0 109.931 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.536 ' HB2' ' OD1' ' A' ' 85' ' ' ASP . . . -112.36 -179.18 3.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.256 -0.903 . . . . 0.0 111.363 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -115.29 100.06 7.85 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.714 -0.617 . . . . 0.0 109.45 179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 34.2 m -94.49 167.98 11.15 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.27 -0.893 . . . . 0.0 111.042 -179.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.626 ' ND2' ' CE1' ' A' ' 104' ' ' HIS . 0.9 OUTLIER -155.97 137.4 14.0 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.444 -0.785 . . . . 0.0 109.952 179.985 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.491 HD12 ' O ' ' A' ' 34' ' ' ALA . 44.2 tp -89.1 146.71 24.64 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.119 -0.988 . . . . 0.0 110.303 179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -140.45 136.37 7.62 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.96 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.486 ' O ' ' HB2' ' A' ' 102' ' ' LEU . . . -122.5 111.45 16.84 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.347 -1.09 . . . . 0.0 109.615 179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.447 ' HA3' CL21 ' A' ' 111' ' ' ROM . . . -157.69 149.46 19.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.573 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 2.0 t30 -102.03 -157.6 0.62 Allowed 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.322 -1.105 . . . . 0.0 110.157 -179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 62.3 p -89.71 43.67 1.16 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.274 -0.891 . . . . 0.0 110.248 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -179.72 -75.53 0.06 OUTLIER Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.151 -179.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.53 HD22 ' OH ' ' A' ' 31' ' ' TYR . 10.4 tt -86.37 147.44 26.03 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.193 -1.181 . . . . 0.0 110.79 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.501 ' N ' HD23 ' A' ' 100' ' ' LEU . 26.8 t70 -111.43 159.52 17.96 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.429 -0.794 . . . . 0.0 109.424 179.892 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.616 HD22 HG13 ' A' ' 22' ' ' VAL . 4.7 mt -114.48 -91.63 0.51 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.988 -1.07 . . . . 0.0 110.418 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -143.69 171.09 25.47 Favored Glycine 0 N--CA 1.487 2.036 0 C-N-CA 119.659 -1.258 . . . . 0.0 110.218 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.626 ' CE1' ' ND2' ' A' ' 92' ' ' ASN . 4.7 t60 -128.43 105.04 8.04 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.722 -0.87 . . . . 0.0 109.407 -179.954 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.778 HG11 HG11 ' A' ' 6' ' ' VAL . 54.3 t -88.34 160.6 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.145 -0.972 . . . . 0.0 110.483 -179.926 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -113.69 154.6 27.01 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.203 -0.935 . . . . 0.0 109.652 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.508 ' HA ' ' O ' ' A' ' 9' ' ' ALA . 15.5 mt -129.3 165.11 22.08 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.139 -0.976 . . . . 0.0 110.174 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 51.8 m -161.87 103.47 1.17 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.043 -1.035 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 60.4 m-85 -83.97 93.01 7.96 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 110.271 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 CA-C-O 118.022 -1.432 . . . . 0.0 109.699 -179.932 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.704 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 120.858 0.361 . . . . 0.0 110.395 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 1' ' ' ALA . 46.3 Cg_endo -72.48 -170.05 0.54 Allowed 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 124.167 1.614 . . . . 0.0 110.632 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.717 ' O ' HG13 ' A' ' 22' ' ' VAL . . . -124.13 -178.29 4.04 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.342 -0.849 . . . . 0.0 110.293 179.947 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.546 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.8 t80 -171.11 124.48 0.62 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.385 -0.822 . . . . 0.0 109.654 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.6 m -146.49 155.36 42.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.924 -1.11 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.831 HG22 ' HD2' ' A' ' 8' ' ' PRO . 11.4 p -115.62 146.07 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.681 -0.637 . . . . 0.0 109.368 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.642 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -60.71 -61.64 7.56 Favored Pre-proline 0 C--N 1.301 -1.503 0 O-C-N 120.746 -1.221 . . . . 0.0 109.135 179.93 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.831 ' HD2' HG22 ' A' ' 6' ' ' VAL . 54.9 Cg_endo -85.68 165.66 10.42 Favored 'Trans proline' 0 C--N 1.32 -0.939 0 O-C-N 123.296 1.156 . . . . 0.0 109.833 179.808 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 10' ' ' SER . . . -168.75 27.64 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.221 -0.924 . . . . 0.0 109.796 179.878 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.485 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 20.6 p -176.43 160.91 2.14 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.44 -0.788 . . . . 0.0 109.772 179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 46.84 47.78 18.83 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 -179.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 86.1 mt -84.17 -162.01 0.61 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.359 -1.083 . . . . 0.0 110.248 179.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.485 ' HB2' ' HB2' ' A' ' 16' ' ' GLN . 13.0 m -151.6 151.38 31.45 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.28 -0.888 . . . . 0.0 110.186 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -67.92 128.12 35.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.232 -0.917 . . . . 0.0 110.315 -179.923 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.97 -24.01 12.34 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 13' ' ' SER . 41.7 tt0 -54.46 157.61 2.78 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.289 -1.124 . . . . 0.0 110.187 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.436 ' N ' ' HG2' ' A' ' 16' ' ' GLN . 0.6 OUTLIER -125.83 112.95 16.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.289 -0.882 . . . . 0.0 110.158 179.986 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.588 ' CG1' ' HG2' ' A' ' 8' ' ' PRO . 24.4 m -80.93 178.48 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.423 -0.798 . . . . 0.0 110.298 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -117.47 97.95 6.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 69.2 t -83.4 169.06 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.272 -0.893 . . . . 0.0 110.477 -179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 1.4 p -162.86 109.86 1.22 Allowed 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.939 HG11 HD22 ' A' ' 102' ' ' LEU . 5.9 t -112.25 151.98 14.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.379 -0.826 . . . . 0.0 110.1 -179.978 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.06 170.47 15.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.372 -0.83 . . . . 0.0 110.384 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 94.83 -18.56 57.01 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 109.199 -1.56 . . . . 0.0 109.199 179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.62 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -77.61 -153.63 0.06 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.29 -1.124 . . . . 0.0 109.868 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.404 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -151.36 137.78 18.58 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.883 -1.135 . . . . 0.0 111.014 179.952 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.62 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.03 126.53 18.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.451 -0.781 . . . . 0.0 110.235 -179.932 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.82 19.05 5.78 Favored Glycine 0 N--CA 1.483 1.828 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.842 ' O ' HG23 ' A' ' 54' ' ' THR . 3.9 mm-40 -135.06 152.1 51.38 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.211 -1.17 . . . . 0.0 110.317 179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.773 HG23 ' OG1' ' A' ' 54' ' ' THR . 1.6 m -135.51 117.25 15.04 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.92 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.591 ' HB2' ' CZ ' ' A' ' 53' ' ' PHE . 37.0 m-85 -100.87 163.61 12.22 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.218 -0.926 . . . . 0.0 109.98 179.936 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.426 ' CD2' ' OG ' ' A' ' 52' ' ' SER . 49.7 m-85 -107.78 127.71 53.94 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.104 -0.998 . . . . 0.0 110.278 179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.947 HD11 HD21 ' A' ' 93' ' ' LEU . 3.5 tt -113.54 137.36 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.089 -1.007 . . . . 0.0 110.026 179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.522 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -149.43 147.24 28.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.236 -0.915 . . . . 0.0 110.309 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 107' ' ' LEU . 26.3 tt0 -94.75 130.67 41.19 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.292 -0.88 . . . . 0.0 109.837 179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 45' ' ' CYS . 0.0 OUTLIER -141.03 164.98 28.79 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.206 -0.934 . . . . 0.0 110.217 179.967 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.507 ' O ' ' HA ' ' A' ' 43' ' ' ASP . . . -125.47 154.1 72.5 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.516 ' HD3' ' ND2' ' A' ' 92' ' ' ASN . 44.0 Cg_endo -73.26 165.5 32.44 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.946 1.498 . . . . 0.0 110.807 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.729 ' O ' HG13 ' A' ' 39' ' ' VAL . 13.9 p -167.44 73.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.265 -0.897 . . . . 0.0 110.725 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.08 -43.03 2.29 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 179.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -173.81 -34.31 0.03 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -99.4 -157.85 0.63 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.346 -1.091 . . . . 0.0 109.298 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.507 ' HA ' ' O ' ' A' ' 37' ' ' ALA . 2.4 p30 -157.43 125.21 5.36 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 120.961 -1.087 . . . . 0.0 110.697 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.907 ' HB1' ' N ' ' A' ' 74' ' ' SER . . . -86.63 131.35 34.18 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.58 -0.7 . . . . 0.0 109.666 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.437 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 0.7 OUTLIER -104.73 173.98 6.07 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.936 -1.103 . . . . 0.0 110.987 -179.897 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.562 ' OD1' ' CE2' ' A' ' 71' ' ' TYR . 1.3 m-20 -90.59 128.59 48.05 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.69 -0.631 . . . . 0.0 110.365 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.675 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.5 Cg_endo -79.26 -18.18 11.23 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.876 1.461 . . . . 0.0 110.068 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.06 -51.74 8.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.37 -0.831 . . . . 0.0 110.105 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.442 HG21 ' HG3' ' A' ' 68' ' ' ARG . 2.9 p -91.48 116.13 28.6 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.327 -0.858 . . . . 0.0 109.949 -179.972 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . -176.84 55.42 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.408 -0.807 . . . . 0.0 110.0 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 15.1 t -81.98 155.39 25.23 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.303 -0.873 . . . . 0.0 110.23 -179.984 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.426 ' OG ' ' CD2' ' A' ' 32' ' ' TYR . 3.1 m -101.93 136.41 41.82 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.942 -179.985 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.591 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 55.0 p90 -111.44 141.41 45.03 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.113 -0.992 . . . . 0.0 110.738 179.925 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.842 HG23 ' O ' ' A' ' 29' ' ' GLU . 38.7 m -106.52 146.2 30.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.373 -0.83 . . . . 0.0 110.058 -179.927 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.62 HG21 ' HB3' ' A' ' 25' ' ' ALA . 1.7 p -62.44 -179.08 0.22 Allowed 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 110.216 179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.62 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 55.0 m-20 -100.16 -163.65 1.05 Allowed 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.549 -0.719 . . . . 0.0 109.56 179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -68.33 -29.83 68.66 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.238 -0.914 . . . . 0.0 109.041 179.843 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -89.52 6.99 38.5 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.466 -0.771 . . . . 0.0 109.622 179.854 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.54 ' HA2' ' N ' ' A' ' 27' ' ' ALA . . . 85.08 2.8 88.03 Favored Glycine 0 N--CA 1.499 2.847 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.993 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -91.37 122.18 33.74 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.928 -1.336 . . . . 0.0 110.215 -179.999 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.518 ' HB1' ' HD1' ' A' ' 53' ' ' PHE . . . -95.6 82.12 3.6 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.324 -0.86 . . . . 0.0 111.338 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 5.4 m -100.6 133.87 44.41 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.189 -0.944 . . . . 0.0 109.037 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.437 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 40.5 p90 -173.87 -179.12 1.68 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.838 -1.164 . . . . 0.0 111.201 -179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' O ' ' A' ' 18' ' ' VAL . 73.9 p -103.44 132.73 49.45 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.51 -0.744 . . . . 0.0 109.721 179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.426 ' O ' HG22 ' A' ' 18' ' ' VAL . 27.9 t80 -118.55 139.97 50.62 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.261 -0.899 . . . . 0.0 110.128 -179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 34.9 t -84.58 161.44 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.037 -1.039 . . . . 0.0 110.873 179.995 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.489 ' O ' ' HG2' ' A' ' 68' ' ' ARG . 15.8 m -136.77 178.87 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.595 -0.691 . . . . 0.0 109.687 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 67' ' ' VAL . 11.0 mtp180 -151.44 106.27 3.27 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.024 -1.048 . . . . 0.0 110.24 179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.597 ' HG3' ' CD2' ' A' ' 109' ' ' PHE . 6.8 ttmm -38.32 -58.85 0.95 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.72 -0.612 . . . . 0.0 111.776 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.426 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 27.8 t -122.3 160.93 24.29 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.807 -1.183 . . . . 0.0 111.59 -179.909 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.562 ' CE2' ' OD1' ' A' ' 46' ' ' ASN . 29.3 p90 -177.66 156.55 1.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.561 -0.712 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 1.5 m -77.49 132.63 38.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.97 -1.081 . . . . 0.0 109.885 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -78.95 148.18 31.39 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.907 ' N ' ' HB1' ' A' ' 44' ' ' ALA . 1.8 p 178.33 117.85 0.04 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.413 -1.051 . . . . 0.0 109.88 -179.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.474 ' HB ' ' HD2' ' A' ' 76' ' ' PRO . 36.8 p -42.67 165.38 0.1 Allowed Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.354 -0.841 . . . . 0.0 110.36 -179.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.526 ' HA ' " O'7" ' A' ' 111' ' ' ROM . 42.4 Cg_endo -69.23 -18.57 39.45 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.89 1.468 . . . . 0.0 110.63 179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 175.67 87.2 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.183 -0.948 . . . . 0.0 110.063 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -174.95 -74.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.488 ' OG1' ' HD2' ' A' ' 80' ' ' PRO . 9.9 t -150.01 153.52 35.73 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.278 -1.13 . . . . 0.0 110.239 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.488 ' HD2' ' OG1' ' A' ' 79' ' ' THR . 41.0 Cg_endo -68.09 128.6 17.89 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 O-C-N 123.875 1.461 . . . . 0.0 110.345 179.988 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG23 ' HA ' ' A' ' 74' ' ' SER . 9.8 t -92.01 -27.62 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.47 -0.769 . . . . 0.0 110.45 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 131.38 -156.73 21.98 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.981 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 3.9 m -111.74 163.76 13.79 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.17 -1.194 . . . . 0.0 109.807 179.939 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -141.41 160.84 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.93 -1.106 . . . . 0.0 110.712 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.428 ' O ' ' CG ' ' A' ' 85' ' ' ASP . 11.3 p-10 -156.21 108.17 2.54 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.304 -0.872 . . . . 0.0 110.08 -179.94 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -78.05 2.81 16.61 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.079 -1.013 . . . . 0.0 110.88 -179.94 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -46.84 -40.91 14.74 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.935 -1.103 . . . . 0.0 108.743 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 t -137.87 6.27 2.65 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 179.865 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB3' ' HA ' ' A' ' 86' ' ' CYS . . . -103.08 179.73 4.19 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.47 -0.768 . . . . 0.0 110.21 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -114.01 129.59 56.6 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.365 -0.834 . . . . 0.0 109.995 179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 73.2 m -110.98 171.43 7.47 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.35 -0.844 . . . . 0.0 109.962 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.516 ' ND2' ' HD3' ' A' ' 38' ' ' PRO . 21.3 p30 -146.16 134.42 21.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.198 -0.939 . . . . 0.0 110.614 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.947 HD21 HD11 ' A' ' 33' ' ' ILE . 52.3 tp -96.74 140.65 31.01 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.364 -0.835 . . . . 0.0 110.052 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.526 ' CA ' ' CD2' ' A' ' 104' ' ' HIS . . . -129.43 137.49 9.61 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.984 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -124.67 154.7 40.39 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.209 -1.171 . . . . 0.0 110.191 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 143.61 140.82 3.71 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.989 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.521 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 10.5 p-10 -89.27 -150.84 0.21 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.227 -1.161 . . . . 0.0 110.408 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.518 ' HA ' ' H8 ' ' A' ' 111' ' ' ROM . 10.1 t -84.4 27.75 0.68 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.926 . . . . 0.0 110.632 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -172.65 -78.87 0.05 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 4.3 tt -64.11 113.91 3.84 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.213 -1.169 . . . . 0.0 110.336 -179.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -93.44 175.1 6.88 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.358 -0.839 . . . . 0.0 110.044 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.939 HD22 HG11 ' A' ' 22' ' ' VAL . 32.0 mt -132.18 -74.97 0.51 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.115 -0.99 . . . . 0.0 110.394 -179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.83 -179.3 44.38 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.978 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . 0.526 ' CD2' ' CA ' ' A' ' 94' ' ' GLY . 0.5 OUTLIER -130.41 108.77 10.22 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.406 -1.055 . . . . 0.0 110.281 -179.955 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.596 HG12 ' N ' ' A' ' 106' ' ' ALA . 56.6 t -88.89 172.35 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.189 -0.945 . . . . 0.0 110.286 179.99 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.596 ' N ' HG12 ' A' ' 105' ' ' VAL . . . -123.9 133.76 53.68 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.321 -0.862 . . . . 0.0 109.702 179.942 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.522 HD12 ' HG3' ' A' ' 35' ' ' GLN . 14.5 mt -108.35 173.93 6.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.125 -0.984 . . . . 0.0 110.145 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.511 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -165.57 128.65 2.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.719 179.983 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.597 ' CD2' ' HG3' ' A' ' 69' ' ' LYS . 38.8 m-85 -105.99 133.53 50.56 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.109 -0.994 . . . . 0.0 109.846 179.948 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 CA-C-O 117.988 -1.451 . . . . 0.0 109.54 179.999 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.68 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 120.781 0.324 . . . . 0.0 110.291 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.444 ' HG3' HD21 ' A' ' 100' ' ' LEU . 43.0 Cg_endo -71.59 -169.28 0.41 Allowed 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 123.996 1.524 . . . . 0.0 110.386 179.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -161.59 149.66 15.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.154 -0.966 . . . . 0.0 110.822 -179.984 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.899 ' CD1' HG22 ' A' ' 22' ' ' VAL . 45.1 t80 -127.03 122.7 35.16 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.501 -0.749 . . . . 0.0 109.343 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -142.96 157.1 44.89 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.795 -1.191 . . . . 0.0 111.944 -179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.753 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.7 p -124.71 162.02 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.672 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -64.01 -65.91 1.78 Allowed Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 120.671 -1.268 . . . . 0.0 110.729 -179.935 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.724 ' HD2' HG22 ' A' ' 6' ' ' VAL . 51.3 Cg_endo -93.77 -171.21 0.26 Allowed 'Trans proline' 0 C--O 1.214 -0.688 0 N-CA-C 109.634 -0.948 . . . . 0.0 109.634 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . 170.67 33.25 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.081 -1.012 . . . . 0.0 110.489 179.9 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.454 ' HA ' ' HB ' ' A' ' 108' ' ' THR . 0.1 OUTLIER -170.3 161.42 8.19 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.236 -0.915 . . . . 0.0 109.803 179.954 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.07 43.77 8.98 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 108.933 -1.667 . . . . 0.0 108.933 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.6 mt -83.39 -167.42 1.69 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.346 -1.091 . . . . 0.0 111.167 -179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.23 143.28 12.05 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.894 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -52.99 142.87 18.52 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.976 -1.077 . . . . 0.0 110.527 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -25.86 8.66 Favored Glycine 0 N--CA 1.497 2.764 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -179.974 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.692 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.0 tt0 -60.45 137.15 58.19 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.428 -1.042 . . . . 0.0 111.035 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 12.3 m -113.06 121.75 45.52 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.296 -0.877 . . . . 0.0 109.756 179.953 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.716 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.0 m -100.66 153.61 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.155 -0.966 . . . . 0.0 110.696 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.9 m -88.21 103.52 15.85 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.239 -0.913 . . . . 0.0 109.746 -179.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG12 ' N ' ' A' ' 21' ' ' SER . 74.1 t -93.14 169.97 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.255 -0.903 . . . . 0.0 110.294 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.586 ' N ' HG12 ' A' ' 20' ' ' VAL . 3.5 t -171.9 118.25 0.41 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.904 . . . . 0.0 110.446 -179.912 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.899 HG22 ' CD1' ' A' ' 4' ' ' PHE . 4.4 t -99.84 156.99 3.96 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 O-C-N 121.316 -0.865 . . . . 0.0 109.794 179.868 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.1 p -152.14 168.98 23.56 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.06 -1.025 . . . . 0.0 110.14 179.971 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 88.33 -23.36 15.62 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.723 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -62.51 -156.31 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.301 -1.117 . . . . 0.0 109.793 -179.935 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -152.29 138.47 18.32 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.967 -1.083 . . . . 0.0 110.924 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 1.068 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.7 137.87 56.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.415 -0.803 . . . . 0.0 110.288 -179.96 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.71 5.02 18.85 Favored Glycine 0 N--CA 1.485 1.906 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.85 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 25.4 mt-10 -146.1 152.17 38.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.206 -1.173 . . . . 0.0 110.514 179.963 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 54' ' ' THR . 89.1 m -117.36 131.05 56.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.303 -0.873 . . . . 0.0 110.137 179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.81 ' CE2' HD13 ' A' ' 100' ' ' LEU . 88.6 m-85 -101.8 173.39 6.43 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.291 -0.881 . . . . 0.0 110.431 -179.94 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.491 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 47.5 m-85 -130.5 108.97 10.34 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.317 -0.864 . . . . 0.0 109.712 179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.96 HD13 ' N ' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -96.51 137.91 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.19 -0.944 . . . . 0.0 109.472 179.953 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.96 ' N ' HD13 ' A' ' 33' ' ' ILE . . . -159.78 155.2 25.46 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.995 -1.066 . . . . 0.0 110.92 -179.975 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.573 ' HA ' HD12 ' A' ' 93' ' ' LEU . 8.3 tt0 -98.47 131.91 44.33 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.47 -0.769 . . . . 0.0 109.269 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.447 ' HB3' ' O ' ' A' ' 44' ' ' ALA . 0.4 OUTLIER -139.15 158.56 43.96 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.099 -1.0 . . . . 0.0 110.574 -179.909 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.68 151.96 73.6 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.308 -0.87 . . . . 0.0 109.376 179.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.29 163.45 38.66 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 O-C-N 123.862 1.454 . . . . 0.0 110.874 -179.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.484 HG12 ' O ' ' A' ' 39' ' ' VAL . 59.1 t -138.28 62.16 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.456 -0.777 . . . . 0.0 110.436 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 40.27 28.62 0.18 Allowed Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 39' ' ' VAL . . . -163.74 -79.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.604 ' NE2' HG22 ' A' ' 81' ' ' VAL . 19.2 pt20 -122.39 -146.09 0.36 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.315 -1.109 . . . . 0.0 110.31 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.73 139.59 53.39 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.208 -0.932 . . . . 0.0 110.534 -179.952 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.447 ' O ' ' HB3' ' A' ' 36' ' ' CYS . . . -132.17 142.1 49.34 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.435 -0.791 . . . . 0.0 109.516 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' SG ' ' O ' ' A' ' 35' ' ' GLN . 1.9 t -124.02 165.8 16.83 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.871 -1.143 . . . . 0.0 111.03 -179.941 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.406 ' OD1' ' HD2' ' A' ' 47' ' ' PRO . 59.1 t-20 -90.39 127.95 50.96 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.417 -0.802 . . . . 0.0 109.912 179.948 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.589 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 45.1 Cg_endo -82.8 -34.01 0.4 Allowed 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.902 1.475 . . . . 0.0 111.15 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -62.98 -28.41 70.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.269 -0.894 . . . . 0.0 110.948 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 69.5 p -102.45 1.23 34.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.098 -1.001 . . . . 0.0 110.489 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -68.96 123.99 22.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.914 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 9.9 t -137.17 147.1 45.7 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.173 -0.954 . . . . 0.0 110.69 -179.973 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.4 p -109.51 149.11 30.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.385 -0.822 . . . . 0.0 109.905 179.977 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.618 ' CD1' ' N ' ' A' ' 53' ' ' PHE . 6.5 p90 -143.63 130.87 20.79 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.128 -0.982 . . . . 0.0 110.175 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 30' ' ' THR . 15.4 m -90.05 149.6 22.44 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.276 -0.89 . . . . 0.0 110.369 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.723 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -84.89 168.01 15.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.278 -0.888 . . . . 0.0 110.242 179.978 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 1.068 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 3.5 m-20 -107.4 -160.83 0.75 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.489 -0.757 . . . . 0.0 109.653 -179.927 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.11 -17.75 64.72 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.475 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.403 ' O ' ' OG ' ' A' ' 58' ' ' SER . 1.2 t -99.63 15.89 25.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 0.0 109.597 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.475 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 44.17 36.34 4.01 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.928 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -135.9 135.27 39.55 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.249 -1.148 . . . . 0.0 110.411 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.69 147.56 46.86 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.327 -0.858 . . . . 0.0 110.605 179.97 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.7 m -141.62 131.73 24.77 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.305 -0.872 . . . . 0.0 109.049 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 23.3 p90 -153.49 175.71 12.87 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.951 -1.093 . . . . 0.0 110.756 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.5 p -99.39 126.09 45.21 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.404 -0.81 . . . . 0.0 109.881 179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -122.24 126.88 49.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.256 -0.903 . . . . 0.0 109.903 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 17.9 t -83.57 164.15 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.266 -0.896 . . . . 0.0 110.538 -179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 16' ' ' GLN . 16.0 m -130.53 168.07 24.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.407 -0.808 . . . . 0.0 110.074 179.986 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 -141.79 106.8 4.94 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.198 -0.939 . . . . 0.0 110.264 -179.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.49 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 31.6 tttt -45.22 -23.16 0.15 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 110.931 179.947 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.442 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 1.4 m -145.93 145.05 30.54 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.029 -1.044 . . . . 0.0 110.398 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.478 ' C ' ' CD1' ' A' ' 71' ' ' TYR . 22.4 p90 -177.07 164.28 2.23 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.312 -0.867 . . . . 0.0 109.817 -179.974 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -78.21 122.53 25.8 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.037 -1.04 . . . . 0.0 110.22 -179.968 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.411 ' O ' ' HB3' ' A' ' 74' ' ' SER . . . -79.82 158.6 43.0 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.411 ' HB3' ' O ' ' A' ' 73' ' ' GLY . 19.1 p 179.07 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.221 -1.164 . . . . 0.0 109.937 -179.939 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.818 HG23 HG23 ' A' ' 81' ' ' VAL . 30.6 p -44.16 152.63 0.47 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.213 -0.929 . . . . 0.0 109.932 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.586 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 42.5 Cg_endo -66.05 -45.61 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 124.132 1.596 . . . . 0.0 110.866 -179.965 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -155.91 89.2 1.14 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.125 -0.984 . . . . 0.0 110.271 -179.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 79' ' ' THR . . . 154.43 74.93 0.01 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.479 ' O ' ' O ' ' A' ' 78' ' ' GLY . 38.7 m 58.73 126.48 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.374 -1.074 . . . . 0.0 110.198 -179.991 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.61 -166.12 0.17 Allowed 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.666 1.35 . . . . 0.0 110.626 -179.964 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.818 HG23 HG23 ' A' ' 75' ' ' THR . 99.0 t -139.12 -88.33 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.141 -0.975 . . . . 0.0 110.53 -179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -163.0 -167.44 23.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.494 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 50.6 m -82.21 171.55 14.15 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.289 -1.124 . . . . 0.0 110.192 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 27.9 t -143.26 161.13 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.159 -0.963 . . . . 0.0 110.253 -179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.483 ' OD2' ' HB3' ' A' ' 87' ' ' ALA . 31.5 t0 -163.79 97.79 0.86 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 -179.967 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 89' ' ' ALA . 0.0 OUTLIER -46.87 -26.48 0.99 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.298 -0.877 . . . . 0.0 110.792 179.889 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.49 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -51.19 -48.9 61.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.077 -1.015 . . . . 0.0 109.608 179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 t -110.28 7.49 23.14 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.525 -0.735 . . . . 0.0 109.741 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 86' ' ' CYS . . . -138.43 163.13 32.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.893 . . . . 0.0 110.331 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -104.01 122.73 45.85 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.269 -0.894 . . . . 0.0 109.777 179.863 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . . . . . . . . . 5.1 m -99.79 163.54 12.42 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.001 -1.062 . . . . 0.0 110.749 -179.907 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -148.2 -176.54 5.33 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.626 -0.671 . . . . 0.0 109.356 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 35' ' ' GLN . 14.3 tp -134.93 146.27 48.98 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.156 -0.965 . . . . 0.0 109.558 179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -147.59 143.86 11.76 Favored Glycine 0 N--CA 1.486 1.973 0 C-N-CA 119.366 -1.397 . . . . 0.0 110.016 -179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -125.91 174.7 8.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.585 -0.95 . . . . 0.0 109.843 179.848 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' N ' HD12 ' A' ' 102' ' ' LEU . . . 135.54 170.93 12.23 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.969 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.512 ' O ' ' H8 ' ' A' ' 111' ' ' ROM . 49.4 p30 -121.74 -138.33 0.32 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.319 -1.107 . . . . 0.0 110.13 179.96 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 25.5 m -49.83 -42.56 47.54 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.119 -0.988 . . . . 0.0 110.496 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -177.44 75.05 0.07 OUTLIER Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.944 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.814 HD23 ' O ' ' A' ' 100' ' ' LEU . 6.5 tt -124.87 -28.06 3.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.313 -1.11 . . . . 0.0 110.261 179.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 100' ' ' LEU . 2.8 t0 64.59 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.26 -0.9 . . . . 0.0 110.322 -179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.863 HD22 ' CG1' ' A' ' 22' ' ' VAL . 8.7 mt -98.07 -71.81 0.67 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.308 -0.87 . . . . 0.0 110.225 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.472 ' HA3' ' HB3' ' A' ' 4' ' ' PHE . . . -175.03 171.52 44.67 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.968 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -133.55 128.49 35.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.367 -1.078 . . . . 0.0 110.189 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.753 HG11 ' CG1' ' A' ' 6' ' ' VAL . 94.7 t -113.02 118.91 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.17 -0.957 . . . . 0.0 110.16 179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.39 147.92 30.81 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.058 -1.026 . . . . 0.0 109.864 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 3.4 mt -120.05 164.12 16.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 110.203 -179.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.479 HG22 ' O ' ' A' ' 108' ' ' THR . 2.7 m -153.74 98.06 2.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.254 -0.904 . . . . 0.0 110.111 -179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -68.23 110.77 4.18 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.438 -0.789 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.421 ' HA3' ' HA2' ' A' ' 11' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 -179.941 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.608 ' C6 ' ' C21' ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.663 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 43.3 Cg_endo -71.63 -159.65 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.805 0 O-C-N 123.844 1.444 . . . . 0.0 110.077 179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.462 ' HB2' ' O ' ' A' ' 2' ' ' PRO . . . -177.86 129.27 0.14 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.042 -1.036 . . . . 0.0 110.551 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.687 ' CD2' HG22 ' A' ' 22' ' ' VAL . 3.4 t80 -111.8 128.5 56.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.567 -0.708 . . . . 0.0 109.355 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -143.49 160.72 40.09 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.794 -1.191 . . . . 0.0 111.629 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 105' ' ' VAL . 12.8 p -130.07 165.03 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.743 -0.598 . . . . 0.0 109.644 179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.614 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 2.0 t -77.0 -73.86 0.12 Allowed Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 120.965 -1.085 . . . . 0.0 109.224 179.887 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.614 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 56.2 Cg_endo -78.85 179.88 6.09 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 N-CA-C 109.256 -1.094 . . . . 0.0 109.256 179.798 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' A' ' 8' ' ' PRO . . . -178.07 30.15 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.196 -0.94 . . . . 0.0 109.955 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER -172.65 165.81 5.46 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.396 -0.815 . . . . 0.0 109.717 179.954 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 45.0 45.96 9.4 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.463 ' CD1' ' HB3' ' A' ' 107' ' ' LEU . 78.9 mt -82.71 -161.68 0.51 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.408 -1.054 . . . . 0.0 110.561 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.471 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 41.0 t -160.04 152.03 20.39 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.422 -0.799 . . . . 0.0 110.266 179.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -63.9 130.42 44.05 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.288 -0.882 . . . . 0.0 110.438 -179.977 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.25 -27.05 7.93 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.732 ' O ' HG22 ' A' ' 67' ' ' VAL . 43.7 tt0 -57.69 145.78 33.18 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.293 -1.122 . . . . 0.0 110.067 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.499 ' HA ' ' O ' ' A' ' 65' ' ' PHE . 4.4 m -115.94 133.57 55.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.236 -0.915 . . . . 0.0 109.779 179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.417 ' H ' HG22 ' A' ' 18' ' ' VAL . 27.1 m -101.95 158.81 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.327 -0.858 . . . . 0.0 110.45 -179.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.57 107.72 19.24 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.226 -0.921 . . . . 0.0 109.612 -179.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.584 HG12 ' N ' ' A' ' 21' ' ' SER . 83.1 t -104.92 169.01 2.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.211 -0.931 . . . . 0.0 110.795 -179.9 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.584 ' N ' HG12 ' A' ' 20' ' ' VAL . 67.0 p -167.7 122.14 0.98 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.549 -0.72 . . . . 0.0 109.632 179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.687 HG22 ' CD2' ' A' ' 4' ' ' PHE . 13.4 t -113.59 156.31 14.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.269 -0.894 . . . . 0.0 110.154 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.3 t -155.2 151.56 28.31 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.199 -0.938 . . . . 0.0 110.335 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 2' ' ' PRO . . . 97.96 0.07 58.9 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 1.066 ' HB3' HG21 ' A' ' 55' ' ' THR . . . -80.73 -25.72 37.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -1.205 . . . . 0.0 109.958 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.753 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 76.69 128.84 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.3 0 CA-C-O 121.868 0.842 . . . . 0.0 111.508 179.931 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.833 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -54.43 144.91 19.57 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 121.483 0.659 . . . . 0.0 110.551 179.974 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.21 18.06 16.09 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.405 ' O ' HG23 ' A' ' 54' ' ' THR . 29.6 mp0 -146.87 147.87 31.26 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.192 -1.181 . . . . 0.0 110.31 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' OG1' ' A' ' 54' ' ' THR . 5.5 m -118.14 160.56 21.33 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.429 -0.794 . . . . 0.0 109.779 179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.516 ' CE2' ' HB1' ' A' ' 25' ' ' ALA . 91.2 m-85 -141.81 159.99 41.1 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.155 -0.966 . . . . 0.0 110.385 -179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.64 ' N ' ' CD1' ' A' ' 32' ' ' TYR . 8.3 m-85 -117.95 121.51 40.86 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.357 -0.84 . . . . 0.0 109.916 -179.929 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 6.7 tt -107.68 138.72 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.247 -0.908 . . . . 0.0 109.798 -179.908 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.438 ' CB ' ' O11' ' A' ' 111' ' ' ROM . . . -159.05 156.53 29.43 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.099 -1.0 . . . . 0.0 110.97 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 26.0 tt0 -94.25 133.44 37.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.569 -0.707 . . . . 0.0 109.22 179.884 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.2 m -131.99 -179.52 5.46 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.116 -0.99 . . . . 0.0 111.276 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -161.03 146.01 10.61 Favored Pre-proline 0 N--CA 1.491 1.605 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.982 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.479 ' HD2' ' O ' ' A' ' 90' ' ' ALA . 43.4 Cg_endo -71.31 164.66 34.98 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.553 1.291 . . . . 0.0 110.657 -179.891 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.624 ' O ' HG13 ' A' ' 39' ' ' VAL . 7.2 p -157.4 76.47 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.958 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 71.24 41.29 59.86 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.77 -29.56 6.27 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . 0.8 OUTLIER -77.59 179.59 6.46 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.305 -1.115 . . . . 0.0 109.936 179.997 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -125.38 131.27 53.0 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.208 -0.933 . . . . 0.0 110.069 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.683 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -126.56 109.87 12.61 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.402 -0.811 . . . . 0.0 110.011 -179.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 47' ' ' PRO . 7.1 m -98.49 172.23 7.65 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.17 -0.956 . . . . 0.0 110.18 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -95.51 106.36 26.25 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.114 -0.991 . . . . 0.0 110.231 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.581 ' N ' H7A3 ' A' ' 111' ' ' ROM . 47.9 Cg_endo -73.0 -7.48 20.74 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.069 1.562 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.63 -17.31 39.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 110.476 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 31.6 p -122.61 74.43 1.19 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.163 -0.961 . . . . 0.0 110.662 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.6 67.91 0.7 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.281 -0.887 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 14.3 t -93.81 141.42 28.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.262 -0.899 . . . . 0.0 110.653 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -118.73 137.08 53.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 110.118 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -126.01 137.04 53.63 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.243 -0.911 . . . . 0.0 110.523 -179.953 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.467 ' OG1' HG23 ' A' ' 30' ' ' THR . 23.6 m -99.04 153.75 18.63 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.314 -0.866 . . . . 0.0 109.856 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 1.066 HG21 ' HB3' ' A' ' 25' ' ' ALA . 0.8 OUTLIER -69.93 179.45 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.17 -0.957 . . . . 0.0 110.336 179.963 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.833 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 1.8 m-20 -102.96 -164.03 1.05 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.494 -0.754 . . . . 0.0 109.774 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.5 -32.64 74.36 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.149 -0.969 . . . . 0.0 109.879 179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.1 p -90.25 10.79 23.33 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.319 -0.863 . . . . 0.0 109.731 179.949 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.453 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 69.76 27.96 72.62 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.436 ' O ' ' HB2' ' A' ' 56' ' ' ASP . . . -131.51 127.75 37.93 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.217 -1.166 . . . . 0.0 110.109 179.997 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.572 ' HB2' ' HA ' ' A' ' 55' ' ' THR . . . -127.29 157.47 39.79 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.069 -1.02 . . . . 0.0 111.079 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.6 m -151.2 133.58 15.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.599 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 13.3 p90 -160.86 177.22 10.62 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.86 -1.15 . . . . 0.0 111.032 -179.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.5 114.5 28.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.486 -0.759 . . . . 0.0 110.225 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.579 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 42.7 t80 -95.77 160.41 14.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.314 -0.866 . . . . 0.0 110.317 -179.944 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.579 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 11.2 t -111.29 162.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.228 -0.92 . . . . 0.0 109.928 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.732 HG22 ' O ' ' A' ' 16' ' ' GLN . 8.8 m -133.88 178.27 5.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.352 -0.842 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -149.51 100.28 2.98 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 109.862 179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.674 ' HE2' ' HB2' ' A' ' 87' ' ' ALA . 34.7 tttm -43.57 -25.81 0.18 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.455 -0.778 . . . . 0.0 111.567 -179.843 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.6 p -146.28 149.03 33.09 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.762 -1.211 . . . . 0.0 110.997 -179.974 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.559 ' CZ ' HG11 ' A' ' 84' ' ' VAL . 26.8 p90 -174.87 149.6 1.17 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.442 -0.786 . . . . 0.0 109.837 179.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.8 OUTLIER -79.39 125.09 29.08 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.091 -1.006 . . . . 0.0 110.0 179.924 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.683 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -83.53 155.39 32.25 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.956 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 75' ' ' THR . 89.0 p -160.99 26.13 0.14 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.308 -1.113 . . . . 0.0 110.079 179.963 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.572 HG23 HG23 ' A' ' 81' ' ' VAL . 3.9 p 55.79 151.86 0.06 OUTLIER Pre-proline 0 N--CA 1.505 2.309 0 O-C-N 121.76 -0.588 . . . . 0.0 110.627 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.548 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.0 Cg_endo -70.91 -13.58 31.87 Favored 'Trans proline' 0 C--N 1.308 -1.581 0 O-C-N 123.893 1.47 . . . . 0.0 110.716 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.0 tp10 -80.65 -77.93 0.19 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.088 -1.008 . . . . 0.0 110.238 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 170.36 47.8 0.04 OUTLIER Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.96 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.81 134.26 25.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.172 -1.193 . . . . 0.0 110.273 -179.987 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -73.13 109.74 2.9 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.931 1.49 . . . . 0.0 110.264 179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.572 HG23 HG23 ' A' ' 75' ' ' THR . 73.7 t -91.42 -55.68 5.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.308 -0.87 . . . . 0.0 110.337 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 160.82 -161.08 32.53 Favored Glycine 0 N--CA 1.488 2.105 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 15.8 p -96.43 146.18 25.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.268 -1.136 . . . . 0.0 110.228 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.559 HG11 ' CZ ' ' A' ' 71' ' ' TYR . 16.3 t -123.8 155.81 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.272 -0.893 . . . . 0.0 110.202 -179.958 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.73 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 4.5 m-20 -150.03 105.3 3.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -0.828 . . . . 0.0 109.821 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.453 ' HA ' ' HB2' ' A' ' 91' ' ' CYS . 31.2 m -60.87 -12.79 12.13 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.34 -0.85 . . . . 0.0 110.525 -179.895 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HE2' ' A' ' 69' ' ' LYS . . . -64.32 -54.85 26.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.177 -0.952 . . . . 0.0 109.735 179.977 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.8 t -112.8 10.82 19.21 Favored 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -118.22 161.4 19.96 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.354 -0.841 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.479 ' O ' ' HD2' ' A' ' 38' ' ' PRO . . . -76.84 93.58 3.76 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.32 -0.862 . . . . 0.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.453 ' HB2' ' HA ' ' A' ' 86' ' ' CYS . 0.8 OUTLIER -98.07 129.65 44.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.254 -0.904 . . . . 0.0 109.837 179.958 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -133.17 -176.31 4.09 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.31 -0.869 . . . . 0.0 110.327 179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.483 ' HB3' ' O ' ' A' ' 105' ' ' VAL . 46.2 tp -130.25 135.95 48.67 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.445 -0.785 . . . . 0.0 109.498 -179.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -138.0 147.02 18.96 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.131 -179.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -142.07 138.07 31.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.53 -0.982 . . . . 0.0 110.073 179.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 170.64 163.75 25.19 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 34.0 t30 -108.69 -165.44 1.03 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.27 -1.135 . . . . 0.0 110.263 179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 36.2 t -59.81 -34.41 73.02 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.058 -1.026 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -141.16 53.93 0.64 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.581 HD13 ' C ' ' A' ' 100' ' ' LEU . 0.9 OUTLIER -168.12 78.68 0.15 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.242 -1.151 . . . . 0.0 110.148 179.955 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.491 ' O ' ' OD1' ' A' ' 101' ' ' ASP . 2.2 p30 -75.81 128.14 34.51 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 110.021 179.953 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 55.9 mt -91.28 -86.71 0.21 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 110.013 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -154.13 -179.2 29.27 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.962 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -139.96 119.14 12.76 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.411 -1.053 . . . . 0.0 109.871 -179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 6' ' ' VAL . 41.0 t -104.05 125.74 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.319 -0.863 . . . . 0.0 110.406 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -80.28 142.67 34.34 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.078 -1.014 . . . . 0.0 110.089 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.463 ' HB3' ' CD1' ' A' ' 12' ' ' LEU . 19.7 mt -117.44 175.9 5.41 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.255 -0.903 . . . . 0.0 110.497 -179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.493 ' O ' ' N ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER -161.06 118.14 2.31 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.341 -0.849 . . . . 0.0 110.057 179.969 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.547 ' CD2' ' HB2' ' A' ' 69' ' ' LYS . 36.7 m-85 -89.53 150.66 22.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.27 -179.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 CA-C-O 118.002 -1.444 . . . . 0.0 109.541 -179.956 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.608 H6A2 " O3'" ' A' ' 111' ' ' ROM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.71 -157.08 0.05 OUTLIER 'Trans proline' 0 C--N 1.307 -1.632 0 O-C-N 123.952 1.501 . . . . 0.0 110.435 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 102' ' ' LEU . . . -153.66 177.97 10.37 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.168 -0.958 . . . . 0.0 110.39 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.625 ' HB2' HD22 ' A' ' 102' ' ' LEU . 4.7 t80 -175.66 118.12 0.16 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.429 -0.795 . . . . 0.0 108.873 -179.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 t -143.33 165.13 28.34 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.777 -1.202 . . . . 0.0 111.968 -179.802 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.657 ' CG1' HG11 ' A' ' 105' ' ' VAL . 9.5 p -133.81 141.51 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.906 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.74 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.2 m -48.77 -76.77 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 120.63 -1.294 . . . . 0.0 109.961 -179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.872 ' HG2' HG12 ' A' ' 18' ' ' VAL . 55.5 Cg_endo -89.64 170.3 4.5 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 N-CA-C 109.588 -0.966 . . . . 0.0 109.588 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -167.05 26.3 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.132 -0.98 . . . . 0.0 109.923 179.997 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.429 ' O ' ' C ' ' A' ' 11' ' ' GLY . 0.9 OUTLIER -165.04 168.71 17.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.54 -0.725 . . . . 0.0 109.743 179.988 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 10' ' ' SER . . . 43.36 38.02 3.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.452 HD12 ' HB3' ' A' ' 107' ' ' LEU . 87.2 mt -76.17 -159.34 0.11 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.273 -1.133 . . . . 0.0 110.503 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.501 ' O ' ' HB3' ' A' ' 16' ' ' GLN . 0.5 OUTLIER -164.07 160.25 21.43 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.237 -0.914 . . . . 0.0 110.212 179.998 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -62.49 128.04 34.13 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.056 -1.028 . . . . 0.0 109.531 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.2 -25.6 12.06 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.254 -1.539 . . . . 0.0 109.254 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.559 ' O ' HG22 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -47.97 130.65 15.37 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.416 -1.049 . . . . 0.0 110.327 179.973 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.2 m -109.98 126.98 54.51 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.276 -0.89 . . . . 0.0 109.916 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.872 HG12 ' HG2' ' A' ' 8' ' ' PRO . 34.6 m -105.01 153.68 6.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 O-C-N 121.27 -0.894 . . . . 0.0 110.274 179.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.5 t -93.78 108.04 19.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.08 -1.012 . . . . 0.0 109.656 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.568 HG22 HG23 ' A' ' 6' ' ' VAL . 90.1 t -92.86 167.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.083 -1.01 . . . . 0.0 111.15 -179.886 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.552 ' N ' HG12 ' A' ' 20' ' ' VAL . 48.7 p -168.35 114.06 0.65 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.741 -0.599 . . . . 0.0 109.442 179.939 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.462 ' CG1' HD21 ' A' ' 102' ' ' LEU . 8.3 t -107.28 171.77 2.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.336 -0.852 . . . . 0.0 110.213 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.406 ' N ' HG12 ' A' ' 22' ' ' VAL . 5.3 t -169.55 154.96 5.83 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.202 -0.936 . . . . 0.0 110.407 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 95.16 -7.84 69.58 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 1.009 ' HB3' ' CG2' ' A' ' 55' ' ' THR . . . -72.57 -24.47 61.11 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.079 -1.248 . . . . 0.0 110.579 -179.954 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.732 ' HB3' ' O ' ' A' ' 25' ' ' ALA . . . 74.49 133.73 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.325 -0.86 . . . . 0.0 111.167 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.959 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -57.4 138.86 54.47 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.472 0.653 . . . . 0.0 110.837 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.474 ' O ' ' HG3' ' A' ' 29' ' ' GLU . . . 115.13 8.53 14.86 Favored Glycine 0 N--CA 1.484 1.854 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.75 ' O ' HG23 ' A' ' 54' ' ' THR . 2.7 mt-10 -144.5 146.65 32.52 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.099 -1.236 . . . . 0.0 110.811 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 97' ' ' ASN . 51.1 m -118.08 165.13 14.13 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 179.872 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.654 ' OH ' HD13 ' A' ' 100' ' ' LEU . 97.4 m-85 -144.89 157.23 44.22 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.083 -1.011 . . . . 0.0 110.174 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.531 ' CE2' ' OG ' ' A' ' 52' ' ' SER . 63.1 m-85 -120.17 124.23 45.22 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.068 -1.02 . . . . 0.0 109.453 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.899 HG12 HD11 ' A' ' 93' ' ' LEU . 20.9 tt -106.2 137.92 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.158 -0.964 . . . . 0.0 110.296 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.56 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -152.38 145.84 24.86 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.34 -0.85 . . . . 0.0 110.511 -179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.75 131.75 37.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.463 -0.773 . . . . 0.0 110.242 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 96.7 m -126.6 174.78 8.43 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.375 -0.828 . . . . 0.0 110.565 179.966 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -175.12 135.55 0.51 Allowed Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.427 -0.795 . . . . 0.0 110.248 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.767 ' O ' HG23 ' A' ' 39' ' ' VAL . 48.5 Cg_endo -80.68 165.68 20.05 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 O-C-N 123.965 1.508 . . . . 0.0 110.984 -179.963 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 38' ' ' PRO . 24.3 t -162.08 111.23 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.954 0 O-C-N 121.481 -0.762 . . . . 0.0 110.219 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.79 -6.14 81.68 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 126.16 -34.66 3.17 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.904 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -81.92 173.72 11.96 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.241 -1.153 . . . . 0.0 110.016 179.995 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.45 ' HA ' ' HA ' ' A' ' 38' ' ' PRO . 45.5 m-20 -116.99 140.52 49.38 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.146 -0.971 . . . . 0.0 110.047 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -139.23 130.71 27.09 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.164 -0.96 . . . . 0.0 110.371 179.92 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . . . . . . . . . 7.2 m -102.66 165.35 11.12 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.208 -0.932 . . . . 0.0 110.584 -179.967 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD1' ' A' ' 71' ' ' TYR . 20.4 t30 -105.53 108.85 62.38 Favored Pre-proline 0 N--CA 1.497 1.899 0 O-C-N 121.242 -0.911 . . . . 0.0 110.598 -180.0 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.561 ' HB3' H7A2 ' A' ' 111' ' ' ROM . 49.4 Cg_endo -74.99 -11.37 21.5 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 123.909 1.478 . . . . 0.0 110.48 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.05 -49.06 14.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.226 -0.921 . . . . 0.0 110.455 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.522 ' O ' ' HB2' ' A' ' 50' ' ' ALA . 65.9 p -93.45 117.1 29.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.348 -0.845 . . . . 0.0 110.445 -179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 49' ' ' THR . . . 178.35 136.19 0.08 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.298 -0.877 . . . . 0.0 110.114 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.7 t -139.02 150.77 46.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.259 -0.901 . . . . 0.0 110.334 -179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.531 ' OG ' ' CE2' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -105.22 129.54 53.57 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.237 -0.915 . . . . 0.0 110.119 -179.962 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 53' ' ' PHE . 42.8 p90 -130.0 134.63 47.55 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.322 -0.861 . . . . 0.0 110.694 -179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.75 HG23 ' O ' ' A' ' 29' ' ' GLU . 93.6 m -108.39 158.18 17.74 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.265 -0.897 . . . . 0.0 109.774 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 1.009 ' CG2' ' HB3' ' A' ' 25' ' ' ALA . 1.0 OUTLIER -80.54 161.15 24.93 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.134 -0.979 . . . . 0.0 110.26 179.952 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.959 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 32.9 m-20 -93.48 -165.09 1.26 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.432 -0.793 . . . . 0.0 109.672 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -65.75 -25.93 67.5 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.162 -0.962 . . . . 0.0 110.048 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -92.93 12.07 25.1 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.367 -0.833 . . . . 0.0 109.659 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.487 ' HA2' ' HB ' ' A' ' 55' ' ' THR . . . 58.23 61.53 7.31 Favored Glycine 0 N--CA 1.486 2.013 0 N-CA-C 109.17 -1.572 . . . . 0.0 109.17 -179.975 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -159.87 128.73 5.05 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.214 -1.168 . . . . 0.0 110.474 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -123.85 163.34 21.43 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.213 -0.93 . . . . 0.0 110.695 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -164.2 125.62 2.25 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.935 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.525 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 24.5 p90 -158.31 177.84 10.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.957 -1.09 . . . . 0.0 110.836 -179.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.21 132.63 46.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.429 -0.794 . . . . 0.0 110.525 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 40.9 t80 -124.09 151.39 43.93 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.564 -0.71 . . . . 0.0 109.265 179.891 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 67' ' ' VAL . 18.0 t -111.81 164.44 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 120.885 -1.134 . . . . 0.0 110.99 -179.91 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.559 HG22 ' O ' ' A' ' 16' ' ' GLN . 29.5 m -129.97 172.98 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.496 -0.752 . . . . 0.0 110.312 179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.468 ' HD3' ' CG2' ' A' ' 49' ' ' THR . 0.5 OUTLIER -145.01 110.92 5.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.135 -0.978 . . . . 0.0 110.396 -179.997 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.423 ' CG ' ' CD2' ' A' ' 109' ' ' PHE . 0.1 OUTLIER -54.1 -31.23 51.39 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.514 -0.741 . . . . 0.0 111.555 -179.941 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 58.9 m -136.7 147.42 46.76 Favored 'General case' 0 N--CA 1.503 2.212 0 O-C-N 120.746 -1.221 . . . . 0.0 110.369 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.604 ' CE2' HG11 ' A' ' 84' ' ' VAL . 5.3 p90 -177.74 157.27 1.19 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 110.423 -179.979 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -90.18 123.57 34.11 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.12 -0.988 . . . . 0.0 108.832 179.847 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -95.17 170.31 28.7 Favored Glycine 0 N--CA 1.493 2.483 0 C-N-CA 119.759 -1.21 . . . . 0.0 110.658 -179.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.531 ' O ' ' O ' ' A' ' 75' ' ' THR . 71.4 m -166.81 29.99 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.512 -0.993 . . . . 0.0 109.527 -179.981 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.979 HG23 HG21 ' A' ' 81' ' ' VAL . 79.5 p 52.4 145.71 0.03 OUTLIER Pre-proline 0 N--CA 1.517 2.883 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.987 ' HA ' H7A3 ' A' ' 111' ' ' ROM . 38.2 Cg_endo -63.11 -6.48 9.78 Favored 'Trans proline' 0 N--CA 1.488 1.186 0 O-C-N 123.917 1.482 . . . . 0.0 110.904 -179.885 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -88.16 -112.01 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.001 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 79' ' ' THR . . . -158.36 81.47 0.15 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.947 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.415 ' O ' HG23 ' A' ' 79' ' ' THR . 14.3 t -174.96 135.57 0.53 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.325 -1.103 . . . . 0.0 109.938 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -73.12 115.57 4.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 O-C-N 123.926 1.487 . . . . 0.0 110.526 -179.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.979 HG21 HG23 ' A' ' 75' ' ' THR . 78.6 t -96.25 -44.66 12.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.4 -0.813 . . . . 0.0 110.003 179.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.97 -173.3 36.63 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 3.5 m -94.31 165.28 12.66 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.241 -1.152 . . . . 0.0 110.002 -179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.604 HG11 ' CE2' ' A' ' 71' ' ' TYR . 24.9 t -132.34 152.47 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.178 -0.951 . . . . 0.0 110.164 179.945 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.435 ' CG ' ' O ' ' A' ' 84' ' ' VAL . 11.7 m-20 -160.24 96.63 1.2 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.458 -0.776 . . . . 0.0 110.394 179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.443 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -63.59 -6.1 4.83 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 111.337 179.92 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.443 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -43.72 -39.8 3.89 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.038 -1.039 . . . . 0.0 109.106 179.99 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 t -135.32 -1.13 2.62 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-O 121.362 0.601 . . . . 0.0 109.578 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -102.8 177.44 4.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.234 -0.916 . . . . 0.0 110.345 -179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -107.74 141.83 38.68 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 110.03 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 92' ' ' ASN . 5.1 m -139.92 145.16 37.61 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.155 -0.966 . . . . 0.0 109.866 179.982 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' OD1' ' O ' ' A' ' 91' ' ' CYS . 32.1 m-20 -134.51 156.32 48.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.138 -0.976 . . . . 0.0 110.539 179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.899 HD11 HG12 ' A' ' 33' ' ' ILE . 21.4 tp -107.68 136.95 46.57 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.574 -0.704 . . . . 0.0 109.649 179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -129.21 149.18 18.5 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.135 -179.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -116.9 159.85 21.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.487 -1.008 . . . . 0.0 109.788 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.28 141.87 3.24 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.516 ' HB3' ' O ' ' A' ' 30' ' ' THR . 9.5 p-10 -103.31 -34.3 8.83 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.302 -1.117 . . . . 0.0 110.508 -179.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' C8 ' ' A' ' 111' ' ' ROM . 18.3 t -172.42 -49.8 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.282 -0.886 . . . . 0.0 110.298 -179.994 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -147.69 41.67 0.91 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.654 HD13 ' OH ' ' A' ' 31' ' ' TYR . 6.3 tt -122.97 138.43 54.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.154 -1.204 . . . . 0.0 110.381 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -97.15 61.85 1.77 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.628 ' N ' HD23 ' A' ' 100' ' ' LEU . 0.5 OUTLIER -53.72 -76.74 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.211 -0.931 . . . . 0.0 110.247 179.962 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.84 176.16 47.28 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.44 129.62 16.58 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.447 -1.031 . . . . 0.0 109.902 179.991 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.657 HG11 ' CG1' ' A' ' 6' ' ' VAL . 65.6 t -114.46 123.95 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.043 -1.036 . . . . 0.0 109.951 -179.931 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -78.71 147.54 33.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.154 -0.966 . . . . 0.0 110.279 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.765 HD11 ' HB2' ' A' ' 93' ' ' LEU . 8.2 mt -118.72 173.8 6.65 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.32 -0.862 . . . . 0.0 110.34 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.52 161.85 40.82 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -0.853 . . . . 0.0 110.134 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.423 ' CD2' ' CG ' ' A' ' 69' ' ' LYS . 39.3 m-85 -136.15 80.63 1.84 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 110.217 179.971 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 CA-C-O 117.952 -1.471 . . . . 0.0 109.567 -179.999 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.987 H7A3 ' HA ' ' A' ' 76' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 120.73 0.3 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.44 ' HG3' HD21 ' A' ' 100' ' ' LEU . 45.0 Cg_endo -71.83 -170.25 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.013 1.533 . . . . 0.0 110.42 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.698 ' HB3' ' OG ' ' A' ' 23' ' ' SER . . . -109.14 156.05 20.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.883 . . . . 0.0 110.754 179.937 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . 0.823 ' HD1' HG22 ' A' ' 22' ' ' VAL . 54.9 t80 -162.53 113.8 1.56 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.401 -0.812 . . . . 0.0 109.276 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.78 159.94 41.2 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.896 -1.127 . . . . 0.0 111.606 -179.876 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.575 ' CG1' HG11 ' A' ' 105' ' ' VAL . 11.9 p -121.89 154.28 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 179.899 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.648 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 4.9 m -56.26 -85.23 0.01 OUTLIER Pre-proline 0 CA--C 1.559 1.317 0 O-C-N 120.547 -1.346 . . . . 0.0 108.918 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.648 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 55.4 Cg_endo -80.6 174.91 10.64 Favored 'Trans proline' 0 C--O 1.212 -0.819 0 N-CA-C 109.326 -1.067 . . . . 0.0 109.326 179.783 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -168.31 25.06 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.96 -1.088 . . . . 0.0 110.042 179.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.5 p -163.06 157.34 20.66 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.365 -0.834 . . . . 0.0 109.58 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' THR . . . 48.84 43.9 30.73 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 107' ' ' LEU . 65.7 mt -79.67 -160.01 0.24 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.311 -1.111 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.515 ' N ' ' OE1' ' A' ' 16' ' ' GLN . 73.3 m -166.17 155.88 11.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.887 179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -63.77 136.4 57.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -0.951 . . . . 0.0 110.189 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.32 -28.2 6.41 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.947 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.77 ' O ' HG22 ' A' ' 67' ' ' VAL . 56.4 tt0 -52.0 134.04 32.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.201 -1.176 . . . . 0.0 109.782 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 10.3 t -113.59 128.5 56.46 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.288 -0.883 . . . . 0.0 110.363 179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.582 HG12 ' HG2' ' A' ' 8' ' ' PRO . 28.3 m -110.82 150.61 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.337 -0.852 . . . . 0.0 110.228 -179.961 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.6 t -88.89 101.08 13.7 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.197 -0.939 . . . . 0.0 109.667 -179.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 21' ' ' SER . 55.7 t -84.79 163.03 2.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.223 -0.923 . . . . 0.0 110.486 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.486 ' N ' HG12 ' A' ' 20' ' ' VAL . 23.0 p -159.64 124.4 3.98 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.863 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.823 HG22 ' HD1' ' A' ' 4' ' ' PHE . 5.8 t -110.24 155.14 11.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 O-C-N 121.369 -0.832 . . . . 0.0 109.704 179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.698 ' OG ' ' HB3' ' A' ' 3' ' ' ALA . 28.4 p -150.2 171.61 16.65 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.125 -0.984 . . . . 0.0 110.062 179.928 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.25 -8.46 52.51 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.578 ' CB ' HG21 ' A' ' 55' ' ' THR . . . -73.16 -142.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.153 -1.204 . . . . 0.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.486 ' HA ' ' HA3' ' A' ' 59' ' ' GLY . . . -166.08 130.95 2.29 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.089 -1.007 . . . . 0.0 110.895 179.913 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.831 ' HB2' ' O ' ' A' ' 56' ' ' ASP . . . -52.99 133.06 38.43 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.465 -0.772 . . . . 0.0 110.313 179.933 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 115.59 15.11 7.69 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.767 -1.206 . . . . 0.0 110.087 179.943 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.407 ' O ' HG23 ' A' ' 54' ' ' THR . 24.0 mt-10 -147.89 148.35 30.73 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.041 -1.27 . . . . 0.0 110.999 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.446 HG23 ' OG1' ' A' ' 54' ' ' THR . 2.0 m -120.54 134.63 55.25 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.562 -0.711 . . . . 0.0 109.979 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.585 ' HA ' ' HB3' ' A' ' 97' ' ' ASN . 35.0 m-85 -115.7 147.96 40.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.776 -179.958 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.47 ' CD2' " O'2" ' A' ' 111' ' ' ROM . 75.6 m-85 -91.04 131.12 36.82 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.352 -0.842 . . . . 0.0 109.792 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.655 ' C ' HD13 ' A' ' 33' ' ' ILE . 0.0 OUTLIER -118.39 130.52 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 120.995 -1.066 . . . . 0.0 110.228 -179.97 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.583 ' O ' HD12 ' A' ' 93' ' ' LEU . . . -164.01 157.36 18.32 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.085 -1.009 . . . . 0.0 110.687 179.995 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' GLN . . . . . 0.564 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 7.5 tt0 -84.85 145.1 28.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.311 -0.868 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 87.7 m -139.69 -178.55 5.46 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.213 -0.93 . . . . 0.0 110.805 -179.961 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' CB ' ' OH ' ' A' ' 71' ' ' TYR . . . -171.06 119.56 0.48 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.474 -0.766 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.41 168.22 25.31 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.817 1.43 . . . . 0.0 110.149 -179.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.569 ' O ' HG13 ' A' ' 39' ' ' VAL . 12.9 p -140.73 61.83 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.169 -0.957 . . . . 0.0 110.482 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 39' ' ' VAL . . . 35.08 58.94 0.77 Allowed Glycine 0 N--CA 1.499 2.871 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 179.932 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 159.86 -64.92 0.28 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -119.56 -161.14 0.85 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.187 -1.184 . . . . 0.0 110.385 -179.917 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -137.71 127.41 25.31 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.258 -0.901 . . . . 0.0 110.133 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.796 ' HB1' ' HA3' ' A' ' 73' ' ' GLY . . . -117.14 123.6 47.12 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.236 -0.915 . . . . 0.0 110.43 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' CYS . . . . . 0.488 ' SG ' H141 ' A' ' 111' ' ' ROM . 2.3 m -108.46 175.51 5.44 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.254 -0.904 . . . . 0.0 110.201 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' OD1' ' CD2' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -95.24 116.3 66.2 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.143 -0.973 . . . . 0.0 110.44 179.954 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.653 ' CA ' H7A3 ' A' ' 111' ' ' ROM . 49.1 Cg_endo -79.04 -9.93 15.32 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.938 1.494 . . . . 0.0 110.333 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.71 -49.27 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.21 -0.931 . . . . 0.0 110.46 -179.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 3.5 p -88.1 61.98 6.56 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.341 -0.849 . . . . 0.0 110.112 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -112.09 78.35 1.12 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.268 -0.895 . . . . 0.0 110.098 179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 5.5 t -105.52 154.45 20.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.232 -0.918 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.0 p -114.18 118.77 34.93 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.305 -0.872 . . . . 0.0 109.829 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' TYR . 41.3 p90 -113.35 134.53 54.58 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.286 -0.884 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.446 ' OG1' HG23 ' A' ' 30' ' ' THR . 43.8 m -94.96 159.95 14.8 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.319 -0.863 . . . . 0.0 110.449 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.578 HG21 ' CB ' ' A' ' 25' ' ' ALA . 0.7 OUTLIER -80.01 -178.67 6.61 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.258 -0.901 . . . . 0.0 110.399 179.91 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.831 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -102.31 -164.31 1.08 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.437 -0.789 . . . . 0.0 109.745 -179.93 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -63.99 -35.16 79.79 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.156 -0.965 . . . . 0.0 109.981 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -89.35 16.31 7.69 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.393 -0.817 . . . . 0.0 109.729 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 26' ' ' ALA . . . 62.96 35.65 92.37 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -122.76 155.01 37.38 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.255 -1.144 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -144.42 164.53 30.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -0.868 . . . . 0.0 110.746 -180.0 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' SER . 1.5 p -175.3 120.27 0.19 Allowed 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.936 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 11.1 p90 -153.05 179.32 8.8 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.018 -1.051 . . . . 0.0 110.622 -179.823 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.2 m -101.86 118.98 38.06 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.536 -0.727 . . . . 0.0 110.146 179.967 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 66' ' ' VAL . 61.0 t80 -116.15 128.02 55.29 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.241 -0.912 . . . . 0.0 109.993 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 65' ' ' PHE . 17.7 t -82.77 164.88 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.32 -0.863 . . . . 0.0 110.156 -179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.77 HG22 ' O ' ' A' ' 16' ' ' GLN . 14.8 m -131.05 172.04 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 0.0 110.273 179.917 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.439 ' O ' ' C ' ' A' ' 69' ' ' LYS . 1.4 mtt-85 -141.75 103.28 4.33 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.333 -0.854 . . . . 0.0 110.143 -179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.507 ' HA ' ' CE2' ' A' ' 109' ' ' PHE . 15.0 ttmt -36.95 -59.4 0.71 Allowed 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 110.581 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.9 147.13 28.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.318 -0.864 . . . . 0.0 110.033 179.97 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.564 ' CE1' ' OE1' ' A' ' 35' ' ' GLN . 26.4 p90 -171.4 139.35 1.28 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.236 -0.915 . . . . 0.0 110.1 179.998 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 0.2 OUTLIER -65.28 127.38 31.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.189 -0.945 . . . . 0.0 110.17 -179.954 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.796 ' HA3' ' HB1' ' A' ' 44' ' ' ALA . . . -80.99 165.96 48.0 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.964 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 75' ' ' THR . 0.3 OUTLIER 177.37 113.24 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.323 -1.104 . . . . 0.0 109.994 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.543 HG23 HG21 ' A' ' 81' ' ' VAL . 19.8 p -41.57 143.19 0.91 Allowed Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.305 -0.872 . . . . 0.0 110.351 -179.974 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.53 ' HA ' " C'7" ' A' ' 111' ' ' ROM . 43.8 Cg_endo -69.76 -10.65 29.07 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 123.928 1.488 . . . . 0.0 110.353 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -70.51 -30.86 67.74 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.28 -0.888 . . . . 0.0 110.348 179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.46 ' O ' ' OG1' ' A' ' 79' ' ' THR . . . 124.53 61.43 0.18 Allowed Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 179.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.46 ' OG1' ' O ' ' A' ' 78' ' ' GLY . 19.0 m -164.93 134.14 2.78 Favored Pre-proline 0 N--CA 1.494 1.754 0 O-C-N 121.347 -1.09 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.93 134.58 19.98 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.917 1.483 . . . . 0.0 110.183 -179.999 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 75' ' ' THR . 84.6 t -112.55 -29.95 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.174 -0.953 . . . . 0.0 110.428 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.82 -164.69 30.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.99 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 72' ' ' THR . 21.6 p -108.39 155.53 20.45 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.179 -1.189 . . . . 0.0 110.504 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.413 HG11 ' CE1' ' A' ' 71' ' ' TYR . 11.7 t -129.73 155.32 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.286 -0.884 . . . . 0.0 109.997 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.658 ' O ' ' HB3' ' A' ' 89' ' ' ALA . 11.2 p30 -150.21 111.39 4.39 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.297 -0.877 . . . . 0.0 110.141 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' CYS . . . . . 0.408 ' O ' ' C ' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -77.52 -1.46 30.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.266 -0.896 . . . . 0.0 110.672 -179.994 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.408 ' C ' ' O ' ' A' ' 86' ' ' CYS . . . -47.22 -39.07 13.28 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.035 -1.041 . . . . 0.0 108.707 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.3 13.63 1.41 Allowed 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' A' ' 85' ' ' ASP . . . -110.08 -179.29 3.75 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.566 -0.709 . . . . 0.0 110.746 -179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.43 ' C ' ' SG ' ' A' ' 91' ' ' CYS . . . -104.04 145.16 30.57 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.488 -0.758 . . . . 0.0 110.377 179.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' CYS . . . . . 0.43 ' SG ' ' C ' ' A' ' 90' ' ' ALA . 8.1 m -145.61 167.19 23.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.325 -0.859 . . . . 0.0 109.555 179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.44 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 31.0 t-20 -163.35 128.3 3.01 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.084 -1.01 . . . . 0.0 110.059 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.583 HD12 ' O ' ' A' ' 34' ' ' ALA . 8.9 tp -82.04 144.88 30.53 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.287 -0.883 . . . . 0.0 109.654 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -134.65 151.62 20.43 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.578 ' HB1' HD12 ' A' ' 102' ' ' LEU . . . -134.63 173.47 11.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.423 -1.045 . . . . 0.0 110.072 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.19 171.75 14.65 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.694 -1.363 . . . . 0.0 109.694 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.585 ' HB3' ' HA ' ' A' ' 31' ' ' TYR . 11.2 p-10 -138.12 -156.86 0.72 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.279 -1.13 . . . . 0.0 110.367 180.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 76.97 8.2 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -0.851 . . . . 0.0 110.203 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 154.52 -34.34 0.7 Allowed Glycine 0 N--CA 1.488 2.145 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.565 HD13 ' OH ' ' A' ' 31' ' ' TYR . 5.8 tt -140.43 114.29 8.92 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.247 -1.149 . . . . 0.0 110.426 -179.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.444 ' OD1' CL21 ' A' ' 111' ' ' ROM . 27.6 t70 -92.72 128.68 38.66 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.222 -0.924 . . . . 0.0 109.971 -179.996 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.778 HD22 ' CG1' ' A' ' 22' ' ' VAL . 26.4 mt -77.2 -92.75 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.173 -0.955 . . . . 0.0 110.451 179.953 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -156.78 -178.82 31.24 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -130.86 112.1 12.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.438 -1.037 . . . . 0.0 110.084 -179.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.575 HG11 ' CG1' ' A' ' 6' ' ' VAL . 74.4 t -101.21 127.66 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.084 -1.01 . . . . 0.0 110.126 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -84.67 139.01 32.34 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.061 -1.024 . . . . 0.0 110.037 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.559 HD11 ' HB2' ' A' ' 93' ' ' LEU . 14.1 mt -114.7 175.72 5.37 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.764 179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.431 ' O ' ' N ' ' A' ' 11' ' ' GLY . 2.5 m -161.81 103.43 1.18 Allowed 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.125 -0.984 . . . . 0.0 110.326 179.907 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.507 ' CE2' ' HA ' ' A' ' 69' ' ' LYS . 32.6 m-85 -75.04 132.43 41.3 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.4 -0.812 . . . . 0.0 110.175 -179.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 CA-C-O 117.997 -1.446 . . . . 0.0 109.539 -179.931 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' ROM . . . . . 0.653 H7A3 ' CA ' ' A' ' 47' ' ' PRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_